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Abstract
Households represent a setting of frequent and intense contacts and hence are 
conducive to the spread of respiratory viruses, such as respiratory syncytial virus 
(RSV). Infants are most vulnerable to severe RSV disease but a vaccine is not yet 
available hence the need to explore alternate strategies of protecting them. Such 
strategies would require better understanding of who infects the infants. During the 
RSV season of 2009/2010, we undertook a prospective study in rural Kenya involving 
493 members of 47 households each with a child bom after the preceding RSV 
epidemic and at least one elder sibling. Throughout the epidemic a nasopharyngeal 
swab (NPS) was collected every 3-4 days irrespective of symptoms, from all 
household members, and tested for a range of respiratory viruses including RSV using 
a molecular diagnostic assay. Partial sequencing of the attachment protein (G) gene 
from positive swabs was used to compare RSV strains within the household. In 
addition, once-a-week a specimen of oral fluid (OF) from around the gums was 
collected for RSV-specific antibodies screening and for assessment of sensitivity of 
the OF in detection of RSV using molecular diagnostics. This is the first prospective 
study to investigate introduction and transmission of RSV in families using molecular 
techniques over a complete RSV season. Analysis of RSV infection data is reported in 
this thesis with particular interest to identifying from where infants derive their 
infection, estimating the duration of RSV shedding and identity factors influencing 
the recovery rates, and estimating parameters of RSV susceptibility and transmission 
probability. In addition, data on diagnostic performance of OF in detection of RSV by 
molecular methods is presented.
A total of 16,924 NPS were collected, representing 86% of planned. RSV was 
detected in 40 (85%) households and 179 (36%) of the participants. In 28 of the 44 
households with complete data, there was transmission of RSV to the infants 
experiencing their first epidemic. The probable source of RSV infection of the naive 
infants was a household member in at least 54% of the cases. Co-primary infection 
between a household member and the RSV-naive infant was ascribed in 4 of the 
cases. Older children were assigned the primary case for 11 (39%) of the infant cases 
and 10 (91%) of these were attending school. The infants appeared to play a role 
transmitting the introduced infections to the other members of the household 
including to the mothers.
These findings support vaccination strategies that target school age children and 
pregnant women. Both of these vaccination strategies can have profound benefits to 
RSV naive infants directly by augmenting neutralizing antibodies against RSV 
(immunization of the pregnant women) and indirectly by reducing transmission from 
siblings to RSV-naive infants. Results from this study provide increased confidence in 
the rationale for RSV vaccination of individuals who are not the key targets for 
protection.
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CHAPTER ONE
1 General Introduction
1.1 Background of respiratory syncytial virus
Respiratory syncytial virus (RSV) is the major viral cause of childhood acute respiratory 
infection (ARI) worldwide. It is estimated about 60% of all children are infected during their 
first year of life and almost all by the end of their third year (Glezen et al. 1986). A recent 
review reported more than 30 million cases of RSV-associated ARI and at least 66,000 deaths 
occurred worldwide (99% of these deaths occurring in developing countries) in children 
under 5 years of age in 2005 (Nair et al. 2010). Studies undertaken in our setting of a rural 
developing country population typical of sub-Saharan Africa suggest around 1-2 in every 100 
infants are admitted to hospital with RSV-associated severe pneumonia each year and RSV 
accounts for up to one fifth of all infant severe pneumonia, comparable to any other single 
respiratory pathogen (Nokes et al. 2009; Berkley et al. 2010).
Currently no RSV vaccines are licensed for use (Nokes and Cane 2008). Immunological 
immaturity and maternal antibodies represent major obstacles to vaccines targeting the key 1- 
3 month age group (Karron et al. 2005). Live attenuated vaccines in age groups 6 months and 
over are safe and immunogenic (Karron et al. 2005; Wright et al. 2007). However, the delay 
in delivery is at the cost of failing to directly protect a proportion of those most at risk.
Hence, there is a need to carefully evaluate alternative approaches (Nokes and Cane 2008; 
Anderson et al. 2013), such as targeting any one or more of older infants, household siblings, 
school children or mothers. The potential impact of such alternative strategies will be 
intimately linked to who is acquiring infection from whom (WAIFW) (Anderson and May
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1991), and in particular which groups are most important in infecting the infant. This forms 
the basis of the current study.
Household represents an important unit for the spread of infectious disease, and has been a 
focus for observational studies of respiratory illnesses in the past (Longini et al. 1982; 
Viboud et al. 2004). The close interactions in the household offer favorable environment for 
the spread of respiratory viruses. The household also represents an important setting through 
which demographic changes can translate to population effects on infectious disease 
transmission, for the spread of emergent infectious diseases, and on which to focus control 
strategies (Becker and Dietz 1995; Hall and Becker 1996; House and Keeling 2008; 
Goldstein et al. 2009; House and Keeling 2009). The primary interest in this thesis thus rests 
with understanding the transmission patterns of RSV in households. Given that disease 
following primary infection in infants is the major focus for vaccination, studies in the 
household setting are important in determining from where infants derive their infection and 
how these infections can be prevented.
The advent of broad-range molecular diagnostics provides sensitive tools for the study of the 
viral population dynamics which underpin disease aetiology (Gunson et al. 2005; Levine et 
al. 2012). Elucidation of within household transmission patterns of RSV calls for intensive 
sampling irrespective of symptoms using techniques of high sensitivity with particular 
demands of study infrastructure and community engagement, possible in few settings. In our 
settings, a nasopharyngeal specimen collected using the flocked swab has been shown to be 
acceptable in the community (Munywoki et al. 2011). However, oral fluid offers an 
alternative specimen for virus detection using either enzyme linked immunosorbent assay 
(ELISA) (Okiro et al. 2008) or molecular diagnostics (von Linstow et al. 2006). Data on the
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diagnostic performance of this painless sampling method is limited and will thus be explored 
in the current study.
1.2 Objectives
This research feeds into a larger project whose central interest is to develop strategies for 
optimal vaccine intervention for the prevention of RSV disease. The main objective for this 
work is to define who acquires infection from whom within households in a developing 
country setting, with primary interest in the introduction and spread of RSV. The principle 
questions are related to who infects the infant of the household with RSV and which factors 
influence the duration of RSV shedding.
1.2.1 Primary objectives
a) Determine the proportion of primary infant infections that arise from within the 
household (e.g. from elder siblings, the mother, father and other household members) or 
from outside the household.
b) Estimate the duration of RSV shedding and identify factors influencing the rates of RSV 
recovery
c) Estimate transmission probability and susceptibility parameters key in defining WAIFW 
in the households.
1.2.2 Secondary objectives
a) Evaluate the use of oral fluid (OF) in detecting infection using multiplex PCR and ELISA 
methods
b) Determine the risk of subclinical RSV infections by age
1.3 Approach
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During an RSV epidemic, which spanned December 2009 to June 2010, we undertook a 
study to investigate the introduction and spread of respiratory viruses in 50 households 
selected from a well-defined rural developing country community (Scott et al. 2012). Eligible 
households had an infant bom since the previous RSV epidemic and one or more older 
siblings aged below 13 years. All members were swabbed twice weekly from the 
nasopharynx, and tested for a range of respiratory viruses using an in-house multiplex 
molecular diagnostic assay, and once a week from around the gums and assayed for RSV- 
specific antibodies. The sampling frequency set for this study was thought out carefully and 
arrived at after consideration of the different sampling intervals vis-a-vis shedding duration 
of RSV as outlined in Chapter 3 on study methods. The reasons for the broad vims screen on 
nasal swabs were: (i) identification of other respiratory vimses, which spread by a similar 
route to RSV, which would increase power of study to identify who infects whom, (ii) 
intrinsic interest in other vimses as causes of morbidity in the community, (iii) in order to 
assess the interaction of RSV and other respiratory vimses. Selection of the ‘other’ vimses to 
screen was based on the observation of the most prevalent during the study period. However, 
for the purpose of this thesis focus was on detection of RSV vims. With the RSV infection 
data, we quantify who acquires infection from whom and in particular identify from where 
the infants derive their infection. Elucidating the potential of different vaccination strategies 
and the impact at the population level of such approaches on RSV infection especially on the 
vulnerable infants will benefit from understanding of transmission dynamics of RSV.
1.4 Declaration of the author’s role
The author was the principal investigator of the parent study (whose proposal is attached, 
appendix A) from which the analyzed data arise. He took lead role in conceptualization, 
design and implementation of the household study. The author addressed all scientific and
ethical issues raised by the research review boards in Kenya and UK. In terms of the study 
conduct, the author was the overall study manager. He was in charge of the field team, which 
consisted of one study coordinator, one study clinician, one senior field worker and 10 field 
workers; and data entry team, comprising of three data entry clerks. The author worked 
closely with the Laboratory Manager for the Viral Epidemiology and Control research group 
and the laboratory team in processing and screening as well as in storing of the study 
specimens. The custom-made Filemaker (version 11) database was developed and 
administered by the author. The study data were double entered and the author merged and 
cleaned the database. The author led all the analyses unless otherwise stated. The study was 
funded by Wellcome Trust grant (Grant number 090853).
During the period of registration, the candidate published the following articles:
a) Berkley JA, Munywoki P, Ngama M, Kazungu S, Abwao J, Bett A, Lassauniere R, 
Kresfelder T, Cane P, Venter M, Scott J, Nokes D. (2010) Viral etiology of severe 
pneumonia among Kenyan infants and children. JAMA 303: 2051-2057.
b) Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton R, O’Brien K, Roca A, 
Wright P, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih E, Ngama M, 
Munywoki P, Kartasasmita C, Simoes E, Rudan I, Weber M, Campbell H. (2010) Global 
burden of acute lower respiratory infections due to respiratory syncytial virus in young 
children: a systematic review and meta-analysis. Lancet 375: 1545-1555.
c) Munywoki PK, Hamid F, Mutunga M, Welch S, Cane P, Nokes D. (2011) Improved 
detection of respiratory viruses in pediatric outpatients with acute respiratory illness by 
real-time PCR using nasopharyngeal flocked swabs. J Clin Microbiol 49: 3365-3367.
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d) Onyango CO, Welch SR, Munywoki PK, Agoti CN, Bett A, Ngama M, Myers R, Cane 
P, Nokes D. (2012) Molecular epidemiology of human rhino virus infections in Kilifi, 
coastal Kenya. J Med Virol 84: 823-831.
e) Webb C, Ngama M, Ngatia A, Shebbe M, Morpeth S, Mwarumba S, Bett A, Nokes D, 
Seale A, Kazungu S, Munywoki P, Hammitt L, Scott J, Berkley J. (2012) Treatment 
Failure among Kenyan Children with Severe Pneumonia - a Cohort Study. Pediatr Infect 
Dis J 13: 13
f) Kamuya DM, Theobald SJ, Munywoki PK, Koech D, Geissler WP, Molyneux S. (2013) 
Evolving friendships and shifting ethical dilemmas: fieldworkers' experiences in a short 
term community based study in Kenya. Dev World Bioeth 13: 1-9.
g) Munywoki PK, Ohuma EO, Ngama M, Bauni E, Scott JA, Nokes D. (2013) Severe 
lower respiratory tract infection in early infancy and pneumonia hospitalizations among 
children, Kenya. Emerg Infect Dis 19: 223-229
h) Munywoki PK, Koech D, Agoti CN, Lewa C, Cane PA, Medley, GF, Nokes DJ; The 
source of respiratory syncytial virus infection in infants: a household cohort study in rural 
Kenya, submitted
i) Munywoki PK, Koech D, Agoti CN, Cane PA, Medley, GF, Nokes DJ; Duration of RSV 
shedding and factors influencing the recovery rates, in preparation
1.5 Overview of the thesis
Following this introduction is a comprehensive review of literature. The review covers RSV 
epidemiology and transmission with focus on providing background for the questions 
addressed in this thesis. A summary of the studies reporting spread of RSV in families is also 
presented, highlighting the key methodological considerations for the current study. The third 
chapter provides the detailed description of the study design and implementation and
challenges encountered. General results on household recruitment and retention, details on 
home visits and sample collections and prevalence of RSV in the inpatient surveillance over 
the study period are also presented. Chapter 4 provides further general results on baseline 
characteristics of the study households and individuals, seasonality of RSV and other 
respiratory viruses, probability of subclinical RSV infections by age and diagnostic 
performance of oral fluid in RSV detection using molecular techniques. Chapter five presents 
data on the source of RSV infection in study infants with particular focus on who introduces 
RSV into the households. Characteristics of infected and uninfected households and 
individuals are also presented and discussed. The sixth chapter describes the analysis of RSV 
shedding durations and factors influencing the infection recovery. In chapter seven using a 
mathematical model, transmission and susceptibility parameters are estimated. Results on the 
relative contribution by different household members on RSV infections are shown i.e. who 
infects whom. The final chapter provides a summary and discussion of the main findings 
stating the implications on strategies for vaccine delivery. The final chapter also discusses the 
study limitations while offering possible areas of improvement as well as directions for future 
research.
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CHAPTER TWO
2 Literature Review
2.1 Summary
Respiratory tract infections are common and a major source of morbidity and mortality 
globally, particularly in low-income countries. About 155 million episodes of pneumonia 
occur in children younger than 5 years leading to the death of 1.5 million young children 
every year (Liu et a l 2012; Rudan et al. 2012; UNICEF et a l 2012). A recent review of 89 
published and unpublished studies on acute lower respiratory tract infection (LRTI), 
estimated about 12 million hospitalisations for severe LRTI and 3 million for very severe 
LRTI occurred in 2010 worldwide in under five year olds. The majority (96%) of the 
episodes were in low-income countries. It is in this regard that childhood pneumonia has been 
identified as a priority for research (Adegbola 2012).
Data from aetiology studies identify Streptococcus pneumoniae and Haemophilus influenzae 
type b as the main bacterial causes of childhood pneumonia. Viruses are detected in up to 
80% of pneumonia and bronchiolitis episodes in young children particularly in low-income 
countries (Gilani et a l 2012). Respiratory syncytial virus (RSV) and rhinoviruses are the 
most frequently isolated viruses (Berkley et a l 2010; Gilani et a l 2012) and RSV in 
particular has been identified as the main viral cause of infant and early childhood pneumonia 
and bronchiolitis worldwide. With improved access to childhood vaccines, such as 
Haemophilus influenzae type b, pertussis and pneumococcal conjugate vaccines, the role of 
viruses and in particular RSV will assume greater importance in efforts to reduce further the 
burden of childhood pneumonia (English and Scott 2008). An on-going multicentre study by 
the Pneumonia Etiology Research for Child Health (PERCH) group in seven low-income
countries will provide updated data on role of RSV in causing severe LRTI (Levine et al 
2012). The current study, will also add our knowledge on the role of respiratory viruses in 
causing acute respiratory infections (ARI) by identifying the circulating viruses in the 
community among potentially health individuals.
In a recent systematic review and meta-analysis, it was estimated 34 (19 -  66) million cases 
of RSV-associated ARI and 66000- 199000 deaths (99% of these deaths occurring in 
developing countries) occurred worldwide in children under 5 years in 2005 (Nair et al 
2010). The Global Burden of Disease study reported 253,500 (215000 -  296600) deaths due 
to RSV in all age groups in 2010 (Lozano et a l 2012). These estimates were higher than 
those reported by Nair et al (Nair et a l 2010) probably due to lack of good quality mortality 
data and differences in study methods.
Disease due to RSV is principally the result of primary infection, which, because of high 
virus transmissibility, occurs predominantly in infants, and particularly in those under 6 
months of age (Glezen et a l 1986; Weber et al 1998; Nokes et a l 2004; Robertson et a l 
2004; Nokes et a l 2008; Hall et a l 2009). Surveillance of paediatric admissions in rural 
coastal Kenya, Kilifi district, over the period 2002-07 has defined incidence estimates (per
100,000 per year) of RSV-associated severe or very severe pneumonia admissions of 1,107 
(95% Cl, 1012-1211) in infants, and 293 (271-317) in the under 5 year olds, contributing 
some 15% and 12%, by age group, respectively, of all admissions for these conditions (Nokes 
et al 2009). This is comparable with the proportion of clinical severe pneumonia prevented 
by 9-valent conjugate pneumococcal vaccine in The Gambia (12%) (Cutts et a l 2005). 
Similar estimates of incidence of severe RSV disease have been observed in developed 
countries. In every 100 infants, about two experienced severe RSV disease requiring
hospitalisation in their first year of life in United States and England (Sims et a l 1976;
9
Glezen et a l 1986). Within a birth cohort in the Kilifi Health and Demographic Surveillance 
System (KHDSS), followed up between 2002 and 2005, the incidences of RSV-associated 
pneumonia, severe pneumonia, and hospital admission among infants were 10400, 6600 and 
1300 cases per 100,000 child years of observation, respectively. The proportion of cases of 
all-cause pneumonia, severe pneumonia and hospitalisations attributable to RSV in the cohort 
was 13%, 19% and 5%, respectively (Nokes et al. 2008). Hence, there is a considerable 
burden of RSV in the community not identified by hospital surveillance. Incidence of 
hospitalisation with RSV infection appears to decline with distance from the hospital, as 
demonstrated in studies from The Gambia (Weber et al 2002) and also our inpatient studies 
(see Figure 2.1), which is most probably attributable to ease of access and health seeking 
behaviour. There is evidence that RSV predisposes to future respiratory disease in the short 
and longer term (Weber et al. 1999; Poulsen et al. 2006; Munywoki et a l 2013), adding to 
the ill-health burden. In summary, it is therefore apparent that there is a significant burden of 
RSV disease which warrants development of novel treatment and prevention strategies.
Glezen et al, in a birth cohort study, showed that approximately 60% of all children 
experienced RSV infection in their first year of life and almost all by their third year (Glezen 
et al 1986). Furthermore, RSV repeatedly reinfects throughout life (Hall et a l 1976; 
Henderson et a l 1979). Undoubtedly this translates to a large pool of infectious individuals 
likely to be fundamental to endemic maintenance of infection and transmission to young 
children. The contribution of re-infections to the spread of RSV within the community is not 
well elucidated, but will be dependent upon the prevalence of individuals with re-infections, 
and their infectivity and patterns of contact with others in the population. These factors 
combine to define ‘who acquires infection from whom’ (WAIFW), which is central to
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understanding the transmission dynamics of infectious diseases, and predicting vaccine 
impact (Anderson and May 1991).
No licensed RSV vaccine exists but promising live-attenuated vaccines are under 
development (Karron et al. 2005). With most of the severe RSV disease occurring in the first 
year of life, and particularly in the first 6 months of life, it is a priority that a vaccine protects 
this early age group. Live attenuated vaccines have been shown to he highly immunogenic 
and well tolerated in children 6 months and older, but poorly tolerated in children under 3 
months of age without over-attenuation (Karron et a l 2005; Wright et al. 2007). It is 
apparent that alternative delivery strategies need to be explored (Anderson and Grenfell 
1985; Collins and Murphy 2007; Anderson et al. 2013; Kaaijk et al. 2013), including 
delaying vaccination to older infants (>3 months) or targeting elder siblings, school children 
or mothers. The potential of such strategies to protect against severe RSV disease depends 
not only on the proportion of disease directly preventable in those receiving the vaccine but 
also on resultant reduced spread of infection from those vaccinated to those too young to 
receive vaccine (<3 months). Our studies identify over 60% of RSV severe disease occurring 
in children >3 months of age (Nokes et al. 2009); hence direct protection from delayed 
delivery may be substantial. Protection from infection afforded indirectly may be in the form 
of a reduced risk of transmission between presumed key transmission contacts (for example, 
mother to infant), or more generally due to reduced circulation of the infectious agent in the 
population, the so called herd immunity effect (Anderson and May 1991). These indirect 
protective and herd immunity effects are not quantified for RSV but well quantified for 
measles, influenza and hepatitis. Mathematical modelling of infection transmission has been 
previously used to evaluate this impact; exploring different vaccination strategies (Anderson 
and Grenfell 1986; Wilson et al. 2007; Vynnycky et al. 2008). However, such models require
well-determined parameters for WAIFW and particularly who is infecting vulnerable infants 
in the case of RSV. This study aims to delineate transmission patterns of RSV in the 
households with particular interest in identifying where infants derive their infection from 
(Chapter 5), investigating factors affecting RSV shedding durations (chapter 6), and 
quantifying parameters that define WAIFW matrix (Chapter 7).
to Malindi
Indian
Ocean
Legend
Incidence <5yr RSV admissions 
(/100,000/year)
I I 0-157
I I 158-314
m  315-472
■ B  473-629
M om basa-M alindi road  (tarm ac) 
—  m ain road  
(H) Kilfi District H ospital 
C Kilifi c reek
Kilometers
to Mombasa,
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et al. 2009)
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2.2 Epidemiology of RSV
2.2.1 The virus
Human RSV was first isolated in children with respiratory illness in 1957 (Chanock et al. 
1957), a year after being discovered in chimpanzees with coryza (Morris et al. 1956). The 
vims has since been antigenically characterised into two broad groups, A and B, initially by 
neutralisation tests using polyclonal sera (Coates et al. 1966) and monoclonal antibodies 
(Anderson et al. 1985) and later by gene sequencing (Collins et al. 1986; Johnson et al.
1987; Johnson and Collins 1988). RSV is an enveloped vims classified within the family 
Paramyxoviridae, genus Pneumovirus. The RSV genome is a non-segmented negative sense, 
single-stranded RNA molecule of approximately 15,200 nucleotides, which has 10 genes 
encoding for 11 distinct proteins. The proteins include two non-stmctural proteins, NS1 and 
NS2, which have been shown to antagonize interferon mediated antiviral responses (Cane 
and Pringle 1995). The nucleocapsid proteins are nucleoprotein (N) and phosphoprotein (P), 
essential for transcription, and the RNA polymerase (L). The vims has the matrix proteins M, 
M2-1 and M2-2 thought to be involved in viral assembly, transcription elongation and 
regulation of viral transcription, respectively. Three surface proteins are also encoded; small 
hydrophobic (SH) protein, glycoprotein (G) and Fusion (F) proteins. The role of the SH 
protein is not yet clear. The G protein is important in RSV attachment to cellular receptors 
(hence referred as the attachment protein) while F protein is the molecule responsible for the 
fusion of the vims and cell membranes and formation of a syncytium (Taylor et al. 1992). 
Both F and G proteins are major antigenic determinants and are involved in the acquisition of 
protective immunity against infection and disease (Piedra et al. 2003). The G protein has 
been shown to be more variable (about 47% variability in the amino acid sequences) 
compared to the F protein (20%) between the prototype RSV groups (Johnson et al. 1987).
There are several genotypes within each RSV group, distinguishable mainly by G gene 
nucleotide sequences, enhancing the antigenic variability of RSV to possibly allow re­
infections to occur (discussed below). Studies investigating the genetic diversity of RSV 
have primarily focused on the variable G gene as reviewed by Cane (Cane 2007) and Melero 
(Melero 2007). In the current study, the long ectodomain region of the RSV G gene was 
sequenced to identify genetic relatedness of viruses circulating in the community and 
specifically within households.
2.2.2 Transmission characteristics
RSV is transmitted by close direct contact between individuals or material contaminated with 
nasal secretions (fomites), rather than over longer distances (e.g. two metres) by aerosol (Hall 
and Douglas 1981). Large droplets, not small, are required for spread presumably because it 
is an enveloped virus and labile to desiccation. Vims survival varies in relation to the surface 
or material type on which it is found and has been shown to survive for up to 6 hours on non- 
porous surfaces, such as countertops (Hall et al. 1980). Nosocomial spread of infections can 
occur when hospital staff touch secretions or contaminated objects while caring for an 
infected infant (Hall et al. 1975). With contaminated hands, self-inoculation may occur by 
the inadvertent rubbing of the nose or eyes, the major portals of RSV entry (Hall et al. 1981). 
The propensity for infection seems to depend on the amount of RSV inoculum transmitted as 
reported in an experimental challenge study (Lee et al. 2004) and, to a large extent, on the 
susceptibility of the host, measured by the amount of neutralising antibody titres prior to 
inoculation (see section on RSV immunity below) (Hall et al. 1981; Lee et al. 2004). The 
fact that RSV spreads via close contact makes settings such as households and schools 
important in studying RSV transmission and delineating RSV epidemiology.
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2.2.3 Seasonality o f RSV
RSV circulation occurs periodically and in most places every year albeit with considerable 
variation of the peak months of the RSV outbreak. Studies in Birmingham, UK, reported 
RSV outbreaks peaking in December every year (Cane et al. 1994) like in other parts of 
Europe (Mlinaric-Galinovic et al. 1994). In North America, RSV outbreaks appear to peak in 
February (Felton et al. 2004). The pattern is different in Finland with RSV activity occurring 
every two years with minor peaks in April followed by a major peak in December (Waris 
1991). Recent studies in Croatia, have reported similar biennial cycle with one larger and one 
smaller RSV outbreak every 23-25 months (Mlinaric-Galinovic et al. 2008; Mlinaric- 
Galinovic et al. 2012). In the tropics most of the RSV epidemics occur annually peaking 
mainly between November and January (Reese and Marchette 1991; Bedoya et al. 1996; 
Chew etal. 1998; Weber et al. 1998; Chan and Goh 1999; Chan et al. 1999; Ahmed et al. 
2012). The factors influencing the heterogeneity in timing of the RSV seasons are unclear. In 
temperate countries epidemics appear to occur in winter while in tropics the association with 
meteorological factors is less clear. Studies in countries in Asia, Africa and South America 
have reported association of RSV outbreaks and the wet season. There is contradicting 
evidence of RSV occurring in dry seasons (Cherian et al. 1990; Bedoya et al. 1996; Chan et 
al. 1999). In a retrospective study of samples positive for RSV in Singapore carried out from 
1990 to 1994, the peaks were not associated with rainfall but with higher environmental 
temperature, lower relative humidity and higher maximal day-to-day temperature variation 
(Chew et al. 1998). A population-based surveillance of RSV in 1999 to 2001 among children 
younger than 5 years in Indonesia, South Africa, Nigeria and Mozambique using a 
standardised WHO protocol, reported peaking of RSV outbreak in rainy season in Indonesia 
and Mozambique while in Nigeria and South Africa RSV occurred primarily in the dry
season. The mechanism of the seasonal triggers of RSV in both temperate and tropical 
countries has been hypothesized to relate to changes in airway physiology, socio-behavioural 
patterns, and favourable conditions for the virus survival. In winter susceptible individuals 
crowd indoors and there is decreased protection in respiratory mucosa due to cooling of nasal 
passages. In the tropics, children tend to be kept indoors during rainy season, and the 
resultant crowding may also account for the increased transmission of RSV in this period. 
Others have suggested high humidity (in the wet season) may be favourable to viral survival 
by preventing drying and loss of infectivity of the virus (Hall and Douglas 1981). RSV is 
known to be a labile virus, and does not survive well under high temperatures which may 
explain the relationship with cooler weather. However, this trend was not observed in the 
Singapore study (Chew et al. 1998). Genetic variation of RSV viruses coupled with waning 
of RSV immunity and accumulation of susceptible individuals at the population level offer 
alternative explanations to the seasonal nature of RSV epidemics, as discussed in sections 
below.
2.2.4 Molecular epidemiology o f RSV
The seasonal occurrence of RSV is associated with considerable genetic variation of the 
circulating strains. Evidence from most of the longitudinal studies show both of the RSV 
groups co-circulate during the RSV outbreaks although in most epidemics one group 
predominates. Studies in different regions have identified varying but consistent patterns of 
circulation of RSV group A and B with sequential replacement of genotypes. In the 
Birmingham, UK, a cyclic triennial pattern in groups A and B was observed from 1989 to 
2000. Group A isolates were most commonly detected in eight epidemics with group B 
predominating every third year. Similar patterns have been observed elsewhere (Zlateva et al.
2007). In Finland, group dominance alternates every two years (Waris 1991). In general
16
group A genotypes have been found to predominate in most epidemics as has been observed 
in our settings (Figure 2.2). Multiples genotypes are detected in each epidemic with yearly 
replacement of the predominating genotype (Cane et al. 1999; Cane 2001; Roca et al. 2001; 
Seki et a l 2001; Zambon et a l 2001; Scott et a l 2006; Zlateva et a l 2007). Analysis of 
strain variability within epidemics has almost exclusively focused on isolates from 
hospitalised infants. However, studies comparing RSV variability in hospital with field 
isolates found similar viruses were circulating in the two populations (Zambon et a l 2001; 
Venter et a l 2002; Nokes et a l 2004; Scott et a l 2004). In South Africa, the same strain of 
RSV was found to cause both mild ARI and severe LRTI (Venter et a l 2002). These 
observations indicate inpatient surveillance of RSV could provide information on the 
epidemics in general. In our study, we used district hospital inpatient RSV surveillance to 
identify the start and end of the RSV epidemic in the community, thus enabling the timed 
focus of resources for active home follow up and sample collection to when the virus was 
circulating in the community.
As noted earlier the G gene is highly variable and is the target for most molecular 
epidemiology studies. The variations in the G gene present an opportunity to track RSV 
transmission and dissemination (Cane et al 1991; Cane 2007). A review on molecular 
evolution of RSV by Cane showed new RSV genotypes are continuously emerging but also 
some previously circulated ones have disappeared (Cane and Pringle 1995). The extreme of 
RSV evolution was demonstrated in the occurrence of a RSV group B genotype (referred to 
as BA variant) with a 60-nucleotide duplication in the variable region of the G gene. The BA 
variant was first observed in South America in 1999 (Trento et a l 2003). The variant which 
probably arose from a single mutation event has increasingly become the dominant group B 
variant worldwide in recent years (Zlateva et al 2005; Scott et al 2006; Trento et a l 2006;
Zlateva et al. 2007; Trento et al. 2010; Agoti et al. 2012). It is thus apparent when new 
strains occur, they can rapidly spread around the world. Another review by Cane et al showed 
very similar viruses circulate worldwide at the same time (Cane et al. 1992) and viruses 
isolated in geographically distant places and in different years may be more closely related 
genetically than viruses isolated in the same location in the same week (Cane et al. 1999).
The mechanism for the change of dominant strains each year is not yet established but may 
be influenced by the build up of immunological resistance in the community to successive 
epidemics of the same strain i.e. accumulation of herd immunity. Emergence of new variants 
might also play a role in occurrence of epidemics. Social networks including travelling 
patterns could help in the global dissemination of the viruses. At a local scale, understanding 
the transmission patterns of RSV in households, which represents the smallest social unit in 
the community with intense interactions, would provide valuable insight into the RSV spread.
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Figure 2.2: Seasonal variation of RSV groups A and B in children admitted to Kilifi District 
Hospital, Kenya, from January 2002 to December 2012
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2.2.5 RSV disease burden
RSV is associated with a wide spectrum of respiratory symptoms ranging from mild upper 
respiratory tract illness (URTI) such as common cold to severe LRTI, mainly pneumonia and 
bronchiolitis in younger children. Published pneumonia aetiology studies have identified 
RSV as the main viral cause of pneumonia in children (Forgie et al. 1991; Berkley et al. 
2010; Hammitt et al. 2012). In The Gambia, RSV was frequently detected among cases 
(49%) relative to the controls (19%) in a community study involving 90 cases of pneumonia 
in infants (<1 year old) and 43 age-matched community controls. The study involved a small 
number of cases in a restricted age group (<1 year) but other studies with bigger sample sizes 
have replicated these results as reviewed by Weber and colleagues (Weber et al. 1998). A 
pneumonia aetiology study in rural Kenya, detected RSV in 34% of the 760 severe and very 
severe pneumonia paediatric (<15 years) admissions and in 5 % of 56 healthy community 
controls using highly sensitive molecular techniques (Berkley et al. 2010). RSV was the only 
virus significantly associated with pneumonia admissions in children younger than 5 years 
(odds ratio, 12.5; 95% confidence interval, 3.1-51.5) in another recent study in the same 
Kenyan settings (Hammitt et al. 2012). The second Kenyan study employed a more rigorous 
study design and methods (Hammitt et al. 2012). The evidence taken together firmly implies 
that RSV is a major player in causing LRTI in children.
i) RSV infection and disease in children 
RSV is a highly contagious virus with infections occurring in the early months after birth. 
Birth cohort studies show approximately 60% of newborns are infected before the first 
birthday with approximately 20% of these infections being associated with symptoms of 
LRTI. Almost all children are infected by their third birthday. This was demonstrated in a 
classic study in Houston, Texas, where 125 newborns were actively followed at home from
birth to the age of 5 years with collection of nasal samples when symptoms of ARI were 
recognized (Glezen et al. 1986). The nasal samples were tested for RSV using viral culture.
In the Houston study, 69% of infants had RSV infection in the first year of life; of which a 
third developed LRTI. In the second year, 83% of children were infected and 16% were 
associated with LRTI. Even during the third and fourth years, a third to half of the children 
were infected, with LRTI occurring in a quarter of these infection (Glezen et al. 1986). 
Repeated infections were thus not uncommon and in some instances occurred within one year 
or less (Glezen et al. 1986). Another birth cohort in Kilifi, Kenya, reported a risk of -40% 
and 10% of primary and secondary RSV infections in infancy (Nokes et al. 2004). The risks 
were lower than those in the Houston family study perhaps due to differences in study 
methods and population. The Houston study used virus detection in culture and 4-fold rise in 
Neutralising antibodies in paired sera while the Kilifi study used immunofluorence antibody 
test (IFAT).
The incidence of RSV infection and disease in children is largely similar in both developed 
and developing countries. Two birth cohorts, one in the low-income urban families in the 
Cali, Colombia, and the other in rural Kilifi, reported a rate of RSV associated LRTI of 224 
and 154 per 1000 child-year (cy) in infants respectively (Borrero et al. 1990; Nokes et al.
2008). In the Kilifi birth cohort study the incidence of severe RSV disease in the community 
(-100/1000 cy) was approximately ten times that seen in the inpatient settings (~13/1000cy) 
suggesting that a considerable proportion of severe RSV cases within the community does 
not present in health facilities (Nokes et al. 2008). A finding that may be related to poor 
hospital access and health seeking behavior particularly in developing countries. The 
denominator-based studies reviewed in Table 2.1, show the incidence of RSV-LRTI to be 
consistently higher in infants relative to the older children (<5 years) in same populations
(Berman 1991; Weber et al. 2002; Djelantik et al. 2003; Robertson et al. 2004). There is 
considerable variation in reported incidences in different population settings ranging from 
9/1000cy in Western Gambia to 220/1000 cy in Cali, Columbia in infants and from 3/1000cy 
in Hong Kong, China, to 116/1000cy in Ibadan, Nigeria among the under five year olds. 
Differences in study design (community versus hospital surveillance), location (rural vs. 
urban), year of study, specimen collection method (nasopharyngeal aspirate versus nasal 
wash or nasal swab), methods of RSV detection (culture versus IF AT or molecular 
techniques), surveillance methods (active versus passive), definition of LRTI (mild vs. severe 
or very severe) among others, play a role in this variation (Nokes 2007).
Since 2002, we have conducted a continuous surveillance of RSV in the Kilifi district 
hospital (KDH) paediatric wards (Nokes et al. 2009). Children admitted with clinical features 
of WHO defined severe or very severe pneumonia or clinician’s diagnosis of LRTI are 
recruited and a nasal wash or NPS collected soon after admission. The samples are tested for 
RSV by IF AT and real time multiplex polymerase chain reaction (M-PCR) from 2007 
distinguishing the RSV groups in circulation. Figure 2.3 shows the age distribution of the all 
the RSV-associated admissions from January 2002 to December 2012 showing an association 
of burden of severe RSV disease and age. Children aged less than 3 months experience the 
highest burden of severe RSV disease but an appreciable burden in the older age groups 
exists. Approximately 64% of severe RSV-LRTI has been in children aged 3 months or more 
and 43% in children aged 6 months or more (Nokes et al. 2009) (plus unpublished data).
Globally, 22% of all episodes of acute LRTI among the under five year olds are associated
with RSV translating to about 34 million episodes of RSV-associated LRTI per year and 3
million episodes requiring hospital admission (Nair et al. 2010). The burden of RSV-LRTI in
children is thus substantial and effective RSV vaccines could be the next ‘frontier’, after
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introduction of pneumococcal conjugate vaccines, with great potential of reducing the LRTI 
morbidity and mortality, worldwide.
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children under 5 years old to KDH paediatric wards from January 2002 to December 2012
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ii) RSV infections and disease in adults 
RSV infection data in adults is limited with a few studies in developing countries (Karstaedt 
et al 2009; Olsen et al 2010; Feikin et a l 2012). In Western Kenya, the incidence for RSV- 
associated ARI was 0.98 per 100 person-years among HIV positive adults (>18 years) and 
0.13 per 100 person-years in HIV negative adults. A study in South Africa did not find an 
excess of hospitalisation or mortality in adults during RSV seasons (Karstaedt et al 2009). In 
developed countries, RSV infections are not uncommon in adults particularly in those with 
cardiac, pulmonary and immunodeficiency diseases and the elderly (Falsey and Walsh 2000). 
Outbreaks of RSV in long-term care facilities and studies in hospitalised adults have 
suggested RSV may be important cause of illness in community-dwelling elderly people 
(Zambon et a l 2001). A prospective cohort evaluated all respiratory illnesses using culture, 
serology and RT-PCR in healthy elderly patients and high-risk adults (those with chronic 
heart and lung disease) and inpatients hospitalized with acute cardiopulmonary conditions 
during 4 consecutive winters. The annual prevalence of RSV infections was 3 - 7 %  and 4 -  
10% among the healthy elderly patients and the high-risk adults, respectively. Based on 
discharge diagnoses, RSV infection accounted for 11% of admissions with pneumonia, 11% 
with chronic obstructive pulmonary disease, 5% with congestive heart failure, and 7% with 
asthma. The authors estimated RSV infection would approximately account to 177,000 and 
14,000 admissions and deaths annually, respectively, in the US. Thompson et al. have 
estimated that RSV accounts for approximately 10,000 deaths annually in the United States 
in persons over the age of 65 years using mathematical models linking viral activity in 
children with hospitalization and death in adults (Thompson et a l 2003). RSV related 
outpatient visits made by elderly adults for respiratory illnesses have been reported to be high 
during winter; up to 18% in the UK (Zambon et a l 2001). The burden of RSV disease in this 
age group cannot be disregarded as it is associated with considerable resource utilization. It is
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estimated hospitalization costs would exceed $1 billion and outpatient costs would be also 
substantial. RSV vaccines targeting this particular age group are thus warranted.
in) RSV mortality
As highlighted earlier on, data is scarce on RSV associated mortality. The available data 
suggest mortality resulting from RSV is low with most studies reporting case fatality rates 
(CFR) of zero (range, 0 -  9%) (Weber et al. 1998; Stensballe et al. 2003; Nokes 2007). 
However, the mortality appears higher among children with underlying medical conditions 
(CFR of 3 -  5%) such as those with chronic lung disease, congenital heart disease and 
immune deficiency (Wang et al. 1995) and in developing countries (CFR of up to 9%) 
(Stensballe et al. 2003). Studies from developed countries report a CFR of less than 0.1%, 
reviewed in Stensballe et al (Stensballe et al. 2003). It is possible the reported RSV mortality 
is under-estimated in low income countries, since it has been reported that most LRTI 
associated deaths occur before a nasal specimen can be collected (Djelantik et al. 2003;
Nokes et al. 2009) or outside the clinical setting at home where the cause of death may not be 
ascertained (Moisi et al. 2011).
2.3 Immunity to RSV infection and disease
RSV infection elicits both humoral and cellular immune responses. The role of cellular
responses appears to be in enabling viral clearance during infection while antibodies response
are associated with resistance to infection (Lee et al. 2004) and disease (Piedra et al. 2003).
The Lee et al study showed a correlation between the level of pre-challenge neutralizing
antibody titer and risk of a successful infection (Figure 2.4). Young adults with low
neutralizing antibody titres had a higher risk of infection compared to those with high titers
(Lee, Walsh et al. 2004). RSV infection induces antibodies against a variety of viral proteins
but it is only those that are against the F and G proteins that have been shown to be
neutralizing in vitro and protective in vivo (Taylor et al. 1984; Walsh et al. 1984; Connors et
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al. 1991). Antibodies against the F protein are strongly cross-reactive against the 
heterologous RSV group (Hendry et al. 1988). However, those against the G protein show 
limited cross-reactivity between the two RSV groups (Hendry et al. 1988; Scott et al. 2007; 
Taylor 2007). The RSV G gene is characterized by the accumulation of amino acid changes 
at estimated rate of 0.25% per year for the whole molecule (Cane and Pringle 1995). In 
addition, the attachment protein has the highest ratio of nonsynonymous-to-synonymous 
nucleotide mutations (Cane and Pringle 1995) and number of positively selected sites of all 
RSV genes, suggesting these changes and sites might be immune driven (Botosso et al. 2009). 
A recent study in Kilifi, Kenya investigated the RSV group-specific neutralizing antibody 
responses to both contemporary and historical test viruses (Sande et al. 2013). The results 
showed that individuals had stronger neutralizing antibody responses to test viruses of the 
same infecting group (homologous seroconversion of 40 - 50%) than to viruses of the 
alternative group (heterologous seroconversion of 8 -  12.5%). The group-specific 
neutralizing response was not lost even after significant genetic changes within the RSV 
groups. The 60-nucleotide duplication (BA variant), which was thought to be a phenotype 
resistant to previous host group-specific immunity due to its increased global transmission 
(Trento et al. 2010), did not confer an ability to escape neutralizing responses to previous 
non-BA viruses in vitro (Sande et al. 2013). Together these data imply that the observed 
cyclic alternation in circulation of RSV group A and B could be due to population-level 
group-specific immunity and the effect of future RSV vaccines at reducing the infection 
would be enhanced if they contain representative strains from both group A and B.
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Figure 2.4: The relationship between pre-challenge RSV neutralizing antibody titres in serum 
and risk of infection. The graph shows the cumulative number of subjects at each neutralizing 
antibody titre who shed RSV or were infected. Infection detected by viral culture or a ^four­
fold response in serum antibody (adapted from Lee et al (Lee et al. 2004))
2.4 Subclinical RSV infections
Evidence from experimental challenge studies in adults and epidemiological studies
demonstrate subclinical RSV infections are common in older populations. Results of an
experimental study using RSV A2 strain in young adult volunteers, reported a greater risk of
infection in individuals administered with a high dose of RSV inoculum compared to those
with low dose (57% vs. 36%) with asymptomatic infections occurring in 63% and 40 % of
the infections, respectively (Lee et al. 2004). The authors observed that infected individuals
had statistically lower serum neutralising antibody titres (9.5 log2 vs. 10.6, p=0.04) than
uninfected individuals (Table 2.2). In another experimental infection study involving 13 adult
volunteers, with low neutralising antibody titres, 12 had detectable viral shedding and
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respiratory illness when administered a high dose of RSV A2 inoculum (Lee et al. 2004). The 
prevalence of symptomatic infection is high in families exposed to RSV, which could be due 
to exposure to large inoculum from close social contacts within the household (Hall et al 
1976). In the Hall family study, only two of the 39 infected individuals had asymptomatic 
infection (Hall et al. 1976). Crowcroft et al reported a high prevalence of asymptomatic of 
48% and 49% in siblings and parents, respectively, of infants admitted to intensive care units 
with RSV (Crowcroft et al. 1999). The Hall et al study (Hall et al. 1976) might have missed 
subclinical infection particular in older children and adults. In general, it appears subclinical 
RSV infections are likely in two scenarios: First, when individuals are exposed to low viral 
load of RSV such as in inter-family contacts as for the case of introducers of RSV into the 
households (Hall et al. 1976). Second, among individuals with high levels of neutralizing 
antibodies such as older children and adults (Lee et al. 2004). In order to identify chains of 
transmission in households it would be necessary to collect samples regardless of symptoms 
and test using very sensitive molecular based techniques to minimize the probability of 
missing infection episodes. The risk of asymptomatic infection, by age, is estimated in the 
present study. This is of interest as it has implications on the conduct and interpretation of 
RSV epidemiological studies. If individuals change their behaviour as a result of symptoms 
e.g. reducing their contacts, the period of shedding before symptoms appear or prevalence of 
asymptomatic infection is likely to have a role in transmission of RSV in the population.
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2.5 RSV reinfections
The Houston family study and other community studies report RSV episodes in older 
children and adults with history of previous infections (Berglund 1967; Monto and Cavallaro 
1971; Cooney et al 1975; Hall et a l 1976; Glezen et a l 1986; Nokes et al 2008; Agoti et al 
2012). In the Houston study, 76% of the young children infected in the first year of life were 
reinfected in the second year and overall 53% (98/185) of the children had a reinfection in the 
follow up period (Glezen et a l 1986). Hall et al reported substantial attack rates in all age 
groups; 17% in adults compared to 29% in infants (Hall et al 1976). Frequent and potential 
ease of repeat infections even with the same viral strain has been demonstrated in a challenge 
study in adults (Hall et a l 1991). In the study, over 70% of the adults were re-infected two 
times or more after a natural infection (Hall et a l 1991). Additional studies have shown RSV 
to be an important cause of respiratory tract infection in adults and especially in the elderly 
(Falsey and Walsh 2000). The mechanism for repeat infections is perhaps due to waning or 
partial immunity (Ohuma et a l 2012) and/or due to antigenic variation of the virus (Cane 
2007; Agoti et a l 2012). Primary infections and, independently, young age have been 
associated with higher risk of severe disease relative to re-infections and are more likely to 
lead to hospital admission (Henderson et a l 1979; Glezen et a l 1986; Nokes et a l 2004; 
Nokes et a l 2008). However, re-infections are likely to constitute the bulk of RSV infections 
during the annual epidemics observed worldwide. It follows that re-infections probably play a 
major role in the overall transmission of RSV in the population. The importance of RSV 
infected older children and adults, many experiencing repeat infection, in the transmission of 
virus to infants may be considerable and needs to be quantified. Estimates are required of the 
incidence of infection in these age groups, the level and duration of viral shedding.
Probability of reinfections occurring within the same epidemic and characterisation of the re-
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infecting virus will be assessed in the current study. It would be important to assess whether 
there is any preponderance for reinfection with different genotypes.
2.6 RSV shedding
Current understanding on the patterns of RSV shedding following natural infections arise 
from studies in developed countries (Hall et al 1975; Hall et a l 1975; Hall et a l 1976; Hall 
et al 1976; Hall 1977; Frank et al 1981; Waris et a l 1992; Hall et a l 2001) with only one 
exception (Okiro et a l 2010). Table 2.3 presents a summary of the studies reporting duration 
of RSV shedding. The data suggest durations of RSV shedding are of the order of days. 
However, the duration seems to vary depending on individual characteristics such as age and 
disease severity (Hall et a l 1976). A study involving 23 children hospitalized with 
respiratory illness (18 pneumonia, 5 URTI) followed until shedding ceased, reported an 
average duration of RSV shedding of 6.7 days (range 1-21  days) (Hall et a l 1976). In this 
study shedding duration did not correlate with age but with disease severity (Hall et a l 1976). 
Children with LRTI shed for a significantly longer period than those with URTI (mean 
duration of 8.4 days vs. 1.5 days). Other markers of disease severity such as pulmonary 
consolidation and the presence of underlying cardiopulmonary disease were also significantly 
associated with longer durations of shedding (mean 11.5 vs. 5.2 days and 9.9 vs. 5.4 days, 
respectively) (Hall et a l 1976). This was a hospital-based study with small samples sizes to 
be very sure of the differences observed and likely to provide biased estimates towards 
infections causing severe disease and/or of younger age groups. Inpatient studies in general 
suffer from additional limitations related to the observation that RSV shedding starts prior to 
clinical symptoms (Frank et al 1981) and continues in most cases after clinical recovery 
(Hall et a l 1975; Hall et a l 1976). It is thus plausible the actual durations are longer for the 
hospitalized patients than those reported. Community studies offer best estimates. One such 
study following 36 families in Rochester, United States of America, through home visits by a
nurse during two months of a single RSV epidemic, reported an average duration of 3.4 -7.4 
days (range 1 -  36 days) in 39 otherwise healthy children (Hall et al. 1976). Young age, a 
risk factor for severe RSV disease (DeVincenzo 2005), was correlated with longer shedding 
duration i.e. children aged less than 2 years had a longer mean shedding duration of 9 days 
compared to 1.6 days for those 16 years and older (Hall et al. 1976). A recent community 
study involving 193 RSV infected children aged less than 15 years from 151 rural Kenyan 
families, recorded a mean duration of 4.5 (range 1 -14)  days (Okiro et a l 2010). The 
duration of shedding was not significantly associated with gender, infection severity and age 
but was reduced in children with a prior history of infection: 4.0 days in children with prior 
history of infection compared to 5.1 days in those never infected (Okiro et al. 2010). In the 
Kenyan study, follow up to determine the shedding duration started when an individual was 
identified as RSV positive by immunofluorescent antibody test (IFAT) in nasal washing 
collected upon signs of ARI. The study design again suffered from bias through possible 
shedding prior to illness and from excluding asymptomatic individuals. Studies on viral 
shedding in adults are few. Observations from a study in the USA, reported a mean duration 
of RSV shedding among 118 infected young adults of 3.9 (range 1 - 7 )  days. Shedding was 
detected for less than a week in 93% of the infected adults (Hall et al. 2001).
Prolonged shedding of RSV does occur. In the Rochester family study 5 -  10% of individuals 
shed RSV for more than two weeks and periods of shedding of one month or more have been 
observed (Hall et al. 1976; Waris et al. 1992). In South Africa, RSV cases were observed 
during the inter-epidemic period and this was ascribed to the prolonged shedding in the HIV 
infected individuals (Madhi et al. 2000). Unbiased estimation of the duration of RSV 
shedding by age, disease severity, infecting group, sex, history of prior exposure, is of 
importance to the understanding of RSV transmission and persistence in the community, and 
is focus for the current study.
2.7 Effect of HIV infection on RSV epidemiology
There are limited studies assessing the effect of HIV status on RSV epidemiology. Studies in 
children with immunodeficiency from other causes in the late 1970s reported a variation in 
the pattern of shedding (Fishaut et al. 1980; Hall et a l 1986). In one such study, 
immunocompromised children shed RSV for >2 times longer and for significantly greater 
mean peak titers than their normal age-matched controls (Hall et al. 1986). The mechanism 
of the increased duration and amount of RSV shed is not clearly understood. However, there 
is evidence suggesting that humoral and moreso cell-mediated immunity, which is depressed 
in immunocompromised children, is key in viral clearance (Fishaut et al. 1980). Individuals 
with HIV infection have poor cell mediated response against viral infections and likely to 
have a longer duration of RSV shedding compared to the HIV negative counterparts. The 
impact of HIV infection on the duration and amount of viral load shed has never been 
evaluated. However, there is indirect evidence from South Africa showing this could differ 
between HIV infected and non-infected children with a potential of altering the transmission 
dynamics of RSV infection especially in children. In South Africa, it was reported that (i) 
HIV infection was associated with 2.5 times greater incidence of RSV admissions (Madhi et 
al. 2001), (iii) the risk for developing RSV-LRTI persists beyond first 6  months of life among 
HIV infected children (Madhi et al. 2001) and (iii) RSV infection occur throughout the year 
in HIV infected children (Madhi et al. 2000). In the current study, the HIV status was not 
determined among the study infants due to ethical and logistical reasons. The HIV prevalence 
in coastal Kenya has been estimated to be at 4.2% according the recent Kenya Demographic 
Health Survey (Kenya National Bureau of Statistics 2010).
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2.8 RSV treatment
Available therapies for the treatment of RSV infections are limited to ribavirin, intravenous 
immunoglobulin, and palivizumab. Oxygen supplementation, administration of intravenous 
fluids and occasionally mechanical ventilation are offered to the severely ill as supportive 
therapies (Simoes 1999). Though approved by the US Food and Drug Association, Ribavirin 
use has remained controversial with the American Academy of Pediatrics recommending 
against its routine use (American Academy of Pediatrics 2012). Randomized controlled 
clinical trials comparing ribavirin with placebo in children with RSV-LRTI have yielded 
mixed results. Some studies have demonstrated improvement in illness severity, shortened 
duration of mechanical ventilation, oxygen supplementation and hospitalisation, and 
decreased viral shedding (Hall et a l 1983; Taber et a l 1983; Hall et a l 1985; Rodriguez and 
Parrott 1987; Smith et a l 1991), unlike others (Meert et a l 1994; Moler et a l 1996; Law et 
al 1997; Guerguerian et a l 1999). A Cochrane review of randomized trials comparing 
aerosolised ribavirin with placebo in infants and children with RSV-associated LRTI found 
that trials of ribavirin were small and lacked adequate power to offer reliable estimates of the 
effects (Ventre and Randolph 2007).
Passive immunization with RSV hyperimmune immunoglobulin or Palivizumab, a 
neutralizing humanized mouse monoclonal antibody directed against the F protein is the 
alternative in high-risk infants such as those premature, with bronchopulmunary dysplasia or 
with congenital heart disease (Baker and Ryan 1999; DeVincenzo et a l 2003). The 
prophylactic treatment is administered in the months preceding the start of the RSV season 
(Hemming et a l 1987; Simoes et al 1998; Singleton et a l 2006). Despite the observed 
merits of Palivizumab, high costs have impeded its widespread use. There are no studies 
looking at the effect of the two approved treatment options on the transmission dynamics of
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RSV in the community settings. Ribavirin and Palivizumab are not available for use in low- 
income settings.
2.9 RSV vaccines
The profile of severe RSV disease suggests a vaccine is primarily required in the paediatric 
population and high-risk adults such as the elderly and those with chronic pulmonary or 
cardiac disease. An effective vaccine has, however, remained elusive despite over 50 years of 
relentless research (Collins and Murphy 2007). The risk of severe RSV disease is highest in 
infants under 6  months of age and consequently vaccine development in the past has 
principally been targeted to protect infants in the first few weeks of life. This approach, 
however, has had several major obstacles: First, the young infants have a relatively immature 
immune system compared to older children and adults hence are poor responders to vaccine 
immunogens. Second, the presence of maternal RSV-specific antibodies in newborn seems to 
interfere with immune responses elicited by the administered vaccines (Murphy et a l 1988; 
Crowe 2001). It is fascinating that RSV infections occur in young infants despite the presence 
of maternally derived passive antibodies (Ochola et al. 2009). Third, infants are extremely 
susceptible to reaction against even attenuated viruses, used in live-attenuated vaccines 
(LAV), thus complicating vaccine production regarding balancing between attenuation and 
immunogenicity (Wright et a l 2000; Karron et al 2005). A paradoxical observation of repeat 
infections by same or similar strains throughout life raises an additional challenge in vaccine 
development. It appears natural infection confers incomplete immunity to subsequent 
infections and antigenic variation appears to play only a minor role (Agoti et a l 2012). 
Following infection, protection against re-infection has been estimated to be partial (around 
70%) lasting for up to 6  months (Ohuma et al 2012). This protection seems to be dependent 
on the level of the neutralising antibodies which appear to decay after infection to pre­
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infection levels after 3 months {Sande, 2013 #8 6 8 }. Developing vaccines to offer a superior 
protection than a natural infection continues to be a hindrance. Heightened safety concerns 
following the failure of the first RSV vaccine, a formalin-inactivated RSV (FI-RSV), is a 
further obstacle to paediatric vaccine development. The vaccine failed to protect young 
seronegative infants against RSV disease. Vaccine recipients experienced enhanced disease 
after the wild-type RSV infection, resulting in two deaths. The mechanism of the enhanced 
disease is still not fully elucidated. Lastly, existence of multiple RSV antigenic variants also 
hampers vaccine development efforts (Durbin and Karron 2003; Nokes and Cane 2008; 
Medley and Nokes 2009).
During the past decades, several candidate vaccines have undergone clinical trials in humans, 
reviewed in Table 2.4. These include LAV for intranasal use such as the cold-passaged, 
temperature sensitive (cpts) RSV vaccine (Wright et al. 2007), and live RSV/PIV3 
chimeric virus vaccine candidate (Gomez et a l 2009; Bernstein et al. 2012); subunit RSV 
vaccines for intramuscular administration such as Purified F protein (Munoz et al. 2003; 
Piedra et al. 2003), a purified fragment of the RSV G protein fused to albumin-binding 
domain of streptococcal protein G (BBG2Na) (Power et al. 2001), subunit RSV-A vaccine 
containing purified F, G, M proteins (Falsey et al. 2008; Langley et al. 2009) and RSV 
nanoparticle vaccine candidate (Glenn et al. 2013). Other RSV vaccines in early stages of 
development are epitope based vaccines (Anderson et al. 2010) and live vaccine virus 
attenuated by deletion of non-essential genes or the G-protein (Teng et al. 2000; Jin et al. 
2003; Widjojoatmodjo et al. 2010).
Of the vaccines in development, one LAV is promising. This recombinant LAV is well 
tolerated and immunogenic in young seronegative children aged over 6  months old (Karron et
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al. 2005). However, in addition to targeting the young infants, alternative strategies for 
delivery of the vaccine require consideration (Anderson et al. 2013). First, by targeting older 
children ( 6  -  24 months) who are still at risk of severe disease and probably play a role in 
spread of the virus in households. Second, to target pregnant women by a maternal vaccine 
(Munoz et al. 2003) in order to protect newborns by passive placental transfer of antibodies 
and possibly block mother-infant transmissions. Lastly, target the elderly (Falsey et al. 2008) 
and high-risk adults with aim of reducing the disease severity. Deciding on the best strategy 
or strategies will depend on our further understanding of transmission patterns of the virus in 
the community. In particular, identifying the groups (e.g. older siblings, mothers or other 
family members) that transmit RSV to infants for possible targeted immunization is essential. 
The current study aims to fill this gap and quantify the relative contribution of these groups in 
RSV spread within household. It is plausible that blocking transmission in the household or 
reducing the amount of virus circulating in the community can indirectly protect the young 
infant ( < 6  months of age). However, to assess the impact of this strategy it is necessary to 
quantify who acquires infection from whom.
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2.10 Who contacts whom and who infects whom
RSV is transmitted through large nasal droplets and fomites, and has a short survival time in 
the environment. This suggests that close contact is important for effective transmission (Hall 
et al 1978). Social interaction patterns (contacts and mixing patterns among individuals) thus 
have a direct impact on transmission dynamics of RSV. This underlies the growing interest in 
describing and quantifying contacts that can lead to infection spread (Edmunds et al 1997; 
Edmunds et a l 2006; Mossong et al 2008; Read et a l 2008; Vynnycky et a l 2008; Zagheni 
et al 2008). The use of contact data in transmission dynamics modelling requires the 
inference of the transmission probability following contact -  which is a serious obstacle due 
to its considerable uncertainty. Longitudinal studies of infection and contact can estimate this 
transmission probability more directly (Melegaro et a l 2004).
It is plausible social contexts with high contact rates such as households and schools would 
provide environments of disproportionate importance for infection transmission. Family 
studies indicate the importance of household size and school age siblings as risk factors of 
RSV infection in infants (Hall et a l 1976; Okiro 2007). Various studies indicate RSV 
infection is frequently introduced to the home by siblings, resulting in high secondary attack 
rates within households (Berglund 1967; Hall et a l 1976; Okiro 2007) -  although a recent 
study implicated the young infants (Crowcroft et a l 2008). Direct evidence of mother-to- 
child infection has been reported in one study from Guinea Bissau (Stensballe et a l 2004). It 
remains, however, that patterns of transmission, so important to determine the influence of 
infection (or control) in one age group on other groups, are poorly defined and will provide a 
focus for the present study.
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2.11 Household studies
Households have been a focus of epidemiological studies on spread of infectious diseases in 
the past (Longini et al. 1982; Viboud et al. 2004) and are important in transmission of 
respiratory viruses due to factors alluded to in the previous sections. Improved understanding 
of household transmission may inform on the merits of targeted control strategies. For 
example, investigation of who introduces infection into the household, and who infects the 
infant, could identify key groups for vaccination such as elder and school age siblings. Data 
is scarce on intra-family spread of RSV and other viral respiratory infections especially in 
developing countries. Of the few studies undertaken, most were conducted in 1960s - 70s in 
developed countries as shown in Table 2.5. The classic family study on RSV spread recruited 
36 US families for intensive surveillance over two months in one RSV season, with repeated 
nasal sampling every 3-4 days regardless of illness (Hall et al. 1976). The authors reported an 
appreciable secondary attack rate within the family of 27%, rising to 45% in infants. The risk 
of infection was high across all ages in the family: in young children (1-5 years), older 
children ( 5 -1 6  years) and adults (>17 years) the attack rate was 27%, 19% and 17%, 
respectively. The attack rate was 29% in infants. The proportion of infected older children 
(43%) and adults (38%) in RSV-exposed families was comparable to young children (46%). 
These data together with corresponding secondary attack rates of 21% and 33% suggested 
older children and adults play a role in the RSV spread within families. However, this study 
had several limitations. First it was initiated after the start of the annual RSV epidemic and 
hence some families might have experienced the infection before the study started. Second, it 
covered a short period of the RSV season: it is possible they missed a number of infections 
occurring before or after the study period. The nasal wash or throat samples were screened 
using viral culture which is reported to be less sensitive compared to molecular methods
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(Falsey et al. 2003). Lastly, the study was carried out in the US with demographic features 
differing from those characteristics of low-income countries such as Kenya. For instance the 
mean household occupancy was lower compared to rural Kenya (3.5 members versus 8  
members in Kilifi, Kenya) (Kenya National Bureau of Statistics 2010). Therefore, it can be 
asserted that there is need for a longer study covering a full RSV season in a developing 
country setting with frequent regular nasopharyngeal swab collections regardless of 
symptoms from all household members and tested using sensitive molecular techniques. The 
success of such a study will be intimately linked with the acceptability of the specimen 
collection method in the study population.
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2.12 RSV diagnosis
2.12.1 Specimen type
Nasopharyngeal aspirate and nasal wash (NW) has been the preferred specimen for RSV 
diagnosis but deep nasopharyngeal specimens collected using flocked swabs have been 
shown to be a good alternative (Chan et al. 2008; Munywoki et al. 2011). Nasopharyngeal 
flocked swabs (NPS) are easier to collect, standardize across age groups and acceptable in a 
wider range of settings than aspiration or nasal washing. Prior to the present study, we 
conducted a study to assess the diagnostic performance of NPS relative to NW in outpatient 
settings (Pingilikani Health Centre in Kilifi District, Kenya) recruiting children presenting 
with clinical features of URTI such as runny/blocked nose and/or cough, or difficulty in 
breathing. Using real time M-PCR (the assay used in the current study, see Chapter 3 for 
details), we found NPS was not inferior to NW in detecting RSV and other respiratory 
viruses (Table 2.6) (Munywoki et al. 2011). However, the mean cycle threshold (Ct) values 
in detection of RSV were significantly lower (an indication of higher viral yield) compared to 
NW (P values <0.001. Use of M-PCR increased the prevalence of RSV detection from 14% 
(by IF AT) to 22%, an indicator of additional benefit of using molecular techniques. In terms 
of acceptance, most caretakers (60%) and participants (72%) preferred NPS method 
compared to the NW (Munywoki et al. 2011). However, for longer-term studies requiring 
frequent sample collection, a less invasive specimen such as a pemasal swab or oral fluid 
(OF) will be required.
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Table 2.6: Relative sensitivity of NW and NPS in detection of respiratory viruses using real­
time multiplex-PCR among 299 Kenya children visiting outpatient settings with ARI
Relative sensitivity (95% C l1)
Viruses NW NPS P value2
Rhinovirus 73.4 (62.2-82.7) 89.9 (81.0-95.5) 0.024
RSV 87.8 (78.2-94.3) 94.6 (86.7-98.5) 0.146
RSV A 88.2 (72.5-96.7) 88.2 (72.5-96.7) 1
RSV B 87.5 (73.2-95.8) 100 (91.1-100) 0.063
PIV 86.5 (71.2-95.5) 81.1 (64.8-92.0) 1
Adenovirus 45.5(24.4-67.8) 86.4 (65.1-97.1) 0.035
Corona virus 86.4 (65.1-97.1) 86.4 (65.1-97.1) 1
hMPV 86.7 (59.5-98.3) 93.3 (68.1 -99.8) 1
Any virus detection4 79,2(73.6-84.1) 89.6(85.1-93.1) 0.0043
Key: 1, one-sided 97.5% Cl reported i f  sensitivity was 100%; 2, Exact McNemar’s 
significance probability values comparing sensitivities for NW and NPS. NPS, 
nasopharyngeal flocked swab; NW, nasal wash; RSV, respiratory syncytial virus; PIV, 
parainfluenza virus 1,2,3 & 4; hMPV, human metapneumovirus; Cl: confidence interval. 
Table adapted from Munywoki et al (Munywoki et al. 2011))
2.12.2 Oralfluid as an alternative specimen for RSV detection
RSV specific-antibody measurements in sequential sera have previously been shown to be a 
useful supplement to virus detection methods in identifying infection (Hall et al. 1976; 
Henderson et al. 1979; Glezen et al. 1986). Okiro et al (Okiro et al. 2008) evaluated the use 
of oral-fluid (OF) samples in replacement of serum, finding that RSV specific IgG antibody 
profiles in OF closely matched those in sequential paired serum samples. However, RSV 
antibody levels change rapidly and weekly sampling would be ideal to support temporal
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resolution of infections (Okiro et al. 2008). There is preliminary evidence to indicate 
reasonable potential for OF samples to detect viral infections using RT-PCR methods, though 
with lower sensitivity (~70%) relative to nasopharyngeal specimens (von Linstow et al. 2006; 
Robinson et al. 2008). The OF method is subject of further investigation in this study 
particularly as possible alternative in detection of RSV using either ELISA or M-PCR.
2.12.3 Real time multiplex PCR
Molecular methods are becoming more widely used for the detection of respiratory 
pathogens, in part because of their superior sensitivity, rapid turnaround time, and ability to 
identify pathogens that are difficult to culture. Over the years, PCR has been the dominant 
amplification method. However, recently, modifications of this technology have emerged, 
some of which allow for the rapid detection of multiple pathogens in a single test, like the 
proposed multiplex PCR. The multiplex PCR is still challenging because amplification 
conditions for multiple targets are often incompatible and the high concentration of primers 
typically yields elevated background readings and reduced amplification efficiency. It is 
therefore important to ensure that a multiplex real-time PCR would not only be cost effective, 
but also sensitive enough to detect pathogens in multiple infections. Using the samples from 
the Pingilikani study, we validated the assay used in this study (details provided on the 
methods Chapter).
2.13 Other respiratory viruses
The advent of molecular diagnostics for a broad range of respiratory viruses has enhanced the 
study of virus epidemiology due to increased sensitivity and range of pathogens detectable 
over traditional methods. In the family setting, screening for viruses with modes and patterns 
of transmission similar to RSV would increase the capacity of the proposed study to identify
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household spread and hence improve the definition and quantification of WAIFW for a given 
sample size. Such data in combination with data on rates of contacts (collected in parallel 
contact studies -  details not contained in this report) is key to validating the use of contact 
pattern data in predicting the possible spread of emerging viruses (Mossong et al. 2008).
In Kilifi District Hospital setting, we have investigated the occurrence of 13 respiratory 
viruses in nasal specimens collected from 760 severe and very severe pneumonia paediatric 
admissions throughout 2007 (Berkley et al. 2010). RSV was detected in 34% of cases (and 
5% of 56 well controls) using real-time M-PCR, compared with 21% of cases using 
immunofluorescence. At least one virus was present in 56% of cases, with peak occurrence in 
the months of January-March and November-December, coincident with peak pneumonia 
admissions. Although longer-term surveillance is required to fully define seasonal trends, we 
found co-occurrence temporally with RSV of hMPV as previously identified by van den 
Hoogen et al (van den Hoogen et al. 2003), PIV3 (in previous studies not always co- 
circulating) and some coronaviruses (though all at much lower frequency). As an important 
respiratory pathogen, rhinovirus has elsewhere been reported to be prevalent throughout 
much of the year and not uncommonly co-circulating with RSV (Phillips et al. 1990; Monto 
2002; Souza et al. 2003; Kusel et al. 2006).
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Figure 2.5: Distribution of the detected viruses in 426 children admitted with viral associated 
severe or very severe pneumonia to Kilifi District Hospital in 2007. RSV, respiratory 
syncytial virus; PIV, parainfluenza; Flu, influenza; HMPV, human metapneumovirus 
(adapted from Berkley et al (Berkley et al. 2010).
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CHAPTER THREE
3 Materials and Methods
3.1 Introduction
Epidemiological studies in the past have identified households/families as an important 
element in the spread of infectious disease in the community (Fox and Hall 1971; Longini et 
al. 1982; Cauchemez et a l 2009). Members of the same household are thought to have close 
contacts facilitating spread. Households are also potential social units for delivery of targeted 
interventions and with the growing interest on alternative approaches in prevention and 
control of RSV infections and disease, studies in these social units will be informative (Nokes 
and Cane 2008; Anderson et al. 2013). Improved understanding of RSV epidemiology and 
transmission dynamics in the community should thus involve detailed studies of RSV 
infection and spread in the households. In particular, there is need for a study to establish 
who introduces RSV into the household and infects the vulnerable young infant by 
delineating the chains of transmission within the household. Such a study would require 
identification of most (if not all) infection chains within the household. In order to identify all 
infections, frequent sampling even in absence of symptoms from all the household members 
and screening the samples with sensitive detection techniques is necessary. Given the 
intensity of such a study, a careful engagement with the local community at all levels and 
stages of the study would be mandatory.
Previous studies investigating the spread of RSV in families have had several limitations as 
highlighted in Chapter 2. We designed our study with a view of mitigating most of these 
limitations. Two studies were pivotal in designing the current study: a family study in the US 
and another one in Kenya. The family study in Rochester, US, recruited 36 families for
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intensive surveillance over two months during the peak of RSV season, with repeated nasal 
sampling every 3-4 days regardless of illness (Hall et a l 1976). The nasal samples were 
inoculated into viral cultures for detection of RSV. The authors reported most individuals 
were shedding the virus at the start of sampling restraining the ability to identify who 
introduces the infection into the families. This pointed to a need to have a clear track of when 
RSV begins and ends in the community to enable sampling over the epidemic period. 
Molecular techniques, which are highly sensitive for virus detections, are now available.
The other study was a family study on RSV transmission in Kilifi, Kenya (Okiro 2007). The 
study conducted by Okiro et al aimed at investigating the risk factors of RSV spread and 
severity. Its methodology, however, had limitations for evaluating who acquires infection 
from whom (WAIFW) in the household (Okiro 2007). Home visits were conducted once-a- 
week with nasal washings (NW) collected only when symptoms of acute respiratory illness 
(ARI) were reported. Screening was by immunofluorescence antigen test (IFAT), which is 
less sensitive than molecular methods (Casiano-Colon et al. 2003; Munywoki et a l 2011). 
Acceptance of the NW method in older children and especially in adults was poor 
highlighting the need for search of widely acceptable specimen collection methods.
An alternative nasal specimen collection method increasingly used in viral diagnostics was 
the nasopharyngeal-flocked swab (NPS) (Chan et a l 2008). We conducted a study to 
evaluate the diagnostic performance and acceptability of the NPS against NW in outpatient 
clinic before the start of the present study. Children (299) under the age of 13 years attending 
the health clinic in Kilifi District were recruited and paired NPS and NW specimens 
collected. We demonstrated the NPS was more acceptable to a wider participant age range 
without loss of sensitivity, relative to the NW (more details in Chapter 2) (Munywoki et al
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2011). The samples from the above study were screened using a real time multiplex PCR (M- 
PCR) assay system on the ABI7500 platform for multiple respiratory virus detection set up 
with support from the Health Protection Agency, UK. The targets include RSV A and B, 
influenza (Flu) A (panspecific) and B, parainfluenza (PIV) 1-4, rhino virus, human 
metapneumovirus (hMPV), adenovirus and coronaviruses.
The Okiro’s et al study also collected oral fluid (OF) samples to detect specific anti-RSV 
antibodies to supplement infection data. However, the sampling interval was too infrequent 
(once every 3 months) to identify infections at the required temporal resolution based on 
antibody profiles (Okiro et al. 2008). Studies from our group suggested that levels of RSV 
specific IgG (and to a lesser extent IgA) in OF track those of serum, but with very rapid post­
infection antibody dynamics (Okiro et al. 2008), suggesting that weekly sampling could help 
in identification of infections. In addition, emerging evidence indicate OF samples could be 
used to detect viral infections using PCR methods (von Linstow et al. 2006). The sensitivity 
of the OF in detection of RSV using molecular diagnostics was assessed in an effort to 
identify alternative methods to supplement RSV infection data. This was assessed in the 
current study.
Given the need to detect chains of transmissions within the household, reliance on the 
occurrence of symptoms to identify infected persons certainly would result in failure to 
recognize links in transmission events hence need to collect samples regardless of clinical 
status. Efforts were required to detect all RSV infection which may frequently be mild, of 
short duration or sub-clinical in older children and adults (Henderson et al. 1979). Given a 
mean duration of RSV shedding of between 3.5 and 9 days (dependent upon age, severity, 
mode of collection and method of antigen detection) (Hall et al. 1976; von Linstow et al.
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2006; Okiro 2007), frequent sampling intervals would be a prerequisite to avoid a significant 
loss in detectable cases.
With the chief aim of defining “Who Acquires Infection From Whom” (WAIFW), we 
mitigated the above limitations by using the most favourable infection detection methods. 
This included frequent NPS (twice-a-week) and OF (once-a-week) sampling irrespective of 
symptoms, and use of highly sensitive assays for identification of viruses. Antibody profiling 
of oral fluid was to provide additional data on infection status. No previous study has 
combined all these characteristics. Furthermore, we used PCR based methods to genotype the 
infecting strain providing an added benefit in offering a degree of finger printing of clusters 
of infection. The aim of the current Chapter is to present details of the methods underpinning 
this investigation.
3.2 Chapter outline
Detailed descriptions of the study methods are provided in this Chapter. Initially, a general 
description of the study site and population, together with details on the study design, 
implementation and data management, are provided. The process of community engagement 
and sensitization exercises, identification of eligible households, consenting process, data and 
specimen collection procedures during home and clinic visits, sample processing and testing 
methods in the laboratory and set data quality control measures are then presented. While 
detailed results are presented in Chapter 4, results on household recruitment and retention and 
on sample collection rates are provided here. In addition, temporal patterns of RSV 
occurrence from the KDH paediatric wards and results from experiments to assess the 
diagnostics performance of the M-PCR assay are included. The candidate in close 
collaboration with Professors James Nokes and Graham F. Medley designed the study and
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was funded by Wellcome Trust grant (Grant number 090853). The candidate (herein referred 
to as the project manager) managed day-to-day study activities, and was incharge of a team 
of fieldworkers, with oversight from Professor James Nokes.
3.3 Study area
The study was conducted in the rural coastal setting of Kilifi County, in Kenya. The County 
covers a total surface area of 12,610km2 with a total population of 1,109,735 and around
200,000 households according to 2009 Kenya Population and Housing Census estimates 
(Kenya National Bureau of Statistics 2010). Kilifi County borders those of Tana River to the 
North, Taita Taveta to the West, Mombasa and Kwale to the South, and the Indian Ocean is 
to the East. The study took place in Kilifi District one of the six administrative Districts in the 
County (Figure 3.1). Kilifi District normally experiences two rainy seasons; long rains 
between April and July and short rains between October and December. On average, the 
annual rainfall is about 1,300mm along the coastal belt. It is generally hot (range of 
maximum daily temperatures 28°C -  34°C) and humid (relative humidity of 70-80%) 
throughout the year with hottest months in the period of October to April. The main 
economic activity is subsistence farming, particularly of maize and cassava. Palm wine 
harvesting from coconut trees is also common in the rural areas. Firewood and charcoal are 
the common source of fuel, although in a minority of the households paraffin and gas are also 
used. The main water source is from open or closed boreholes with some areas having piped 
water (KHDSS, unpublished data) (Scott et al. 2012).
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3.3.1 The KEMRI- Wellcome Trust Research Programme
The study was carried out at KEMRI-Wellcome Trust Research Programme (KWTRP), 
which is situated adjacent to Kilifi District Hospital (KDH). The KWTRP is a collaboration 
between the KEMRI Centre for Geographical Medicine Research - Coast (CGMRC), and the 
Wellcome Trust, UK. The KWTRP was established in 1989 and runs the children’s wards of 
the District hospital, including a ~60-bed general ward and a 6-bed high dependency unit. In 
order to facilitate conduct of epidemiological studies, estimate burden of important diseases 
to the community and evaluate the impact of interventions, the Kilifi Health and 
Demographic Surveillance System (KHDSS) was set up in 2000 (Scott et al 2012). The 
KHDSS (light yellow area in Figure 3.2) covers an area of 891 Km2 and was designed at the 
outset to capture 80% of the paediatric admissions to KDH (Moisi et al. 2010; Moisi et al.
2011; Scott et al. 2012). Enumeration rounds of all births, deaths and migrations (i.e. into, out 
of and within) in the KHDSS are conducted approximately every four months. In 2009, 
approximately 250,000 people were resident in the KHDSS area. Since April 2001, the 
KHDSS has been integrated with the KDH paediatric wards data (clinical, laboratory and any 
epidemiological surveillance studies or clinical trials) using a FileMaker Pro Advanced 
database (FileMaker Inc, US). Furthermore, the KHDSS is linked to an RSV inpatient 
surveillance study, which has been on-going since 2002 (Nokes et al. 2009). The inpatient 
RSV surveillance study recruits all children aged <60 months admitted to KDH with 
syndromic severe or very severe pneumonia (Nokes et al. 2009). Children are investigated 
using a nasal specimen (nasal wash (NW) or nasopharyngeal aspirate (NPA)) collected by 
trained medical assistants soon after admission (Ngama et al. 2004) and assayed for RSV 
antigen by Immunofluorescence antibody tests (IFAT), (DAKO Imagen RSV kit or 
Chemicon Light Diagnostics DFA kit) (Nokes et al. 2009) and additionally by molecular
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T h e  d isp e n sa r ie s  p r o v id e  p r im ary  h e a lth  care; an d  are s ta f fe d  b y  n u rses , c lin ic ia n s ,  an d  a  
p u b lic  h e a lth  o f f ic e r , a ll w ith  a d ip lo m a  le v e l  tra in in g .
wa Ndeg*
Sokoke
Ktilifi Towrtsh.0
•  H ealth  fa c ilitie s  
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F ig u re  3 .2 : M a p  o f  th e  K il if i  D is tr ic t  s h o w in g  a d m in is tr a tiv e  lo c a t io n s  in  K H D S S  ( lig h t  
y e l lo w  a rea s) and  h ea lth  fa c il i t ie s  (c ir c le s  f i l le d  in  red ) in  th e  d istr ic t a s at S e p te m b e r  2 0 0 9
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3.4 The population
Kilifi is predominantly inhabited by members of the Giriama comunity, one of the nine sub­
ethnic groups of the Mijikenda people found along the Kenyan coast. In addition to local 
Kigiriama, Swahili language is well established in the region. The community is culturally 
diverse with various religious practices (Islamic, Christian and traditional).
3.5 Methodology
3.5.1 Study design
A household-based prospective cohort study design was used. Households from the KDHSS 
register were systematically selected from within a single administrative location until 50 
households, which fulfilled the eligibility requirements, were identified. Eligible households 
had an infant (hereafter referred as the study infant) bom since the previous RSV epidemic 
(i.e. bom after 1stApril 2009) and one or more siblings <13years old. A household was 
defined as the group of individuals living in the same compound and eating food from the 
same kitchen, regardless of their relationships with one another (Table 3.1). The target 
households had at least one other child potentially increasing the probability of RSV 
introduction in the household. We aimed to recruit all the members from each eligible 
household prior to the start of the 2009/2010 RSV season (Figure 3.3). RSV season was 
formally defined in Table 3.1. RSV seasonality (start and end of RSV epidemic) was 
identified from our long-term KDH paediatric RSV surveillance (Nokes et al. 2009). From 
the start of the 2009/2010 epidemic, NPS for virology and standard illness assessment were 
requested every 3-4 days from all individuals, irrespective of symptoms, until the end of the 
RSV season. Oral fluid (OF) (also referred to as saliva) samples were collected weekly, 
during a swabbing visit, to investigate OF as an alternative to nasal sampling for respiratory 
vims detection using M-PCR assay and to assist in identifying infections serologically. A
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piloting phase preceded full sampling, in which participants were visited ‘once-a-week’ for 
about four weeks. The pilot phase aimed at establishing the household routines and best times 
for home visits as well as confirming the household members’ willingness to participate in 
the study. The flow of the study processes were streamlined during this phase. Households 
lost to follow-up during the early phase of the study were replaced by enrolling new 
households. Newborns into the study households were recruited as individuals who became 
residents during the course of the study (note that even so there remained only one study 
infant per household).
i) A summary o f the inclusion criteria:
a) Household located within Matsangoni location and registered in KHDSS
b) Household with a child bom after 1st April 2009 and at least one sibling <13 years old.
c) Household in which agreement to participate was established for all members who were 
resident at start of study i.e. envisaged to be living in the location for at least the next 
three months
ii) Summary o f the exclusion criteria:
a) Household with at least one individual refusing to participate at the outset
b) Household in which one or more members withdrew during the study pilot phase
c) Household members who emigrated from the study area in the course of the study
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Table 3.1: Definition of terms
Term
Household
Study infant 
RSV season
Definition
Away
Visit
ARI
Individual 
episode or 
RSV 
infection 
episode
A group of individuals living in the same compound and eating food from 
same kitchen
The youngest child in the household at the time of the recruitment. All the 
study infants were bom after 1st April 2009 and considered RSV naive.
The ‘periods delimited by weeks in which one or more RSV cases were 
identified in our hospital surveillance and within which at least 3 RSV cases 
were found in any contiguous 3-week period’ (Nokes et al. 2009)
Status recorded if an individual was out of the household for more than 3 
consecutive days e.g. the individual having travelled or in a boarding school 
Includes the instances where the field workers formally met the study 
participants either at home or at the study clinic verified by filling of the 
home or clinic visit form. This also includes records of missed appointments 
for instance, when the participants were away
Presentation with one or more of the following symptoms: cough, runny 
nose/blocked nose, or difficulty in breathing
Period within which an individual provides specimens which are PCR 
positive for the same infecting RSV group with no more than 14 days 
separating any two positive samples. If an individual was diagnosed with both 
RSV group A and B in the first sample of the individual episode this was 
coded as a coinfection and counted as one individual episode. Individual 
episodes are also referred as RSV infection episodes in the text.
Key: ARI, acute respiratory illness; PCR, polymerase chain reaction
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Figure 3.3: Schematic diagram showing the household study design. The dotted triangular 
represents rise and fall of RSV cases throughout epidemic. Light grey area shows the 
recruitment and active home follow-up phases; Arrows (black) indicates the regular active 
home visits while red marks indicate possible passive clinic visits (see section 3.5.1 for 
details)
3.5.2 Sample size estimation
The unit of sampling was the household. Previous community studies indicated 30-70% of 
newborns are usually infected during their first epidemic season (Hall et al. 1976; Glezen et 
al. 1986; Nokes et al. 2004). Our estimate, from the Kilifi birth cohort, (Nokes et al. 2004) of 
around 39% was based on less sensitive methods and was likely to be much higher in the 
current study -  which used molecular virus detection methods. Our primary outcomes were 
related to RSV infections. We aimed to estimate the proportion of households (i) with at least 
one occupant infected with RSV at the end of the RSV season, (ii) in which infants 
experienced a primary RSV infection and (iii) in which infants were infected from within 
(elder siblings or parents) and from outside the immediate household. Using standard 
sampling theory (Smith and Morrow 1992; Kirkwood and Sterne 2003) the precision
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estimates of the possible proportions for each of the above outcomes at varying sample sizes 
are shown in the Figure 3.4 below. For instance if the proportion of households with detected 
RSV infection is 30%, this would give a precision of +/-13% for a sample of 50 households. 
We thus set up a prospective cohort study of 50 households (estimating that in each 
household had an average of eight members), to be followed for one complete RSV 
epidemic.
0.35
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0.3
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0.2
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n=40
n=500.15
0.1
0.05
0
0.1 0.2 0.3 0.4 0.5
Proportion infected
Figure 3.4: Precision estimates of the risk of infection at 5% significance level (two-sided) 
for specified sample sizes of households (n)
3.5.3 Sampling frequency estimation
The following rationale was used to determine the NPS collection frequency. Assuming 
individuals shed virus for a mean duration of between 3.5 and 9 days (Okiro et a l 2010), 
with a constant rate of recovery from shedding, and an onset on average half way between 
any sampling interval, then the proportion of individuals predicted to remain shedding, and 
thus detectable, would range from 61 -  82% (for 3 .5 -9  days duration) for a 3.5 day 
sampling interval (Figure 3.5 and further details in Appendix B). The comparable range was
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37 -  6 8 % for a 7-day interval in sampling. Given the need to detect infection in mild cases 
and in older children and adults with likely lower range of shedding duration, sampling twice 
weekly was preferred. While frequency of sampling greater than twice weekly would 
undoubtedly yield higher detection rates this was deemed unacceptable for reasons both 
logistic and to do with participant acceptability. The option of less frequent sampling but 
inclusion of more households was deemed insensitive in detection of RSV transmission 
events within the household and suboptimal in addressing the study objectives.
05c
' c l  0 .8
J>-----0.6
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0.4
■■—  Interval 3.5 days
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3.5 7 9
Average duration of shedding (D days)
Figure 3.5: Estimated proportion of individuals continuing to shed RSV at the next sampling 
by average duration of shedding for the two sampling intervals i.e. twice- and once-a-week
3.5.4 Choice o f the study site
Due to the intensive nature of the proposed sampling regime and for practical reasons, the 
study was conducted in one administrative area. The aim was to select a locality fulfilling the 
following requirements:
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a) Relatively easy to access. The roads to be accessible even during the rainy season and 
with journey time of less than 1 hour from KWTRP in Kilifi
b) Availability of active Community Health Workers (CHW) charged with specific 
households, to allow easy identification of eligible households and help in community 
entry
c) Evidence from the ongoing hospital surveillance that RSV recurrently occurs in the 
location. All the locations within the KHDSS were suitable based on this criterion (Figure 
3.6)
d) Availability of a nearby health facility. For participant referral and to set up a study clinic 
and office for the field team
e) Acceptability of the study by the community leaders
The choice was made after visiting several sites and holding discussions with community 
leaders including KEMRI-Community Representatives (KCR) 1 (Marsh et al. 2008), health 
facility staff, and local administration in the respective locations. In these meetings, the 
details of the proposed study were presented and community leaders allowed to ask questions 
related to acceptability of the study. A leaflet with study details (Appendix C) and another 
one with list of frequently asked questions (Appendix D) were also shared in these meetings.
1 The KCR are community leaders voted in by the community members as part o f KWTRP 
community engagement policy in the KHDSS. The KCR meet with members o f Community 
Liaison Group (CLG) three times a year at location level to get their views about KWTRP 
and its activities, address their concerns and pass any information KWTRP may have to the 
community.
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Matsangoni location, 20 km from Kilifi town in the northern part of the KHDSS was the only 
location with ‘active’ CHW and fitted well with the other requirements. This is a rural 
location with a population of predominantly subsistence farmers and is under regular health 
and demographic surveillance. This location has three administrative sub-locations of which 
two East of the main Kilifi-Malindi road were chosen i.e. Uyombo and Matsangoni (see 
Figure 3.4).
The location had a total population of 14,998 in 1,835 homesteads2 in 2009 (KHDSS 
unpublished data, 2009) distributed as shown in Table 3.2.
2 Homesteads comprise o f a group o f individuals living in the same compound. They may 
consists o f one or more households
Table 3.2: Population distribution in Matsangoni location based on KHDSS data as at July 
2009
Sub-locations No. of homesteads Population Individuals per homestead1
Matsangoni2 544 4513 8.3
Uyombo2 624 4984 8.0
Mkongani 667 5501 8.2
Total 1,835 14,998 8.2
Key: 1, average number o f individuals per homestead; 2, the study sub-locations
Table 3.3: Homesteads in Matsangoni location based on the Kilifi Heath and Demographic 
Surveillance System (KHDSS) data as at 20th July 2009
Number of homesteads 
Homestead composition Matsangoni Mkongani Uyombo Total
All homesteads 544 624 667 1,835
Homesteads with at least one infant 6 6 70 71 207
Homesteads with an infant and another 65 65 65 195
child <13 years
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Figure 3.7: Matsangoni map showing distribution of the recruited households (navy blue). 
Insert at top-right shows the legend and on the bottom-right is the map of the KHDSS area 
with the grey region showing Matsangoni location
3.6 Study implementation
3.6.1 Recruitment offield staff and training
A careful selection and thorough training of staff was obligatory, given the intensity in
sampling and community interactions in the study. Recruitment of the field staff was done in
September and October 2009, about two months prior to start of the study to allow proper
training. The underlying principle in these appointments was to build a field team with
knowledge of the local area and who spoke and understood the local languages and would
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easily adapt to the study households’ daily routines for ease of sampling. Initially, five field 
workers, two data clerks, a senior field worker, a study coordinator and clinician were hired. 
Later in March 2010, two field workers and three community-based assistants were recruited 
when the full scale of the workload became apparent. Figure 3.8 shows the composition of 
the study team. The candidate took a lead role in these appointments -  creating the job 
description, advertisement of the positions, preparing the shortlist and interviewing. The field 
workers and community-based assistants were tasked with conducting the home visits for 
specimen and data collection and were under direct supervision of the senior field worker. 
The study clinician assisted by the study coordinator conducted regular (once every month) 
home visits to carry out health checks on family members and ad hoc home visits to discuss 
any arising issues related to the study participation. The field workers were assigned specific 
households and the respective field workers were involved in these ad hoc visits and on most 
occasions only aimed at addressing a specific issue. During the early phase of the study, the 
candidate (the project manager) always accompanied the clinician in these visits.
Prior to start of the study the field team was trained on the following areas, part of a well 
developed curricula (Appendix E) for new field staff in the programme: -
a) KEMRI and its roles
b) What is medical research & medical ethics, i.e. the protection of participant rights in 
research
c) Communication skills including problem solving skills
d) Information giving and consenting, involving role-plays simulating home visits and the 
consenting process
e) Sample collection procedures, nasal swabbing, using nasopharyngeal flocked swabs 
(NPS) and oral fluid collection
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f) Identification of clinical symptoms especially respiratory related, i.e. cough, running 
nose, counting respiratory rate, heart rate etc
g) Household study details, i.e. Study objectives and implementation process including 
conduct of home visits for sample collection and referral process to the dispensary
h) Data collection procedures including reviewing of all the data collections forms and 
piloting
The details of the above training were summarised in a study manual issued to all the field 
staff for reference (see Appendix F). Refresher training on communication and study 
procedures was carried out intermittently in the course of the study.
Study clinician Senior data clerk Laboratory staff1Study coordinator
Senior field worker
Field workers (n=7)
Data entry clerks (n=2)
Community-based assistant (n=3)
(The candidate)
Project manager
Figure 3.8: An organization chart of the household study team. 1, the laboratory 
technologists were under direct supervision of a laboratory manager but for the household 
study sample screening the candidate scheduled their daily activities
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3.6.2 Community engagement and sensitization
A detailed community engagement plan was drawn up at the outset of the fieldwork. This 
was in consultation with a ‘communication advice for specific studies’ (CAST) group which 
is spearheaded by the centre’s Community Liaison Group (CLG) (Marsh et al. 2008). As part 
of this plan, we held several (i) consultative and sensitisation meetings with the local 
administration and community leaders or their representatives at various levels from the 
district to the village (Figure 3.9), (ii) public meetings i.e. barazas for sensitisation, and (iii) 
meetings with the household heads in the area. This helped to establish proper 
communication channels and foster a favourable environment in the community as well as to 
obtain community consent. In particular, we could receive concerns easily from the 
community members through the CHW or other community leaders. The Ministry of Health 
(MoH) was engaged from the District Medical Office, including the District Health 
Management Team, to the dispensary level. In particular, the Matsangoni Dispensary Health 
Committee (DHC) was deeply involved in the sensitisation exercise in view of its pivotal role 
in the delivery of health care services in the community. The study team was vigilant and 
proactive in identifying any community fears or problems, which were duly discussed and 
addressed with the concerned parties. At least once a month, we shared with the local 
administration on the progress of the study and addressed any concerns raised through their 
office. Feedback of the study progress and findings were made periodically to the community 
leaders during their monthly developement meetings at the location. At the end of the field 
work a comprehensive feedback was made involving local administrative officers, the CHW, 
various community leaders and health facility staff. The final feedback meeting was held on 
14th November 2012 once most of the study findings were identfiied.
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F ig u re  3 .9 : P ic tu res  o f  c o m m u n ity  se n s it iz a t io n  m e e t in g s , (a )  T h e  p ro jec t m a n a g e r  (s ta n d in g )  
d em o n stra tin g  O F  k it  d u rin g  a m e e t in g  w ith  h o u se h o ld  h e a d s  in  U y o m b o  p r im a ry  sc h o o l;  (b )  
a m e e t in g  w ith  th e  K E M R I-C o m m u n ity  R e p r e se n ta tiv e s  o u ts id e  M a tsa n g o n i C h i e f s  o f f ic e
3.6.3 Household selection and recruitment
E lig ib le  h o u se h o ld s  w ith in  U y o m b o  an d  M a tsa n g o n i su b - lo c a t io n s  w e r e  in it ia lly  id e n t if ie d
u s in g  th e  K H D S S  reg isters . T h e  h o u se h o ld  lis ts  fo r  e a c h  su b - lo c a t io n  w e r e  su b se q u e n tly
r e v ie w e d  in  c o n su lta t io n  w ith  th e  lo c a l  CE1W and  th e  f ie ld  w o r k e rs  w h o  w e r e  p r iv y  to  th e
h o u se h o ld  d e ta ils . T h is  r esu lted  in  th e  a d d itio n  o f  a f e w  h o u se h o ld s , p a r ticu la r ly  th o s e  w h o
had  n e w b o rn  n o t y e t  e n u m era ted  b y  th e  K H D S S  sta ff. F ie ld  w o r k e rs  v is ite d  th e  p o te n tia l
h o u se h o ld s  a c c o m p a n ie d  b y  lo c a l  C H W s as part o f  a h o u se h o ld  en try  p lan . T h e  a im  o f  th is
first h o m e  v is i t  w a s  to  ( i)  c o n f ir m  e lig ib ili ty ,  ( i i)  n o t ify  th e  h o u se h o ld  h ea d  a b o u t th e  p la n n e d
stu d y , i f  th e y  w e r e  n o t y e t  a w a re  an d  ( i i i )  in v ite  th e  h o u se h o ld  h e a d s  or  r e p re se n ta tiv es  to  a
jo in t  se n s it iz a t io n  m e e t in g  in  th e  n ea rb y  sc h o o l . U p o n  se n s it iz a t io n , th e  f ie ld  w o r k e rs
arran ged  a  se c o n d  h o m e  v is i t  fo r  in d iv id u a liz e d  in fo r m a tio n  g iv in g  an d  fo r  c o n se n t in g  ( s e e
A p p e n d ix  G ). In lin e  w ith  lo c a l p r a c tic e , th e  f ie ld  w o r k e rs  w e r e  a g a in  in tro d u ced  to  th e
h o u se h o ld  m e m b er s  b y  th e  C H W s b u t th e  C H W s w e r e  n o t in v o lv e d  in  th e  c o n se n t in g
p r o c e s s . In fo rm a tio n  w a s  d e liv e r e d  in  th e  lo c a l la n g u a g e  and  c o m p r e h e n s io n  a s s e s s e d
th ro u g h  a se t  o f  q u e s t io n s  o n  k e y  m e s s a g e s  o f  th e  stu d y . M e m b e r s  w e r e  g iv e n  a d e q u a te  t im e
(w ith in  o n e  w e e k )  to  d is c u s s  a m o n g s t  th e m se lv e s  b e fo r e  d e c id in g  w h e th e r  to  p a r tic ip a te  in
th e  stu d y  and  in  m o s t  in s ta n c e s  c o n se n t  w a s  n o t g iv e n  b y  a ll h o u se h o ld  m e m b er s  o n  th e  sa m e
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day. Some required more time to make the voluntary decision to participate. Individual 
written informed consent was sought from each of the household members. Consent for 
children under the age of 18 years was sought from their parents or guardians. Verbal assent 
was also sought from children aged 5 - 1 7  years with particular focus on the ensuring the 
teenagers understand and voluntarily agree to participate in the study. Households were 
excluded if one or more individuals declined to give consent even if some individuals had 
already consented. Upon consent, the field workers collected baseline demographic and 
living arrangement data using an Initial Home Visit Form (Appendix H). The contents of the 
form are described in the data handling section. Household recruitment started in Uyumbo 
area and progressed into Matsangoni sub-location until the required sample size of 50 
households was achieved.
3.6.4 Householdfollow-ups
Sampling was scheduled to start when the KDH in-patient paediatric surveillance showed 
two successive weeks with more than two children admitted with RSV positive infections, 
signalling the start of the RSV epidemic (Nokes et al. 2004). For the first three weeks, home 
visits were made once-a-week but increased to the stipulated frequency of every 3-4 days 
(nasal swabbing in all the visits and OF in one of them) thereafter. The early phase of 
sampling allowed the study team to develop a logistical framework/system synchronised with 
the community activities and culture and replace non-compliant households before the 
epidemic peaked in the local community. During each visit, a Home Visit form was filled. 
The form, described in detail later, captured data on samples collected and presence of 
respiratory symptoms (see Appendix I). Field workers made arrangements to revisit 
participants who were not available during a scheduled home visit and at least three attempts 
were made. Participants who were ‘away’ from the home for more than three consecutive
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days were noted. During the field workers’ home visits, participants with fast breathing for 
age and/or fever or any other clinical features of severe illness were referred to the 
Matsangoni dispensary for medical care, which was provided at no charge at the study clinic. 
Self or passive referral was also encouraged. At the dispensary, a detailed clinical assessment 
was made and documented in a Clinic Visit form (Appendix J for details) by the study 
clinician. Data on a range of household characteristics (e.g. income, education level, housing, 
anthropometric measures) was also collected towards the end of the study, when a good 
rapport had already been established with the families, via an interviewer-administered 
questionnaire (see Appendix K). Home visits (and specimen collection) were terminated 
when two or more household members repeatedly failed to comply with the sampling regime 
(i.e. failure to collect samples for a period of more than 4 weeks) or the RSV 2009/2010 
epidemic ended (<2 RSV infections detected from the KDH inpatient surveillance of 
paediatric pneumonia in two successive weeks).
3.6.5 Study monitoring
A field office and study clinic was set up at the Matsangoni dispensary (see map in Figure 3.2 
and 3.7). The field workers had access to the field office even during weekends and outside 
working hours on weekdays. Every day the field team reported to the office before departing 
for the home visits. All study supplies including data collection forms and sample collection 
devices were available from this office. The study coordinator replenished stocks regularly 
from KWTRP main stores. The field workers kept a log of the daily activities in their 
individual ‘field’ books. A main sample collection and reception logbook was kept in the 
office, which was updated on a daily basis noting when samples were received at the study 
office and transported to KWTRP laboratories. A separate logbook existed for recording 
reception of completed data collection forms and when they were forwarded for data entry.
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The field team including data clerks and laboratory staff had regular weekly meetings to 
discuss the study progress. The project manager chaired these meetings. The agenda included 
a review of the work done and experiences in the preceding week. Any concerns from the 
study participants or the community were raised and discussed. In instances where matters 
related to community engagement were to be discussed, field officers from the CLG were 
invited. This forum was also used for continuous training of the field team on sample 
collection and data collection. On average, the meetings lasted 2 hours.
The project manager randomly selected days to accompany the fieldworkers during the 
routine home visits for sample collection and illness assessment. The participatory 
supervision helped in early identification of any issues that required attention of the project 
manager such as difficulties in sampling some of the participants and was useful in tracking 
of the study progress.
3.7 Sample collection and handling
3.7.1 Specimen collection
A description of NPS and OF specimen collection procedures is provided below.
i) Nasopharyngeal flocked swab (NPS)
The method adopted, described in Chan et al (Chan et al. 2008), was rigorously tested in our
setting for sensitivity and acceptability before use in the current study (Munywoki et al
2011). This is a simple procedure using a commercially available nasopharyngeal flocked
swab (Copan Diagnostics Inc, Brescia, Italy). Briefly (see Appendix L for the detailed
standard operating procedure (SOP), the distance between the participant’s nares and earlobe
was measured to estimate the length of insertion. The swab was then gently inserted up the
nostril towards the pharynx for the measured distance. The swab was rotated 3 times, to
obtain epithelial cells and surface colonising viruses and held in place for 5 seconds to allow
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absorbance. The swab was then withdrawn gently and placed in tube with 1 ml of viral 
transport medium (WHO 2006).
ii) Oral fluid (OF)
Oral fluid was collected using a sponge swab (Oracol, Malvern Medical Developments, 
Worcester, UK), consisting of a cylinder of expanded polystyrene foam attached to a plastic 
stick and was used like a toothbrush (Nokes et al 2001; Okiro et al. 2008). The swab was 
brushed along the gums and mouth for 60 seconds and the device was then inserted into a 
plastic tube and stoppered. The SOP is detailed in Appendix M.
3.7.2 Specimen handling, transportation and storage
Upon collection, samples (NPS and OF) were stored in a cool box (with ice-packs) and 
delivered to the field office within 4 hours in Matsangoni dispensary for storage in a 4°C gas- 
powered fridge. Samples were transported to the KWTRP virology laboratory in Kilifi within 
24 hours for processing and storage. In the laboratory, 1ml of preservative buffer (20% foetal 
calf serum and 0.2% sodium azide in phosphate buffered saline (PBS)) was added to the OF 
sample. The oral fluid was then squeezed out of the foam and clarified by centrifugation and 
the supernatant stored. Details on the freezer position were appended to the specimen tube 
before storage of both specimen types in a -70°C freezer for later testing.
3.8 Laboratory procedures
The following describes the procedures for (a) identifying the presence of specific viral 
nucleic acids in NPS samples (b) serological testing of OF for RSV specific IgG and (c) 
detecting RSV specific nucleic acid in OF.
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3.8.1 RNA extraction methods
Viral RNA was extracted from NPS using MagNA Pure LC RNA Isolation Kit - High 
Performance (HP) following manufacturers instructions (Roche Diagnostics, Mannheim, 
Germany). This is a semi-automated method of RNA extraction using the MagNA Pure LC 
Instrument. The performance of the HP extraction kit was initially compared to MagNA Pure 
total nucleic acid (TNA) isolation kit and manual extraction by QIAamp Viral RNA Mini Kit 
(QIAGEN, Valencia, CA, USA). The main aim was to assess for non-inferiority of the HP kit 
against the Qiagen manual extraction in detection of RSV.
3.8.2 Multiplex real-time polymerase chain reaction (M-PCR) assay
We used a multiplex real-time polymerase chain reaction (M-PCR) assay to detect a range of 
respiratory viruses. The M-PCR assay employed uses dual-labelled hydrolysis probes to 
generate the positive signals (Gunson et al. 2005). The assay consists of five triplex reactions 
and one single reaction and detects specific nucleic acid sequences of the following 
pathogens: RSV group A and separately group B; influenza virus types A, B and C; 
parainfluenza (PIV) virus types 1 to 4; human coronaviruses (HCoV) strains 229E, OC43 and 
NL63; adenovirus; human metapneumovirus (hMPV) groups A and B; Mycoplasma 
pneumoniae; and human rhinovirus. Although the hMPV primers for group A and B are 
present, the fluorescence of the probe specific to each target are close in wavelength and 
cannot be distinguished. The West of Scotland Specialist Virology Centre originally 
developed the M-PCR assay and kindly provided the relevant standard operating procedures 
(SOPs). The assay has been successfully implemented in KWTRP virology laboratory 
(Appendix N) as a diagnostic and epidemiological tool with support from the Health 
Protection Agency, Centre for Infections, UK and has been used in a number of studies 
(Hammitt et al. 2011; Munywoki et al. 2011; Hammitt et al. 2012). The real time M-PCR
assay used undergoes 40 cycles of amplification and a cycle threshold (Ct) 3 value of 35 or 
less was considered positive.
In order to further examine the performance of the M-PCR assay in virus detection, we (i) 
compared the sensitivity of a uniplex (single pathogen detection) versus triplex (detecting 
three pathogens in a single tube) for RSV A/B and adenoviruses, and (ii) assessed the Ct 
profile of multiplex PCR in IF AT positive and IF AT negative samples. The latter was aimed 
at assessing the nature (by viral load terms) of any additional sensitivity by our M-PCR 
assay. In this experiments, we used nasal samples from a previous outpatient study conducted 
by the candidate (Munywoki et al. 2011).
3.8.3 Attachment (G) Gene sequencing
In a select number of samples (details on the selection criterion provided in Chapters 4 and 5) 
the sequencing of the long ectodomain region of the RSV G gene was carried out as 
previously described (Agoti et al. 2012). This sequencing work was done in close 
collaboration with Charles Agoti, a PhD student in the Viral Epidemiology and Control 
(VEC) group interested in molecular diversity of circulating RSV viruses.
3.8.4 Sample screening strategy
A large number of specimens (NPS and OF) was expected, necessitating a well-defined 
screening strategy to ensure the screening kits were used most efficiently to achieve the
3 Ct values are inversely proportional to the amount o f target nucleic acid in the sample i.e. 
the lower the Ct value the greater the amount o f target nucleic acid in the sample
desired goal of identifying who infects whom within the household. The project focused on 
transmission of RSV and all samples were screened for RSV A and B. Only the most 
prevalent of the remaining respiratory viruses were targeted for screening in all the samples.
i) NPS screening:
In order to identify the common viruses present during the study period, samples from six 
households were screened for the full range of the respiratory pathogens included in the M- 
PCR assay. The relevant components of the M-PCR assay were then selected to cover 
detection of the most prevalent viruses for the remaining sample set.
ii) OF screening with M-PCR assay
To assess the sensitivity of oral fluid relative to NPS in detection of viral antigens, a selected 
number (60) of samples were tested by the M-PCR assay. The OF samples were selected 
randomly from a list of samples whose paired NPS (collected on the same day) was PCR 
positive. Principally this was for RSV but to be extended to cover other viruses if a promising 
sensitivity (>80%) was reported for RSV detection.
Hi) OF screening with RSV-specific antibody assay 
RSV specific antibodies in OF samples were quantified by optimised indirect enzyme-linked 
immunosorbent assay (ELISA) established in our laboratory that uses crude RSV A2 lysate 
(Okiro et al 2008). Interpretation of changes in specific antibody concentration and the 
definition of re-infection were made based on the antibody profiles as described elsewhere 
(Okiro et al. 2008). It was envisaged that older individuals especially adults would have poor 
PCR detection, due to low viral loads and that the ELISA data would supplement the RSV 
infection data.
3.9 Data collection, handling and analysis
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3.9.1 Data collection forms
Field data were collected using four different forms, which have been highlighted previously. 
These include Initial Home Visit form, regular Home Visit form, Clinic Visit form and 
Household Risk Survey Questionnaire.
i) The Initial Home Visit Form
This form was developed before the start of the study by the project manager and 
administered immediately after the household consenting. The form captured baseline 
demographic characteristics at household and individual level. Data collected included 
household head name, his/her marital status, and highest educational level and number of 
families in the household. In addition, participant specific details such as date of birth 
(mainly from birth certificate or national identity card), occupation, education status, 
relationship to the study infant, as well as living arrangement (live or sleep in same house as 
the study infant) were collected. The field workers collected these data.
ii) Regular Home and Clinic Visit Forms
The two forms were developed and piloted during the early phase of the study. Following 
feedback from the participants, field workers and clinician administering the forms the 
questions were revised. For the Home Visit Form, which was filled twice a-week for every 
participant, the priority was to make the data collection exercise brief and targeted. Thus the 
form was restricted to collecting data on specimen (NPS and OF) collection, quick illness 
assessment for presence of respiratory symptoms (cough, runny nose/blocked nose, difficulty 
in breathing etc.) or other complaints and recording of vital signs such as temperature and 
respiratory rates for the under five year olds. Reasons for not collecting specimen or any 
other complaints were also captured. For ease of data collection each household had a 
customised form with the list of members already included and the required data on a tabular
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format on one side and allowance for entering additional comments on the back of the form. 
The field workers were required to record either ‘yes or no’ response for most of the 
questions though in some instances a value record was required. The Clinic Visit form was 
similar to the Home Visit form except that the illness assessment was elaborate. The form 
was adopted from earlier studies (Okiro 2007; Munywoki et al. 2011). The Clinician 
collected the data during the participant attendance at the study clinic. Additional data on 
anthropometric measures (weight, Mid Upper Arm Circumference (MUAC), height), oxygen 
saturation (using pulse oximeter), heart rate, any laboratory tests done, diagnosis and 
treatment given were also recorded.
iii) Household Risk Survey Questionnaire 
The questionnaire was also modified from a previous study in our site (Okiro 2007; Okiro et 
al. 2008). Data on potential risk factors of virus transmission and infection in the household 
were collected. This included details on who and how the study infant was taken care of in 
the household, ownership of property and quality of the household head’s house for assessing 
socio-economic status, presence of a toilet and waste management as well as source of water 
for domestic use. Individual level characteristics, such as whether in school, smokes, and 
anthropometric measures such as weight, mid-upper arm circumference (MUAC) and height 
were recorded.
3.9.2 Data handling and entry
The project manager assisted by the study coordinator reviewed the forms at the field office.
Corrective action was taken if any anomalies were identified at this stage mainly involving a
revisit of the household. The filled forms were forwarded to KWTRP in Kilifi on daily basis
for data entry. All the field and laboratory data were doubled-entered on a Filemaker database
specially designed and coded by the project manager, in consultation with the Centre’s
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programmers (FileMaker Pro version 9, FileMaker Inc, US). In addition to the strict data 
checks at entry (e.g. set date formats, decimals allowed and provision of drop down menus 
etc.), random checks were regularly conducted on the database to ensure the data were 
accurate and up-to-date. The regular checks involved selecting randomly ~10 data collection 
forms every week and crosschecking against the entered data. Appendix O shows screen 
shots of the database. All the source documents were sorted by household identity and 
chronologically stored in a cabinet accessible only to the study team.
3.9.3 Data cleaning and analysis
The double entered data were exported in comma separated values files and loaded into 
STATA (version 11.2, STATACORP, College Station, Texas, US) for data cleaning. Original 
forms were used to resolve any disparities in the two entries. The clean data with the 
household, participant, visit, sample level variables and laboratory results were used for 
subsequent analysis. Table 3.1 in this Chapter shows the definition of terms that formed the 
guide to structuring of the data in readiness for analyses. The specific analysis plans are 
presented in the methods section of the subsequent Chapters. All analyses were done in 
STATA version 11.2 unless otherwise stated.
In this chapter, we analysed data arising from samples collected in a study conducted in
Pingilikani Health Centre, an outpatient clinic, where the original objective was to assess the
diagnostic performance of NPS relative to NW (Munywoki et al. 2011). In the outpatient
study, a total of 299-paired samples were collected, RNA extracted using Qiagen kit and
tested using the M-PCR assay. For the current work, we selected 30 archived nasal samples at
random and extracted RNA using three different kits (QIAamp Viral RNA Mini (Qiagen)
Kit, MagNa pure LC Total nucleic acid (TNA) and MagNa pure LC High performance (HP)
kits). This was to assess the sensitivity of the various kits in detection of RSV and other
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respiratory viruses. Another set of 112 nasal specimen were also randomly selected and RNA 
extracted using the HP kit and divided into two aliquots: one was used for uniplex and the 
other for triplex real time RT-PCR to test for RSV A, RSV B and adenoviruses. This second 
set of samples was made to assess the effect of multiplexing in detecting of RSV and other 
respiratory viruses. Specimens were assigned positive for a particular pathogen if the Ct 
value was <35.0. A sample was considered a true positive if either of the extraction methods 
was positive and comparisons made using McNemar’s chi-square test. The Binomial Exact 
method was used to determine 95% confidence intervals (Cl) for the sensitivities (one-sided 
97.5% reported if sensitivity was 100%). The mean (95% Cl) of the Ct values by extraction 
or the screening method was calculated and comparisons made using paired t-test for each 
virus.
3.10 Ethical considerations
The consenting process was thorough and participants were allowed to seek clarification or 
withdraw at any stage during the study. The key areas considered in planning and conduct of 
the study are highlighted.
3.10.1 Risks
No procedures used in this study represented a significant risk to the participants. The nasal 
sampling could result in mild discomfort which was explained to each participant prior to 
collection. Suitably trained staff performed all study procedures, and these procedures were 
carefully explained in advance to the older children and adults. The frequency of home visits 
was discussed with the household head and all individual members so that a convenient 
schedule was agreed upon. The scheduling was flexible and would vary from week-to-week 
depending on participant’s availability.
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3.10.2 Benefits
There were no direct benefits accruing from the frequent nasal/oral sampling and testing 
since there is no established treatment for viral respiratory infections. However, the 
participants may well have benefited from close monitoring for any illness by the study 
coordinator (a nurse) during the home visits and were referred to the study clinic promptly for 
treatment when necessary. All costs of treatment including drugs for acute illnesses incurred 
in Matsangoni dispensary were paid for by the project. Expenses for referral to KDH and 
costs of inpatient treatment were also incurred by the project. The community, in general, 
benefited from enhanced supply of drugs to the dispensary. The project supported the 
Ministry of Public Health and Sanitation in dealing with a cholera outbreak that occurred in 
the area during the study period. We provided vehicle for ease of referral of severe 
‘suspected’ cholera cases to KDH and more substantially provided supplies used in cleaning 
and covering of open water wells. Other benefits to the study households were in form of 
reading books and pens to the school going children but our main efforts to promote 
education in the area was through supply of text books and holding of career days in each of 
the six public primary and one secondary school in the area. In line with local culture we 
recognised the household involvement by offering a gift hamper at the end of the study. This 
was not planned for at the outset and the CAST (while planning on the household and 
community exit strategy) decided on the package. This consisted of household consumables 
that would last an average family (8  members) about 1 - 2  days.
3.10.3 Data confidentiality
Data were stored on password-protected database, accessible only to study investigators and 
under close monitoring by the project manager. Data were archived by the Centre’s database 
administrator. Project manager created the analysis databases with all personal identifiers
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removed from the main study database. All the source documents were stored in cabinets 
under lock and key.
3.10.4 Feedback o f information
The individual test results of the nasal and oral fluid samples were not conveyed to the 
participants for they were not likely to affect their health care. This was clearly explained 
during the consenting process. A feedback meeting was organised at the end of the study to 
share the major study experiences and results.
3.10.5 Scientific and ethical approval
The following scientific and ethical committees approved the project:
a) The Scientific Coordinating Committee (SCC) based in KWTRP, Centre for Geographic 
Medicine and Research - Coast (CGMRC) in Kilifi, Kenya, reviewed and approved the 
study proposal on 5th June 2009. The affiliated Communications and Consent Committee 
(CCC) had reviewed the ethical aspects of the study and recommended for approval prior 
to the SCC meeting.
b) KEMRI Scientific Steering Committee (SSC), based in KEMRI headquarters in Nairobi, 
Kenya, approved the scientific basis of the study on 30th June 2009. The registration 
number for the study is: SSC no. 1651.
c) National Ethical Review Committee (NERC), which is an independent Kenyan ethics 
board, approved the study on 16th September 2009. Ethical approval has been since 
renewed twice in accordance to the local ethics guidelines. The current approval has been 
granted until 12th August 2013.
d) Biomedical Research Ethical Sub-Committee, University of Warwick, UK. This 
committee reviewed and approved the study on 8 th September 2009.
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All the study approval letters are provided in Appendix P
3.10.6 Consent forms and consenting process
Informed consent documents used in this study (Appendix G) were developed and submitted 
for approval to the consent review committees (see the above committees) as an appendix to 
the proposal. The consent forms were later translated from English to Kiswahili and 
Kigiriama, which are languages used by the local community. The process of translation and 
back translation was done jointly by the candidate and the experienced4 field workers, who 
are from the local community and are fluent in both languages. The household study field 
workers (as they were commonly referred) also proof read and made the final corrections in 
consultation with the project manager and the final documents reviewed by the CLG, whose 
members form part of Centre’s Communication and Consent Committee. This final review 
was mainly to ensure the original message in the English consent forms was preserved during 
the translation process.
Informed consent was obtained from the household head and all members of the household 
only after adequate explanation of the study procedures. The study was also explained to 
those aged less than eighteen years (as appropriate) and their verbal assent obtained before a 
signed informed consent was obtained from their parents or guardian. Specific consent was 
sought for storage and later use of the samples.
4 Field workers who have been working in KDH paediatric wards particularly those who 
were involved in the conduct o f RSV surveillance studies since 2002
3.11 Quality control on sample and data collection
Before inception of the study, all the field workers were trained on the conduct of the study 
including its rationale, objectives, procedures and the required documentations. They had 
instructions on filling the data collection forms at all times and the study coordinator and the 
project manager crosschecked the filled forms regularly. The field workers were trained to be 
methodical in their actions as well as to make sure they were clear on exactly what they 
intended to do before arriving at the household. At the end of each visit, a review of the entry 
was carried out before leaving the home. On the return, to the field office at Matsangoni 
dispensary, the field workers had to (i) go through their individual home visit forms to ensure 
that no obvious mistakes had been made (ii) relate any problems encountered in the field to 
the senior field worker or the study co-ordinator or the project manager and also note them 
down for discussion during the weekly meetings and, (iii) enter the details of participants 
from whom NPS and OF had been collected on each day into the sample reception book in 
the dispensary.
The senior field worker, study coordinator and the project manager reviewed the Home Visit 
forms and sample reception log prior to their transfer to KWTRP in Kilifi for data entry. Any 
errors were referred to the respective field worker for immediate corrective action. During the 
initiation and regularly in the course of the study, the project manager and study coordinator 
accompanied the field workers on the home visits to ensure that study questions were asked 
correctly, that samples were collected in proper manner and that the information provided by 
the participants was entered into the forms correctly. Any mistakes made were reviewed and 
the fieldworker advised accordingly. Training of the field workers on study protocol and 
sample collection was done periodically throughout the whole study period.
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Strict measures were taken to ensure that (i) all bottles and tubes for NPS and OF specimens 
were labelled properly before any sample was taken, (ii) all samples had the participant’s 
name, serial number, sample designation and the date of sample collection, and (iii) saliva 
samples were collected for one minute to ensure uniformity. NPS were collected once a week 
from all the field team members including the project manager for viral testing using M-PCR. 
Any infected staffs were relieved off their duties of home visits until recovery (tested 
negative) to minimise chances of infection transmission into the households by the field team 
themselves. Other measures to minimise infection transmission and cross contamination in 
samples included use of gloves in specimen collection and hand washing (using hand 
sanitizers after every specimen collection). Household members were not allowed handle the 
field worker kit.
Data entry was into a specially designed Filemaker database with logical and range checks 
and flags for the reduction of entry errors. The project manager checked the data regularly 
and double entry was done. The two entries were compared and any disparities corrected 
using the original source documents.
3.12 Challenges and how they were addressed
A number of challenges were encountered in the course of the study, most of which are 
highlighted below:
a) Difficulties in community entry: Though we had an elaborate strategy of community 
engagement and sensitisation at the outset various challenges were encountered. This 
included some community members spreading rumours on the nature of our work. Our 
inclusion criteria was challenged in certain areas because of the general concern in the 
local population that the Centre’s research largely ‘targets’ families with young children.
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Community members requested to see more studies involving adults who are similarly 
affected by diseases. Following several meetings with various community groups we 
were able to explain that young children experience a higher burden of diseases and are at 
an increased risk of severe and fatal outcomes relative to adults hence the tendency to 
focus research on this vulnerable age group.
b) Poor acceptability of nasal swabbing: This was one of the anticipated challenges. During 
the first week of sampling when six households withdrew, most citing dislike of the 
swabbing, it appeared this would be a real obstacle to the implementation of the study. 
Sensitisation on the study procedures at this point was heightened and perceived fears 
addressed. Field workers were regularly monitored (and retrained when necessary) to 
ensure the nasal swabbing was done well, i.e. specifically that the swab was inserted 
sufficiently deep and with minimal discomfort. We also started sample collection (once- 
a-week) within the field team members themselves. This helped in rationalising the 
anxiety, fear and discomfort reported during nasal swabbing of the participants as well as 
an opportunity to have peer assessment of the quality of sampling. As the field workers 
gained experience, sample collection was infrequently raised as a concern.
c) Lack of fridge (electricity) in Matsangoni dispensary for ice pack and sample storage. 
Initially it was envisaged samples would be transported to the Kilifi laboratory at the end 
of every day. However, this was found very difficult for the samples collected after 
working hours (after 5pm). Matsangoni dispensary had no electricity supply hence a gas- 
powered fridge was purchased for sample and ice pack storage, distributing workload 
over the entire working hours and beyond.
d) Demanding workload. Long working hours were required in part because of the need to 
fit into the working day of household members and thus visits early and late each day.
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This necessitated recruitment of additional field staff and overtime payment of the field 
workers.
Overall, the above challenges were discussed and solutions found in our weekly meetings. A 
CAST representative regularly attended the weekly meetings especially during the study 
initiation and was invited when community engagement issues were being discussed. This 
was a very important process not only for review of performance and set weekly targets but 
to share good practice and any field issues facilitating early detections of community 
concerns.
3.13 Results
3.13.1 Sensitivity ofM-PCR in detection o f RSV by RNA extraction method 
Previously in Kilifi (Munywoki et al. 2011), viral RNA was extracted using the Qiagen 
extraction method, but due to the large number of samples in the current study, we acquired a 
semi-automated extraction machine that uses either total nucleic acid (TNA) or high 
performance (HP) extraction kits. Before deciding on the kits to use, we conducted an 
experiment to establish the diagnostic performance of the TNA and HP extraction kits in 
detection of RSV A/B against the Qiagen method. Thirty nasal samples collected from an 
outpatient setting study (Munywoki et al. 2011) were randomly selected. The selection was 
limited to only samples previously extracted by Qiagen manual extraction method and 
recording a cycle threshold (Ct) value of above 0. The samples were screened using ‘RSV 
A/B and adenovirus’ triplex after separate extraction of the samples by Magna Pure LC TNA 
and HP extraction kits. Twenty-six samples were positive for either RSV A or B by Qiagen 
(Ct value of <35). Of these positive samples, 17 (65%) and 23 (88%) were found RSV 
positive (using the same Ct cut off value of <35) by TNA and HP extraction kits, 
respectively. Detailed tabulation of the results using varying cut offs are shown in Table 3.4
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below. On comparison of the Ct values from the three extraction methods (Figure 3.10 and 
Table 3.5), the HP kit had similar mean Ct values relative to Qiagen (25.76 vs. 26.26, 
respectively). The TNA kit yielded higher Ct values (Mean Ct value of 31.68).
A further attempt to compare the Qiagen and HP using a large set of nasal samples (n=l 11) 
yielded similar results (see results in Appendix Q).
40-
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Figure 3.10: Scatter plot showing the distribution of Ct values for RSV A/B detection using 
RNA from the three extraction methods. The red lines show the mean Ct values. The Qiagen 
extraction method is used as the reference for the paired t-test.
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3.13.2 Sensitivity o f RSV detection using uniplex and triplex real time M-PCR in 
detection ofRSV A, B and adenoviruses 
A total of 111 samples were screened for RSV A/B and Adenoviruses using both 
uniplex and triplex assays. The samples were randomly selected from the Pingilikani 
outpatient study ensuring a similar representation of the infection status: Positive 
sample for RSV A (30), RSV B (29), Adenovirus (22) and the rest were negative for 
the three viruses based on the initial M-PCR testing (Munywoki et al. 2011). Most 
(88.3%) of the samples used in this experiment were NW. Male participants were 50 
(45.1%). The median age (interquartile range) of the 102 participants with recorded 
birth date was 1.8 (0.8 to 3.9) years. The youngest was 1.3 months and oldest 10.6 
years. Infants were 35 (34.3%).
A set of 60 samples was screened using uniplex real time PCR for RSV group A and 
B while 51 samples for adenoviruses uniplex. All the samples (111) were also 
screened by ‘RSV A/B and adenoviruses’ triplex real-time M-PCR. The uniplex and 
triplex assays had comparable sensitivities in detection of RSV A (95.0% vs. 92.5% 
respectively) and RSV B (97.0% vs. 100%, respectively), Table 3.6. However, the 
adenovirus uniplex assay was more sensitive than triplex method (100% vs. 75% 
respectively) and this was statistically significant (p-value= 0.0156). These results 
were reflected in high correlation of the Ct values for RSV group A and B (97% and 
98%, respectively) unlike for adenovirus (66%) when comparing uniplex Ct values 
with triplex Ct values (Figure 3.11). However a detailed analysis showed Ct values 
for the triplex assay were consistently higher than for uniplex and that was significant 
for RSV group B and adenoviruses, p values =<0.0001 and 0.0003 respectively 
(Table 3.7). However, these differences were in the 1 -  2 Ct range.
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Table 3.6: Respiratory pathogens detected and their sensitivity by screening method
Detections Uniplex sensitivity Triplex sensitivity P value3
Virus (samples1) N n % (95% Cl1) n % (95% Cl2)
Any virus (111) 95 90 94.7 (88.1-98.3) 86 90.5 (82.8-95.6) 0.424
RSV A (60) 40 38 95.0 (83.1-99.4) 37 92.5(79.6-98.4) 1
RSV B (60) 33 32 97.0 (84.2-99.9) 33 100 (89.4-100) 1
Adenoviruses (51) 28 28 100 (88.1-100) 21 75.0 (55.1-89.3) 0.0156
Key: N, total number o f virus detections by either uniplex or triplex which is used as 
the reference for calculation o f sensitivity; n, number ofpositive samples by the 
respective method; %, sensitivity; Cl, confidence interval; RSV, respiratory syncytial 
virus; 1, number o f samples tested; 2, one-sided 97.5% Cl reported sensitivity is 
100%; 3, exact McNemar’s significance probability values reported.
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_ ______    _r __„_____ _r _________________ /  A, RSV B and
adenovirus.
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Table 3.7: Comparison of the Ct values by the screening method
Uniplex Triplex
Virus Mean (95% Cl) Mean (95% Cl) P value
RSVA 3 0 ^ 7 (^ 7 8 6 -_32l8) 30.43(28.29-32.56) '  0.1555
RSVB 30.19(27.70-32.68) 31.76(29.62-33.89) <0.0001
Adenoviruses 32.01 (29.70 -  34.33) 35.42 (33.64 -  37.21) 0.0003
Key; N, total number o f virus detections by either uniplex or triplex used as the 
reference for calculation ofsensitivity; n, number ofpositive samples by the 
respective method; %, sensitivity; Cl, confidence interval; RSV, respiratory syncytial 
virus; adeno, adenovirus; 1, one-sided 97.5% Cl reported sensitivity is 100%; 2, 
exact McNemar’s significance probability values reported.
3.13.3 Comparison o f Ct values for IF AT positive and negative samples 
The IF AT method detects RSV virus in the infected epithelial cells signalling that the 
virus was replicating (and most likely infectious) while the PCR methods detect 
nucleic acid material (in infected epithelial cells or lying in the upper airway). 
Analysis of the Pingilikani data was made to assess the Ct value (from M-PCR) 
distribution in IF AT positive and negative samples. The 43 NPS collections positive 
by IF AT were PCR positive with Ct values of less than 30 except for two NPS 
collections that had no PCR amplification. Additional 31 samples were found RSV 
positive by M-PCR from the 256 NPS collections that were RSV negative by the 
IF AT method. Examining the Ct values further (Figure 3.12) revealed IF AT positive 
had lower mean Ct value compared to the IF AT negatives (22.69 versus 29.19, 
respectively; t-test p-value<0.0001). Older children (>2 years) had higher median Ct 
value relative to the younger counterparts but the difference was not statistically 
significant (Table 3.8 and Figure 3.13).
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Figure 3.12: Histogram of the RSV Ct values by IF AT status. The red vertical line 
shows the cut off for virus positivity. IF AT negative samples with no amplification 
signal (n=219) were excluded from the histogram
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Figure 3.13: Frequency distribution of RSV Ct values by age class. The vertical red 
line indicates Ct value of 35, cut off for viral positivity
Table 3.8: Comparison of Ct values in 78 nasal samples stratified by age
Age classes N Mean1 Median2 IQR
<1 year 29 26.14 23.74 20.00-30.42 Ref
1 -  <2 years 21 25.41 23.46 20.73-29.57 0.8983
2 -  <5 years 19 28.53 28.5 22.7-33.21 0.1429
5 -1 2  years 9 28.84 29.22 22.55-35.4 0.2501
All 78 26.84 25.32 21.00-32.32
Key: N, number samples with a Ct value; IQR, interquanrtile range; 1, mean Ct 
values; 2, median Ct value
3.14 Discussion
The study called for high level of community interaction and a structured community 
engagement process was developed at outset and followed with the aim of involving 
most of the stakeholders. Eligible households were recruited before the start of the 
RSV season of 2009/2010 with sampling initiated immediately after the start of the 
epidemic which was established through the continuous inpatient RSV surveillance at 
Kilifi District Hospital (KDH) (Nokes et al. 2009). Follow-up of study participants 
was through active home visits by a study field team and passive participant visits at 
the study clinic. Sensitive and specific molecular methods were used to screen the 
nasal swabs for a range of common respiratory viruses including RSV. The elaborate 
approach in the study design and implementation involved careful community 
sensitization, adequate training of the field team on communication and sample 
collection procedures, thorough consenting process and continuous feedback from 
study participants, field staff and community leaders. Weekly field team meetings 
closely monitored the study progress and provided a forum to share experiences and
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offer customised response of any concerns was raised. This careful approach yielded 
the high retention rates, as it will be shown in the next Chapter.
The pilot phase of the study allowed time to set up the logistics for frequent home 
visits and sample collection. However, the active surveillance was not easy in study 
phase as scheduled home visits were not always successful and repeat visits were 
often arranged which called for more time. This extra load necessitated recruitment of 
additional field workers in the course of the study. Even though we had one vehicle 
and one motorbike available on weekdays for the project work, it is the use of 
bicycles for follows up (due to poor road network) that facilitated access to all 
households. This also proved to be quite cost-effective.
The quality of samples was important for this study and standardised methods were 
used. The field workers had a month in hospital settings for practice. The pilot phase 
also helped in acquitting themselves with field conditions. The integrity of the 
samples was assured by cold chain storage to maintain adequate epithelial cells: 
though not major issue when using PCR methods. Despite the lack of electricity 
supply in the study clinic, a ‘gas powered fridge’ for temporarily storage was used. 
Samples were transported to the main laboratories at KWTRP in Kilifi town within 24 
hours of collection.
The set frequency of sampling in order to identify most infection cases, and help in 
identifying from whom the infections, arose from careful consideration of the 
reported RSV shedding durations (Okiro et al. 2010). However, infection data would 
be missing in some instances, as the sample collection at all participants’ contacts was 
not possible. In addition, acceptability of NPS collection method among the adults 
and teenagers was initially challenging but our patience in explaining the procedure
seemed to have helped to improve compliance. It is also not clear to what extend our 
decision to offer textbooks to the school going and sweets to the young children 
during the home visits influenced the acceptability rates. We have shown in our 
setting that the NPS is the preferred (-70%) method by both parents/guardians and the 
children relative to NW collection method (Munywoki et al. 2011).
We used sensitive molecular methods in detection of viruses. Earlier studies used 
culture (Hall et al. 1976) and more recent work involved use of IF AT (Okiro 2007). 
These methods (culture and IF AT) have been shown to be less sensitive to PCR 
(Falsey et al. 2003) and more likely to miss infections associated with low viral load 
particularly in older children and adults (Stockton et al. 1998; West et al. 1998; van 
Elden et al. 2003). Molecular techniques detect viral nucleic acid and thus the 
increased sensitivity of the PCR raised questions about the viability of the detected 
virus in causing the infection. This is an area that would require further investigation 
but data from our inpatient studies suggest IF AT identifies participants with high viral 
load and PCR has additional benefit of even detecting individuals with low viral titre 
as depicted by distribution of Ct values for IF AT positive vis-a-vis IF AT negative 
samples. The M-PCR method is expensive but the study was adequately funded by 
the Welcome Trust. Further screening of the nasal samples from the Pingilikani study, 
provided invaluable information on the diagnostic performance of the adopted M- 
PCR assay. We showed that both the uniplex and triplex had good sensitivities (above 
90%) in detecting RSV with no statistical difference in sensitivity of detecting RSV A 
and RSV B by either method. However, there was a slight increase in the sensitivity 
of uniplex in the detection of adenoviruses compared with triplex (p=0.0156). Though 
uniplex seems superior in producing better (lower) Ct values in detection of RSV B 
and adenovirus, the method was labour intensive and costly and therefore lacks merit

in implementation in a large epidemiological surveillance study. The triplex thus, 
offered a suitable alternative for detection of RSV A and B but further evaluation of 
the adenovirus detection is warranted. On extractions, the HP kit was more sensitive 
in detection of RSV relative to Qiagen and TNA kits. Overall, the HP kit had better 
(lower) Ct values compared to Qiagen kit for detection of RSV A, RSV B and 
adenovirus. Therefore these data favoured adoption of HP extraction method and 
indicated non-inferiority in use of our routine real time M-PCR method in detection of 
RSV A, B and adenovirus.
The candidate has experience in field work and sample collection both in hospital and 
community set up (Nokes et al. 2009; Berkley et al. 2010; Munywoki et al. 2011; 
Munywoki et al. 2013). This helped in designing and conducting staff training and in 
the initiation and monitoring of the study progress with particular focus on ensuring 
the study protocol was observed throughout. For instance, experience in working in 
hospital setting helped in training on recognition of respiratory symptoms and sample 
collection, thus standardising the study procedures. Moreover, data collection was 
with a standardized proformas, which have been in use in our site, with questions 
adapted to suit the community study and piloted for clarity and suitability. A manual 
was used as the day-to-day reference guide for the field team.
In conclusion the study employed an elaborate study procedures and the choice of real 
time multiplex PCR would offer advantage in increased sensitivity to detect the target 
viruses.
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CHAPTER FOUR
4 General Results
4.1 Introduction
Household studies are dependent on assessment of infection (s). Increased sensitivity 
and range of pathogens detectable by molecular diagnostics over traditional method 
has boosted the study of virus epidemiology. In order to identify infections in the 
household and the possible chains of transmission, detailed surveillance is required. 
Such surveillance work requires use of suitable and acceptable sample collection 
methods and collection of samples regardless of illness. Reliance on the occurrence of 
symptoms to identify infected persons might result to failure in recognizing sub- 
clinical infections and to identify links in transmission events. However, there are 
very few studies or respiratory viruses which have collected samples frequently and 
irrespective of symptoms (Hall et al. 1976). As a consequence, estimates of the 
proportion of RSV infections that are subclinical are limited, and transmission 
patterns in households are poorly mapped out, especially in older children and adults 
where shedding levels are less than for younger aged individuals. Thus, these issues 
find focus in this study. Even with the intensive sample collections, it is possible that 
some infections, especially mild infections associated with short duration of shedding 
(less than 3 days) or sub-clinical in older children and adults with low viral titers are 
likely to be missed. Efforts to capture these infections require alternate approach such 
as measuring antibody responses in serum. However, blood collection is invasive and 
regular sampling would not be acceptable in the community. Oral fluid (OF) has been 
suggested as alternative specimen for RSV-specific antibody measurement (Okiro et 
al. 2008) and even for viral detection using molecular methods (von Linstow et al.
2006) and was collected once a-week in the current study to supplement infection 
data. The diagnostic performance of this painless collection method was also 
investigated.
This chapter provides the general results of the household study, which lay the 
foundation for the findings presented in the subsequent Chapters.
4.2 Chapter outline
In this Chapter, baseline characteristics of households and the study participants are 
reported. Temporal distributions of RSV and other respiratory viruses are shown with 
particular focus on co-infection with RSV. Included also are the general study results 
related to RSV infections, which set the scene for the findings presented in the 
subsequent Chapters. The proportion of subclinical infections by age and sensitivity 
of oral fluid in the detection of RSV by M-PCR relative to NPS is also presented.
4.3 Methods
Detailed descriptions of the study methods are provided in Chapter 3.
4.3.1 Data analysis
STATA Version 11.2 (StataCorp, College Station, Texas, USA) was used for all data 
analyses in this Chapter. Student’s t-test, Wilcoxon rank-sum test, chi-square test, and 
Fisher’s exact test were used as appropriate. The terms and their definitions used in 
this analysis were described in Chapter 3. Additional terms specific to RSV infections 
are provided in Table 4.1.
Household members were categorised based on the relationship to study infants 
(which was the youngest child at the time of household recruitment) into six groups; 
namely, (i) the study infant, in some instances referred to as self, (ii) siblings, (iii) 
cousins and other relatives (nephew and niece) aged <15 years referred generally as
cousins, (iii) mother, (iv) father or (v) other adults in the household (which included 
aunts, uncles, grandparents, step-mother and other relatives aged >15 years). Trends 
in household recruitment and loss of follow up are presented in the previous Chapter. 
The characteristics of the retained households were compared to those lost to follow 
up. The NPS compliance rates were calculated as the percentage of the collected 
samples divided by the total expected samples based on the specimen collection 
regime (twice-a-week for NPS and once-a-week for OF). The frequency distributions 
of the Ct values for the various targets in the M-PCR assay were also examined. The 
Ct values distributions by age were plotted for RSV, adenoviruses, human 
coronaviruses (OC43, NL63 and 229E) and rhinovirus. Weekly data on virus 
detections were plotted to show the temporal distributions and co-circulation. 
Prevalence of RSV infections and other respiratory viruses in households, individuals 
and samples are shown. In order to calculate the risk of viral infection by clinical 
status at the time of sampling, NPS collections were tested for the full range of targets 
in the M-PCR assay. The prevalence of the detected viruses by clinical status is 
presented.
Primary and co-primary cases of RSV were identified as defined in Table 4.1. Any 
other RSV infection episodes were considered as secondary cases (also defined in 
Table 4.1). Household and age-specific crude attack rates were determined by 
dividing the number of RSV individual episodes by the total number of individuals in 
the respective category. Similarly, secondary attack rates constituted the number of 
secondary cases divided by total uninfected household contacts. Proportions of 
subclinical RSV infections by age and other characteristics were also calculated.
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Table 4.1: Definition of terms related to RSV positivity in the households
Term Definitions
RSV Refers to PCR positive for either RSV groups A or B
Household Period within which one or more individual episodes occurred in
episode members of the same household without an interval of 14 days or more 
in which a positive specimen was absent from the household.
Household Where more than one individual episode occurs within a household
outbreak episode (i.e. where a primary infection spreads to at least one other 
household member)
Primary or The first individual episode within a household based on the dates of
co-primary sample collection. If individual episodes started on the same date in >2
case members of the same household, they were referred as co-primary.
Secondary Any RSV infection episodes occurring after the introduction of the
case virus into the household i.e. all non-primary cases.
Household Household members who were present and not infected during a
contacts household episode.
Key: RSV, respiratory syncytial virus; PCR, polymerase chain reaction 
4.4 Results
4.4.1 Households recruitment
Household recruitment started on 4th November 2009 in Uyombo sub-location. 
Recruitment was extended to include households from Matsangoni sub-location later. 
Regular specimen sampling began on 8th December 2009, after consenting 50 
households and establishing the RSV season had began (see Table 3.1 for definition) 
based on data from our inpatient surveillance at KDH. Nine households withdrew 
during the pilot phase, with 2 replacements. All the study procedures, including NPS
collections every 3 - 4  days, were fully implemented by 11th January 2010, the 
official study start date. Subsequently, a further 4 households were lost to follow-up 
and 8 household replacements recruited with the last recruitment taking place on the 
5th March 2010 and last withdrawal occurring on 7th March 2010. The study closed on 
4th June 2010 after 24 weeks of follow up, Figure 3.10. Overall, 60 households (596 
participants) were recruited and 13 households (103 participants) were lost to follow- 
up. The distribution of the consented households by village and sub-location are 
shown in Table 4.2.
Table 4.2: Distribution of recruited households and participants by residency
Uyombo
Overall
Village HH1 PP2 Mean3 Median (IQR)4 Min Ms
Madeteni 17 ‘ " ~ 7.7 7 0 (5 -  8)~ ~4 28
Sidzeni 5 51 10.2 9.0 (8 -11) 8 15
Kilodi 1 16 16 16 - -
Gongoni 1 7 7 7 - -
Sub-total 24 205 8.5 7.5 (5 -9 ) 4 28
Chambuko
. _  . ..
136 9.7 9.5 (7 -11 ) 4 23
Wireless 7 95 13.6 8.0 (5 -1 9 ) 5 37
Madeteni 7 72 10.3 9.0 (6 -16 ) 4 16
Uyombo 4 46 11.5 10.5 (9 -1 4 ) 9 15
Maweni 4 42 10.5 8.0 (8 -1 4 ) 7 19
Sub-total 36 391 10.9 9 .0 (7 -13) 4 37
60 596 9.9 8 .0 (6 -11) 4 37
Key: 1, number o f households (HH); 2, number o f study participants (PP); 3, the 
mean household occupancy; 4, median household occupancy; Min, minimum number 
o f household members per household; Max, maximum number o f household members 
per household
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4.4.2 Withdrawn households
Of the 13 households lost to follow up, six households were never sampled (declined 
the initial sampling (3) or became ineligible due to separation of parents (2) or out- 
migrated (1)), another six households withdrew in the course of the study with the 
members citing dislike or fear of the frequent nasopharyngeal swabbing, and one out- 
migrated after sampling had started. Most (10/13, 76.9%) of the withdrawn 
households were from Uyombo sub-location where household recruitment started.
Comparisons of the characteristics of the retained and withdrawn households are 
presented in Table 4.3. Most (10/13, 76.9%) of the withdrawn households were from 
Uyombo sub-location where household recruitment started. The proportion of male 
participants in the withdrawn households was higher (57.1%) compared to the 
proportion in retained households, (43.8%), chi square p-value=0.002. The withdrawn 
households had few school-going children relative to the retained households 
(p<0.001). In all the other recorded characteristics the withdrawn (13) households 
were similar to the retained (47) households, Table 4.3. All the subsequent analyses in 
this chapter exclude data from the 13 withdrawn households. The retained households 
were followed for a median (interquartile range, IQR) duration of 24.6 (23.6 -  25.3) 
weeks.
4.4.3 Baseline household characteristics
The mean household occupancy was 10.5 members with a median (interquartile
range, IQR) of 8 (6 -  12) members, Table 4. 3. The smallest households had 4
members (e.g. the study infant, a sibling, mother and father) while the largest
household had 37 members. The frequency distributions of the household sizes are
shown in Figure 4.1. The households comprised of one or more related nuclear
families (parents and children units) as shown in Table 4.4. The prevalence of males
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per household had a mean of 43.8% (95% Cl, 36.4 -  57.1%) while the median (IQR) 
number of older children per household was 4 (3 -  6). On average, the household 
members in each household were 15.5 (95% Cl, 13.2 -  17.9) years old. The youngest 
participant was 13 days old and the oldest 92 years, at recruitment. About a quarter 
(12/46) of the mothers to the study infant had no formal education i.e. had never 
attended school. Uyombo sub-location had bigger household sizes compared to 
Matsangoni, median (IQR) of 9.0 (7 -1 3 ) and 7.5 (5 -  9), respectively, although the 
difference was not statistically significant (p = 0.1475).
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Figure 4.1: Frequency distribution of the size of the 47 retained households. The red- 
dotted line denotes the mean household size
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Table 4.4: Distribution of the number of families per household in the 47 retained households 
by size
Household sizes No. of nuclear families per household
1 2 3 4
4 3 0 0 0
5 5 0 0 0
6 5 0 0 0
7 4 0 0 0
8 8 0 0 0
9 2 1 0 0
10 2 1 0 0
11 2 1 0 0
12 2 0 0 0
14 1 0 0 0
15 0 2 0 0
16 2 1 0 0
19 1 0 0 0
20 0 0 0 1
23 0 0 0 0
28 0 0 0 0
37 0 1 0 0
All households 36 8 0 1
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
2
Key: HH, household; n, number o f households
4.4.4 Baseline characteristics o f  the study participants
The 47 retained households had a total of 493 participants. The age distribution of the cohort 
is shown in Figure 4.2. The characteristics of the study infants are presented first followed by 
the other household members.
60-
50-
%
c  30-
h —o
oZ 20 -
10 -
40 60
Age (years) at start of sampling
80 1000 20
Figure 4.2: Age distribution of the 493 study participants. The red line denotes the mean age 
(see text for details)
i) The study infants
The study infant was the youngest child from each household at the time of recruitment. The 
median (IQR) age at recruitment was 3.9 (2.3 -  6.4) months. The age ranged from 13 days to 
almost 10 months, Figure 4.3(a). Twenty-two (46.8%) were boys. All the study infants were 
bom after 1st April 2009 (see Figure 4.3(b)). The 2008/09 RSV epidemic ended in the first 
week of April 2009 and it was assumed that these children had no RSV exposure before the 
start of the study (as presented in Chapter 3). In 42 of the households, the study infant was 
the only child aged less than one year, while four households had one additional infant and
117
o n e  h o u se h o ld  had  fo u r  o th er  in fa n ts . S ix  o f  th e  a d d itio n a l in fa n ts  w e r e  o ld e r  th an  th e  stu d y  
in fa n t w h ile  tw o  fro m  o n e  h o u se h o ld  w e r e  b o m  and  r e c m ite d  d u rin g  th e  co u r se  o f  th e  stu d y .  
O v er a ll, th e  stu d y  h a d  5 5  c h ild ren  a g e d  le s s  than  o n e  y ear.
0 1  2 3 4 5 6 7 8 9  10
Age, months
1 Apr  1 J u n  1 Au g  1 Oc t  1 De c  1 Fe b  
Date of birth
F ig u re  4 .3 : A g e ,  at recru itm en t, (a ) and  b irth d ate  (b ) d istr ib u tio n  o f  th e  stu d y  in fa n ts . T h e  red  
l in e  s h o w s  th e  m e a n  a g e . T h e  d ate  o f  b irth  sp a n s fro m  1st A p r il 2 0 0 9  to  2 8 th F eb ru a ry  2 0 1 0
ii) Other household members 
In  a d d itio n  to  th e  4 7  s tu d y  in fa n ts , 4 4 6  o th er  h o u se h o ld  m e m b e r s  w e r e  recru ited . T h is  g ro u p  
c o m p r ise d  s ib lin g s  (1 6 4 ,  3 6 .8 % ), c o u s in s  (1 2 4 ,  2 7 .8 % ), m o th e rs  (4 6 , 10 .3 % ), fa th ers (3 3 ,  
7 .4 % ) an d  o th er  a d u lt r e la t iv e s  (7 9 ,1 7 .7 % ) o f  th e  s tu d y  in fa n ts . T h e  m e d ia n  a g e  o f  th e se  
h o u se h o ld  m e m b er s , at r e c m itm e n t, w a s  1 2 .6  (IQ R , 6 .3  -  2 5 .6 )  y e a rs , an d  the a v e r a g e  a g e  
w a s  1 7 .9  y ea rs . F ig u re  4 .4  s h o w s  th e  a g e  d istr ib u tio n  str a tifie d  b y  h o u se h o ld  r e la t io n sh ip s .  
T h is  gro u p  c o m p r ise d  1 99  (4 4 .6 % ) m a le s  and  171 (3 8 .3 8 % ) w e r e  a tten d in g  s c h o o l  at 
r e c m itm e n t. A n  a d d itio n a l 33  c h ild re n  jo in e d  s c h o o l  in  2 0 1 0 .  T h e  p e r ce n ta g e  o f  in d iv id u a ls
1 1 8
sharing a house, sleeping room and bed with the study infant was 53.1%, 33.9% and 22.3%, 
respectively. More details on the characteristics of the study participants are shown in Table 
4.5.
Table 4.5: Baseline characteristics of the study infants and other household members
a) Study infants In study
Number 47
No. of boys (%) 22 (46.8)
Age in months at recruitment, 3.9 (2.3 -  6.4)
median (IQR)
Mother has no formal education 12/46 (26.1)
Father’s occupation status
Employed 7/33 (21.2)
Self-employed 16/33 (48.5)
Farmer 9/33 (27.3)
Not employed 1/33 (3.0)
b) Other household members
Number 446
Male gender, n (%) 199 (44.6)
Age in years at recruitment, mean 17.9
(95% Cl) (16.4-19.4)
Age groups, n (%)
<ly 8(1.8)
l-4y 82(18.4)
5-14y 165 (37.0)
Withdrawn P-value
13 
7 (53.9)
5.0 (2.5 -  5.7)
3/13(23.1)
5/11 (45.5) 
4/11 (36.4) 
4/11 (18.2) 
0(0)
90 
55 (61.1) 
27.9 
(5.7-50.1)
0
21 (23.3) 
30 (33.3)
0.445
0.929
0.569
0.577
0.003
0.059
0.442
119
15-39y
>40
Relation to the study infant 
Siblings 
Cousins 
Mothers 
Fathers 
Others 
Occupation status
Unemployed 
Employed 
Self-employed 
Peasant farmers 
In school1 
Highest education level 
None 
Primary 
Secondary 
Living arrangement2 
In same house 
Sleep in same room 
Sleep in same bed
147 (33.0) 
44 (9.9)
164 (36.8) 
124 (27.8) 
46 (10.3)
33 (7.4)
79 (17.7)
. 164 (36.7) 
16(3.6)
34 (7.6)
61 (13.7) 
171 (38.3)
171 (38.3) 
261 (58.5) 
14(3.1)
237(53.1) 
151/445 (33.9) 
99/445 (22.3)
33 (36.7) 
6(6.7)
34 (37.8) 
18 (20.0) 
13 (14.4) 
11 (12.2) 
14(15.6)
40(44.4)
5 (5.6) 
6(6.7) 
10 (11.1) 
29 (32.2)
35 (39.9) 
53(58.9)
2 (2.2)
55/88 (62.5) 
47/85 (55.3) 
34/85 (40.0)
0.169
0.305
0.024
0.107
<0.001
0.001
Key: 1, additional 33 children joined school in 2010; 2, judged in relation to the study infant
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F ig u re  4 .4 : A g e  d istr ib u tio n s  o f  th e  s ib l in g s  (a ) , c o u s in s  (b ), m o th e rs  (c ) ,  fa th ers (d ) a n d  o th er  
a d u lts  (e )  in  th e  4 7  stu d y  h o u se h o ld s
4.4.5 RSV epidemic o f2009/2010
T h e  start an d  en d  o f  th e  R S V  se a so n  w a s  b a se d  o n  data  fro m  a R S V  su r v e illa n c e  s tu d y  in  
p a ed ia tr ic  w a rd s o f  K D H . M a tsa n g o n i is  o n e  o f  th e  c a tc h m e n t areas o f  th e  K D H  (F ig u r e  4 .5 ) .  
T h e  R S V  e p id e m ic  o f  2 0 0 8 /2 0 0 9  e n d e d  in  th e  w e e k  b e g in n in g  o n  6 th A p ril 2 0 0 9  w h ile  th e  
R S V  e p id e m ic  o f  2 0 0 9 /2 0 1 0  b e g a n  o n  2 3 rd N o v e m b e r  2 0 0 9  an d  e n d e d  o n  4 th J u n e 2 0 1 0  
b a se d  o n  ou r  in p a tien t data. T h e se  d a te s  in fo r m ed  th e  start o f  p ilo t  p h a se  as w e l l  as th e  e n d  o f  
th e  current stu d y , as sh o w n  in  F ig u re  4 .6 .
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Figure 4.5: Surveillance of RSV infection in KDH paediatric wards from 1st January 2009 to 
31st December 2010. The green line (with x markers) shows the weekly number of samples 
tested for RSV while the black and red bars shows number of RSV A and B positive samples, 
respectively. The green and blue bars indicate the pilot and main household study phases, 
respectively
4.4.6 The pilot phase
Sample collection started on 8th December 2009, when RSV season was deemed to have 
begun based on the inpatient surveillance data presented above (Figure 4.5). During the pilot 
phase, households were visited once-a-week for NPS and OF collection for a period of one 
month, up to 10th January 2010. A total of 1,314 individual visits were recorded resulting in 
1224 (93.2%) and 1205 (91.7) collection of NPS and OF, respectively. RSV group A was 
detected in one NPS sample collected on 4th January 2010 from a secondary school-going 
individual, aged 22.0 years, (Figure 4.6).
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4.4.7 The study phase
This phase started from 11th January 2010 to 4th June 2010, when RSV was prevalent in the 
study population, with home visits and NPS collections every 3-4 days. This period 
constitutes the main study data presented.
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Figure 4.6: Standing number of households (HH) participating (blue dotted line) and weekly 
number of RSV group A (black bars) and B (red bars) individual episodes detected, over the 
study period
4.4.8 Home visits and sample collections
Based on our sampling regime of twice-a-week, a total of 19,707 NPS collections were 
expected in the study phase. In practice there was a total of 17,604 (89.3%) participant 
contacts and from these 16,498 (83.7 % of the expected) were collected, Table 4.6. NPS 
collection compliance was highest in study infants (93.5%) and lowest in other adult relatives 
in the households (65.1%). Fathers had 876 (67.1% of the expected) NPS collected compared 
to 1,716 (93.3%) from mothers. In 3,963 (22.5%) of the home visits the study participants
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had one or more symptoms of ARI while in 2,304 (11.7%) of the planned visits the 
participants were away and neither the samples nor the health status data were collected. The 
median (IQR) number of home visits and NPS per individual was 42 (39 -  43) and 39 (30 -  
42), respectively (Figure 4.7). Twenty (4.1%) of the participants from 10 different 
households had no NPS collected during the study phase even though they had one or more 
samples collected during the pilot phase. The trends of the number of home visits, NPS and 
OF collected and ARI over the study period are shown in Figure 4.8.
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Figure 4.8: Trends in number of home visits, NPS, OF and ARI over the follow up 
period
4.4.9 Participant follow up and sample collections
A total of 21,566 visits were recorded during the pilot and main study phase: 21,193 
(98.3%) were home visits, and the remainder clinic visits. In 2,300 (10.9%) of the 
home visits the participant was not available and recorded as being away, i.e. having 
travelled out of the village for more than 3 days. 239 (48.5%) individuals from 40 
different households were reported to have been away at least once in the follow up 
time. The study clinic was utilized by 207 (42.0%) of all the study participants from 
45 different households. A total of 16,924 NPS collections were collected and tested 
from 483 participants. The remaining ten (2.0%) participants (siblings (2), fathers (3), 
grandparent (1) and other relatives (4)) from 8 households were never sampled (NPS). 
The table below (Table 4.7) details the reasons for not sampling from these ten 
individuals. All the 493 individuals from the participant households were included in
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the subsequent analyses unless otherwise stated. While the ten individuals were not 
tested, they could have contributed to transmission in the household and the 
anticipated effect of their inclusion could have minimal reduction in the estimates of 
attack rates since they were few.
Table 4.7: Characteristics of the participants and reasons of no NPS collections
Individual Relations1 Age2 Reason for no NPS collection
1 Father3 41.6 Refused nasal sampling
2 Father 33.5 Mostly absent
3 Father 32.0 Declined nasal sampling
4 Uncle 29.4 Initially refused sampling and later travelled
5 Uncle4 27.5 Refused sampling citing nose bleeding
6 Uncle 21.5 Consistently left the house early and 
returned late from work
7 Grandfather4 81.7 Mostly absent
8 Sister 11.5 Away in boarding school
9 Sister3 8.4 Had oral cavity tumour and died in the 
course of the study
10 Aunt 26.5 Refused nasal sampling citing it was painful
Key: 1, relationship o f the participant to study infant; 2, age in years at recruitment; 
3, indicates individuals from the same household; 4, indicates individuals from the 
same household
4.4.10 RSV infection detections
A total of 16,924 NPS were tested by M-PCR for RSV group A and B from the 493 
individuals of the 47 households. In those PCR positive, RSV group A alone was 
detected in 231 (1.4%) samples, group B alone in 287 (1.7%) and co-infection of
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group A and B in 19 (0.1%). The two RSV groups co-circulated peaking at the same 
time, March to May 2010 (Figure 4.9 and Figure 4.10). A total of 205 individual 
episodes were detected in 179 individuals; 155 individuals had one episode, 22 had 
two episodes and 2 had three episodes. Household episodes were observed in 40 
(85.1%) of the 47 study households (Table 4.8). Further details on RSV infections in 
households including spread within the households are presented in Chapter 6.
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Table 4.8: Summary of RSV infections in households, individuals and NPS
collections
Level RSV A RSV B RSV
a) Households (47)
No. of HH ever infected (%) 25 (53.2) 34 (72.3%) 40 (85.1)
No. of HH episodes per HH
None 22 13 7
One 18 22 17
Two 6 8 12
Three 1 4 8
Four - - 2
Five - - 0
Six - - 1
b) Individuals (493)
No. of individuals ever infected 88 (17.8) 113(22.9) 179 (36.3)
No. of episodes
None 405 380 314
One 81 102 155
Two 5 11 22
Three 1 0 2
No. of RSV episodes 94 124 205
Repeat infections, n (%) 7(7.4) 11 (8.9) 26 (12.7)
c) Samples (16,924)
RSV positive, n (%) 250(1.5) 306(1.8) 537(3.2)
Key: RSV, includes detection o f either RSV group A and/or B; HH, household
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Figure 4.9: Weekly detections of RSV in NPS collections (a), individuals (b), and 
households (c). The navy blue, green and maroon lines denote RSV, RSV A and RSV 
B, respectively. The dashed light grey vertical line shows the start of the main study 
phase
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F ig u re  4 .1 0 :  R S V  A  (a ) an d  R S V  B  (b ) d e te c t io n s  o v e r  th e  stu d y  p e r io d  b y  a g e  in  
y ea rs . T h e  g r ee n  d o ts  in d ic a te  P C R  n e g a t iv e  N P S  c o lle c t io n s  w h ile  P C R  p o s it iv e  N P S  
sa m p le  are red  an d  b lu e  d o ts  fo r  R S V  gro u p  A  an d  B ,  r e s p e c t iv e ly .  T h e  d a sh e d  lig h t  
g r ey  v e r t ic a l lin e  s h o w s  th e  start o f  th e  m a in  s tu d y  p h a se
4.4.11 RSV attack rates and individual episodes
O v er a ll th e  cru d e a ttack  rate o f  th e  c o h o r t w a s  3 6 .3 %  (1 7 9 /4 9 3 ) .  R S V  g ro u p  A  
in fe c t io n  o ccu rred  in  8 8  (1 7 .8 % ) in d iv id u a ls  w h ile  R S V  gro u p  B  w a s  d e te c te d  in  113  
(2 2 .9 % ) in d iv id u a ls . H o w e v e r , th e  r isk  o f  in fe c t io n  w a s  a g e  d e p e n d en t (F ig u r e s  4 .1 1  
an d  4 .1 2  and  T a b le  4 .9 ) .  G iv e n  that th e  a g e  g r o u p s m a p p ed  c lo s e ly  o n to  th e  
ca te g o r iz a t io n  o f  th e  h o u se h o ld  m e m b er s , th e  a tta ck  ra tes b y  a g e  gro u p  an d  b y  
r e la tio n sh ip  to  th e  s tu d y  in fa n t w e r e  s im ila r  (F ig u re . 4 .1 2  a n d  4 .1 0 ) .  T h e  s tu d y  
in fa n ts , s ib l in g s ,  c o u s in s , m o th er , fa ther  and  o th er  h o u se h o ld e r s  h a d  a ttack  ra tes o f  
5 9 .6 % , 4 1 .5 % , 3 9 .5 % , 2 6 .1 % , 18 .2%  an d  2 0 .3 % , r e s p e c t iv e ly .  T h e  cru d e a tta ck  ra tes
^
among those attending school were not statistically different from those for the non­
school goers (38.2% versus 35.0%, p=0.455).
In the 40 households with at least one individual diagnosed with RSV infection, the 
overall attack rate was 40.5% (179/442), Table 4.10. The secondary attack rates were 
again age-dependent with 40.9% of the household contacts aged <lyear being 
infected. Only 11.8% of the household contacts aged 50 or more years were infected. 
Overall, 26.3% (114/432) of the household contacts were infected.
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Figure 4.11: Risk of RSV infection by age at start of sampling (a) and relationship (b) 
to the study infant. See Table 4.9 for details on the age classes used
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Table 4.9: Crude attack rates by age, household size and relationships
RSV A RSV B RSV
Characteristics N n % n % n %
Age in years at 0 -< l 55 16 29.1 21 38.2 31 56.4
start of sampling 1 -< 2 41 10 24.4 12 29.3 20 48.8
1 A U) 41 8 19.5 17 41.5 21 51.2
oV1 89 22 24.7 21 23.6 40 44.9
10 —<15 76 9 11.8 17 22.4 26 34.2
15-<20 44 6 13.6 7 15.9 12 27.3
20-<30 57 7 12.3 6 10.5 10 17.5
30-<40 46 5 10.9 6 13.0 11 23.9
40-<50 25 4 16.0 4 16.0 6 24.0
>50 19 1 5.3 2 10.5 2 10.5
Household size 4 37 11 29.7 18 48.6 22 59.5
6 59 18 30.5 13 22.0 26 44.1
8 91 2 2.2 16 17.6 18 19.8
10 101 7 6.9 27 26.7 32 31.7
15 97 15 15.5 13 13.4 27 27.8
20 108 35 32.4 26 24.1 54 50.0
Relationship to Self 47 13 27.7 21 44.7 28 59.6
the study infant Sibling 164 34 20.7 41 25.0 68 41.5
Cousin 124 21 16.9 31 25.0 49 39.5
Mother 46 8 17.4 7 15.2 12 26.1
Father 33 3 9.1 4 12.1 6 18.2
Other 79 9 11.4 9 11.4 16 20.3
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4.4.12 Subclinical RSV episodes
Of the 205 RSV individual episodes, 87 (42.4%) were not associated with clinical 
symptoms of acute respiratory illness such as cough, runny nose or blocked nose or 
difficulty in breathing. The pattern was not different by RSV groups, RSV group A 
(35/81,43.2%) and group B (50/110,45.5%). Coinfections of RSV A and B were 
linked with fewer asymptomatic infections (2/14,14.3%) (Fisher’s exact P = 0.046 
comparing to the mono-group infections). The proportion of sub-clinical RSV 
infections increased with age (see Table 4.11). Only 3/37 (8.1%) of RSV episodes 
among infants (<1 year) were asymptomatic and that increased across the ages to 
36/45 (80.0%) among the adults (>15 years). RSV episodes associated with male 
gender, presence of other viruses, and individuals not attending school were more 
likely to be asymptomatic compared to their counterparts. The difference on risk of 
subclinical infections by gender was statistically significant only in participants older 
than 12 years.
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Table 4.11: Characteristic of subclinical RSV episodes
Asymptomatic infections
Characteristics Categories N n % P value
Age in years at start 0 -<1 37 3 8.1 <0.0001
of sampling 1 -< 5 49 10 20.4
5 —<15 74 38 51.4
15-<40 36 29 80.6
>40 9 7 77.8
Relationships of the Self 34 1 2.9 <0.0001
households members Siblings 79 31 39.2
to the study infant Cousins 55 24 43.6
Mothers 14 11 78.6
Fathers 6 4 66.7
Others 17 16 94.1
Gender Female 116 59 50.9
Male 89 28 31.5 0.005
Presence other No 122 63 51.6
viruses2 Yes 83 24 28.9 0.001
Other co-infection None 122 63 51.6 Ref.
viruses Adenovirus 23 10 43.5 0.23
Coronaviruses 19 6 31.6 0.092
Rhinoviruses 19 3 15.8 0.001
Mixed 22 5 22.7 0.001
During an RSV No 42 26 61.9
outbreak in HH Yes 163 61 37.4 0.004
Participant in school No 137 47 34.3
Yes 68 40 58.8 0.001
Repeat infections First 179 73 40.8
Second3 26 14 53.9 0.208
Infecting RSV group A 81 35 43.2 Ref.
B 110 50 45.5 0.771
A & B 14 2 14.3 0.072
Key: 1, nonparametric test for trend across the age groups; 2, Presence o f any o f the 
other viruses (rhinoviruses, adenoviruses, and coronaviruses) during the RSV 
episode; 3, includes the second and the third RSV repeat infections per individual; N, 
number o f RSV infection episodes; R ef reference category
4.4.13 The Ct values distribution for the viral targets in the real time M-PCR assay 
A total of 16,924 nasal samples from both the pilot and study phase of the household 
study were screened. In 1226 (7.2%) of the NPS screened, a Ct value for either RSV 
group A or B was recorded. Of the common respiratory pathogens screened for, a 
bimodal distribution of the Ct values was observed in RSV group A and B, NL63 and 
2293 (Figure 4.13). Ct values for adenovirus, OC43 and rhinovirus had a unimodal 
distribution. The mean Ct values increased with age (Table 4.12). Individuals aged 5 
years or more had NPS collections with higher mean Ct values than the younger 
counterparts. This phenomenon was observed for adenoviruses, coronaviruses and 
rhinoviruses (see Figures and Tables in Appendix R).
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OC43, NL63 and 229E are strains of human coronaviruses
4.4.14 RSV ‘suspected’ repeat infections
Twenty-four (13.4%) participants experienced more than two RSV infection episodes. 
Most (17/24, 70.8%) of the repeat infections were with homologous RSV group 
(group A (6) and group B (11)) while 29.2 % (7/24) were with heterologous group 
(Table 4.13). The median (IQR) interval between homologous ‘reinfections’ was 
shorter (24.5 (21 - 37) days) than for heterologous ‘reinfections’ 54 (47 - 62) days), 
Wilcoxon rank sum test, p=0.0006. Data on genetic diversity of the infecting RSV 
variants based on sequencing of the long ectodomain of the RSV attachment gene are 
presented in Chapter 6.
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Table 4.13: Identity of the infecting RSV group of first and second episodes
Second episodes1
RSV groups A B
Interval2 n % Interval2 n %
First episodes A (N=7) 25 (20-31) 6 85.7 49 (-) 1 14.3
B (N=17) 59(45-62) 6 35.3 30.1 (21 -38 ) 11 64.7
Key: 1, two individuals had three episodes but only the second is included in the 
tabulation. One individual had the three RSV group A episodes while the other had 
RSV group B for the first and second and RSV group A for the third episodes; 2, 
median (IQR) interval between episodes in days
4.4.15 The most prevalent respiratory pathogens during the study period 
In line with the strategy to establish the most prevalent respiratory viruses in the 
community during the study period, NPS collections from six households were 
screened for the full range of respiratory viruses targeted by the M-PCR assay. The 
baseline characteristics of these households are presented in Table 4.14 and Figure 
4.14. Of the 2,644 samples screened, 279 (10.6%), 250 (9.5%), 214 (8.1%), 151 
(5.7%), 61 (2.3%), 19 (0.7%), 10 (.4%), and 9 (0.3%) were positive for rhinoviruses, 
adenoviruses, coronaviruses (OC43, NL63, or 229E), RSV (group A or B), PIV (type 
1,2, 3 or 4), Mycoplasma pneumoniae, influenza viruses (type A, B or C) and hMPV, 
respectively (Figure 4.15). In addition to RSV group A and B, rhinoviruses, 
adenoviruses, and coronaviruses (OC43, NL63 and 229E) were the most prevalent 
respiratory viruses and taken forward for screening from the rest of NPS collections.
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Figure 4.14: Age distribution of individuals in the six households screened for a full 
range of respiratory viruses. Red dotted line shows the mean age in years
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Table 4.14: Baseline characteristics of 83 individuals from six households tested for
all virus targets
Characteristic Statistic
Household size, Median (IQR) 10.5 (5 -15 )
No. (%) of school-going children 21 (25.3)
Number (%) male individuals 31(37.4%)
Median (IQR) age, at start of sampling 10.3(3.5-27.5)
Age groups, in years1
<iy 10(12.1)
l-4 y 16(19.3)
5- 14y 24 (28.9)
15- 39y 22 (26.5)
V JL 11(13.3)
Key: IQR, interquartile range; 1, age at start o f sampling
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Figure 4.15: Frequency distribution of the detected respiratory viruses in 2644 NPS 
collections from 83 individuals of the six households with full respiratory screen. 
Rhino, rhinoviruses; Adeno, adenoviruses; OC43, NL63 and 229E are strains of 
coronaviruses; RSV A and B, respiratory syncytial virus group A and B; PIV 1,2, 3 
and 4, parainfluenza type 1, 2, 3, and 4; Mycoplasma; mycoplasma pneumoniae; 
HMPV, human metapneumoviruses; Flu A, B and C, influenza type A, B and C
4.4.16 Common respiratory viruses in the study cohort
The 16,924 NPS collections were tested for rhinovirus, adenovirus, coronaviruses 
(OC43, NL63 and 229E) as well as RSV (group A and B). Of these samples, 4326 
(25.6%) had one or more viruses detected. Rhinovirus and coronaviruses were 
detected in at least one person from the 47 households while adenovirus and RSV 
were detected in 45 (95.7%) and 40 (85.1%) households, respectively, Table 4.15 and 
Figure 4.16. The individual attack rates were 93.4%, 80.1%, 71.6%, 61.5% and 37.1% 
for any virus, rhinoviruses, coronaviruses, adenovirus and RSV, respectively. These
145
viruses circulated throughout the study period as shown in Figure 4.17. On average, 
each individual had three unique viral infections over the ~6-month study period, 
Figure 4.18.
Table 4.15: Virus detections in households, participants and NPS collections from the 
483 participants from the 47 study households
Detected respiratory viruses in:
Virus Households (N=47) Individuals ll OO Ui N—/ NPS (N==16924)
n % n % n %
Any virus 47 100.0 451 93.4 4326 25^6
Rhinovirus 47 100.0 387 80.1 1760 10.4
Coronaviruses 47 100.0 346 71.6 1268 7.5
OC43 44 93.6 212 43.9 645 3.8
NL63 33 70.2 163 33.7 418 2.5
E229 30 63.8 119 24.6 241 1.4
Adenovirus 45 95.7 297 61.5 1232 7.3
RSV 40 85.1 179 37.1 537 3.2
Group A 25 53.2 88 18.2 250 1.5
Group B 34 72.3 113 23.4 306 1.8
Key: 1, Excludes 10 participants who were never sampled.
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Figure 4.17: Weekly detections of the most prevalent viruses in NPS collections from 
the 47 study households. The vertical dashed line denotes the start of the main study 
period. Rhino, rhinoviruses; Adeno, adenoviruses; corona, coronaviruses; RSV A/B, 
respiratory syncytial virus group A and/or B
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4.4.17 Prevalence o f viral co-infections with RSV
A b o u t  a quarter (1 3 3 )  o f  th e  R S V  p o s it iv e  N P S  c o lle c t io n s  w e r e  a lso  p o s it iv e  fo r  
o th er  resp ira to ry  v iru ses: a d e n o v ir u se s  (1 0 .1 % ), r h in o v iru se s  (9 .5 % ) and  
c o r o n a v ir u se s  (8 .6 % ). S im ila r  fr e q u e n c ie s  o f  c o - in fe c t io n s  w e r e  n o te d  fo r  th e  R S V  
in fe c t io n  e p is o d e s  ( s e e  T a b le  4 .1 6 ) .
Table 4.16: Respiratory viruses co-detected with RSV in NPS collections
a) Co-detection o f viruses in RSV A
same NPS collection
n
Any virus 68
Adenoviruses 31
Rhinoviruses 17
Coronaviruses 32
OC43 23
NL63 5
229E 4
R SV B
% %
27.2 72 23.5
7.512.4 23
6.8 38
12.8 18
9.2 8
RSV1
%
133 2478
54 10.1
2.0
1.6
12.4
5.9
2.6
2.3
1.0
51
46
31
9
6
9.5
8.6 
5.8 
1.7 
1.1
b) Viral co-infections during an RSV infection episodes1
No. of co-infection2
Any co-infection
Adenovirus
Coronaviruses
Rhinovirus
Mixed3
53
40
9
11
7
13
57.0 73 61.3
43.0 46 38.7
9.7 14 11.8
11.8 11
122 59.5
83 40.5
7.5
14.0
9.2 
12 10.1
9 7.6
23
19
19
22
11.2
9.3
9.3 
10.7
Key: 1, A total o f537 samples were positive fo r RSV (250 with RSV group A and 306 
with group B) 2, total o f205 RSV episodes (94 with group A and 124 with group B);
2, co-infection defined as detection o f another virus during the period o f an RSV 
episode but not necessarily in the same sample; 3, two or more viruses detected 
during the RSV episode
4.4.18 Prevalence o f viruses stratified by clinical status
The selection of the samples for this analysis was staggered. First, 229 samples
collected when 41 infants were symptomatic for ARI were selected. This samples
covered only the period between 1st January and 31st March 2010. This first batch
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was also aimed at identifying the common respiratory viruses in the cohort hence the 
focus in the susceptible the age group i.e. under one year of age. The second batch 
included 343 samples from 163 participants with ARI at time of collection selected at 
random from the full study period. For comparison purposes, a further 446 samples 
collected during asymptomatic times from 283 participants randomly selected. A full 
respiratory screen was done in all the 1018 NPS collections to identify the prevalence 
of viral detections by ARI status: 572 samples from individuals who had symptoms of 
ARI and 446 samples from individuals without ARI at the time of sample collection. 
The age distributions of the 362 participants involved in this analysis are shown in 
Table 4.17. The two groups (ARI and non-ARI) had statistically significant 
differences by age and sex composition. This is largely to the poor sample selection 
criteria adopted.
Table 4.17: Baseline characteristics of the 362 participants
Characteristic ARI (N=201) No ARI (N=283) P-value
Age in years, mean (95% Cl) 11.4 (9.4-13.4) 16.9(14.9-18.9) 0.0002
Age at the time of <i y 41 (20.4) 34 (12.0) 0.001
sample collection, nl l-<5y 46 (22.9) 49 (17.3)
(%) 5-<10y 39 (19.4) 54 (19.1)
10-<20y 38(18.9) 58 (20.5)
20-<40y 26 (12.9) 56 (19.8)
>40 11 (5.5) 32(11.3)
Male gender, n (%) 96 (47.8) 102 (36.0) 0.0098
Key: ARI, acute respiratory illness
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Table 4.18: Frequency distribution of respiratory virus detection by ARI status
ARI (N=572) No ARI (N=446)
Detected viruses n % n % P value1
Rhinoviruses 158 27.6 16 3.6 <0.0001
Adenoviruses 70 12.2 7 1.6 <0.0001
RSV 71 12.4 17 3.8 <0.0001
Group A 38 6.6 9 2.0 0.0005
Group B 33 5.8 8 1.8 0.0014
Coronaviruses 50 8.7 20 4.5 0.0077
OC43 38 6.6 14 3.1 0.0117
NL63 6 1 5 1.1 1
229E 6 1 1 0.2 0.144
Parainfluenza viruses 22 3.8 0 0 -
Type 1 0 0 0 0 -
Type 2 8 1.4 0 0 -
Type 3 12 2.1 0 0 -
Type 4 2 0.3 0 0 -
hMPV 3 0.5 0 0 -
Influenza viruses 1 0.2 3 0.7 0.325
Type A 0 0 0 0 -
Type B 0 0 1 0.2 -
Type C 1 0.2 2 0.5 0.585
Mycoplasma pneumoniae 0 0 0 0 -
Key: l,from chi- square test except for NL63, 229E and Influenza viruses; ARI, acute 
respiratory illness; Rhino, rhinoviruses; Adeno, adenoviruses; OC43, NL63 and 229E 
are strains o f coronaviruses; RSV A and B, respiratory syncytial virus group A and B
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Figure 4.19: Prevalence of viruses by ARI status. Rhino, rhinoviruses; Adeno, 
adenoviruses; corona, coronavirures (OC43, NL63 and 229E); RSV, respiratory 
syncytial viruses (group A and B); PIV, parainfluenza viruses (type 1,2, 3 & 4); FLU, 
Influenza viruses (type A, B and C); hMPV, human metapneumoviruses
4.4.19 Oral Fluid sensitivity in detecting RSV by the M-PCR assay 
In assessing the diagnostic performance of oral fluid, 59 randomly selected OF 
samples with paired NPS that were RSV positive were screened for RSV by M-PCR. 
Overall, 23 OF samples were reported positive giving a sensitivity of 39. 0 (95% Cl;
26.5 -  52.6), Table 4.19. The sensitivity was similar for detection of the two RSV 
groups (36.1% and 42.9% for group A and group B, respectively, p=0.583). The 
sensitivity of OF samples increased where the paired NPS had low Ct values (56.3% 
for Ct values <25), were from young ages (61.5% for under 5 years) or were from 
symptomatic episodes (52.2% when associated with ARI). On average the Ct values 
from the OF samples were lower than those for NPS (28.14 vs. 36.14 respectively; 
Paired t-test P value <0.001.) The pattern did not differ on limiting the analyses to 
samples positive by both sampling method, Table 4.20. Use of an alternative
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screening test (Fast-track Diagnostics, Luxembourg) did not improve the diagnostic 
performance of OF in detection of RSV (Data shown in Appendix S).
Table 4.19: Sensitivity of oral fluid in detection of RSV by M-PCR
No. of RSV Sensitivity
Characteristic Categories N Positives % 95% Cl P-value
Overall All 59 23 39.0 26.5 -52.6 -
NPS Cts >30-35 23 7 30.4 13.2-52.9 0.107
> 25-30 25 10 40.0 21.1-61.3 0.309
<25 16 9 56.3 29.9-80.2 Ref.
RSV group RSV A 36 13 36.1 20.8-53.8 0.583
RSV B 28 12 42.9 24.4-62.8
Age (years) <5 y 26 16 61.5 40.6-79.8 0.002
>5y 33 7 21.2 9.0-38.9
Age (years) <i y 9 5 55.6 21.2-86.3 Ref.
1 -  <5 y 17 11 64.7 38.3-85.8 0.692
5 -  <10 y 13 4 30.8 9.1-61.4 0.3842
>10 y 20 3 15.0 3.2-37.9 0.067
Gender Female 29 12 41.3 23.5-61.1 0.711
Male 30 11 36.7 20.0-56.1
ARI Yes 23 12 52.2 30.6-73.2 0.097
No 36 11 30.6 16.3-48.1
Key: ARI, acute respiratory illness; 1, chi-square test except for characteristic with 5 
or less RSVpositive samples; Ref; reference category
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Table 4.20: Comparison of NPS and OF Ct values for detection of RSV by M-PCR
NPS OF
Detection Mean Ct 95% Cl Mean Ct 95% Cl P value
a) Both NPS and OF positive (N=25)
RSV 26.9 24.8-29.0 30.9 29.3-32.5 0.001
Group A (16) 18.9 12.6-25.1 31.1 28.8-33.4 0.009
Group B (9) 19.2 9.9-28.5 30.5 28.4-32.5 0.023
b) All the screened sample (N=59)
RSV 28.1 26.9-29.4 36.1 34.8-37.5 <0.001
Group A (38) 28.6 27.0-30.3 37.2 35.6-38.8 <0.001
Group B (28) 26.3 24.6-28.0 37.7 36.0-39.4 <001
Key: Comparison in (a) included only samples that were PCR positive (Ct value <35) 
for both NPS and OF while (b) included all samples (recoding the Ct values for OF to 
40 i f  the Ct was indeterminate); N, number ofsamples tested
4.4.20 RSV-specific antibody profiles in OF samples
Samples of OF from a household with five members consisting of the study infant (1 
month old at start of sampling), a sister (2 years), two brothers (6 and 9 years) and 
mother (29 years) were tested for RSV-specific antibody titers using ELISA method 
as described in Chapter 3. All except the study infant and the mother had low 
antibody titres at the start of the study (Figure 4.20). There was measurable antibody 
rise for the four individuals with PCR-detected RSV infections. However, additional 
peaks were observed which were not associated with RSV detections by M-PCR.
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Figure 4.20: Antibody profiles for five members of the same household with 
consistent weekly OF collections. The navy blue line shows the RSV-specific 
antibody profiles while the maroon filled circles show the PCR detections of RSV in 
NPS collections. The vertical dashed line denotes the start of the main study phase. 
O.D, adjusted optical density; age shown was at the start of sampling
4.5 Discussion
We report infection data from 47 households with 493 individuals followed for 24 
weeks during a single RSV epidemic. A total of 16924 deep nasopharyngeal swabs 
were collected twice-a-week regardless of symptoms and screened for a range of 
respiratory viruses including RSV. The detailed infection data provided adequate data 
to allow investigation of transmission of the viruses within the household. Data on 
transmission patterns within the household are presented in Chapter 6.
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The study was carefully implemented and monitored (as detailed in Chapter 3) 
yielding a high retention rate of 78% of the recruited households and high compliance 
in sample collection of over 80%. About 16,500 (about 84% of the expected) NPS 
were collected over the 24-week study period. Compliance in sample collection was 
higher among the study infants, older children and their mothers (over 80%) in 
comparison to their fathers and other adults in the households (~ 65%). Previous 
family studies have reported poor compliance from male parents and our compliance 
of about 65% is relatively high (Hall et al. 1976; Okiro 2007). It is also likely that the 
provision of free health care at the study clinic and monthly home visits by the 
clinician for health check contributed to the high acceptability and compliance in 
sampling.
RSV seasonality as captured from the inpatient RSV surveillance at KDH paediatric 
wards, guided the start and end of the household study. KDH is the main inpatient 
facility in the district and it has been estimated that over 60% of the paediatric 
admission arise from the area under demographic surveillance which covers 
Matsangoni location, the site of the current study (Moisi et al. 2011; Scott et al. 2012). 
Based on the inpatient data, the household study was initiated in time before the RSV 
epidemic began covering the 24 weeks of RSV circulation in the community. There 
was a lag of about 6 weeks in detection of RSV cases in Matsangoni relative to the 
District hospital auguring well for the present study. This could be attributed to 
variability in temporal and/or spatial patterns of RSV infections throughout the KDH 
catchment area. It would be worthwhile to assess whether RSV spreads systematically 
within the District or by pure chance causing the local epidemics. For study purposes, 
the lag allowed the pilot phase to be completed in time with the study phase
157
conveniently capturing most of the local RSV epidemic. It is no surprise the RSV 
epidemic in Matsangoni was shorter relative to KDH for it is a function of susceptible 
population size within the study location -  the household study captured cases within 
a small area of Matsangoni location only.
Co-circulation of both the RSV Group A and B during the 2009/2010 RSV season 
was captured in the two concurrent studies (Matsangoni household and KDH inpatient 
study). This was useful in distinguishing infection episodes and transmission events 
within households as reported here and in Chapters 5 and 6.
The study cohort had appreciable RSV attack rates with (85.1%) of the household and
(36.3%) of the study participnats being infected. Existing data suggests infants are
most susceptible to RSV infection (Glezen et al. 1986; Nokes et al. 2009) and in the
current study; they had high attack rates of about 60%. The risk of infection declined
with age with a slight increase in attack rates for 30-49 year olds which could be
related to higher contact rates between young children and parents particularly
mothers. Mothers had higher attack rate relative to the fathers (26.1% vs. 18.2).
Similar pattern of attack rates by age were reported in the Rochester family study
(Hall et al. 1976) and could be attributed to acquisition of partial protective immunity
following virus exposure in successive RSV epidemics (Glezen et al. 1986). Our
estimates of attack rates were higher relative to the Hall et al study, which could be
explained by methodological differences. In the current study, deep nasopharyngeal
samples were collected over a longer period (24 vs. 8 weeks) and screened with a
more sensitive molecular method (relative to culture in the Hall study). Other family
studies such as the Seattle virus-watch studies (Cooney et al. 1972; Cooney et al.
1975) and Berglund serologic study (Berglund 1967) of family members of children
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admitted with RSV infection reported considerable attack rates in older ages 
(reviewed in Chapter 2). The role of the older children and adults in transmission is 
further investigated in Chapters 5 and 8. Smaller households with 4 - 7  members had 
high attack rates relative to large households probably due to close contact network in 
these households: all were nuclear family units compared to households with more 
than 8 members which comprised of several nuclear family units (45.5% had two or 
more families).
About half (42.4%) of the reported RSV episodes were asymptomatic occurring 
mainly in older children and adults. These findings have implications for the 
interpretation of results from studies relying on symptoms for RSV surveillance. Such 
studies would underestimate the RSV infection rates particularly in older ages groups 
and are not suitable for identifying links of infection spread. Clinical severity during 
the first and second RSV episode was similar. Males were more likely to be 
asymptomatic relative to females indicating a possible reporting bias.
Rhinoviruses, adenovirus and coronaviruses were the most prevalent respiratory 
viruses co-circulating with RSV. It is surprising very few cases were positive for 
influenza viruses despite the scare of pandemic influenza during the course of the 
study. Previous studies have reported co-circulation of hMPV with RSV, which was 
not obvious in this study (Semple et al 2005). Over 90% of the study participants had 
at least one virus detected and on average three different viral infections over the six- 
month period of the study. Co-infections were not uncommon with about 40% of the 
RSV episodes being associated with coronaviruses, rhinoviruses, or adenoviruses. A 
long-term (at least one year) community surveillance study would offer a more
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comprehensive data on seasonality of these respiratory viruses and their temporal 
association with RSV.
More viruses were detected in samples collected during a concurrent acute respiratory 
illness relative to when no ARI symptoms were present. This pointed to an aetiologic 
link of the viruses, however, a properly designed nested case-control study with 
clearer definition of ARI and proper matching of randomly selected controls would 
provide better data.
Poor diagnostic performance of OF in detecting of RSV by M-PCR and ELISA 
limited the use of OF to supplement the RSV infection data. Few studies have 
evaluated the sensitivity of OF but available data suggest higher sensitivity of about 
73% relative to nasopharyngeal aspirate (von Linstow et al. 2006). Our estimate of 
39% was generally low. However, the sensitivity was better in samples with lower Ct 
value (75% when Ct value was <25 in the paired NPS) or when symptomatic (52%) 
and in young age groups (61.5% in <5years old). The above observations suggest OF 
would be useful in settings associated with high viral load like hospital inpatient 
settings or studies targeting children in their first few years of life. Further work is 
recommended to explore whether use of alternative molecular screening methods 
such as RNA UltraSense (One-Step Quantitative RT-PCR System, optimised for low 
viral load detections, Applied Biosystems) to improve the sensitivity. Collection of 
OF was acceptable to most of the study participants resulting in high compliance of 
over 90% as shown in Chapter 3. Even though only OF samples from one household 
were screened, the observed RSV-specific antibody profiles were qualitatively less 
discriminatory in detecting additional RSV infections. However, screening of more
OF samples is justified before a conclusive assessment is made.
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CHAPTER FIVE
5 Who Brings RSV Infection into Households and Who Infects the Infants
5.1 Introduction
Human respiratory syncytial virus (RSV) is a major cause of childhood acute lower 
respiratory tract infection (LRTI) worldwide (Nair et al. 2010). The virus is 
characterised by seasonal outbreaks usually, though not always, occurring annually, 
(Waris 1991; White et al. 2005; White et al. 2007), and is transmitted efficiently in 
early life: approximately 60% of newborns are infected during their first epidemic 
(Glezen et al. 1986). Infection can occur in young infants despite the transfer of 
maternally derived passive antibodies (Ochola et al. 2009). The risk of severe 
respiratory disease following RSV infection is highest in infants, particularly those 
under 6 months of age (Ohuma et al. 2012). Together these factors lead to the 
observation of the vast majority of severe RSV disease cases, including seasonal 
congestion in hospital admissions, comprises infants and especially young infants 
(Vardas et al. 1999; Hussey et al. 2000; Nokes et al. 2009).
Set in this context, vaccine development, in particular live attenuated virus vaccines, 
has primarily targeted infants aged under 3 months. However, no human RSV 
vaccine has yet been licensed. The early infant presents severe obstacles to 
vaccinologists in the form of immunological immaturity, presence of maternal RSV- 
specific antibodies, and balancing between immunogenicity and the risk of upper 
respiratory tract congestion associated with live vaccines (Karron et al. 2005). 
Alternative strategies for RSV vaccination have therefore been proposed (Anderson et 
al. 2013), including delaying delivery to an older age (Nokes and Cane 2008), for
which there is empirical support. Live attenuated vaccines have been found safe and 
immunogenic in seronegative children 6 months of age and over (Gonzalez et al. 
2000; Karron et al. 2005; Wright et al. 2007); sub-unit RSV vaccines boost protective 
antibodies in previously infected individuals (Paradiso et al. 1994; Englund et al. 
1998; Power et al. 2001; Langley et al. 2009) and 40%-60% of RSV associated 
community severe and hospitalised disease occurs in children 6 months and above 
(Nokes et al. 2008; Hall et al. 2009; Nokes et al. 2009). Delaying vaccination of 
young infants to 6 months of age would fail to directly protect those most at risk of 
severe RSV disease. However, the risk of severe disease arising from RSV infection 
falls rapidly with increasing age beyond 6 months (Ohuma et al. 2012), probably as a 
result of physiologically maturation leading to increased airway size (Machata et al. 
2010). Thus significant reduction of infection in young infants during their first RSV 
season would have a big impact on RSV associated mortality and morbidity. Delayed 
first infection of infants could move them to an older age group where the risk of 
RSV is significantly lowered. Consequently, a natural question is whether vaccination 
of older (>6 months) individuals in a community can provide additional, indirect 
benefit, by preventing them infecting the vulnerable early infant. This could be 
achieved by either targeted interruption of chains of transmission leading to infant 
infection, or reducing virus circulation within the community that eventually leads to 
a more indirect lowering of the risk of infant exposure (Fox et al. 1971). The potential 
impact and design of vaccination programmes aimed at delaying infant infection will 
be intimately linked to understanding the source of the infection for infants, which is 
the subject of the current chapter.
5.2 Chapter outline
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This chapter presents data on the spread of RSV in the study households. The aim is 
to ascertain where infants derive their infection from and whether particular members 
of a household play significant roles in transmission to infants. A subsequent chapter 
(Chapter 7) will address in details the estimation of transmission probability of RSV 
in households and in the community.
5.3 Methods
The study methods were described in Chapter 3.
5.3.1 Statistical analysis
The set of terms and their definitions used in the data analysis are given in Tables 3.1, 
and 4.1. The characteristics of households with infant infections were compared with 
those with no infant infections. Infected individuals were categorised as (i) study 
infant, also referred hereafter as the infant, (ii) older child (sibling or cousin), (iii) 
mother, (iv) father or (v) other adults in the household in line with description 
provided in methods section of Chapter 4. Infant infections were categorised as 
originating from outside the household when the infant was the only primary case or 
was the first individual identified RSV positive in a household outbreak, and from 
within the household if at least one individual other than the study infant was the first 
identified as RSV positive in a household outbreak. The origin was deemed 
inconclusive where the infant and another household member were concurrently first 
to be identified as RSV positive (i.e. co-primary cases) during a household outbreak. 
For within household spread and co-primary cases, RSV attachment (G) gene 
nucleotide sequences (see method below) for the primary case(s) and infant infections 
were compared.
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5.3.2 Attachment (G) gene sequencing and phylogenetic analysis 
Sequencing targeted the long ectodomain region of the RSV G gene as previously 
described (Agoti et al. 2012). The sequences were aligned using the Bioedit program 
(http://www.mbio.ncsu.edu/bioedit/bioedif). RSV group A and B separately. 
Comparison of the primary-infant cases for RSV group A involved a 648 nucleotide 
long region and a 732 long region for RSV group Bs. Only one RSV positive 
specimen (with the lowest Ct values) from each of the pairs was selected for 
sequencing. Phylogenetc trees were constructed in MEGA 5 program with Maximum 
Likelihood methods and branch support was assessed by 1000 bootstrap iterations.
5.4 Results
Details on household recruitment and loss to follow-up are found in the results section 
of Chapter 4. Of the 47 households with complete follow up data, three households 
were excluded from analysis because the study infant was not sampled during the 
periods when RSV was detected in their households. All subsequent analyses in the 
current chapter thus include data from the remaining 44 households.
5.4.1 Baseline characteristic o f the 44 households and their members
The baseline characteristics are similar to those reported in the results section of
Chapter 4. In summary, the household mean occupancy was 10 members with a range
of 4 to 37 members, Table 5.1. The prevalence of males per household was on
average 46.5 (95% confidence Interval, Cl, 41.2-51.8) while the median (IQR)
number of older children per household was 4 (3 -  6). Members in each household
were on average aged 15.9 (range, 9.3 -  24.6) years. The median (IQR) age of the 44
study infants was 4.2 (2.4, 6.4) months and range of 13 days to 9.9 months, at
recruitment. Twenty-one (47.7%) were male (Table 5.1).
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Table 5.1: Baseline characteristics of the study participants and households
Characteristic
a) Study infants (N=44)
Description Statistics
Male gender
Age at recruitment in months 
b) Other household members (N=407)
Number (%) 
Median (IQR)
21 (47.7) 
4.2 (2 .4 -6 .4 )
Male gender Number (%) 186(45.7)
In school Number (%) 154 (37.8)
Age in years at recruitment Mean (IQR) 12.6 (6.6-26.5)
Frequency distribution 0-<ly Number (%) 6(1.5)
of members by age in 1 -4y 74 (18.2)
years at recruitment 5-14y 153 (37.6)
15-39y 133 (32.7)
40+y 41 (10.1)
c) Households (N=44)
Household sizes Median (IQR) 8(6 -11 .5 )
No. of older children (1-14 years) per HH Median (IQR) 4 ( 3 - 6 )
No of school-going children per HH Median (IQR) 4 ( 3 - 6 )
No. of members living in the same house Median (IQR) 5 ( 3 - 6 )
as the study infant
Mothers with no formal education Number (%) 10/43 (23.3)
Duration of HH follow-up in weeks Median (IQR) 24.8 (23.6-25.3)
Key: HH, household; IQR, interquartile range
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5.4.2 Household visits and sample collections
From the 44 households, a total of 16434 contacts with the participants were made 
obtaining 15,396 (93.7%) NPS. The median (IQR) number of NPS collections per 
individual was 39 (30 -  42). Further details on the overall sample collections are as 
found in Chapter 3.
5.4.3 RSV infections in households
Overall, 84.1% (37/44) and 38.4% (173/451) of the households and individual 
participants, respectively, had one or more episodes of RSV infection. The RSV 
infection patterns are presented in Appendix T. A total of 73 separate introductions 
into households were identified with 32 (43.8%) resulting in a household outbreak. 
The 32 outbreaks were identified in 27 households: one outbreak in 23 households (8 
with RSV group A, 14 with RSV group B and 2 with a co-infection of both) and two 
outbreaks in 4 households (2 with RSV group A followed by group B, and 2 with 
consecutive RSV group B). The study infant was infected in 28 (87.5%) of the 
household outbreaks. 5.2. The age distribution of the RSV infections in the 28 
infected infants is shown in Table 5.2. Households with RSV spread among the 
members had a higher mean number of older children than those without RSV 
infection, though not statistically significant (mean, 95% Cl, of 6.0,4.4 -  7.6, vs. 3.3, 
1.8-4.8; P value= 0.08), Table 5.3.
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Table 5.2: RSV infections among the 44 study infants
Age in months No. in study No. Infected Crude attack rates
0 1 0 13/19 (68.4%)
1 6 4
2 6 5
3 6 4
4 5 3 9/16 (56.3%)
5 5 3
6 6 3
7 5 2 6/9 (66.7%)
8 1 1
9 3 3
Total 44 28 63.6%
Key: 1, age at the start o f sampling by month
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5.4.4 Characteristics o f households with and without study infant RSV infections 
There was no statistically significant difference in households with study infant 
infections relative to those without in terms household size, household composition 
and the infant characteristics, Table 5.4.
Table 5.4: Characteristics of households with and without study infant RSV infections
Characteristic1
HHs with no infant 
infection (n=16)
HHs with infant 
infection (n=28)
P
value
Household size 8 ( 7 - 9 ) 9(6-14.5) 0.4
Mean age of HH members, years 16.0(14.2-17.8) 15.8 (14.3-17.2) 0.8
Age of the study infant, months 4.3 (3.1-5.5) 4.7 (3.7-5.7) 0.6
Number of older children in HH 4 ( 3 - 5 ) 5(3-7.5) 0.2
Percentage Male per HH 50.0(40.0-57.1) 41.4 (35.8-57.7) 0.4
No. of school-going children 4 ( 2 - 4 ) 4 ( 3 - 7 ) 0.2
No. of HH members living in 6 (4 .5 -6) 4.5 (3 -  6.5) 0.2
same house with study infant
Key: HH, household; 1, Reported statistics are the median and interquartile range 
except for age, mean and 95% confidence interval
5.4.5 Who introduces RSV into the households
From the 73 household episodes, a total of 71 different individuals were primary 
cases among which 31 (43.7%) individuals were associated with the 32 household 
outbreaks detected, Table 5.5. Primary cases of all household episodes were study 
infants, 15 (20.5%); older children, 36 (49.3%); study infants and older child, 4 
(5.5%); mothers, 9 (12.3%); fathers, 4 (5.5%); and other household members, 5
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(6.8%). The corresponding distribution of the primary cases for household outbreaks 
was 7 (21.9%), 16 (50.0%), 4 (12.5%), 2(6.3%), 1(3.1%), and 2 (6.3%), Table 5.5.
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5.4.6 Source of the infant infections
Of the 73 separate household episodes identified, 37 were linked with study infant 
infections involving 28 of the 44 (63.6%) study infants: 21 had one episode, 5 had 
two episodes and 2 had three episodes. Household episodes of infection that resulted 
in the infection of the study infant are depicted in Figure 5.1. The 28 first infant 
infections were associated with an outbreak in 24 (85.7%) households. Subsequent 
results on the infant infections were limited to the first episodes, when the infants 
were RSV nai've. Seven infants (25.0%) had RSV A infection (s), 15 (53.6%) RSV B 
infection(s) and the remaining 6 (21.4%) had both RSV A and B infection in their 
first episode. Based on the temporal pattern of infections in each household, 15 
(53.6%) of the 28 study infant infections were acquired through transmission within 
household while 9 (32.1%) were acquired from outside the household. The source of 
infant infections in the remaining 4 (14.3%) households was inconclusive because the 
household episodes had a sibling and the infant as co-primary cases, Figure 5.2. 
Samples were successfully sequenced for the RSV G gene region in 10 of 15 primary 
case and study infant pairs with all pairs showing complete homology of nucleotide 
sequence (Table 5.6 and Figure 5.3.) In the remaining 5 in which sequencing failed 
one or more samples of each pair had a high cycle threshold (Ct) value from the real 
time M-PCR, a proxy for low virus load. Sequences from the co-primary cases were 
identical in three of the four sibling-infant pairs. The primary cases for the 15 study 
infants who acquired the infection from within the household were older children 
(11), mothers (1), fathers (1) and other adults (2). A similar distribution of primary 
cases was seen for analysis of all household episodes and outbreaks (Table 5.4). Ten 
of the 11 older children who were primary cases were attending school and one, an
adult (uncle to the study infant, aged 17 years), was in secondary school. The mean 
age at recruitment of these older children was 6.9 years with the youngest 2.3 years 
and oldest 11.5 years. In the 4 households where siblings were co-primary ca'ses with 
infants, two were attending school.
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Sibling or cousin 
(11,39.3%)
Study infant and 
sibling (4,14.3%)
II Infected study infants \
Mother (1, 3.5%)
Study infant 
(9, 32.1%)
Father (1, 3.5%)
/Other adults 
(2, 7.1%)
Figure 5.2: Distribution of the primary cases linked with the 28 study infant infections in 
rural Kenyan households. Only the first household episodes/outbreaks involving the study 
infants were considered. The light and dark shades indicate outside and within household 
acquisition of the infant infections, respectively, and the area of the circle is in proportion to 
numbers of cases in each category
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Table 5.6: Sequencing the G gene of infant-primary case pairs
HH Sequenced2 No. of nt
ID. Relation1 Infant? Index? G gene changes3
26 Sibling4 Yes Yes Identical -
51 Sibling4 Yes Yes Identical -
16 Sibling Yes Yes Identical -
29 Sibling Yes Yes Identical -
40 Sibling Yes Yes Identical -
57 Sibling Yes Yes Identical -
14 Sibling Yes Yes Identical -
5 Sibling Yes Yes Identical
38 Sibling Yes Yes Identical
45 Sibling Yes Failed - -
3 Cousin Yes Failed - -
25 Mother Yes Failed - -
17 Father Yes Failed - -
44 Other Yes Failed - -
47 Other Yes Yes Identical -
19 Self & Sibling Yes Yes Different 1
31 Self & Sibling Yes Yes Identical5 -
35 Self & Sibling Yes Yes Identical -
6 Self & Sibling Yes Yes Identical -
Key: 1, relation o f the primary cases to the study infant; 2, the G gene region sequenced in 
RSVpositive samples where the study infant appear to have acquired the infection from  
within the household or the study infant was a co-primary case; 3, all nucleotide changes 
were non-synonymous; 4, more than one sibling was primary cases; 5, two household
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participants were not sampled while the infant got the infection and one was shedding the 
virus on the first sample collected and the virus in the infant matches with virus in the index 
but one position showed mixed population; HH ID, household identifier; nt, nucleotide; 
index refers to the primary and co-primary case
a) RSV group A (b)RSV group B
HH'4703/02-04-2010 
A  HtV5701/1003-2010 
A  H1V4701/06U4-2010 
HH/2904/21-02-2010 
A  HW2901/24-02-2010 
HH/1404/01-03-2010 
A  HH/1401/08-03-2010 
HH/5707/0J4»-2010
A  HH/3101/16-04-2010 
A  HH/3101/17-05-2010 
HH/310KK5-04-2010 
HH/3105/26-04-2010 
HH/3108/30-03-2010 
A  HH/0504/25-03-2010 
8^0516/12 03-2010 
A  HH/4001/22-02-2010 
HK'4004/15-02-2010
HHOSOaOOOI-ZQIO 
AHH/3801/27-02-2010 
A  HHU501«M!1-2010 
MH/18Q3/2S-02-2010
 A  Hm901/02-03-2010
HH/3803/14-02-2010 
HH/1602/24-02-2010 
A  HH/1601/07-03-2010
A  HH0601/0904-2010 
A  1#W)601/11-03-2010 
HH13603/11-03-2010 
A1W5101/0OOJ-2010 
HH'5104/24-02-2010 
HH'5106/24-02-2010
100
100
Figure 5.3: Phylogenetic tree showing the G gene similarity in the study infant-primary case 
pairs for RSV (a) group A and (b) group B. Infant cases are preceded by a dark filled triangle. 
The scales for branch lengths of group A versus B are different. The name of the taxon HH/ 
household number with individual ID/ date of sampling
5.4.7 Timing o f RSV infections among the study infants
When considering day 0 to be the day of first RSV detection in the household outbreaks, the 
median (IQR) duration to infection of the study infant, first older child, mother, father and the 
first other household adults was 5 (0.8 -  5), 0(0 -  3), 5 (3 -  12), 18 (8.5 -  21.5) and 14.5 (0 -  
15) days. Overall the infants were infected early in course of household outbreaks, Figure 
5.4.
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Figure 5.4: Distribution of days to onset of RSV shedding during household outbreaks by 
household members. Day 0 is the first day of RSV detection in the household
5.5 Discussion
The Chapter reports on analysis designed to determine who introduces the RSV infection into 
the household with particular emphasis on the source of RSV infection to RSV naive infants, 
as those who are most vulnerable to disease from RSV infection. The aim was to establish the 
proportion of infants infected from a source from within the immediate household and, if so, 
which household member was responsible for introducing RSV into the infant household. 
Data from rural coastal Kenya are presented for 44 households with 451 members recruited 
and followed actively for NPS collection every 3-4 days regardless of symptoms during a full 
RSV epidemic. RSV infection was detected in 84% of the households and 38.4% of the 
participants. Both the two known RSV subtypes (A and B) circulated in the community 
during the study period, which assisted in distinguishing transmission events.
180
The study infant was infected at least once in 28 of the 44 households with about a third 
(32.1%) acquiring the infection from outside the household and about half (53.6%) from 
within the household. In the remaining (14.3%) households, the source of infant infection 
was undetermined as the infant and sibling were co-primary cases. Children attending school 
were key (80%) contributors in the within household transmission. Mothers or fathers were 
less likely to be the primary cases. There were no statistical differences between the 
individual or household characteristics of infected and uninfected infants, suggesting that 
differences between households are largely based on chance or unobserved characteristics. In 
addition, the distribution of the primary cases for all household episodes and outbreaks of 
RSV was similar, indicating it is not the person who brings the infection into the household 
that determines if the infection spreads or not, but may be chance, or an unobserved 
characteristic of the household such as whether an outbreak was experienced in the previous 
year(s).
Only one study in the past has looked at the spread of RSV within households in detail (Hall 
et al. 1976). Hall and colleagues recruited 36 US families with young infants, collecting nose 
or throat samples twice-a-week regardless of symptoms during two months of an RSV 
season, assessing infection using viral culture (Hall et a l 1976). RSV was detected in 16 
(44.4%) of the families and 21.9% of the 188 members, which were lower than in the current 
study (84.1% and 38.4%, respectively). Based only on temporal occurrence of infections, 
RSV appeared to be introduced into the 16 infected families by siblings in 8 (50%) families; 
other household members including parents in 3 (18.8%) families and 5 (31.3%) involved an 
infant (co-primary cases). The corresponding statistics for the 32 household outbreaks 
recorded in our study, was 16 (50%), 5(18.8%) and 11 (34.4%). As in our study, these 
findings highlight the importance of older children in introducing RSV into households with 
young infants. Our study also shows that children with daily contact with many other children
particularly in schools are important in bringing RSV infections into the households. Other 
less comparable studies have implicated siblings (Badger et al. 1953; Berglund 1967; Fox et 
al. 1975; Okiro 2007; Crowcroft et al. 2008) and mothers (Stensballe et al. 2004) with 
infection of the infant in the family. However, none of these previous studies (Badger et al. 
1953; Berglund 1967; Fox et al. 1975; Stensballe et al. 2004; Okiro 2007; Crowcroft et al. 
2008) were designed specifically to identify the source of infant RSV infections in families. 
The present study and that of Rochester family study (Hall et al. 1976) were designed for the 
purpose of identifying transmission chains by sampling frequently and irrespective of 
symptoms. However, methodologies have changed since that of Hall et al (Hall et al. 1976). 
The current study has the advantages of increased sensitivity in case detection using PCR and 
of sequence data support for observed primary-infant infection pairs. Additionally, the US 
study is likely to have missed infections early in the RSV epidemic due to sampling delay 
and suffered a high proportion of co-primary cases restricting the ability to identify the 
relative individual contributions as infection sources into the families. Nevertheless, the 
consistency of results given the contrasting locations and different times, suggest that the 
important role of a school-age sibling in bringing infection into the household is not unique to 
a particular social and demographic setting.
The results support the notion that preventing infection in school-going children could 
indirectly reduce RSV infection in infants. However, an assessment of the impact of such an 
intervention requires consideration of the competing risks, e.g. somebody else might 
introduce infection if not the vaccinated individual, or the infant might be infected in the 
community if not the household. However, targeted sibling immunisation would nonetheless 
result in fewer susceptible individuals within the household which would reduce spread and 
provide indirect infant protection, and any reduction in rate of infection to infants will 
translate into a delay in infection to an older age which is associated with reduced risk of
severe disease. These results also point to schoolchildren as the “core-group” for RSV. 
Consequently, universal immunisation of children (regardless of their sibling status) could 
have an impact on circulation of RSV in the community (especially in communities such as 
this one in typical rural Africa with a large numbers of children), thus further reducing the 
risk of infant infection. However, such an intervention is more likely to interrupt the 
transmission dynamics of RSV and potentially change seasonality and the age-distribution of 
susceptibility and infection. A postdoctoral scientist in our research group in Kilifi, is 
currently conducting modeling studies to further understand the detailed transmission within 
the household and the impact of mass immunization to address these issues.
The current study has also some limitations. First, generalizability of the results is limited in 
that households were specifically selected if they had an older child, and the number of 
households was small in number and within a tight geographical area populated by rural 
farmers. Second, the frequency of sampling might have missed short duration RSV shedding 
(if less than 3 days), including primary cases, despite the intensive sampling. For some cases 
where the infant is the primary or co-primary, the index case may have gone unidentified. 
This risk is bigger than the alternative (where the infant was actually the first but was not 
detected), because the sampling of infants was more complete and was mainly infected in the 
first few days once the infection was introduced into household. It is therefore plausible that 
our estimate of the importance of within household spread as a source of infant infections is 
an under-estimate. Third, given that diagnosis of RSV in adults is more difficult than in 
children (Falsey et al. 2003), the role of parents or other adults in household RSV may have 
been under-estimated. However, the use of sensitive real time PCR will have mitigated this to 
a significant degree. The use of serological identification of cases might have reduced 
misclassification of infection but would not have assisted in resolution of transmission 
chains. Following a recent collaboration with Sanger Institute in United Kingdom, there is
ongoing work using next generation sequencing and full genome sequencing to identify any 
molecular fingerprinting that might help to delineate the chains of RSV spread within the 
households.
In conclusion, the study demonstrates that in this rural Kenyan location, for a larger 
proportion of infant RSV infections the most likely source is from an individual from within 
the household and also predominantly introduced into the household by an elder school-going 
sibling. Thus there is potential for targeted immunisation of older siblings of naive infants, or 
universal vaccination of older infants and children, in reducing the spread of RSV and the 
risk of infection entering households and delay first infection in infants to an older age where 
associated severe disease is less of a risk.
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CHAPTER SIX
6 Duration Of RSV Shedding
6.1 Introduction
RSV primarily infects the upper respiratory tract, with predilection for the deep nasopharynx, 
where it multiplies and is shed from epithelial cells to exit via nasal secretions. The virus also 
spreads to the lower respiratory tract infection (LRTI) but only in a small proportion of 
infected individuals, suggesting that upper respiratory tract infection (URTI) is more 
important than LRTI in the shedding and spread of virus, although this will also depend on 
the viral load shed. Community-based studies are thus likely to provide a more complete 
representation of the RSV shedding patterns. Further more, RSV repeatedly infects 
throughout life (Henderson et al. 1979; Glezen et al. 1986; Agoti et al. 2012). While repeat 
infections are considered less severe relative to the primary infections, they constitute the 
bulk of RSV infections during the annual epidemics observed worldwide. The role of the 
repeat infections in the overall transmission of RSV in the population is likely to be related to 
the amount and duration of shedding.
Studies estimating duration of RSV shedding reviewed in Chapter 2 (Table 2.3) report the 
duration to be in order of days albeit with considerable variations in the estimates. The 
variation in the reported estimates could be explained by differences in: (i) sampling regimes 
i.e. the type of specimen and frequency of collection and whether collected regardless of 
respiratory symptoms; (ii) differences in study settings: hospital studies are biased to young 
children with severe RSV disease with the additional problem of failing to objectively 
establish the start, and, in some instances, the end of shedding particularly when patients 
recover before they stop shedding, a phenomenon in RSV (Frank et al. 1981) and, (iii) 
differences in sensitivity of the specimen screening methods, culture versus
immunofluorescence methods. Early studies relied much on viral culture and with labile 
nature of the RSV virus specimen handling was likely to affect the sensitivity especially if 
samples were not inoculated immediately on collection, a concern raised in some of the 
studies (Frank et al. 1981). The current study was designed with the above factors in 
consideration. Given that samples were collected every 3 to 4 days regardless of symptoms 
and tested using PCR, the accruing RSV infection data is detailed to allow estimation of 
shedding duration. Even with this design, the problems of ascertainment and analysis (i.e. 
censoring and test sensitivity) cannot be completely eliminated. Short infectious episodes 
(occurring between sampling times) would be missed.
Other viruses infecting the respiratory epithelium might interfere with RSV infections and 
possibly alter the disease severity if they occur concomitantly. Presence of other respiratory 
viruses, before or during RSV infections, might alter the RSV infection duration since they 
are likely to have ecological competition. These possibilities have received very little 
attention in the literature, and are explored in the current Chapter.
Estimates of the duration of shedding are key to delineating the virus transmission dynamics 
in mathematical models to predict the potential population impact of vaccines against RSV. 
The basic reproductive number is directly proportional to the duration of viral shedding, for 
instance the basic reproductive number would be greater by two times if the duration of 
shedding was doubled in an randomly mixing and susceptible population, underscoring the 
importance of realistic estimates. In addition, development of RSV control strategies is likely 
to depend on the mechanisms of the virus persistence and spread within a population, which 
are intrinsically related to the viral shedding patterns. Detailed data on the shedding duration 
among non-hospitalized individuals in relation to factors such as age, RSV group (A or B), 
infection severity, presence of viral co-infections and gender would help in identifying from 
whom most viruses come from.
6.2 Chapter outline
In this chapter, RSV shedding duration is estimated from all episodes of RSV infections 
within the household study. The effect of age, RSV group, clinical severity, gender, presence 
of concurrent infections and other persons infected in the household on rate of cessation of 
RSV shedding is assessed. Of these, the factor of key interest is age, which can also be used 
as a proxy for the number of previous infections.
6.3 Materials and methods
The data arise from the household study, which was described in Chapter 3. In this Chapter, 
data from the 179 individuals from 40 households infected with PCR positive NPS during the 
study period were included.
6.3.1 Statistical analysis
Data were analyzed using STATA version 11.2 (Statacorp, College Station, Texas, US) and 
first converted to time-to-event data. Student’s t-test, Mann-Whitney U test, chi-squared test, 
and Fisher’s exact test were used as appropriate for descriptive analysis. The time of sample 
collection was recorded and plotted graphically to determine if the sensitivity of the test (i.e. 
viral shedding) had an obvious diurnal rhythm or collection bias. An individual RSV episode 
was defined as the period within which an individual provided specimens which were PCR 
positive for the same infecting RSV group with no more than 14 days separating any two 
positive samples (defined in Table 3.1). Episodes whose first sample of the infection was 
positive for both RSV A and B were considered as a co-infection and counted as one 
individual infection episode.
6.3.2 Estimation o f shedding durations
Since the exact date of start and end of RSV shedding could not be directly determined from 
the interval censored data, three estimates of shedding duration were made based on the
following criteria as illustrated in Figure 6.1. Let the first day of an infection episode be 
defined as i and the last day as j ,  and the first negative sample day prior to the infection 
episode defined as k  and the first negative sample after the last positive sample of an episode 
defined as /, assigning day k arbitrarily a value 0 increasing by daily units up to day /.
Further, assume that i and j  contribute each one full day of shedding and days k and / 
contribute 0 days of shedding, then for:
a) Minimum estimates: shedding begins on day i and ends on day j  (inclusive) with the 
shedding duration defined as j - i + 1 days.
b) Midpoint estimates: shedding begins mid-way between day k+1 and day i, and ends mid­
way between date j  and date l- l , with the shedding interval defined as (j+(l-j)/2)-(i-(i- 
k)/2). For episodes, whose interval between the last negative and first positive (left 
censored) and last positive and first negative (right censored) was greater than 7 days, one 
half of the average interval between sample collection was subtracted from the date of the 
first positive and added to the date of the last positive sample, respectively, to define the 
start and end of shedding.
c) Maximum estimates: shedding begins a day after k and ends day before 1, hence the 
shedding duartion is defined as l-k-1. For left and right-censored episodes the average 
interval between sample collections was subtracted and added to define start and end of 
the shedding respectively.
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Figure 6.1: Schematic diagram illustrating the timeline for each individual and important time
points used in estimating shedding durations. Minimum estimates, j-i+1, Midpoint estimates,
(j+(l-j)/2)-(i-(i-k)/2), and maximum estimates, 1-k-l
The person-time was calculated as the number of days from start date of shedding to the end 
of the infection episode (recovery date). An individual whose last NPS was PCR positive or 
the last sample of an infection episode was followed by duration of more than 7 days without 
NPS collection was considered right censored. Recovery rates were calculated as the number 
of recovery events, in RSV infected individuals, divided by the sum of person-days of being 
PCR positive. Kaplan-Meier plots were used to show the distribution of survival times 
(probability of shedding cessation over the observed PCR positive periods) for all categorical 
variables explored. Estimation of shedding durations (and recovery rates) by age, gender, 
presence of acute respiratory infection (ARI) symptoms, and presence of other viral co- 
infections were made. ARI was defined as presence of one or more of the following 
respiratory symptoms at the time of sample collection; cough, nasal discharge/blocked nose, 
or difficulty in breathing (Table 3.1). Co-infection was assigned when within the RSV 
infection episode any sample was PCR positive for another virus (see Table 4.1 for 
definition). Presence of other respiratory viruses in the samples collected in the period of 14 
days prior to start of RSV episodes was also defined. Household outbreak was defined as a 
period within which one or more individual episodes occurred in members of the same 
household without an interval of 14 days or more in which a PCR positive specimen was 
absent from the household. The proportion of the household members infected during 
household outbreaks measured the intensity of the outbreak.
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6.3.3 Cox regression analysis
Cox proportional hazards model was used to assess factors influencing the RSV shedding 
durations. The null hypothesis was that there is no association between the duration of viral 
shedding and age, presence of ARI or other viral infections or concurrent infections in the 
household. The unadjusted hazard ratios (HR) from the univariate analysis based on the data 
from the three approaches are presented but only the midpoint data were used in the final 
multivariate model. The multivariate Cox regression model was developed by a forward 
stepwise procedure rejecting variables with a p-value >0.05 in likelihood ratio tests. Infecting 
RSV group, gender and detection of a second RSV infection were selected apriori for 
inclusion in the final model as possible confounders. Covariates were introduced in 
descending order of strength of association determined from univariate analysis. Robust 
variance estimator (Huber-White sandwich estimator) was used to derive adjusted 95% 
confidence intervals (Cl) to account for within-household correlation of recovery. The effect 
of left censoring was accounted for by including a dummy variable denoting the left censored 
infection episodes or by excluding the left censored episodes. Schoenfeld residuals were used 
to test the proportionality assumption, which underlies the Cox regression method.
6.3.4 Attachment (G) gene sequencing and phylogenetic analysis
This was aimed at delineating cases of suspected repeat infections by sequencing the part of 
the G gene and phylogenetic analysis as described in Chapter 3 and 5. For sequencing, only 
one RSV positive sample (with the lowest Ct values) from each of the paired episodes was 
selected for sequencing.
6.4 Results
6.4.1 Baseline characteristics o f the RSV infected individuals
Data from the household prospective cohort study was used in this analysis with focus on the 
179 individuals infected with RSV (Table 6.1). Thirty-one (17.3%) were under 1 year,
41(22.9%) between 1 to 4 years, 66 (36.9%) 5 to 15 years and the rest (22.9%) above 15 
years of age at the time of infection. The individuals were between the ages of 1.9 months 
and 78 years at time of infection; only 9 were above 40 years. The median age (inter quartile 
range, IQR) was 6.5 (2.4 -  14.5) years, and females numbered 96 (53.6%). A total of 205 
infection episodes were recorded with 155 individuals experiencing one episode, 22 with two 
episodes and two individuals experiencing three episodes during the single RSV epidemic. 
RSV group A was associated with 88 infection episodes, RSV group B with 113 while 7 
episodes were with co-infection of RSV group A and B. Figure 6.2 shows all the observed 
infection episodes stratified by the infecting RSV group.
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(a) RSV group A (b) RSV group B
113- 40+y
100 15-39y
5-14y
1-4y
<iy
0 10 20 30 40 50 60 70 80
88- 40+y
80:
15-39y
5-14y
1-4y
<iy
0 10 20 30 40 50 60
Duration in days Duration in days
Figure 6.2: RSV group A (a) and group B (b) episodes ordered by age of the individuals 
infected. RSV positive samples are marked by blue ‘x’ while the red line links PCR positive 
samples from the same infection episode. Appendix U shows the RSV infection episodes by 
order of occurrence within the households.
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Table 6.1: Baseline characteristics of the 179 study participants and the associated
RSV infection episodes
Persons1 Episodes Shedding periods3 
(N=493) (N=205) (N=2176.9)
Covariates Categories n % n % n %
Age in <iy 55 11.2 37 18.1 613.7 28.2
years, at l-<5y 82 16.6 49 23.9 540.7 24.8
start of 5-<15y 165 33.5 74 36.1 654.1 30.1
sampling 15-<40y 147 29.8 36 17.6 276.5 12.7
>40y 44 8.9 9 4.4 91.9 4.2
Relations4 Study infant 47 9.5 34 16.6 586.7 27.0
Sibling 164 33.3 79 38.5 739.7 34.0
Cousin 124 25.2 55 26.8 553.1 25.4
Mother 46 9.3 14 6.8 124.9 5.7
Father 33 6.7 6 2.9 34.0 1.5
Other 79 16.0 17 8.3 138.5 6.4
Gender Female 272 55.2 116 56.6 1223.4 56.2
Male 221 44.8 89 43.4 953.5 43.8
RSV group A - - 81 39.5 796.4 36.6
B - - 110 53.7 1138.3 52.3
A andB - - 14 6.8 242.2 11.1
Infection First - - 179 87.3 1932.9 88.8
Second - - 26 12.7 244.0 11.2
ARI No - - 87 42.4 635.3 29.2
Yes _ 118 57.6 1541.6 70.8
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Coinfection No - - 119 58.1 958.6 44.0
Yes - - 86 42.0 1218.3 56.0
During HH No - - 42 20.5 290.8 13.4
outbreak Yes - - 163 79.5 1886.1 86.6
Outcomes
Durations5 <7 days 74 36.1 328.0 15.1
7 -< 1 4  days - - 75 36.6 683.9 31.4
15-<21 - - 32 15.6 517.5 23.8
days
>=21 days - - 24 11.7 647.5 29.7
Key: 1, number o f individuals in the parent study; 2, RSV infection episodes; 3, total 
infection durations based on midpoint estimation; 4, the relationship o f a household 
members with the study infant; 5, duration o f RSV shedding episodes; ARI, acute
respiratory illness; HH, household
6.4.2 Sampling collection times
There was no association of sample collection hour and RSV detection (Figure 6.3), 
hence all the shedding duration estimates assumed the samples were collected at the 
same time of the day.
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Figure 6.3: (a) Frequency distribution of the total, RSV group A and RSV group B 
positive, sample collections by time of collection and (b) percentage of the samples 
positive for RSV group A, RSV group B or either group by time of sample collection, 
‘m’ on the x-axis represents samples with missing time of collection
6.4.3 Censoring and sample collection intervals
Of the 205 RSV episodes, 177 (86.3%) were fully observed i.e. negative samples 
before and after the RSV episode were collected within 7 days. Two individuals 
tested positive in their first sample and 9 infection episodes were detected following a 
period of absence of more than 7 days from the household (left censoring). Right 
censoring was observed in 15 infection episodes; in 4 episodes the last PCR positive 
sample was the last sample collected for the individual while in 11 the last positive 
sample was followed by a period of no sample collection (mainly occurring when the 
individual travelled) for more than 7 days. Two episodes had both left and right 
censoring. Table 6.2 shows the distribution of sampling intervals, age at infection and
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estimated shedding duration by the censoring type. The average interval between 
sample collections during RSV infection episodes was 3.5 (95% Cl, 3.4 -  3.6) days 
with a median (IQR) of 3 (3 -  4) days (Figure 6.4). The mean intervals prior to and 
immediately after the infection episodes for the fully observed episodes were not 
statistically different; 3.7 (95% Cl, 3.6 -  3.9) versus 3.7 (95% Cl, 3.6 -  3.8) days 
respectively; t-test P-value=0.4819. The correlation of sampling intervals before and 
after RSV episodes is graphocally shown in Appendix V.
(a) RSV negative
50-
40-
30-
c©o Median (IQR): 3 (3 - 4) days 95th percentile: 8 days 
Mean (SD): 4.3 (3.8) days20-<DQ.
10 -
30$1510 20 250 5
(b) RSV positive
50-
40-
30-cocj Median (IQR): 3 (3 - 4) days 95th percentile: 5 days 
Mean (SD): 3.7 (1.6) days
20 -<D
CL
10 -
Interval (in days)
Figure 6.4: Distribution of the intervals between NPS collections during RSV 
negative (a) and PCR positive periods. The red dashed vertical line represents the 
mean interval; $, in 29 instances the interval between RSV negative samples was 
more than 30 days
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6.4.4 Duration ofRSV shedding
The mean duration (95% Cl) ofRSV shedding based on minimum, midpoint and 
maximum estimates was 8.6 (7.5 -  9.7), 11.2 (10.1 -  12.3) and 14.0 (12.8 -  15.2) 
days (Table in Appendix W). The corresponding mean durations of shedding for the 
fully ‘observed’ episodes were 8.2 (7.1 -  9.4), 10.9 (9.8 -  12.1) and 13.6 (12.4 -  14.8) 
days. The duration of shedding from the midpoint approach had a median (IQR) of
8.5 (5.5 -  14.0) days and range of 1 -  44 days (Figure 6.5). The RSV recovery rates 
are shown in Appendix X.
(a) Minimum
50-
25-
o-
Median (IQR): 5.9 (2.9 -12.0) days
r t J L r f l  x i EL
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c) Maximum
_ r r j Q j I L J
Median (IQR): 12.0 (8.0 -17.0) days
X I
10 20 30
Shedding duration (days)
40
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(b) Midpoint
E  50-
Median (IQR): 8.5 (5.5 -14.0) days
25-
50
Figure 6.5: The frequency distribution of the days to cessation of shedding by method 
of estimation using the data from all the 205 episodes. The dotted red line shows the 
mean duration of shedding (see text for values). IQR, interquartile range
6.4.5 Univariate analysis: Factors influencing the rate o f cessation o f RSV shedding 
The Kaplan-Meier plots showing the association of the various factors and recovery 
probability arising from midpoint analyses are shown in Figures 6.6 and 6.7. The
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hazard ratios (HR) for the various factors from univariate Cox regression were similar 
for minimum, midpoint and maximum estimates data and are shown in Appendix Y.
(a) Age groups (b) RSV groups (c) Gender
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RSVA 
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Figure 6.6: Kaplan-Meier survival function plots of midpoint data for cessation of 
RSV shedding stratified by age at infection in years (a), RSV groups (b), Gender (c), 
order ofRSV infection episodes (d), presence of acute respiratory symptoms during 
the RSV episode (e) and number of other co-infecting viruses (f). The legend for each 
graph is shown in the respective inserted text box.
200
(a) Prop, infected in HH (b) Prop, infected in HH
1.00" ~*^
<0.33
0.33-0.65
&0.66
0.75-
~  0.50-c0
0.25-
0.00-
0 10 30 40 5020
1.00 -
<0.25
0.25-0 .49
0.5-0 .74
£0.75
0.75-
0.50-
0.25-
0.00-
0 10 20 30 40 50
(c) No. infected in HH (d) Concurrent infections in HH
1.00- -rqj
2-4
5-9
£10
0.75-
§  0.50-
0.25-
0.00-
0 10
Time to recovery (days)
20 30 40 50
1.00 -
No
Yes0.75-
0.50-
0.25-
0.00-
0 10 20
Time to recovery (days)
30 40 50
Figure 6.7: Kaplan-Meier survival function plots for cessation ofRSV shedding 
stratified by various markers of concurrent RSV infections within the household (HH). 
Graphs (a) and (b) show results by the proportion of household members infected; 
graph (c) by the number of persons infected and graph (d) by the presence of another 
person infected in the household. The legend for each graph is shown in the respective 
inserted text box.
6.4.6 Multivariate analysis: Factors influencing rate o f RSV recovery 
The midpoint data were taken forward for the multivariate analysis and the final Cox 
regression model is reported in Table 6.3. The results were similar with and without 
inclusion of the left censored RSV episodes (see Appendix Z for final model with left 
censored data). The proportionality assumption in the final Cox regression model was 
not violated based on the test of the Schoenfeld residuals (see Appendix AA).
i) Age o f infection
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The duration of shedding was significantly associated with age. Infants (<1 year of 
age) shed the virus for 18.0 (14.2 -  21.8) days while the older individuals shed for 
shorter durations; 11.8 (9.7 -  14.0), 9.1 (7.7 -  10.4), 8.4 (6.6-10.2) and 11.2 (7 .4-
15.0) days in 1 -  4,5 -  14,15 -  39 and >40 age groups, respectively based on 
midpoint estimates. Using the infants as the reference group, the adjusted rate of loss 
of infection was 1.98 (95% Cl, 1.30 -  3.02), 1.82 (1.16 -  2.87), 2.10 (1.20 -  3.66) and 
1.31 (0.36 -  4.81) times in 1-4, 5-14 years, 15-39 and >40 age groups, respectively. 
Infants aged >6 months had a decreased recovery rate by 48% relative to those <6 
months (adjusted HR, 0.52; 95% Cl, 0.20 -  1.31) but this was not statistically 
significant (Wald test p= 0.164).
i) Symptomatic infections
The duration of shedding differed between those individuals who had symptomatic 
infections and those with no symptoms: 13.5 (95% Cl, 11.9 -  15.1) vs. 7.8 (6.7 -  8.8) 
days. The rate of recovery was lower by 44% in symptomatic infections relative to 
asymptomatic infections (adjusted HR 0.56; 95% Cl, 0.40 -  0.79).
ii) Presence o f other respiratory viruses
The presence of one or more additional virus (rhinovirus, coronavirus or adenovirus)
was detected in 86 RSV infection episodes. Co-infections were associated with
increased duration ofRSV shedding of 14.8 (12.9 -  16.8) days relative to duration of
8.5 (7.4 -  9.5) when no co-infections were detected. Rate of cessation ofRSV
shedding was lower by 50% in episodes with co-infection compared to those without
(adjusted HR, 0.65; 95% Cl, 0.23 -  0.51). Examination of co-detected viruses
individually (adenovirus, coronavirus, rhinovirus) or mixed; each identified a
significant association with decreased recovery rate relative to RSV infection alone
(adjusted HR, 0.40 (95% Cl, 0.22 -  0.73), 0.36 (0.21 -  0.62), 0.33 (0.17 -  0.62) and
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0.30 (0.17 -  0.50), respectively). This association did not linearly vary with the 
increase in the total number of the viruses co-detected with RSV. Detection of 
infection with any one or more of rhinovirus, adenovirus or coronavirus, in the two 
weeks preceding the start ofRSV infection, but not during the RSV episode itself, 
was associated with 56% increase in the recovery rate ofRSV infection (adjusted HR, 
1.56 (1.02 -  2.39), p=0.041; Table 6.3). In contrast, RSV episodes associated with 
detection of other viruses in the two weeks prior to and also during the RSV infection 
were associated with 52% decrease in rate of recovery relative to those with no other 
virus prior and during the RSV episode (adjusted HR, 0.48 (0.32 -  0.73); Table 6.3).
in) Presence o f contemporaneous RSV infections in the household 
RSV episodes linked with spread of the virus in the household were associated with 
an increased duration of shedding. The rate of shedding cessation was significantly 
lower for infection episodes associated with household outbreak relative to single 
infection episodes (adjusted HR 0.58; 95% Cl, 0.43 -  0.78). A variable denoting the 
proportion of individuals infected during the household outbreak improved the model 
fit and was used in the multivariate analyses (likelihood ratio test p-value=0.0229), 
Table 6.3, and Figure 6.7.
iv) Gender
The rate of recovery between males and females did not differ significantly (adjusted 
HR, 0.97; 95% Cl, 0.77 -  1.23), Table 6.3.
v) Infecting RSV group
RSV group B was associated with 9% (adjusted HR 1.07 (0.77 -  1.23) increased rate 
of recovery relative to RSV group A but this result was not statistically significant 
(Table 6.3).
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vi) Number o f episodes 
Recovery rate was similar in subsequent RSV infection episodes occurring within the 
study period compared to the first observed infections episodes (adjusted HR, 0.91 
(0.53 -  1.56), Table 6.3).
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6.4.7 Prolonged shedders
Twenty-four individuals shed RSV for 21 or more days; 10 (41.7%) were < 1 year 
old, 6 (25.0%) were aged 1-4 years, 7 (29.2%) aged 5-14 years while the remaining 
was aged 17.2 years. The median (IQR) age at infection was 14.7 (9.4 -  69.7) months 
with a range of 3.8 months to 17.2 years. Twenty-two (91.7%) of the infection 
episodes were symptomatic. The prolonged shedders contributed 647.5 days ofRSV 
shedding which was 29.7% of the entire shedding durations from the 205 episodes 
based on the midpoint estimation.
6.4.8 RSV group A and B co-detections
In 14 RSV infection episodes, one or more samples were identified to contain RSV 
group A and B. The timing of these co-detections was as shown in Figure 6.8. In most 
instances, (12/14) RSV group A was shed for longer duration relative to group B.
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Figure 6.8: RSV shedding in episodes associated with co-detections ofRSV group A 
and B. The filled red circle and blue marker (x) represents RSV group A and B, 
respectively. The red line links PCR positive samples denoting the RSV episode
6.4.9 Sequencing o f the RSV G gene from individuals with 'suspected ’ reinfections 
with same RSV group 
In 17 (9.5%) of the infected individuals, we observed an apparent ‘suspected’ repeat 
infection with same RSV group: 6 with RSV group A and 11 with RSV group B. The 
two or more phases ofRSV shedding are shown in Figure 6.9. The mean age at time 
of the first infection for individuals with RSV group A and group B was 2.3 and 7.2 
years, respectively. The duration between the positive samples ranged from 17 to 54 
days with median of 28 days. Sequencing of the RSV G gene was successful in 10 
(59%) of the 18 possible pairs of samples; one individual had three suspected RSV 
episodes (Table 6.4). The failure to sequence was mainly in samples with a Ct value 
of >28.0 by M-PCR, an indicator of low viral load, explaining the difficulty in
sequencing. Only one of the successfully sequenced paired samples had nucleotide 
differences: 13 nucleotide differences associated with three non-synonymous changes 
and a change in the stop codon position. The episodes in this individual (ID 1803 in 
Figure 6.9)) occurred 54 days apart.
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same RSV group showing RSV G gene variability. The red crosses indicate RSV 
positives samples; filled red or blue circles show one or more RSV positives samples 
from each ‘episode’ were successfully sequenced. If red is in both episodes then the 
variants in each episode were identical and if one episode is red and the other blue 
then they were non-identical (Table 6.7). Green filled circles mean samples were 
collected but RSV negative. Pink diamonds represent detection of other viruses; while 
hollow black circles show when the individual had respiratory symptoms. The values 
in blue are ages at the start of the first episodes and the ‘ID’ represents the unique 
identification of the individuals. The intervals between the episodes are also shown in 
the graph region in days
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Table 6.4: RSV G gene variability in 17-paired PCR positive samples from 17 
individuals with suspected repeat infections
ID1 RSV  Sequenced episode G gene identical or No. nt
Group First Second Third different? changes
3101 A No Yes Yes Identical2 -
1402 A Yes Yes - Identical -
3105 A Yes Yes - Identical -
5801 A Yes No - - -
5701 A Yes No - - -
5702 A Yes No - - -
0603 B Yes No - - -
0601 B Yes Yes - Identical -
1803 B Yes Yes - Different 123
1903 B Yes Yes - Identical -
3804 B Yes No - - -
4202 B Yes Yes - Identical2 -
4204 B No No - - -
4407 B Yes Yes - Identical -
4405 B Yes Yes - Identical -
4605 B Yes No - -
4902 B Yes Yes Identical _
Key: 1, the values in this column denote the individual identity with the first two digits 
denotes the household ID followed by the individual number; 2, the second episode 
sequence has a mixed population o f C or T at one o f the positions; 3, the differences 
between the two strains involves three non-synonymous changes and a change in the 
stop codon position
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6.5 Discussion
These analyses involved 179 individuals from 40 households who had regular and 
frequent nasopharyngeal swab collections regardless of symptoms during a single 
RSV epidemic experiencing 205 infection episodes. We report a mean duration of 
RSV shedding of between 8.6 to 14.0 days based on the most conservative to least 
conservative approach. A more realistic estimate of 11.2 (95% Cl, 10.1 -  12.3) days 
was based on the assumption that shedding starts midway between the date of the last 
negative sample and the first positive sample and ends midway between last positive 
sample and the next negative sample. The median duration of shedding using this 
approach was 8.5 (95% Cl 5.5 -14.0) days with a range of 1 to 44 days. Okiro et al 
conducted a similar study in Kenya recruiting family members of infants involved in 
the Kilifi birth cohort (Okiro et al. 2010). Study cases were identified as RSV positive 
by Immunofluorescence antibody test (IFAT) on nasal washes collected from 
individuals with symptoms of acute respiratory infections and identified through 
weekly home visits (Okiro et al 2010). These cases were then repeatedly sampled by 
nasal washing every 2-3 days until the first IF AT negative sample. A mean duration 
of shedding of 4.5 days was estimated from 193 infected children in 151 families 
(Okiro et al. 2010), compared with the corresponding estimate of 13.5 days from the 
current study. In a subset of the children whose start of symptoms could be 
established from the clinic records, the authors reported longer duration of 7.7 (6.4 -
9.0) days (Okiro et al. 2010). Given that RSV shedding has been reported before start 
of illness (Frank et al. 1981) the actual duration in the symptomatic children would 
have been an underestimate and our estimate of 13.5 days is likely to be more 
accurate. Other limitations of the Okiro’s study were the lower sensitivity of IF AT 
compared to M-PCR used in the present study, and the terminations of sampling at the
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first negative follow up sample. The present study revealed instances where negative 
samples arose within RSV episodes. Even though this observation raises questions on 
the relationship between infectivity and shedding duration, accounting for periods of 
RSV negative samples would still result to longer shedding duration compared to 
previous estimates. Alternative estimation of the shedding patterns by calculating the 
area under the Ct (viral load) curve would have some additional advantages and 
would be explored in future.
The Rochester family study with similar design as the present study (collecting 
samples every 3 to 4 days regardless of symptoms) reported lower estimates of 
duration of shedding of 3.4 to 7.4 days (Hall et al 1976). However, the Hall et al 
study used the less sensitive screening method of viral culture, and most individuals 
were shedding the virus at the start of sampling. As a counter argument, it is not 
known to what degree PCR positivity equates with shedding of viable and infectious 
virus. Thus while molecular methods might be more sensitive, the resultant increase 
in duration of shedding over more traditional methods such as culture (which directly 
measures viral infectivity) may not necessarily translate to increased period of 
infectivity. Further work is warranted.
Of the previous studies noted, prolonged shedders for more than 3 weeks were
reported (Hall et a l 1976; Frank et a l 1981). In the present study, 24/179 (13.4%)
individuals shed RSV for more than 3 weeks whose median age at infection was 14.7
months. Most (22, 91.7%) of these episodes were symptomatic. It is not clear why the
individuals had poor viral clearance and we did not test for HIV. Individuals with
compromised immunity due to HIV infection or underlying medical problems
(transplant receipts), have been known to shed RSV for longer (Madhi et a l 2000). In
settings where HIV prevalence is high, the effect of the prolonged shedders might
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influence the temporal epidemiology possibly continuing the spread of the virus 
during the low season (Madhi et al 2000). Further studies are required to assess the 
epidemiological implications of the prolonged shedders.
More than two RSV episodes were experienced in 24 (13.4%) individuals in the 
single RSV epidemic. On average, the episodes were 4 weeks apart. Most of the 
suspected ‘repeat’ infections were with homologous RSV group (17/24. 70.8%). In 
the heterologous scenario, all except one were with RSV group B in the first episode 
followed by group A for the homologous infections, we sequenced the long 
ectodomain region of the G gene which encodes for the antigenically variable region 
of the attachment protein. Only 10/17 (59%) of the paired samples for the ‘suspected’ 
repeat infections with the same RSV group were successfully sequenced. Most (9/10) 
of the successfully sequenced infection-pairs had the same RSV variant. The second 
episodes occurred within 3 to 4 weeks interval. It is not apparent whether the two 
phases ofRSV infection were clearly repeat infections or were persistence RSV 
infection with periods of low viral load undetectable from nasopharynx or by the M- 
PCR method. Using postmoterm lung tissue from infants, RSV RNA has been 
detected even in children dying during inter-epidemic periods suggesting persistence 
ofRSV in lungs of these infants. Additionally, in an experimental RSV infection in 
mice, RSV RNA was found in lungs for more than 3 months after initial infection 
(Schwarze et a l 2004). Infective virus was detected albeit at low levels from lungs in 
mice subjected to T-cell depletion initiated over 4 months after the experimental 
infection. Similarly in experimental infection of rhesus macaques with measles virus, 
RNA was shown to persist in blood, respiratory tract or lymph node during 
intervening periods of non-infectiousness (Lin et a l 2012). The mechanism ofRSV 
persistence is still unclear but there are suggestions it might be by means of low-grade
replication (Schwarze et al. 2004). The lack of variability in the virus identified in the 
two phases of infections suggests virus mutation might not be the primary mechanism 
for virus persistence or reinfection. The two phases ofRSV shedding regardless of 
whether they are persistent infections or reinfection within the same RSV epidemic 
represents an interesting phenomenon ofRSV which has potential importance on our 
existing view of acute RSV infection, the development of prolonged immunity and 
viral transmission and would benefit from further investigation.
Of the covariates examined, age, infection severity, presence of other viruses before 
and during RSV infection, and concurrent RSV infections in the household were 
significant determinants of the duration of shedding. Infants shed on average for 18 
days indicating a low recovery rate relative to their older counterparts who shed for 
less than 12 days. The rate of recovery increased by age with individuals within 1 - 4  
years, 5 -1 5  years and >15 years age groups recovering 2.16, 3.40 and 2.56 times 
faster than the infants, respectively. The Rochester family study reported similar 
findings where longer shedding was observed for children <2 years compared to those 
aged 2 -1 6  years (9 versus 4 days). The Okiro et al study did not find any association 
of age and duration of shedding but found that children with previous RSV infection 
(including those older than 3 years) had 37% increased recovery rate relative to those 
with no history of infection. In the present study, a subsequent RSV infection during 
the same RSV season was not significantly associated with reduced shedding 
duration. However, only 24 individuals experienced more than one RSV episode, a 
small sample size to allow detection of even large differences. The current study is of 
a shorter duration, so that distinguishing between primary and subsequent infections 
is not possible, so age must act as a proxy of previous exposure to RSV. Prolonged 
shedding enhances the possibility of person-person transmission and makes young
children a potential source of community spread of infection. These have important 
implications in the control and prevention ofRSV infection.
Symptomatic RSV infections were associated with 43% reduced recovery rate relative 
to asymptomatic infections. A study involving 23 hospitalized children aged less than 
2 years who were followed even after discharge reported an association of duration of 
shedding and infection severity (Hall et al. 1976). Children with lower respiratory 
tract infection shed for longer than those with upper respiratory tract infection (8.4 vs.
1.4 days). Duration of shedding may be related to severity of disease but evidence is 
controversial on the link between disease severity and viral load (Hall et al. 1975; 
Devincenzo 2004; Kuypers et al. 2004; DeVincenzo et al. 2005).
No published data exists on the effect of other viruses and concurrent household 
infections on the shedding durations ofRSV. Coronavirus, rhinovirus and adenovirus 
were screened for all the nasal swabs collected. Presence of viral co-infection, defined 
by one or more viruses detected during the shedding period ofRSV, was associated 
with 50% reduced recovery rate. The effect was similar even on examining the co­
detected viruses i.e. coronavirus, rhinovirus and adenovirus, independently. In 
contrast, presence of other viruses before start of, but not during, the RSV episode 
was associated with an increased rate of cessation ofRSV shedding by almost 50%, 
but with borderline significance. Individuals with co-infections might have had lower 
immunity hence the high susceptibility to multiple viral infections and low viral 
clearance relative to those experiencing only RSV infection. Conversely, individuals 
experiencing longer RSV infections would have greater chance of experiencing a 
concurrent viral infection. Recovery from a viral infection just prior to RSV might 
have led to up-regulation of innate viral immunity or non-specific cross-reactivity that
reduced subsequent RSV shedding. While the possible mechanism of the observed
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interference of prior viral infections on duration ofRSV shedding is speculative, the 
interaction or interference of other viruses on RSV shedding patterns requires further 
assessment in a mathematical model framework to help tease out the direction of the 
interaction/effect and implications on virus transmission within households and the 
population.
Individuals from households where a third or more of the members had concurrent 
RSV infections had a reduced recovery rate by 46% than those from households with 
less than a third of the members infected. Close contacts in household might facilitate 
transmission of large viral inoculum resulting in more severe and prolonged shedding. 
It is impossible to rule out the role of super reinfections during the household RSV 
outbreaks.
The median RSV shedding durations presented in this study are generally longer than 
published estimates from non-hospital settings which could be attributed to 
methodological differences. The present study was informed by critical review of the 
previous studies and it incorporates frequent sampling regardless of symptoms and 
screening by highly sensitive PCR methods. Clearly, the use of the sensitive viral 
detection methods (PCR) results in longer estimates of shedding. However, more 
research is required to determine what level of shedding is related to infectiousness -  
it could be that highly sensitive methods are finding viral RNA, but that the level is 
too low for the virus to be effectively transmitted as recently observed in measles (Lin 
et al. 2012). Use of acceptable sample collection methods ensured wider involvement 
of all ages including older children and adults (Munywoki et al. 2011) and data on 
important covariates were systematically collected.
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One of the main limitations of the present study arose from failure to determine the 
exact time of start and end of the shedding periods but analysis using the three 
assumptions helped to estimate the possible durations. Nevertheless, this did not 
affect the association of the explored factors with recovery rate (see Appendix Y). 
Short RSV infections occurring between specimen collections particularly in older 
individuals might have been missed but this is likely to be at random (non differential 
misclassification bias) leading to possible underestimation of the hazard ratios. 
Noteworthy is that midpoint imputation in the Cox model used in the current analysis 
would lead to the impression of greater precision in hazard ratio than is actually 
available from the data collected. Future work would be improved by directly taking 
the interval censoring into account in the models.
In conclusion, this study provides the best estimates of duration ofRSV shedding and 
explores effects of various factors on recovery rate in naturally infected persons 
within a rural community setting. Of the covariates examined, age, infection severity, 
presence of other respiratory viruses and concurrent RSV infections in the household 
were significant factors related to the duration of shedding. The estimates of the RSV 
infectious durations are important in understanding the spread of infection in a 
population and will contribute to the development of transmission dynamic models to 
investigate the impact of interventions against RSV.
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CHAPTER SEVEN
7 Estimation of Susceptibility and Transmission Parameters
7.1 Introduction
RSV is transmitted by large nasal droplets and fomites, with short survival time in the 
environment. This suggests that close contact is important for effective transmission.
It follows that social interaction patterns (contacts and mixing patterns among 
individuals) is likely to have a direct impact on transmission dynamics ofRSV. 
Households and schools are key social contexts with high contact rates providing 
environments with disproportionate importance for RSV transmission. Family studies 
indicate the importance of household size and school-age siblings as risk factors of 
RSV infection in infants (Hall et al. 1976; Okiro 2007). Various studies indicate RSV 
infection is frequently introduced into the home by siblings, resulting in high 
secondary attack rates within households (Berglund 1967; Hall et al. 1976; Okiro
2007), although a recent study reported contrasting findings (Crowcroft et al. 2008). 
Direct evidence of mother-to-child infection has been reported in one study from 
Guinea Bissau (Stensballe et al. 2004). It remains, however, that patterns of 
transmission, so important in determining the influence of infection (or control) in one 
age group on other groups, are poorly defined.
A prerequisite to assessing the impact of implementing various control strategies in 
prevention ofRSV infections is the availability of realistic estimates of parameters 
that define the ‘who acquires infection from whom’ (WAIFW) matrix. Early work on 
childhood viruses concentrated on age-group related contact patterns (Schenzle 1984; 
Anderson and May 1991), and defined the WAIFW matrix by inference from age- 
stratified sero-prevalence or case notification data (Anderson and May 1985; Dietz
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and Schenzle 1985; Grenfell and Anderson 1985). If there are n age groups, then the 
WAIFW matrix has n2 elements, but there are only n estimates of the age-related rates 
of infection, so the WAIFW matrix is unidentifiable by this method without further 
assumptions. Three approaches have been proposed to overcome this problem. First, 
Medley suggested using multiple infections, each using the same WAIFW matrix 
(Farrington et a l 2001). Second, Edmunds et al pioneered the direct measurement of 
contact rates (Edmunds et a l 1997). Third, Kaanan et al used prior probabilities to 
inform the choice of matrix structure (Kanaan and Farrington 2005). It should be 
noted that heterogeneity in mixing patterns may not only be functions of age 
groupings, but also other forms of social stratification such as household structure and 
population demographics (e.g. urban or rural) -  but these have not featured 
extensively in the development of models to predict vaccine impact (Anderson and 
May 1991). The use of contact data in transmission dynamics modelling requires the 
inference of the transmission probability following contact -  which is a serious 
obstacle. Longitudinal studies can estimate this transmission probability more directly 
from more accurate, high-density observations of infections (Melegaro et al 2004; 
Cooper et a l 2008). In the current study, we used the detailed RSV infection data 
from the household study, to directly estimate the relative susceptibility and 
transmission probabilities. Improved understanding of household transmission may 
inform on the merits of targeted control strategies.
7.2 Chapter outline
A transmission model incorporating time-dependency in community probability of 
infection, age-related susceptibility, household heterogeneity and contact structure is 
presented in this Chapter. Using the parameter estimates of transmission probability, 
relative susceptibility by age and post-infection, effects of household size and contact
structure in transmission, the relative contribution of various groups in the household 
in RSV acquisition are shown. The approach and results presented should be regarded 
as preliminary, and more development is required to reach publication standard.
7.3 Methods
7.3.1 Data
Data consist of the PCR detections ofRSV in the household study. No distinction was 
made between RSV groups in the current analysis. Each household was considered 
independently. For the current analysis, we assumed the infection data were complete 
in the sense that all RSV episodes were observed, and the ‘midpoint’ approach 
described in Chapter 6 was used to identify the infection onsets and recovery times. 
Briefly, in the midpoint approach, infections were assumed to start (or end) on the 
date between the last negative and first positive (or last positive and first negative) 
samples if the interval between the two observations was 7 days or less. For instances 
where these intervals were greater than 7 days (i.e. left and right censored) a duration 
which was one half of the average interval for the other observations was subtracted 
from the first positive sampling date or added in the last positive sample date to 
estimate the start and end dates, respectively.
From the data, the shedding profile of each individual, i, was extracted, and denoted,
smt = 1 if shedding on day t of the study, where h is the household of the individual,
and Siht = 0 if not shedding. The study had 493 individuals in 47 households and, in
this analysis, were followed for 186 days from 1st December 2009 to 4th June 2010, i.e.
i = l.. .493, t = 1... 186, and h=  1.. .47. Individuals are at risk of onset of shedding
when not already shedding, i.e. Siht = 0. The set of the days of onset of shedding for
individual, i, are defined as Uih. Not all individuals were within the study all the time.
In particular, there are periods when individuals were absent: let mjh (t)= 1 denote
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when individuals were in the study, and mjh (t)= 0 when they were absent or the active 
home follow-up had not yet begun. We assume that individuals who are absent cannot 
be infected by and cannot infect members of their household, and are at risk of 
infection due to community transmission only.
Table 7.1: The distribution of infection episodes between the 493 study individuals 
Number of Episodes Number of Individuals
_   314
1 155
2 22
3 2
Key: 1, Infection episode defined as a period within which an individual provided 
specimens which were PCR positive for the same infecting RSV group with no more 
than 14 days separating any two positive samples (see Table 4.1)
There were 205 onsets of shedding in 91,598 person-days of observation with 2,200 
(2.4%) days of shedding. In 24,380 (26.6%) days the participants were absent (i.e. 
away as defined in Table 3.1) and in 67,113 (73.3%) days the individuals were at risk 
of onset of shedding but did not. There were 5 individuals who were ‘absent’ in the 5 
days preceding onset of shedding. There were 82 infection onsets which could only 
have been from the community i.e. there was no infection in the household in the 5 
days preceding onset, or the individual was absent from the household prior to onset.
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Figure 7.1: Household level pattern of infection. The most heavily infected household 
is on the left and time (in days) goes vertically. The colour scale shows the intensity 
of infections in each household and changes over time (in days)
Age at start of the study was taken as fixed covariates for each individual, denoted by 
Ai while previous occurrence of an observed RSV infection was set as a changing 
covariate over time which was denoted as Bit. For each pairing within the household, 
a set of covariates, which described the relationships or contact structure (e.g. mother- 
child, sibling-sibling etc.) were denoted as C jj.  For each household, the household size 
was taken as a covariate denoted as Dh. Covariates A and B define the state of an 
individual and were used to define relative susceptibility to the same virus exposure. 
Covariates C and D were used to define the relative transmission potential between 
groups of individuals. Covariates that define the infectiousness of individuals were
not included. The parameterization of the models was generally to make the study 
infants the reference group.
7.3.2 Basic model structure
For each individual on each day and for each virus, a variable that represents the 
individual’s relative susceptibility to infection, rcjht, was constructed, which had the 
following structure:
™ ih t ~  I f  Sj/jf =  1
niht = e x p i- fa A i -  y(j)BBit), i f  siht =  0 ........... '
Coefficients of the susceptibility covariates to be estimated were denoted by (j>. This 
formulation does not admit super-infection during the shedding period. If there are no 
covariates being considered then relative susceptibility was 1 when an individual was 
not shedding, i.e. they were at full risk of infection when they were not shedding.
Let the rate of exposure for individual i in household h during day t be X\h (t):
= DjiSjht "1" ^(f).......... (H)
where r| are parameters relating to the covariates describing the relationships between 
individuals in the household and 8 is the risk due to community exposure.
At a minimum level Qj = 1, Dh = 1 and rj determines the relationship between the 
amount of observed shedding and the rate of infection and:
=  Sjht "b ^(0 .......................... (HI)
The contact structure in the household (e.g. infants and other groups) was considered, 
so that, in transmission matrix notation:
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*1 Cn =  7?0
1 T)x
m r)2\ .(iv)
The probability that an individual became infected (i.e. enters the latent phase) during 
day t is then:
a ih(t) =  ( i -  q ...........
This assumes a continuous relationship, i.e. there are no dose response effects, which 
would imply that higher doses/exposures would be more likely to lead to infection.
Because of the latent period (i.e. the time between infection and start of shedding), the 
probability of starting to shed on day t was taken as the weighted sum of the 
probability of infection in days prior to onset of shedding, where the weighting was 
the probability density function of the duration of the latent period:
p(i,h, t ) =  Ejl™ 9jaih(t - j ) m ih(t - j )  (vi)
where the maximum latent period was m, and 0 j  was the probability that the latent 
period was exactly j  days (the 0 have to sum to 1). Data is limited on RSV latency 
period following a natural infection and for this analysis we use data from an 
experimental challenge study in young healthy adults (Lee et al 2004). In the 
challenge study, Lee et al demonstrated a latency period of 2-5 days after inoculation 
with 4,4, 3 and 1 of the 12 infected adults starting to shed the virus at day 2, 3,4, and 
5 respectively. The 0 were thus fixed at 0, 0.33, 0.33,0.25 and 0.083 for day 1,2, 3,4, 
and 5 respectively.
7.4 Estimation
The model describes the infection process in terms of the observed exposure to virus 
(s), individual characteristics (constant, A, and varying, B), relatedness (C) and
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household characteristics (constant D). The parameters determine individual 
susceptibility, both constant and varying ((()) and the relatedness between shedding 
and infection (r|).
The total likelihood for an individual’s observed data is:
Li =  Uueuih P(i> h, u) U muih0- - p ( i , h , u ) )  (vii)
where u denotes all the days of the study. This likelihood was maximized for each 
individual simultaneously. The model was developed and optimized in R Version
2.15.2 with the optim function (R Core Team 2012). The Broyden-Flethcher-Godfarb- 
Shanno (BFGS) method was used for numerical optimization (Broyden 1970;
Fletcher 1970; Goldfarb 1970; Shanno 1970) after some trials. The R code used for 
estimation is included in the Appendix BB.
The time-dependent risk of community infection was estimated using MatLab curve 
fitting tool (http://www.mathworks.eom/products/curvefitting/f (MATLAB, Release 
2012), by fitting the sum of two Gaussian curves on the daily RSV detection data over 
the study period and normalising so that the maximum is unity.
The model was developed systematically starting with a simple model and adding in 
various components of parameter estimation. The parameters from the final model 
were taken forward in estimating the contribution of within household and community 
transmissions of RSV. In particular, the contributions of within household RSV 
acquisitions by relationships were estimated. For each observed onset, the force of 
infection for each household member and the community was weighted by the latency 
distribution and summed, and the contribution is expressed as a percentage. For
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onsets when no household meihber was shedding during the latent period, the 
community has a 100% contribution.
Table 7.2: Summary of symbols and their definitions
Symbol Definitions
i Individual
h Household
t Time (days)
S Shedding
u ih Set of onset days for each individual
mih (t) Set of days an individual was present or absent from the household
Aj Fixed covariates e.g. age at the start of the study -
Bit Time changing covariates e.g. occurrence of infection during follow up
Cy Contact structure irr the household i.e. relationships like mother-infant
Dh Household level covariates i.e household size
i^ht Individual’s relative susceptibility to infection
4> Coefficients of the covariates
i^h (t)
T1
The rate of exposure for individual i in household h during day t 
r| are parameters relating to the covariates describing the relationships
M
between individuals in the household
8 The risk due to community exposure
CCih(t) Probability that an individual becomes infected during day t
P Household infection rate
Y a relative susceptibility post (observed) infection, y
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7.5 Results
7.5.1 Simplest model
The basic model had three parameters: constant community infection rate (e), constant 
household infection rate (p) and a relative susceptibility post (observed) infection, y. 
The results are given in Table 1.2.
7.5.2 Simple model with time-dependent community infection rate
The relative time-dependent risk of community-acquired infection is shown in Figure 
7.2. The inclusion of this process improved the model fit (log-likelihood reduced from 
1291.9 to 1265.9), and was included henceforth (Table 7.2). This modification, 
presumed that the study individuals were representative of the community pattern of 
shedding. Whilst the households were not a random sample of the community, the 
individuals might be more suitable for this purpose. The household individuals were 
not restricted in their interaction with the wider community and the prevalence of the 
detected RSV infections over time likely to be representative of the wave of RSV 
epidemic in the community.
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Figure 7.2: Density fit to time-dependent numbers of individuals shedding in the 
household study. Blue circles are the total number of individuals shedding each day. 
The red line is the fitted curve used in the model
7.5.3 Age-related susceptibility
Age is likely to change the risk of infection. The age (0 -  92 years) was divided into 
discrete groups and a single parameter fit to each (relative to the first age group which 
was considered as the <lyear group, i.e. study infants and their young siblings). 
Inclusion of age-related susceptibility improved the model fit (Table 7.3). Using this 
model, the best fit was with five age groups. The relative risk of infection was 75.6%, 
55.6%, 25.7% and 19.9 % in 1- 4, 5 -  14,15 -  39 and >40 age groups compared to 
the infants (<lyear). Figure 7.3 shows the relative susceptibility with age using the 
final model. The age susceptibility was considered when fitting the contact rate 
parameters.
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Table 7.3: Model fitting results from basic and age-related susceptibility fitting
Model # pars1 LL £ p y Age2 Comments
Simple 3 1291.9 0.002 0.005 0.576 - -
Simple3 3 1265.9 0.005 0.004 0.543 - Time-dep.
2 age groups 4 1252.2 0.011 0.010 0.514 0.393 > iy
2 age groups 4 1242.0 0.009 0.009 0.460 0.381 >5y
2 age groups 4 1236.2 0.008 0.008 0.424 0.348 >10 y
2 age groups 4 1243.8 0.006 0.006 0.464 0.377 >15 y
3 age groups 5 1241.2 0.011 0.011 0.461 0.756 V1
0.321 >5y
4 age groups 6 1232.7 0.011 0.011 0.421 0.756 1 -  <5y
0.556 5 -< 15  y
0.247 >15 y
5 age groups 7 1232.4 0.011 0.011 0.422 0.756
>nV1
0.556
*—<V1
0.257
oV1invH
0.199 >40 y
Key: 1, number ofparameters estimated; 2, Age-related risk o f infection, parameters 
estimates using the infants (<1 year olds) as the reference with ‘complete' 
susceptibility; 3, simple model with time dependent community risk o f infection; LL, 
log likelihood; e, community risk o f infection; fi, within household probability o f 
transmission; y, post-infection susceptibility; y, age in years
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Figure 7.3: Age-related susceptibility parameters. Age was categorized into <1 year, 
l-<5 years, 5-<15years and 15 <40years and >40 years. Based on estimates from the 
final model presented in Table 7.6
7.5.4 Household heterogeneity
Heterogeneity between households manifests itself as a difference in relative contact 
rate. This could be through many environmental factors, but we are only including 
size currently to look for potential density type effects. The households were grouped 
with the effect being relative to the smallest households. Multiple attempts using 
group definitions of household size suggested a single threshold effect with 
households of eight or more members having a lower relative transmission coefficient, 
Table 7.4. The effect was a reduction of transmission probability by 63.2%. The 
household size effect did not appear to interact with the age effect (Table 7.4).
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Table 7.4. Results from household heterogeneity and age-related susceptibility fitting
Model #pars LL s y h Age2 Comments
Base3 3 1265.9 0.005 0.004 0.543 - -
HH4 4 1260.2 0.005 0.011 0.513 0.321 - HH>8
5 age 7 1235.8 0.011 0.012 0.420 - 0.751 Age limits
groups 0.423
0.217
0.191
at 1, 5,15, 
40
HH & 8 1231.1 0.011 0.028 0.406 0.368 0.746 HH & 5 age
age 0.434 groups
0.224
0.187
Key: 1, number ofparameters; 2, Age-related risk o f infection, parameters estimates 
using the infants (<1 year olds) as the reference with ‘complete’susceptibility; 3, 
simple model with time dependent community risk o f infection; LL, log likelihood; 4, 
household (HH) effect included; e, community risk o f infection; f3, within household 
probability o f transmission; y, post-infection susceptibility; h, transmission 
probability in households with 8 or more household members
7.5.5 Estimating transmission parameters
The contact structure was developed by categorizing household members based on the 
relationship to the study infant into infants, siblings, cousins, mother, father, and other 
adult members. In this Chapter, the infants also included any other child in the 
household below the age of one year at the start of the study or newborn during the 
study period. The numbers of different contacts (i.e. where individuals share a 
household) are given in the table below (Table 7.5). Thus, there are 27 pair-wise 
contacts between infants, and 296 pair-wise contacts between infants and siblings.
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Table 7.5: Number of pair-wise contacts within households
Infant Sibling Cousin Mother Father Gparents Other adults
Infant 27 296 118 99 63 34 68
Sibling 434 351 290 189 92 160
Cousin 238 129 64 52 193
Mother 37 67 42 70
Father 11 23 37
Gparents 6 44
Other
adults 82
Key: Gparent, grand parents -  this category was included in the ‘other adults ’ in the 
subsequent analysis
The relationship categories are co-linear with age (see age distributions by 
relationships in Chapter 4), which was used to determine susceptibility, and were 
highly variable by household. For the purposes of fitting, relationships were grouped, 
e.g. nuclear family (study infant, sibling, mother, father) versus the other household 
members to assess whether nuclear families have different infection rates compared to 
non-parent-child relationships; children (infants, siblings and cousins) versus adults 
(mother, father, grandparents and other household members) to explore differences in 
transmission probability in adults relative to children. The possibilities for two group 
models were tried exhaustively with parameter estimates from the best fitting models 
shown in Table 7.6.
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Table 7.6: Results from models exploring different contact structures
Model # pars1 LL £ p xlOOO 7 Comments
Base2 3 1265.9 0.005 4 0.543 Base
Infant/ others3 6 1256.5 0.005 3.0 17.9 0.500 2 groups
8.3 2.8
Child/adult4 6 1258.5 0.005 6.0 6.0 0.504 2 groups
1.6 3.1
Family / other5 6 1260.7 0.005 7.0 1.8 0.513 2 groups
4.1 2.6
Infant/child/adults6 11 1250.5 0.005 2.0 2.8 20.8 0.465 3 groups
26.8 8.4 4.0
4.1 5.8 0.7
Key: 1, number o f parameters; 2, baseline model with time dependent community risk 
o f infection; 3, Others include sibling, cousin, mother, father, grandparents and other 
adults in the household; 4, children included infants, sibling and cousins while adults 
had mother, father, grand parent and other adults in the household; 5, Family 
consisted o f the nuclear family while other were the non-nuclearfamily members in 
the household (see text for details); 6, child included sibling and cousins while adults 
had mothers, fathers, grandparents and other adults in the household
7.5.6 Final models incorporating different contact structures 
Taking the best age and household fits, the various contact groupings was 
incorporated to develop the final model (Table 7.7). There were small differences in 
the log-likelihood using different contact structures and the model with three contact 
groups (infants, children (siblings/cousins) and adults (mothers, fathers, grandparents 
and other adult members)) was taken forward.
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Table 7.7: Final model fits
Model #pars1 ZL £ fixlOOO y Age2 li
~Infants7oThers U 1228^0 0.010 0^8, 28.54' 0390~ 0.782' 0.452
32.28,19.13 0.576
0.267 
0.197
Children/adults 11 1228.8 0.011 29.88,23.96 0.391 0.735 0.377
22.54,19.42 0.541
0.267 
0.206
Family/other 11 1226.7 0.011 28.75,8.50 0.389 0.730 0.545
28.62,14.79 0.524
0.245 
0.176
Infant, child & 16 1229.0 0.010 1041.9,35.0,28.2 0.396 0.847 0.514
Adults 25.2,17.0,16.2 0.488
52.6, 5.0, 37.4 0.250
0.205
Key: 1, number o f parameters
7.5.7 Sources o f RSV infection in the study cohort
Of all the RSV episodes, 55.7% were attributable to community acquisitions (Table 
7.8). Based on the model, 64.9%, 61.3%, 46.0%, 56.1%, 56.5% and 41.8% of the 
RSV infections among infants, siblings, cousins, mothers, fathers and other adults 
were from ‘outside’ the household. For each infection, the probability of infection 
from the groups in the household was calculated using the parameter estimates from
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the final model with age and household effects and summed. Table 7.9 indicates the 
contribution to infection from each contact category within the household. When 
infants become infected, it was the older children particularly the siblings (63.0%) 
who were providing the majority of the risk (Figure 7.4). When siblings become 
infected, the risk was shared between the infants (35.7%), other siblings (44.2%) and 
cousins (10.0%). Similar pattern was observed for cousins, although mostly with each 
other (42.8%), and infants (32.2%) and siblings (12.9%). Mother acquired their 
infections from infants (71.8%) same as fathers (67.7%). Other adults in the 
household had a widely spread source of infections probably reflecting that they were 
a more heterogeneous grouping. Overall, infants, siblings, cousins, mother, father, and 
other adults contributed 34.9,28.4,21.4, 5.8,1.4 and 8.2 of all RSV transmissions 
occurring within the household.
Table 7.8: Sources of RSV infection in the study cohort based on the model with 
three contact structures
i) Number o f infections
N N I NIS NIC I S C M F O Com
Infant 47 20..." 34 11 0.0 ~I 7.5 ..1.7 1.3 0.7 0.7 22.1
Sibling 164 47 79 20 10.9 13.5 3.1 2.7 0.0 0.4 48.4
Cousin 124 41 55 15
:
9.6 3.8 12.7 0.7 0.2 2.7 25.3
Mother 46 22 14 11 4.4 0.6 0.3 0.0 0.0 0.8 7.9
Father 33 11 6 8
;
1.8 0.1 0.2 0.4 0.0 0.3 3.4
Other 79 38 17 18 5.0 0.2 1.5 0.2 0.3 2.6 7.1
All 493 179 205 83 31.7 25.8 19.4 5.3 1.3 7.4 114.1
ii) Percentage contribution
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N N I NIS NIC ! i1 S C M F O Com
Infant 47 20 34 11 1 0.0 22.1 5.1 3.8 2.1 2.0 64.9
Sibling 164 47 79 20 1 13.8 17.1 3.9 3.4 0.0 0.5 61.3
Cousin 124 41 55 15 | 17.4 7.0 23.1 1.3 0.5 4.8 46.0
Mother 46 22 14 11 j  31.6 4.6 1.9 0.0 0.1 5.8 56.1
Father 33 11 6 8 j  29.4 1.0 2.5 6.0 0.0 4.5 56.5
Other 79 38 17 18 | 29.4 1.3 8.9 1.4 1.8 15.5 41.8
All 493 179 205 83 ! 15.4 12.6 9.5 2.6 0.6 3.6 55.7
Key: N, number o f individuals; NI, number ever infected; NIS, number o f infections; 
NIC, number infectedfrom community i.e. Primary and co-primary cases; I, infant; S, 
sibling; C, cousin; M, mother; F, father; O, other adults; Com, Community; 1, the 
columns (of the contact groups) shows the source while the rows are the recipients o f 
the RSV infection
Table 7.9: Who infects whom in the within household transmissions
Relations1 Infant Sibling Cousin Mother Father Others
Infant 0.0 63.0 14.6 10.8 5.9 5.6
Sibling 35.7 44.2 10.0 8.8 0.0 1.2
Cousin 32.2 12.9 42.8 2.3 0.8 9.0
Mother 71.8 10.5 4.3 0.0 0.3 13.1
•
Father 67.7 2.3 5.8 13.8 0.0 10.4
Others 50.6 2.2 15.2 2.4 3.1 26.5
All2 34.9 28.4 21.4 5.8 1.4 8.2
Key: 1, the columns shows the source while the rows are the recipients o f the 
infection; 2, the column sums are the contributions to infection from each group
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F ig u re  7 .4 : W h o  in fe c ts  w h o m  in  w ith in  th e  h o u se h o ld  a c q u is it io n  o f  R S V
7.6 Discussion
W e  rep ort o n  a m o d e l a im ed  at e s t im a tin g  tr a n sm iss io n  an d  s u sc e p t ib ility  p a ra m eters. 
U s in g  th e  in fa n ts  a s the r e fe re n c e , w e  o b se r v e d  a d e c r e a se  in  s u sc e p t ib il i ty  w ith  a g e  to  
le s s  than  a quarter b y  15 y e a rs  o f  a g e . S u sc e p t ib ility  p o s t- in fe c t io n  r e d u c e d  to  3 9 .6 %  
r e la t iv e  to  p r e - in fe c t io n  le v e l  d u rin g  th e  sa m e  e p id e m ic . T r a n sm iss io n  p r o b a b ilit ie s  
w e r e  r e la t iv e ly  h ig h er  in  sm a ller  h o u se h o ld s  (w ith  le s s  than  8 m e m b e r s)  c o m p a r e d  to  
larg er  h o u se h o ld s . S im ila r  f in d in g s  h a v e  b e e n  rep o rted  fo r  w ith in -h o u s e h o ld  
tr a n sm iss io n  o f  in f lu e n z a  a lb e it  w ith  a lo w e r  th r e sh o ld  fo r  c la s s i fy in g  h o u s e h o ld  s iz e  
o f  le s s  th an  3 m e m b er s  (C a u c h e m e z  et al. 2 0 0 9 ) .  R e a n a ly s is  o f  th e  B e lg ia n  
P O L Y M O D  data  (M o s s o n g  et al. 2 0 0 8 )  u s in g  a m o d e l fo r  th e  c o n ta c t n e tw o r k  
d em o n stra ted  sm a ll h o u se h o ld s  (2 -3  m e m b er s) h ad  h ig h er  c o n ta c t rates r e la t iv e  to
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larger households (Potter et a l 2011) which could partly explain the differential in 
transmission probability by household size. In addition, households with more than 8 
members were more likely to have two or more nuclear families as described in 
Chapter 3.
On assessing the relative contribution of the various groups in the household on the 
observed RSV infections, our model indicated everybody had an equal likelihood of 
acquiring infection from the community (Table 7.8). This was a surprising finding, 
given that the age-related susceptibility changed so much. However, we believe that 
there might be an identifiability problem, in that the estimate of the level of 
community transmission necessarily includes some aspects of susceptibility (i.e. we 
can only observe infections that occur), and also includes aspects of community 
mixing (e.g. infections between school children). An alternative approach would be to 
just model transmission within households (i.e. ignoring the risk from the community). 
The current results, however, suggest that infants (who are most susceptible) don’t 
mix as much with the remainder of the community. Siblings and cousins were the 
most common source of infant infections in within household acquisitions of RSV. 
Infected infants were a much greater risk for most of the household members 
especially mothers, fathers and other adults, contributing over 50% of within 
household infections in these categories. Overall, siblings and cousins (64.6%) were 
more likely to introduce infection into the households, which is in some part due to 
their numerical importance within households. Once RSV was in the household, 
children spread the infection amongst themselves, and the young children. Infants 
were infectious to the other household members but especially to their parents and 
other adults. This could be due to the prolonged duration of virus shedding (and high 
viral load) and close contacts associated with this age group.
The developed transmission model was based on a number of assumptions with 
varying limitations. A strong assumption was made in terms of the RSV infection data 
being 100% accurate, no dose effects in exposure and the invariant latency period.
The actual data were interval-censored suggesting infections with short shedding 
durations (less than 4 days) were likely to be missed. Given that shedding duration 
was associated with age (see Chapter 5), there is a high propensity for the short 
infection episodes to be biased to the older children and adults. This is likely to result 
in failure to identify some introductions into the household and chains of transmission 
within the household. On timing of the infections, if two individuals started shedding 
on the same day and were the first to be infected in the household, the current 
framework identified both as infected from the community. Given the 3-4 day 
sampling interval and the short latency period, there is reasonable likelihood that one 
infected the other in reality, but this would be missed in the current model. If infants 
had a one-day shorter latent period, then the results are likely to be significantly 
different. The fact that individuals could only be infected from household members 
known to be shedding means that only few infections was passed from children to 
infants, since infants were usually infected quite early in the course of household 
outbreaks. Future work on this would require a Bayesian framework with modules to 
impute the unobserved first and last days of shedding as missing data (Cooper et al.
2008). There were very few households with more than one infant, which could have 
limited the reliability of the model fit. However, use of other ‘contact’ groups such as 
older children or adults as the reference did not change the interpretation of the 
results. RSV group data were not explicitly used in the current model hence we were 
not able to assess any group specific protection following infection, and relatedness 
between viruses assessed by molecular sequence will be used to inform these
estimates. In Chapter 5, we reported that the presence of other respiratory viruses, 
before and/or during an RSV episode influenced the duration of shedding. It would be 
of considerable interest to incorporate the effect of other viruses on RSV transmission 
to check for any competition or interactions in terms of relative susceptibility and 
transmission probability, and use these viruses to support estimation of contact 
parameters. The ultimate aim is to use these data to parameterise mathematical 
models for assessing the impact of various vaccination strategies.
Even though we captured temporal variations of RSV epidemic by weighting with the 
community probability of infection, we ignored spatial diversity by assuming an equal 
rate of transmission over the study location. Nevertheless this is likely to be of 
minimal significance given the study was constrained in a small geographical area 
likely to have similar exposure to the virus. Our approach also assumed the rate of 
exposure was proportional to the number of people shedding and did not include any 
information on the amount of shedding. Further work would benefit from 
incorporation of Ct values as a proxy for the viral load. Lastly, our model focused on 
relations in the household but RSV transmission could be dependent on other social 
patterns such as gender and employment status which could easily be included in the 
current framework.
In developing the model further, a simulation model for the study to assess the 
sensitivity of our sampling regime in detection of RSV infections would be required. 
The estimates would help in identifying the infections, which could have occurred but 
were not detected in the current framework.
In conclusion, this preliminary work suggests preventing the infection from entering 
the household requires vaccination of the children while prevention of within
household transmission would need vaccination of the infants. Further work would be 
required to assess the role of alternate transmission links such as mother-to-infant.
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CHAPTER EIGHT
8 Overall Discussion
8.1 Chapter outline
This chapter aims to present the key findings and their implications as well as identify 
areas of future research. Limitations of the study and areas of improvements are 
highlighted.
8.2 Summary of main findings and their implications
Using the detailed infection data arising from the screening of 16924 NPS collected 
during a single RSV epidemic in the community, we demonstrate school-going 
children are responsible for introducing a large proportion of RSV into the households 
where there is an RSV naive infant. Only one study in the past has looked at the 
spread of RSV within households in detail (Hall et al. 1976). Older children were 
identified to be introducers of RSV into the US families with young infants by Hall et 
al (Hall et al. 1976). Other less comparable studies report that younger children 
acquire infection from school-aged children within the household (Berglund 1967;
Fox et al. 1975; Okiro 2007), indicating a significant contribution of within-school 
transmission to the overall transmission of RSV. Mothers have also been implicated 
as a source of infant infections in the household in one study (Stensballe et al. 2004). 
Assuming vaccination will lead to at least a short-term immunity to reinfection, 
immunisation of older siblings would reduce the rate at which infection is introduced 
into households and would potentially protect infants from infection during their first 
epidemic. Results from analysis of transmission patterns, albeit preliminary, identify 
infants as important in connecting the chains of transmission within the household 
and direct transmission to the adults in the household. It is epidemiologically
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plausible that older children get their infection from schools where there is increased 
transmission due to intense contacts and introduce the infection to the household. In 
the household, they easily pass on the infection to infants who are highly susceptible 
to RSV. The infant in turn transmits the infection across the other household members 
including the mother due to the prolonged shedding and close contacts associated 
with this age group. This finding implies synchronised immunisation of older children 
and pregnant mothers (for passive transfer of protective immunity to the newborn) 
prior to the RSV season might offer good protection to the infants. The impacts of 
such a strategy require further assessment using mathematical models and in 
purposive field trials.
Our study reported an appreciable risk of infection across all age groups, underscoring 
the importance of reinfections in community transmission. The infection rates in older 
children (1 -14years) and adults (>15 years) were particularly high at 43.3% and 
21.5% respectively. Mothers had higher attack rates compared to fathers (26.1% 
versus 18.1%). Our data not only demonstrate that individuals get reinfected, but also 
that those with reinfections go on to reinfect others and generate chains of 
transmission. Thus we clearly show the importance of reinfections in the process of 
community transmission. Infection in older population can have important 
implications for transmission, infection, and disease in infants as possible reservoirs 
of infection. Nevertheless, an important aspect worthy of further consideration is the 
role of young infants in transmission dynamics. It is possible the infants drive the 
infection in the household due to their longer duration of shedding thus there are 
potential knock on effects of protecting infants.
The risk of clinical infection was dependent on age. The proportion of subclinical
infections increased with age, in line with published literature suggesting risk of
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disease is higher in primary infections than reinfections (Henderson et a l 1979; 
Glezen et a l 1986; Nokes et a l 2008), and that the risk of disease decreases with 
increase in age (Ohuma et a l 2012). These findings have implications for design of 
future studies in the community as they highlight the need for collecting samples 
regardless of symptoms. The amount of the virus circulating in the community would 
be underestimated if the contribution of asymptomatic infections is overlooked, a 
potentially important aspect in assessing the impact of RSV vaccines on viral 
circulation. However, assessment of the viability (infectiousness) of the viruses 
detected in subclinical infections and the role of subclinical infection in transmission 
is warranted. It will be important to assess whether Ct values (amount of viral 
shedding) in the RSV detections have any influence on transmission.
Transmission of infection is dependent on duration of infectiousness. We estimated 
the duration of shedding and factors that are associated with infection recovery. Of 
the covariates examined, age, infection severity, presence of other respiratory viruses 
and concurrent RSV infections in the household were significant factors related to the 
duration of shedding. Duration of viral shedding decreased with age and was shorter 
in subclinical infections relative to symptomatic infections. We did not assess the 
viral load profile of RSV shedding in order to identify possible peak periods for virus 
transmission (probably when viral load is high) and this forms part of intended future 
analyses. About 10% of the infected individuals shed RSV for more than 3 weeks. 
Most of these prolonged shedders were young with no clustering by household. 
Previously researchers showed immune-compromised individuals shed virus for 
prolonged periods (Hall et a l 1986). Our study did not test for HIV infection due to 
practical and ethical reasons.
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We also report discontinuous shedding of RSV in another 10% of the cases: the 
duration between the shedding periods was more than two weeks raising questions of 
whether it was same infection or a repeat infection. Efforts to sequence the hyper­
variable region of the G gene did not conclusively resolve this question and further 
work is planned using next generation (deep) sequencing and whole genome 
sequencing at Sanger Institute
(http://www.sanger.ac.uk/research/proiects/vimsgenomics/). The presence of 
prolonged shedders and/or reinfections within short intervals has a bearing on our 
understanding of the biology of RSV infections particularly on mechanisms of viral 
persistence and immunological basis of reinfection. Even if our observations of 
intervening negative samples or periods was due to limitations in our PCR assay 
sensitivity, it still points to fluctuations in viral load over the course of the infection 
episode which also have an impact on viral spread. These observations were possible 
due to collection of samples irrespective of clinical status again underscoring the 
merits of this approach in community studies.
Human rhino vims, human coronavimses (OC43, NL63 and 229E strains) and 
adenovimses co-circulated with RSV (Figure 8.1). Not surprising the incidence of co- 
infection of these vimses with RSV was not uncommon. Possible interaction of these 
vimses is likely to occur as they compete for the same ecological niche (respiratory 
epithelial cells). The effect of viral infection on nasopharyngeal carriage of bacteria is 
also being investigated using data from this study.
8.3 Study limitations and areas for improvement
Despite the frequent sampling regime for NPS, infections with short durations (<3
days) were likely to have been missed. The probability of missing these infections
was higher in older age groups relative to infant because of the differential NPS
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compliance by age and the associated short durations of shedding in adults. NPS 
compliance was higher in infants compared to other relatives and fathers and this 
could have an effect on estimating the importance of these groups in transmission. 
Unfortunately, efforts to supplement the infection data from the OF proved 
unsuccessful for the RSV-specific ELISA assay or insensitive by M-PCR testing. The 
antibody data would have also helped in assessing the influence of pre-infection 
antibody titres on infection and disease. There is still need for a less invasive but 
sensitive specimen collection method that is acceptable and can be practical for 
frequent sampling (ideally daily) across the ages in the community.
The potential importance of HIV in modifying RSV infection could not be 
established, as HIV status was not determined in the current study. The reported 
prolonged RSV shedding in some participants could be due to HIV infection. It would 
be useful in future to follow the prolonged shedders to see what happened to them as 
they can be easily tracked using the demographic surveillance data.
The study households were biased to those with older children, but it would be 
interesting to study transmissions in households without older children to see how the 
transmission patterns vary. We also followed the households for only one RSV 
season. Including multiple seasons would have provided additional information on the 
risk of reinfection and identify changes in within-household spread of RSV as a result 
of previous transmission.
8.4 Future research
As a natural extension of this work, our group has set up collaboration with Sanger 
Institute in the United Kingdom to develop the method for deep sequencing and 
whole genome sequencing of the RSV positive samples. The aim is to assess the
genetic diversity of the circulating viruses as well as to identify molecular markers to 
use in identifying transmission events (i.e. chains of transmission) within the 
household. The accruing data will also allow assessment of genetic relatedness of the 
virus detected during the same infection episode and between infected individuals of 
the same household over time, enabling analysis based on reconstruction of 
transmission events (Cooper et al. 2012). These data will be used to assess the 
importance of molecular evolution of the virus within individuals and the household.
We can also use Ct values as a proxy measure of viral load, e.g. to estimate the 
relative amount of virus shed over the shedding period. The aim would be to assess 
the relationship between viral shedding and the probability of transmission.
There were disparities in NPS collection rates with higher compliance reported in 
infants and mothers compared to older children and fathers. The compliance for oral 
fluid was high and acceptable across all the ages. The utility of the OF in 
supplementing infection data will be explored further using RNA UltraSense kit 
(Invitrogen), one-step quantitative RT-PCR System designed to detect viruses in low 
quantities.
In order to generate data with daily infections status, a Bayesian algorithm to impute 
missing data are required(Cooper et al. 2008). Data arising from these methods would 
be useful in the calculation of realistic transmission parameters such as duration of 
shedding, age-related susceptibility and transmission probability in the community 
and within the household. Mathematical models such as individual-based models of 
the transmission of RSV within communities incorporating the accruing household 
infection data will be developed. The aim would be to assess the potential impact of 
control measures such as vaccination and social distancing (Milne et al. 2008; Kelso
et al. 2009) on RSV transmission, infection and disease. Of relevance to this study, 
would be an assessment of household-based approaches in delivery of vaccines such 
as immunisation of older siblings or pregnant mothers.
oiiiiiicu «uiiuysi& iui me other com moil respiratory viruses such as rhinoviruses, 
coronaviruses and adenoviruses as those presented in this thesis will be undertaken. 
Initial focus will be on coronaviruses, which have shown clear within-household 
spread (Figure 8.1). Our study suggests an effect of other respiratory viruses on the 
duration of RSV shedding alluding to possible interaction or competition of these 
viruses. These possible interactions will be explored in a mathematical model 
framework.
Older ages had high attack rates bringing infections into the household. We do not 
know from where they get their infection hence a need for broader studies that include 
schools or school-going children. These future studies would benefit from use of 
acceptable and non-invasive specimen collection methods.
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Figure 8.1: Infection patterns of a range of respiratory viruses in a household of 5 members, 
infant (Inf), one girl (S), two boys (B1 and B2) and their mother (Mum). In this household 
NPS were collected twice-a-week for the entire study period from all members. RSV A, 
respiratory syncytial virus group A; Rhino, Rhinovirus; Adeno, adenovirus; and human 
corona virus, OC43 strain
249
9 REFERENCES
Adegbola, R. A. (2012). "Childhood pneumonia as a global health priority and the strategic 
interest of the Bill & Melinda Gates Foundation." Clin Tnfect Pis 54 Suppl 2: S89-92. 
Agoti, C. N., A. G. Mwihuri, C. J. Sanae, C. O. Onyango, G. F. Medley, P. A. Cane and D. J. 
Nokes (2012). "Genetic relatedness of infecting and reinfecting respiratory syncytial 
virus strains identified in a birth cohort from rural kenya." J Infect Pis 206(10): 1532- 
1541.
Ahmed, J. A., M. A. Katz, E. Auko, M. K. Njenga, M. Weinberg, B. K. Kapella, et al.
(2012). "Epidemiology of respiratory viral infections in two long-term refugee camps 
in Kenya, 2007-2010." BMC Infect Pis 12(7): 7.
American Academy of Pediatrics (2012). Respiratory svncvtial virus.. Elk Grove Villag, IL, 
American Academy of Pediatrics.
Anderson, L. J., P. R. Dormitzer, D. J. Nokes, R. Rappuoli, A. Roca and B. S. Graham
(2013). "Strategic priorities for respiratory syncytial virus (RSV) vaccine 
development." Vaccine 31 Suppl 2: B209-215.
Anderson, L. J., J. C. Hierholzer, C. Tsou, R. M. Hendry, B. F. Femie, Y. Stone and K. 
McIntosh (1985). "Antigenic characterization of respiratory syncytial virus strains 
with monoclonal antibodies." J Infect Pis 151(4): 626-633.
Anderson, R., Y. Huang and J. M. Langley (2010). "Prospects for defined epitope vaccines 
for respiratory syncytial virus." Future Microbiol 5(4): 585-602.
Anderson, R. M. and B. T. Grenfell (1985). "Control of congenital rubella syndrome by mass 
vaccination." Lancet 2(8459): 827-828.
Anderson, R. M. and B. T. Grenfell (1986). "Quantitative investigations of different
vaccination policies for the control of congenital rubella syndrome (CRS) in the 
United Kingdom." JHyg fLond) 96(2): 305-333.
Anderson, R. M. and R. M. May (1985). "Age-related changes in the rate of disease
transmission: implications for the design of vaccination programmes." Journal of 
Hygiene (Cambridge! 94: 365-436.
Anderson, R. M. and R. M. May (1991). Infectious diseases of humans: dynamics and 
control. Oxford, Oxford University Press.
Badger, G. F., J. H. Dingle, A. E. Feller, R. G. Hodges, W. S. Jordan, Jr. and C. H.
Rammelkamp, Jr. (1953). "A study of illness in a group of Cleveland families. III. 
Introduction of respiratory infections into families." Am J Hyg 58(1): 41-46.
Baker, K. A. and M. E. Ryan (1999). "RSV infection in infants and young children. What’s 
new in diagnosis, treatment, and prevention?" Postgrad Med 106(7): 97-99, 103-104, 
107-108 passim.
Becker, N. G. and K. Dietz (1995). "The effect of household distribution on transmission and 
control of highly infectious diseases." Mathematical Biosciences 127(2): 207-219.
Bedoya, V. I., V. Abad and H. Trujillo (1996). "Frequency of respiratory syncytial virus in 
hospitalized infants with lower acute respiratory tract infection in Colombia." Pediatr 
Infect Pis J 15(12): 1123-1124.
Berglund, B. (1967). "Respiratory syncytial virus infections in families. A study of family 
members of children hospitalized for acute respiratory disease." Acta Paediatr Scand 
56(4): 395-404.
Berkley, J. A., P. Munywoki, M. Ngama, S. Kazungu, J. Abwao, A. Bett, et al. (2010). "Viral 
etiology of severe pneumonia among Kenyan infants and children." Jama 303(20): 
2051-2057.
Berman, S. (1991). "Epidemiology of acute respiratory infections in children of developing 
countries." Rev Infect Pis 13 Suppl 6: S454-462.
251
Berman, S., A. Duenas, A. Bedoya, V. Constain, S. Leon, I. Borrero and J. Murphy (1983). 
"Acute lower respiratory tract illnesses in Cali, Columbia: a two year ambulatory 
study." Pediatrics 71: 210-218.
Bernstein, D. I., E. Malkin, N. Abughali, J. Falloon, T. Yi and F. Dubovsky (2012). "Phase 1 
study of the safety and immunogenicity of a live, attenuated respiratory syncytial 
virus and parainfluenza virus type 3 vaccine in seronegative children." Pediatr Infect 
DisJ31(2): 109-114.
Borrero, I., L. Fajardo, A. Bedoya, A. Zea, F. Carmona and M. F. de Borrero (1990). "Acute 
respiratory tract infections among a birth cohort of children from Cali, Colombia, who 
were studied through 17 months of age." Rev Infect Pis 12 Suppl 8: S950-956.
Botosso, V. F., P. M. Zanotto, M. Ueda, E. Arruda, A. E. Gilio, S. E. Vieira, et al. (2009). 
"Positive selection results in frequent reversible amino acid replacements in the G 
protein gene of human respiratory syncytial virus." PLoS Pathos 5(1): el 000254.
Broyden, C. G. (1970). "The convergence of a class of double-rank minimization algorithms 
1. general considerations." IMA Journal of Applied Mathematics 6(1): 76-90.
Cane, P., Ed. (2007). Molecular Epidemiology and Evolution of Respiratory Svncvtial Virus. 
Respiratory Syncytial Virus. 2007, Elsevier,.
Cane, P. and C. Pringle (1995). "Evolution of subgroup A respiratory syncytial virus: 
evidence for progressive accumulation of amino acid changes in the attachment 
protein." Journal of Virology 69(5): 2918-2925.
Cane, P. and C. Pringle (1995). "Molecular epidemiology of human respiratory syncytial 
virus." Seminars in Virology 6(6): 371-378.
Cane, P. A. (2001). "Molecular epidemiology of respiratory syncytial virus." Rev Med Virol 
11(2): 103-116.
252
Cane, P. A., D. A. Matthews and C. R. Pringle (1991). "Identification of variable domains of 
the attachment (G) protein of subgroup A respiratory syncytial viruses." Journal of 
General Virology 72: 2091-2096.
Cane, P. A., D. A. Matthews and C. R. Pringle (1992). "Analysis of relatedness of subgroup 
A respiratory syncytial viruses isolated worldwide." Virus Res 25(1-2): 15-22.
Cane, P. A., D. A. Matthews and C. R. Pringle (1994). "Analysis of respiratory syncytial
virus strain variation in successive epidemics in one city." J Clin Microbiol 32(1): 1-
4.
Cane, P. A., M. Weber, M. Sanneh, R. Dackour, C. R. Pringle and H. Whittle (1999). 
"Molecular epidemiology of respiratory syncytial virus in The Gambia." 
Epidemiology and Infection 122flk 155-160.
Casiano-Colon, A. E., B. B. Hulbert, T. K. Mayer, E. E. Walsh and A. R. Falsey (2003). 
"Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial 
virus infection in adults." J Clin Virol 28(2): 169-174.
Cauchemez, S., C. A. Donnelly, C. Reed, A. C. Ghani, C. Fraser, C. K. Kent, et al. (2009). 
"Household transmission of 2009 pandemic influenza A (H1N1) virus in the United 
States." N Engl J Med 361(27): 2619-2627.
Chan, K. H., J. S. Peiris, W. Lim, J. M. Nicholls and S. S. Chiu (2008). "Comparison of
nasopharyngeal flocked swabs and aspirates for rapid diagnosis of respiratory viruses 
in children." J Clin Virol 42(1): 65-69.
Chan, P. and A. Goh (1999). "Respiratory syncytial virus infection in young Malaysian 
children." Singapore Med J 40(5): 336-340.
Chan, P. K., R. Y. Sung, K. S. Fung, M. Hui, K. W. Chik, F. A. Adeyemi-Doro and A. F. 
Cheng (1999). "Epidemiology of respiratory syncytial virus infection among
253
paediatric patients in Hong Kong: seasonality and disease impact." Epidemiol Infect 
123(2): 257-262.
Chanock, R., B. Roizman and R. Myers (1957). "Recovery from infants with respiratory 
illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties 
and characterization." Am JHyg 66(3): 281-290.
Cherian, T., E. A. Simoes, M. C. Steinhoff, K. Chitra, M. John, P. Raghupathy and T. J. John
(1990). "Bronchiolitis in tropical south India." Am J Pis Child 144(9): 1026-1030.
Chew, F. T., S. Doraisingham, A. E. Ling, G. Kumarasinghe and B. W. Lee (1998).
"Seasonal trends of viral respiratory tract infections in the tropics." Epidemiol Infect 
121(1): 121-128.
Coates, H. V., D. W. Ailing and R. M. Chanock (1966). "An antigenic analysis of respiratory 
syncytial virus isolates by a plaque reduction neutralization test." Am J Epidemiol 
83(2): 299-313.
Collins, P. L., L. E. Dickens, A. Buckler-White, R. A. Olmsted, M. K. Spriggs, E. Camargo 
and K. V. Coelingh (1986). "Nucleotide sequences for the gene junctions of human 
respiratory syncytial virus reveal distinctive features of intergenic structure and gene 
order." ProcNatl Acad Sc i USA 83(13): 4594-4598.
Collins, P. L. and B. R. Murphy, Eds. (2007). Vaccines against Human Respiratory Syncytial 
Virus. Respiratory Syncytial Virus. 2007, Elsevier,.
Connors, M., P. L. Collins, C. Y. Firestone and B. R. Murphy (1991). "Respiratory syncytial 
virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, 
but resistance induced by M2 and N proteins is relatively short-lived." J Virol 65(3): 
1634-1637.
254
Cooney, M. K., J. P. Fox and C. E. Hall (1975). "The Seattle Virus Watch. VI. Observations 
of infections with and illness due to parainfluenza, mumps and respiratory syncytial 
viruses and Mycoplasma pneumoniae." Am J Epidemiol 101(6): 532-551.
Cooney, M. K., C. E. Hall and J. P. Fox (1972). "The Seattle virus watch. 3. Evaluation of 
isolation methods and summary of infections detected by virus isolations." Am J 
Epidemiol 96(4): 286-305.
Cooper, B. S., T. Kypraios, R. Batra, D. Wyncoll, O. Tosas and J. D. Edgeworth (2012).
"Quantifying type-specific reproduction numbers for nosocomial pathogens: evidence 
for heightened transmission of an Asian sequence type 239 MRSA clone." PLoS 
Comput Biol 8(4): e l002454.
Cooper, B. S., G. F. Medley, S. J. Bradley and G. M. Scott (2008). "An augmented data
method for the analysis of nosocomial infection data." Am J Epidemiol 168(5): 548- 
557.
Crowcroft, N., F. Cutts and M. Zambon (1999). "Respiratory syncytial virus: an
underestimated cause of respiratory infection, with prospects for a vaccine." 
Communicable Disease and Public Health 2: 234-241.
Crowcroft, N. S., M. Zambon, T. G. Harrison, Q. Mok, P. Heath and E. Miller (2008).
"Respiratory syncytial virus infection in infants admitted to paediatric intensive care 
units in London, and in their families." Eur J Pediatr 167(4): 395-399.
Crowe, J. E., Jr. (2001). "Influence of maternal antibodies on neonatal immunization against 
respiratory viruses." Clin Infect Pis 33(10): 1720-1727.
Cutts, F. T., S. M. Zaman, G. Enwere, S. Jaffar, O. S. Levine, J. B. Okoko, et al. (2005). 
"Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and 
invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo- 
controlled trial." Lancet 365(9465): 1139-1146.
Dagan, R., D. Landau, H. Haikin and A. Tal (1993). "Hospitalization of Jewish and Bedouin 
infants in southern Israel for bronchiolitis caused by respiratory syncytial virus." 
Pediatr Infect DisJ 12(5): 381-386.
Devincenzo, J. P. (2004). "Natural infection of infants with respiratory syncytial virus
subgroups A and B: a study of frequency, disease severity, and viral load." Pediatr 
Res_56(6): 914-917.
DeVincenzo, J. P. (2005). "Factors predicting childhood respiratory syncytial virus severity: 
what they indicate about pathogenesis." Pediatr Infect Pis J 24( 11 Suppl): SI77-183, 
discussion SI82.
DeVincenzo, J. P., J. Aitken and L. Harrison (2003). "Respiratory syncytial virus (RSV) 
loads in premature infants with and without prophylactic RSV fusion protein 
monoclonal antibody." J Pediatr 143(1): 123-126.
DeVincenzo, J. P., C. M. El Saleeby and A. J. Bush (2005). "Respiratory syncytial virus load 
predicts disease severity in previously healthy infants." J Infect Pis 191(11): 1861- 
1868.
Dietz, K. and D. Schenzle (1985). "Proportionate mixing models for age-dependent infection 
transmission." Journal of Mathematical Biology 22(1): 117-120.
Djelantik, I. G. G., B. D. Gessner, S. Soewignjo, M. Steinhoff, A. Sutanto, A. Widjaya, et al.
(2003). "Incidence and clinical features of hospitalization because of respiratory 
syncytial virus lower respiratory illness among children less than two years of age in a 
rural Asian setting." Pediatric Infectious Disease Journal 22(2): 150-156.
Djelantik, I. G. G., B. D. Gessner, A. Sutanto, M. Steinhoff, M. Linehan, L. H. Moulton and
S. Arjoso (2003). "Case fatality proportions and predictive factors for mortality 
among children hospitalized with severe pneumonia in a rural developing country 
setting." Journal of Tropical Pediatrics 49(6): 327-332.
Durbin, A. P. and R. A. Karron (2003). "Progress in the development of respiratory syncytial 
virus and parainfluenza virus vaccines." Clin Infect Pis 37(12): 1668-1677. Epub 
2003 Nov 1620.
Edmunds, W. J., G. Kafatos, J. Wallinga and J. R. Mossong (2006). "Mixing patterns and the 
spread of close-contact infectious diseases." Emerg Themes Epidemiol 3: 10.
Edmunds, W. J., C. J. O’Callaghan and D. J. Nokes (1997). "Who mixes with whom? A 
method to determine the contact patterns of adults that may lead to the spread of 
airborne infections." Proc R Soc Lond B 264: 949-957.
Edmunds, W. J., C. J. O’Callaghan and D. J. Nokes (1997). "Who mixes with whom? A 
method to determine the contact patterns of adults that may lead to the spread of 
airborne infections." Proc Biol Sci 264(1384): 949-957.
English, M. and J. A. Scott (2008). "What is the future for global case management 
guidelines for common childhood diseases?" PLoS Med 5(12): e241.
Englund, J., W. P. Glezen and P. A. Piedra (1998). "Maternal immunization against viral 
disease." Vaccine 16(14-15): 1456-1463.
Falsey, A. R., M. A. Formica, J. J. Treanor and E. E. Walsh (2003). "Comparison of
quantitative reverse transcription-PCR to viral culture for assessment of respiratory 
syncytial virus shedding." J Clin Microbiol 41(9): 4160-4165.
Falsey, A. R. and E. E. Walsh (2000). "Respiratory syncytial virus infection in adults." Clin 
Microbiol Rev 13(3): 371-384.
Falsey, A. R., E. E. Walsh, J. Capellan, S. Gravenstein, M. Zambon, E. Yau, et al. (2008). 
"Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) 
vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given 
concomitantly with influenza vaccine to high-risk elderly individuals." J Infect Pis 
198(9): 1317-1326.
Farrington, C. P., M. N. Kanaan and N. J. Gay (2001). "Estimation of the basic reproduction 
number for infectious diseases from age-stratified serological survey data." Journal of 
the Royal Statistical Society Series C-Applied Statistics 50: 251-283.
Feikin, D. R., M. K. Njenga, G. Bigogo, B. Aura, G. Aol, A. Audi, et al. (2012). "Etiology
and Incidence of viral and bacterial acute respiratory illness among older children and 
adults in rural western Kenya, 2007-2010." PLoS One 7(8): e43656.
Felton, K., I. Pandya-Smith, A. Cums, A. Fry, L. Anderson and N. Keeler (2004).
"Respiratory syncytial virus activity—United States, 2003-2004." MMWR Morb 
Mortal Wklv Rep 53(491: 1159-1160.
Fishaut, M., D. Tubergen and K. McIntosh (1980). "Cellular response to respiratory viruses 
with particular reference to children with disorders of cell-mediated immunity." J 
Pediatr 96(2): 179-186.
Fletcher, R. (1970). "A new approach to variable metric algorithms." The computer journal 
13(3): 317-322.
Forgie, I. M., K. P. O'Neill, N. Lloyd-Evans, M. Leinonen, H. Campbell, H. C. Whittle and 
B. M. Greenwood (1991). "Etiology of acute lower respiratory tract infections in 
Gambian children: II. Acute lower respiratory tract infection in children ages one to 
nine years presenting at the hospital." Pediatr Infect Pis J 10(1): 42-47.
Fox, J. P., M. K. Cooney and C. E. Hall (1975). "The Seattle virus watch. V. Epidemiologic 
observations of rhinovirus infections, 1965-1969, in families with young children." 
Am J Epidemiol 101(2): 122-143.
Fox, J. P., L. Elveback, W. Scott, L. Gatewood and E. Ackerman (1971). "Herd immunity: 
basic concept and relevance to public health immunization practices." Am J 
Epidemiol 94(3): 179-189.
Fox, J. P. and C. E. Hall (1971). "Viruses in families." Lancet 1(7711): 1240-1241.
Frank, A. L., L. H. Taber, C. R. Wells, J. M. Wells, W. P. Glezen and A. Paredes (1981).
"Patterns of shedding of myxoviruses and paramyxoviruses in children." J Infect Pis 
144(5): 433-441.
Gilani, Z., Y. D. Kwong, O. S. Levine, M. Deloria-Knoll, J. A. Scott, K. L. O’Brien and D. R. 
Feikin (2012). "A literature review and survey of childhood pneumonia etiology 
studies: 2000-2010." Clin Infect Pis 54 Suppl 2: S102-108.
Glenn, G. M., G. Smith, L. Fries, R. Raghunandan, H. Lu, B. Zhou, et a l (2013). "Safety and 
immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein 
nanoparticle vaccine." Vaccine 31(3): 524-532.
Glezen, W. P., L. H. Taber, A. L. Frank and J. A. Kasel (1986). "Risk of primary infection 
and reinfection with respiratory syncytial virus." American Journal of Diseases of 
Children 140: 543-546.
Goldfarb, D. (1970). "A family of variable metric methods derived by variational means."
Mathematics of computation 24(109): 23-26.
Goldstein, E., K. Paur, C. Fraser, E. Kenah, J. Wallinga and M. Lipsitch (2009).
"Reproductive numbers, epidemic spread and control in a community of households." 
MathBiosci 22101: 11-25.
Gomez, M., M. A. Mufson, F. Dubovsky, C. Knightly, W. Zeng and G. Losonsky (2009).
"Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory 
syncytial virus and parainfluenza-3 virus in seropositive children." Pediatr Infect Pis J 
28(7): 655-658.
Gonzalez, I. M., R. A. Karron, M. Eichelberger, E. E. Walsh, V. W. Delagarza, R. Bennett et 
al. (2000). "Evaluation of the live attenuated cpts 248/404 RSV vaccine in 
combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults." 
Vaccine 18(17): 1763-1772.
Grenfell, B. T. and R. M. Anderson (1985). "The estimation of age-related rates of infection 
from case notifications and serological data." Journal of Hygiene 95: 419-436.
Guerguerian, A. M., M. Gauthier, M. H. Lebel, C. A. Farrell and J. Lacroix (1999).
"Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, 
placebo-controlled trial." Am J Respir Crit Care Med 160(3): 829-834.
Gunson, R. N., T. C. Collins and W. F. Carman (2005). "Real-time RT-PCR detection of 12 
respiratory viral infections in four triplex reactions." J Clin Virol 33(4): 341-344.
Hall, C., E. Walsh, C. Long and K. Schnabel (1991). "Immunity to and frequency of
reinfection with respiratory syncytial virus." Journal of Infections Diseases 163(4): 
693-698.
Hall, C. B. (1977). "The shedding and spreading of respiratory syncytial virus." Pediatr Res 
11(3 Pt 2): 236-239.
Hall, C. B. and R. G. Douglas, Jr. (1981). "Modes of transmission of respiratory syncytial 
virus." J Pediatr 99(11: 100-103.
Hall, C. B., R. G. Douglas, Jr. and J. M. Geiman (1975). "Quantitative shedding patterns of 
respiratory syncytial virus in infants." J Infect Pis 13212): 151-156.
Hall, C. B., R. G. Douglas, Jr. and J. M. Geiman (1976). "Respiratory syncytial virus
infections in infants: quantitation and duration of shedding." J Pediatr 89(1): 11-15.
Hall, C. B., R. G. Douglas, Jr. and J. M. Geiman (1980). "Possible transmission by fomites of 
respiratory syncytial virus." J Infect Pis 141(11: 98-102.
Hall, C. B., R. G. Douglas, Jr., J. M. Geiman and M. K. Messner (1975). "Nosocomial 
respiratory syncytial virus infections." N Engl J Med 2931261: 1343-1346.
Hall, C. B., R. G. Douglas, Jr., K. C. Schnabel and J. M. Geiman (1981). "Infectivity of
respiratory syncytial virus by various routes of inoculation." Infect Immun 33(3): 779- 
783.
260
Hall, C. B., J. M. Geiman, R. Biggar, D. I. Kotok, P. M. Hogan and G. R. Douglas, Jr.
(1976). "Respiratory syncytial virus infections within families." N Engl J Med 294(8): 
414-419.
Hall, C. B., J. M. Geiman, R. G. Douglas, Jr. and M. P. Meagher (1978). "Control of 
nosocomial respiratory syncytial viral infections." Pediatrics 62(5): 728-732.
Hall, C. B., C. E. Long and K. C. Schnabel (2001). "Respiratory syncytial virus infections in 
previously healthy working adults." Clin Infect Pis 33(6): 792-796.
Hall, C. B., J. T. McBride, C. L. Gala, S. W. Hildreth and K. C. Schnabel (1985). "Ribavirin 
treatment of respiratory syncytial viral infection in infants with underlying 
cardiopulmonary disease." JAMA 254(21): 3047-3051.
Hall, C. B., K. R. Powell, N. E. MacDonald, C. L. Gala, M. E. Menegus, S. C. Suffin and H. 
J. Cohen (1986). "Respiratory syncytial viral infection in children with compromised 
immune function." N Engl J Med 315(2): 77-81.
Hall, C. B., E. E. Walsh, J. F. Hruska, R. F. Betts and W. J. Hall (1983). "Ribavirin treatment 
of experimental respiratory syncytial viral infection. A controlled double-blind study 
in young adults." JAMA 249(19): 2666-2670.
Hall, C. B., G. A. Weinberg, M. K. Iwane, A. K. Blumkin, K. M. Edwards, M. A. Staat, et al 
(2009). "The burden of respiratory syncytial virus infection in young children." N 
EngUM ed360(6): 588-598.
Hall, R. and N. G. Becker (1996). "Preventing epidemics in a community of households." 
Epidemiol Infect 117(3): 443-455.
Hammitt, L. L., S. Kazungu, S. C. Morpeth, D. G. Gibson, B. Mvera, A. J. Brent, et al.
(2012). "A preliminary study of pneumonia etiology among hospitalized children in 
Kenya." Clin Tnfect Pis 54 Suppl 2(2): SI90-199.
261
Hammitt, L. L., S. Kazungu, S. Welch, A. Bett, C. O. Onyango, R. N. Gunson, et al. (2011). 
"Added value of an oropharyngeal swab in detection of viruses in children 
hospitalized with lower respiratory tract infection." J Clin Microbiol 49(6): 2318- 
2320.
Hemming, V. G., W. Rodriguez, H. W. Kim, C. D. Brandt, R. H. Parrott, B. Burch, et al
(1987). "Intravenous immunoglobulin treatment of respiratory syncytial virus 
infections in infants and young children." Antimicrob Agents Chemother 31021: 
1882-1886.
Henderson, F., A. Collier, W. J. Clyde and F. Denny (1979). "Respiratory-syncytial-virus 
infections, reinfections and immunity. A prospective, longitudinal study in young 
children." New England Journal of Medicine 300: 530-534.
Hendry, R. M., J. C. Bums, E. E. Walsh, B. S. Graham, P. F. Wright, V. G. Hemming, et al
(1988). "Strain-specific semm antibody responses in infants undergoing primary 
infection with respiratory syncytial vims." J Infect Pis 157(4): 640-647.
House, T. and M. J. Keeling (2008). "Deterministic epidemic models with explicit household 
structure." Math Biosci 213(1): 29-39.
House, T. and M. J. Keeling (2009). "Household structure and infectious disease 
transmission." Epidemiol Infect 137(5): 654-661.
Hsu, K. H., M. D. Lubeck, A. R. Davis, R. A. Bhat, B. H. Selling, B. M. Bhat, et a l (1992). 
"Immunogenicity of recombinant adenovirus-respiratory syncytial vims vaccines with 
adenovims types 4, 5, and 7 vectors in dogs and a chimpanzee." J Infect Pis 166(4): 
769-775.
Hussey, G. D., P. Apolles, Z. Arendse, J. Yeates, A. Robertson, G. Swingler and H. J. Zar
(2000). "Respiratory syncytial vims infection in children hospitalised with acute 
lower respiratory tract infection." S Afr Med J 90(5): 509-512.
Jin, H., X. Cheng, V. L. Traina-Dorge, H. J. Park, H. Zhou, K. Soike and G. Kemble (2003). 
"Evaluation of recombinant respiratory syncytial virus gene deletion mutants in 
African green monkeys for their potential as live attenuated vaccine candidates." 
Vaccme 21(25-26): 3647-3652.
Johnson, P. R. and P. L. Collins (1988). "The fusion glycoproteins of human respiratory 
syncytial virus of subgroups A and B: sequence conservation provides a structural 
basis for antigenic relatedness." J Gen Virol 69 ( Pt 10): 2623-2628.
Johnson, P. R., M. K. Spriggs, R. A. Olmsted and P. L. Collins (1987). "The G glycoprotein 
of human respiratory syncytial viruses of subgroups A and B: extensive sequence 
divergence between antigenically related proteins." Proc Natl Acad Sci U S A 84(16): 
5625-5629.
Kaaijk, P., W. Luytjes and N. Y. Rots (2013). "Vaccination against RSV: Is maternal
vaccination a good alternative to other approaches?" Hum Vaccin Immunother 9(6).
Kanaan, M. N. and C. P. Farrington (2005). "Matrix models for childhood infections: a
Bayesian approach with applications to rubella and mumps." Epidemiol Infect 133(6): 
1009-1021.
Karron, R. A., R. J. Singleton, L. Bulkow, A. Parkinson, D. Kruse, I. DeSmet, et al. (1999). 
"Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska 
Study Group." J Infect Pis 180(1): 41-49.
Karron, R. A., P. F. Wright, R. B. Belshe, B. Thumar, R. Casey, F. Newman, et a l (2005). 
"Identification of a recombinant live attenuated respiratory syncytial virus vaccine 
candidate that is highly attenuated in infants." J Infect Pis 191(7): 1093-1104.
Karstaedt, A. S., M. Hopley, M. Wong, H. H. Crewe-Brown and A. Tasset-Tisseau (2009). 
"Influenza- and respiratory syncytial virus-associated adult mortality in Soweto." S 
Afr Med J 99(10): 750-754.
Kelso, J. K., G. J. Milne and H. Kelly (2009). "Simulation suggests that rapid activation of 
social distancing can arrest epidemic development due to a novel strain of influenza." 
BMC Public Health 9: 117.
Kenya National Bureau of Statistics (2010). 2009 Population and Housing Census Results. N. 
d. a. v. ministry of State for planning. http://www.knbs.or.ke/Census 
Results/Presentation by Minister for Planning revised.pdf, KNBS.
Kenya National Bureau of Statistics, I. M. (2010). Kenya Demographic and Health Survey 
2008-09. Calverton, Maryland, KNBS and ICF Macro.
Kirkwood, B. R. and J. A. C. Steme (2003). Essential Medical Statistics. Oxford, UK, 
Blackwell publishing.
Kravetz, H., V. Knight, R. Chanock, J. Morris, K. Johnson, D. Rifkind and J. Utz (1961). 
"Respiratory syncytial virus. III. Production of illness and clinical observations in 
adult volunteers." Journal of the American Medical Association. 176: 657-663.
Kusel, M. M., N. H. de Klerk, P. G. Holt, T. Kebadze, S. L. Johnston and P. D. Sly (2006). 
"Role of respiratory viruses in acute upper and lower respiratory tract illness in the 
first year of life: a birth cohort study." Pediatr Infect Pis J 25(8): 680-686.
Kuypers, J., N. Wright and R. Morrow (2004). "Evaluation of quantitative and type-specific 
real-time RT-PCR assays for detection of respiratory syncytial virus in respiratory 
specimens from children." J Clin Virol 31(2): 123-129.
Langley, J. M., V. Sales, A. McGeer, R. Guasparini, G. Predy, W. Meekison, et al. (2009).
"A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine 
with and without aluminum phosphate adjuvantation in adults > or =65 years of age." 
Vaccine 27(42): 5913-5919.
Law, B. J., E. E. Wang, N. MacDonald, J. McDonald, S. Dobson, F. Boucher, et al. (1997). 
"Does ribavirin impact on the hospital course of children with respiratory syncytial
264
vims (RSV) infection? An analysis using the pediatric investigators collaborative 
network on infections in Canada (PICNIC) RSV database." Pediatrics 99(3): E7.
Lee, F. E., E. E. Walsh, A. R. Falsey, R. F. Betts and J. J. Treanor (2004). "Experimental 
infection of humans with A2 respiratory syncytial vims." Antiviral Res 63(3): 191- 
196.
Levine, O. S., K. L. O'Brien, M. Deloria-Knoll, D. R. Murdoch, D. R. Feikin, A. N. DeLuca, 
et al. (2012). "The Pneumonia Etiology Research for Child Health Project: a 21st 
century childhood pneumonia etiology study." Clin Infect Pis 54 Suppl 2: S93-101.
Lin, W. H., R. D. Kouyos, R. J. Adams, B. T. Grenfell and D. E. Griffin (2012). "Prolonged 
persistence of measles vims RNA is characteristic of primary infection dynamics." 
Proc Natl Acad Sci US A 109(37): 14989-14994.
Liu, L., H. L. Johnson, S. Cousens, J. Perin, S. Scott, J. E. Lawn, et al (2012). "Global,
regional, and national causes of child mortality: an updated systematic analysis for 
2010 with time trends since 2000." Lancet 379(98321: 2151-2161.
Longini, I. M., Jr., J. S. Koopman, A. S. Monto and J. P. Fox (1982). "Estimating household 
and community transmission parameters for influenza." Am J Epidemiol 115(5): 736- 
751.
Lozano, R., M. Naghavi, K. Foreman, S. Lim, K. Shibuya, V. Aboyans, et al. (2012). "Global 
and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: 
a systematic analysis for the Global Burden of Disease Study 2010." Lancet 
380(9859): 2095-2128.
Machata, A. M., B. Kabon, H. Willschke, D. Prayer and P. Marhofer (2010). "Upper airway 
size and configuration during propofol-based sedation for magnetic resonance 
imaging: an analysis of 138 infants and children." Paediatr Anaesth 20(11): 994-1000.
265
Madhi, S. A., A. Madhi, K. Petersen, M. Khoosal and K. P. Klugman (2001). "Impact of
human immunodeficiency virus type 1 infection on the epidemiology and outcome of 
bacterial meningitis in South African children." Int J Infect Pis 5(3): 119-125.
Madhi, S. A., B. Schoub, K. Simmank, N. Blackburn and K. P. Klugman (2000). "Increased 
burden of respiratory viral associated severe lower respiratory tract infections in 
children infected with human immunodeficiency virus type-1." J Pediatr 137(1): 78- 
84.
Marsh, V., D. Kamuya, Y. Rowa, C. Gikonyo and S. Molyneux (2008). "Beginning
community engagement at a busy biomedical research programme: experiences from 
the KEMRI CGMRC-Wellcome Trust Research Programme, KilifI, Kenya." Soc Sci 
Med 67(5): 721-733.
Medley, G. F. and D. J. Nokes (2009). "Epidemiology. Does viral diversity matter?" Science 
325(5938): 274-275.
Meert, K. L., A. P. Samaik, M. J. Gelmini and M. W. Lieh-Lai (1994). "Aerosolized ribavirin 
in mechanically ventilated children with respiratory syncytial virus lower respiratory 
tract disease: a prospective, double-blind, randomized trial." Crit Care Med 22(4): 
566-572.
Melegaro, A., N. J. Gay and G. F. Medley (2004). "Estimating the transmission parameters of 
pneumococcal carriage in households." Epidemiol Infect 132(3): 433-441.
Melero, J., Ed. (2007). Molecular Biology of Human Respiratory Svncvtial Virus.
Respiratory Syncytial Virus. 2007, Elsevier,.
Mills, J. t., J. E. Van Kirk, P. F. Wright and R. M. Chanock (1971). "Experimental respiratory 
syncytial virus infection of adults. Possible mechanisms of resistance to infection and 
illness." J Immunol 107(11: 123-130.
266
Milne, G. J., J. K. Kelso, H. A. Kelly, S. T. Huband and J. McVemon (2008). "A small
community model for the transmission of infectious diseases: comparison of school 
closure as an intervention in individual-based models of an influenza pandemic." 
PLoS One 3112k e4005.
Mlinaric-Galinovic, G., T. Chonmaitree, P. A. Cane, C. R. Pringle and P. L. Ogra (1994). 
"Antigenic diversity of respiratory syncytial virus subgroup B strains circulating 
during a community outbreak of infection." J Med Virol 42(4): 380-384.
Mlinaric-Galinovic, G., I. Tabain, T. Kukovec, G. Vojnovic, J. Bozikov, J. Bogovic-Cepin, et 
al. (2012). "Analysis of biennial outbreak pattern of respiratory syncytial virus 
according to subtype (A and B) in the Zagreb region." Pediatr Int 54(3): 331-335.
Mlinaric-Galinovic, G., R. C. Welliver, T. Vilibic-Cavlek, S. Ljubin-Stemak, V. Drazenovic, 
I. Galinovic and V. Tomic (2008). "The biennial cycle of respiratory syncytial virus 
outbreaks in Croatia." Virol J 5: 18.
Moisi, J. C., H. Gatakaa, A. M. Noor, T. N. Williams, E. Bauni, B. Tsofa, et a l (2010).
"Geographic access to care is not a determinant of child mortality in a rural Kenyan 
setting with high health facility density." BMC Public Health 10(142): 142.
Moisi, J. C., D. J. Nokes, H. Gatakaa, T. N. Williams, E. Bauni, O. S. Levine and J. A. Scott 
(2011). "Sensitivity of hospital-based surveillance for severe disease: a geographic 
information system analysis of access to care in Kilifi district, Kenya." Bull World 
Health Organ 8912): 102-111.
Moler, F. W., C. M. Steinhart, S. E. Ohmit and G. L. Stidham (1996). "Effectiveness of 
ribavirin in otherwise well infants with respiratory syncytial virus-associated 
respiratory failure. Pediatric Critical Study Group." J Pediatr 128(3): 422-428.
Monto, A. S. (2002). "Epidemiology of viral respiratory infections." Am J Med 112 Suppl 
6A: 4S-12S.
Monto, A. S., E. R. Bryan and L. M. Rhodes (1974). "The Tecumseh study of respiratory
illness. VII. Further observations on the occurrence of respiratory syncytial virus and 
Mycoplasma pneumoniae infections." Am J Epidemiol 100(6): 458-468.
Monto, A. S. and J. J. Cavallaro (1971). "The Tecumseh study of respiratory illness. II. 
Patterns of occurrence of infection with respiratory pathogens, 1965-1969." Am J 
Epidemiol 94(3): 280-289.
Monto, A. S. and J. J. Cavallaro (1972). "The Tecumseh study of respiratory illness. IV. 
Prevalence ofrhinovirus serotypes, 1966-1969." Am J Epidemiol 96t5): 352-360.
Monto, A. S. and S. K. Lim (1971). "The Tecumseh study of respiratory illness. 3. Incidence 
and periodicity of respiratory syncytial virus and Mycoplasma pneumoniae 
infections." Am J Epidemiol 94(3): 290-301.
Morris, J. A., R. E. Blount, Jr. and R. E. Savage (1956). "Recovery of cytopathogenic agent 
from chimpanzees with coryza." Proc Soc Exp Biol Med 92(3): 544-549.
Mossong, J., N. Hens, M. Jit, P. Beutels, K. Auranen, R. Mikolajczyk, et al (2008). "Social 
contacts and mixing patterns relevant to the spread of infectious diseases." PLoS Med 
5(3): e74.
Munoz, F. M., P. A. Piedra and W. P. Glezen (2003). "Safety and immunogenicity of
respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women." 
Vaccme 21(24): 3465-3467.
Munywoki, P. K., F. Hamid, M. Mutunga, S. Welch, P. Cane and D. J. Nokes (2011). 
"Improved detection of respiratory viruses in pediatric outpatients with acute 
respiratory illness by real-time PCR using nasopharyngeal flocked swabs." J Clin 
Microbiol 49(9): 3365-3367.
268
Munywoki, P. K., E. O. Ohuma, M. Ngama, E. Bauni, J. A. Scott and D. J. Nokes (2013). 
"Severe lower respiratory tract infection in early infancy and pneumonia 
hospitalizations among children, Kenya." Emerg Infect Pis 19(2): 223-229.
Murphy, B. R., R. A. Olmsted, P. L. Collins, R. M. Chanock and G. A. Prince (1988). 
"Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the 
immune response to the RSV fusion (F) and large (G) glycoproteins expressed by 
recombinant vaccinia viruses." J Virol 62(10): 3907-3910.
Murphy, B. R., A. Sotnikov, P. R. Paradiso, S. W. Hildreth, A. B. Jenson, R. B. Baggs, et al
(1989). "Immunization of cotton rats with the fusion (F) and large (G) glycoproteins 
of respiratory syncytial virus (RSV) protects against RSV challenge without 
potentiating RSV disease." Vaccine 7(6): 533-540.
Nair, H., D. J. Nokes, B. D. Gessner, M. Dherani, S. A. Madhi, R. J. Singleton, et a l (2010). 
"Global burden of acute lower respiratory infections due to respiratory syncytial virus 
in young children: a systematic review and meta-analysis." Lancet 375(9725): 1545- 
1555.
Ngama, M. J., B. Ouma, M. E. English and D. J. Nokes (2004). "Comparison of three
methods of collecting nasal specimens for respiratory virus analysis." East Afr Med J 
81(6): 313-317.
Nokes, D. J. (2007). Respiratory syncytial virus disease burden in the developing world. 
Perspectives in Medical Virology: Respiratory Syncytial Virus. P. A. Cane. 
Amsterdam, Elsevier. 14: 205 -210.
Nokes, D. J., F. Enquselassie, W. Nigatu, A. J. Vyse, B. J. Cohen, D. W. Brown and F. T. 
Cutts (2001). "Has oral fluid the potential to replace serum for the evaluation of 
population immunity levels? A study of measles, rubella and hepatitis B in rural 
Ethiopia." Bull World Health Organ 79(7): 588-595.
Nokes, D. J., M. Ngama, A. Bett, J. Abwao, P. Munywoki, M. English, et al. (2009).
"Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan 
children identified through hospital surveillance." Clin Infect Pis 49(9): 1341-1349. 
Nokes, D. J., E. A. Okiro, M. Ngama, R. Ochola, L. J. White, P. D. Scott, et al. (2008). 
"Respiratory syncytial virus infection and disease in infants and young children 
observed from birth in Kilifi District, Kenya." Clin Infect Pis 46(1): 50-57.
Nokes, D. J., E. A. Okiro, M. Ngama, L. J. White, R. Ochola, P. D. Scott, et al. (2004). 
"Respiratory Syncytial Virus Epidemiology in a Birth Cohort from Kilifi District, 
Kenya: Infection during the First Year of Life." J Infect Pis 190(10): 1828-1832. 
Nokes, J. D. and P. A. Cane (2008). "New strategies for control of respiratory syncytial virus 
infection." Curr Opin Infect Pis 21(6): 639-643.
Ochola, R., C. Sande, G. Fegan, P. D. Scott, G. F. Medley, P. A. Cane and D. J. Nokes 
(2009). "The level and duration of RSV-specific maternal IgG in infants in Kilifi 
Kenya." PLoS One 4(12): e8088.
Ohuma, E. O., E. A. Okiro, R. Ochola, C. J. Sande, P. A. Cane, G. F. Medley, et al. (2012). 
"The natural history of respiratory syncytial virus in a birth cohort: the influence of 
age and previous infection on reinfection and disease." Am J Enidemiol 176(9): 794- 
802.
Okiro, E. A. (2007). Transmission dynamics of respiratory svcvntial virus within the 
household and in the community. Doctor of Philosphy, University of Warwick.
Okiro, E. A., M. Ngama, A. Bett, P. A. Cane, G. F. Medley and D. James Nokes (2008).
"Factors associated with increased risk of progression to respiratory syncytial virus- 
associated pneumonia in young Kenyan children." Tron Med Int Health 13(7): 914- 
926.
270
Okiro, E. A., C. Sande, M. Mutunga, G. F. Medley, P. A. Cane and D. J. Nokes (2008). 
"Identifying infections with respiratory syncytial virus by using specific 
immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral- 
fluid samples." J Clin Microbiol 46(5): 1659-1662.
Okiro, E. A., L. J. White, M. Ngama, P. A. Cane, G. F. Medley and D. J. Nokes (2010).
"Duration of shedding of respiratory syncytial virus in a community study of Kenyan 
children." BMC Infect Pis 10051: 15.
Olsen, S. J., S. Thamthitiwat, S. Chantra, M. Chittaganpitch, A. M. Fry, J. M. Simmerman, et 
al. (2010). "Incidence of respiratory pathogens in persons hospitalized with 
pneumonia in two provinces in Thailand." Epidemiol Infect 138(12): 1811-1822.
Paradiso, P. R., S. W. Hildreth, D. A. Hogerman, D. J. Speelman, E. B. Lewin, J. Oren and 
D. H. Smith (1994). "Safety and immunogenicity of a subunit respiratory syncytial 
virus vaccine in children 24 to 48 months old." Pediatr Infect Pis J 13(9): 792-798.
Phillips, P. A., D. Lehmann, V. Spooner, J. Barker, S. Tulloch, M. Sungu, et al. (1990).
"Viruses associated with acute lower respiratory tract infections in children from the 
eastern highlands of Papua New Guinea (1983-1985)." Southeast Asian J Trop Med 
Public Health 21(3k 373-382.
Piedra, P. A., S. G. Cron, A. Jewell, N. Hamblett, R. McBride, M. A. Palacio, et al. (2003). 
"Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial 
virus: a multi-center trial in children with cystic fibrosis." Vaccine 21(19-20): 2448- 
2460.
Piedra, P. A., A. M. Jewell, S. G. Cron, R. L. Atmar and W. P. Glezen (2003). "Correlates of 
immunity to respiratory syncytial virus (RSV) associated-hospitalization: 
establishment of minimum protective threshold levels of serum neutralizing 
antibodies." Vaccine 21(24): 3479-3482.
Potter, G. E., M. S. Handcock, I. M. Longini, Jr. and M. E. Halloran (2011). "Estimating 
within-Household Contact Networks from Egocentric Data." Ann Appl Stat 5(3): 
1816-1838.
Poulsen, A., L. G. Stensballe, J. Nielsen, C. S. Benn, A. Balde, A. Roth, et al. (2006). "Long­
term consequences of respiratory syncytial virus acute lower respiratory tract 
infection in early childhood in Guinea-bissau." Pediatr Infect Pis J 25(11): 1025- 
1031.
Power, U. F., T. N. Nguyen, E. Rietveld, R. L. de Swart, J. Groen, A. D. Osterhaus, et al 
(2001). "Safety and immunogenicity of a novel recombinant subunit respiratory 
syncytial virus vaccine (BBG2Na) in healthy young adults." J Infect Pis 184(11): 
1456-1460.
Power, U. F., H. Plotnicky, A. Blaecke and T. N. Nguyen (2003). "The immunogenicity,
protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) 
vaccine candidate, against RSV-B." Vaccine 22(2): 168-176.
R Core Team (2012). R: A language and environment for statistical computing. R Foundation 
for Statistical Computing. Vienna, Austria.
Read, J. M., K. T. Eames and W. J. Edmunds (2008). "Dynamic social networks and the
implications for the spread of infectious disease." J R Soc Interface 5(26): 1001-1007.
Reese, P. E. andN. J. Marchette (1991). "Respiratory syncytial virus infection and
prevalence of subgroups A and B in Hawaii." J Clin Microbiol 29(11): 2614-2615.
Robertson, S. E., A. Roca, P. Alonso, E. A. Simoes, C. B. Kartasasmita, D. O. Olaleye, et al. 
(2004). "Respiratory syncytial virus infection: denominator-based studies in 
Indonesia, Mozambique, Nigeria and South Africa." Bull World Health Organ 82(12): 
914-922.
272
Robinson, J. L., B. E. Lee, S. Kothapalli, W. R. Craig and J. D. Fox (2008). "Use of throat 
swab or saliva specimens for detection of respiratory viruses in children." Clin Infect 
Dis 46(7): e61-64.
Roca, A., M. P. Loscertales, L. Quinto, P. Perez-Brena, N. Vaz, P. L. Alonso and J. C. Saiz
(2001). "Genetic variability among group A and B respiratory syncytial viruses in 
Mozambique: identification of a new cluster of group B isolates." J Gen Virol 82(Pt 
1): 103-111.
Rodriguez, W. J. and R. H. Parrott (1987). "Ribavirin aerosol treatment of serious respiratory 
syncytial virus infection in infants." Infect Dis Clin North Am 1(2): 425-439.
Rudan, I., E. Theodoratou, L. Zgaga, H. Nair, K. Y. Chan, M. Tomlinson, et al. (2012). 
"Setting priorities for development of emerging interventions against childhood 
pneumonia, meningitis and influenza." J Glob Health 2(1): 10304.
Sakthivel, S. K., B. Whitaker, X. Lu, D. B. Oliveira, L. J. Stockman, S. Kamili, et al. (2012). 
"Comparison of fast-track diagnostics respiratory pathogens multiplex real-time RT- 
PCR assay with in-house singleplex assays for comprehensive detection of human 
respiratory viruses." J Virol Methods 185(2): 259-266.
Sande, C. J., M. N. Mutunga, G. F. Medley, P. A. Cane and D. J. Nokes (2013). "Group- and 
genotype-specific neutralizing antibody responses against respiratory syncytial virus 
in infants and young children with severe pneumonia." J Infect Dis 207(3): 489-492.
Schenzle, D. (1984). "An age-structured model of pre- and post-vaccination measles
transmission." IMA Journal of Mathematics Applied in Medicine & Biology 1: 169- 
191.
Schmidt, A. C., J. M. McAuliffe, B. R. Murphy and P. L. Collins (2001). "Recombinant 
bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory
273
syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal 
immunization against RSV and HPIV3." J Virol 75(10): 4594-4603.
Schwarze, J., D. R. O’Donnell, A. Rohwedder and P. J. Openshaw (2004). "Latency and
persistence of respiratory syncytial virus despite T cell immunity." Am J Resnir Crit 
Care Med 169(7): 801-805.
Scott, J. A., E. Bauni, J. C. Moisi, J. Ojal, H. Gatakaa, C. Nyundo, et a l (2012). "Profile: The 
Kilifi Health and Demographic Surveillance System (KHDSS)." Int J Epidemiol 
41(3): 650-657.
Scott, P. D., R. Ochola, M. Ngama, E. A. Okiro, D. James Nokes, G. F. Medley and P. A.
Cane (2006). "Molecular analysis of respiratory syncytial virus reinfections in infants 
from coastal Kenya." J Infect Pis 193(1): 59-67.
Scott, P. D., R. Ochola, M. Ngama, E. A. Okiro, D. J. Nokes, G. F. Medley and P. A. Cane 
(2004). "Molecular epidemiology of respiratory syncytial virus in Kilifi district, 
Kenya." J Med Virol 74(2): 344-354.
Scott, P. D., R. Ochola, C. Sande, M. Ngama, E. A. Okiro, G. F. Medley, et a l (2007). 
"Comparison of strain-specific antibody responses during primary and secondary 
infections with respiratory syncytial virus." J Med Virol 79(12): 1943-1950.
Seki, K., H. Tsutsumi, M. Ohsaki, H. Kamasaki and S. Chiba (2001). "Genetic variability of 
respiratory syncytial virus subgroup a strain in 15 successive epidemics in one city." J 
Med Virol 64(3): 374-380.
Semple, M. G., A. Cowell, W. Dove, J. Greensill, P. S. McNamara, C. Halfhide, et al. (2005). 
"Dual infection of infants by human metapneumovirus and human respiratory 
syncytial virus is strongly associated with severe bronchiolitis." J Infect Pis 191(3): 
382-386.
274
Shanno, D. F. (1970). "Conditioning of quasi-Newton methods for function minimization."
Mathematics of computation 24(111): 647-656.
Simoes, E. A., H. M. Sondheimer, F. H. Top, Jr., H. C. Meissner, R. C. Welliver, A. A.
Kramer and J. R. Groothuis (1998). "Respiratory syncytial virus immune globulin for 
prophylaxis against respiratory syncytial virus disease in infants and children with 
congenital heart disease. The Cardiac Study Group." J Pediatr 133(4): 492-499. 
Simoes, E. A. F. (1999). "Respiratory syncytial virus infection." Lancet 354(9181): 847-852. 
Sims, D. G., M. A. Downham, J. McQuillin and P. S. Gardner (1976). "Respiratory syncytial 
virus infection in north-east England." Br Med J 2(6044): 1095-1098.
Singleton, R. J., D. Bruden, L. R. Bulkow, G. Varney and J. C. Butler (2006). "Decline in 
respiratory syncytial virus hospitalizations in a region with high hospitalization rates 
and prolonged season." Pediatr Infect Pis J 25(12): 1116-1122.
Smith, D. W., L. R. Frankel, L. H. Mathers, A. T. Tang, R. L. Ariagno and C. G. Prober
(1991). "A controlled trial of aerosolized ribavirin in infants receiving mechanical 
ventilation for severe respiratory syncytial virus infection." N Engl J Med 325(1): 24- 
29.
Smith, P. G. and R. H. Morrow (1992). Methods for Field Trials of Interventions Against 
Tropical Diseases: a 'Toolbox*. Oxford University Press.
Souza, L. S., E. A. Ramos, F. M. Carvalho, V. M. Guedes, C. M. Rocha, A. B. Soares, et al.
(2003). "Viral respiratory infections in young children attending day care in urban 
Northeast Brazil." Pediatr Pulmonol 35(3): 184-191.
Stensballe, L., A. Poulsen, E. Nante, I. P. Jensen, P. E. Kofoed, H. Jensen and P. Aaby
(2004). "Mothers may transmit RSV infection more easily or severely to sons than 
daughters: community study from Guinea-Bissau." Scand J Infect Pis 3614): 291-295.
275
Stensballe, L. G., J. K. Devasundaram and E. A. Simoes (2003). "Respiratory syncytial vims 
epidemics: the ups and downs of a seasonal vims." Pediatr Infect Pis J 22(2 Suppl): 
S21-32.
Stockton, J., J. S. Ellis, M. Saville, J. P. Clewley and M. C. Zambon (1998). "Multiplex PCR 
for typing and subtyping influenza and respiratory syncytial viruses." J Clin Microbiol 
36(10): 2990-2995.
Sutmoller, F., Z. P. Ferro, M. D. Asensi, V. Ferreira, I. S. Mazzei and B. L. Cunha (1995). 
"Etiology of acute respiratory tract infections among children in a combined 
community and hospital study in Rio de Janeiro." Clin Infect Pis 20(4): 854-860.
Suwanjutha, S., P. Sunakom, T. Chantarojanasiri, S. Siritantikom, S. Nawanoparatkul, T. 
Rattanadilok Na Bhuket, et al (2002). "Respiratory syncytial vims-associated lower 
respiratory tract infection in under-5-year-old children in a mral community of central 
Thailand, a population-based study." J Med Assoc Thai 85 Suppl 4: S llll-1119.
Taber, L. H., V. Knight, B. E. Gilbert, H. W. McClung, S. Z. Wilson, H. J. Norton, et al. 
(1983). "Ribavirin aerosol treatment of bronchiolitis associated with respiratory 
syncytial vims infection in infants." Pediatrics 72(5): 613-618.
Taylor, G., Ed. (2007). Immunology of RSV. Respiratory Syncytial Vims. 2007, Elsevier,.
Taylor, G., E. J. Stott, M. Bew, B. F. Femie, P. J. Cote, A. P. Collins, et al. (1984).
"Monoclonal antibodies protect against respiratory syncytial vims infection in mice." 
Immunology 52(1): 137-142.
Taylor, G., E. J. Stott, J. Furze, J. Ford and P. Sopp (1992). "Protective epitopes on the fusion 
protein of respiratory syncytial vims recognized by murine and bovine monoclonal 
antibodies." J Gen Virol 73 ( Pt 9): 2217-2223.
Teng, M. N., S. S. Whitehead, A. Bermingham, M. St Claire, W. R. Elkins, B. R. Murphy 
and P. L. Collins (2000). "Recombinant respiratory syncytial vims that does not
276
express the NS1 or M2-2 protein is highly attenuated and immunogenic in 
chimpanzees." JVirol 74(19): 9317-9321.
Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, N. Cox, L. J. Anderson and K.
Fukuda (2003). "Mortality associated with influenza and respiratory syncytial virus in 
the United States." JAMA 289(2): 179-186.
Trento, A., I. Casas, A. Calderon, M. L. Garcia-Garcia, C. Calvo, P. Perez-Brena and J. A. 
Melero (2010). "Ten years of global evolution of the human respiratory syncytial 
virus BA genotype with a 60-nucleotide duplication in the G protein gene." J Virol 
84(15): 7500-7512.
Trento, A., M. Galiano, C. Videla, G. Carballal, B. Garcia-Barreno, J. A. Melero and C.
Palomo (2003). "Major changes in the G protein of human respiratory syncytial virus 
isolates introduced by a duplication of 60 nucleotides." J Gen Virol 84(Pt 11): 3115- 
3120.
Trento, A., M. Viegas, M. Galiano, C. Videla, G. Carballal, A. S. Mistchenko and J. A.
Melero (2006). "Natural history of human respiratory syncytial virus inferred from 
phylogenetic analysis of the attachment (G) glycoprotein with a 60-nucleotide 
duplication." J Virol 80(2): 975-984.
Tupasi, T. E., L. E. de Leon, S. Lupisan, C. U. Torres, Z. A. Leonor, E. S. Sunico, et al.
(1990). "Patterns of acute respiratory tract infection in children: a longitudinal study 
in a depressed community in Metro Manila." Rev Infect Pis 12 Suppl 8: S940-949.
UNICEF, WHO, World Bank and UN (2012). Levels and trends in child mortality: report 
2012. New York.
van den Hoogen, B. G., G. J. van Poomum, J. C. Fockens, J. J. Comelissen, W. E. Beyer, R. 
de Groot, et al. (2003). "Prevalence and clinical symptoms of human 
metapneumovirus infection in hospitalized patients." J Infect Pis 188(10): 1571-1577.
277
van Elden, L. J., A. M. van Loon, A. van der Beek, K. A. Hendriksen, A. I. Hoepelman, M.
G. van Kraaij, et al. (2003). "Applicability of a real-time quantitative PCR assay for 
diagnosis of respiratory syncytial virus infection in immunocompromised adults." J 
Clin Microbiol 41(91: 4378-4381.
Vardas, E., D. Blaauw and J. McAnemey (1999). "The epidemiology of respiratory syncytial 
virus (RSV) infections in South African children." S Afr Med J 89(10): 1079-1084.
Venter, M., M. Collinson and B. D. Schoub (2002). "Molecular epidemiological analysis of 
community circulating respiratory syncytial virus in rural South Africa: Comparison 
of viruses and genotypes responsible for different disease manifestations." J Med 
Virol 68(3): 452-461.
Ventre, K. and A. G. Randolph (2007). "Ribavirin for respiratory syncytial virus infection of 
the lower respiratory tract in infants and young children." Cochrane Database Svst 
Rev(l): CD000181.
Viboud, C., P. Y. Boelle, S. Cauchemez, A. Lavenu, A. J. Valleron, A. Flahault and F. Carrat
(2004). "Risk factors of influenza transmission in households." Br J Gen Pract 
54(506): 684-689.
von Linstow, M. L., J. Eugen-Olsen, A. Koch, T. N. Winther, H. Westh and B. Hogh (2006). 
"Excretion patterns of human metapneumovirus and respiratory syncytial virus among 
young children." Eur J Med Res 11(8): 329-335.
Vynnycky, E., R. Pitman, R. Siddiqui, N. Gay and W. J. Edmunds (2008). "Estimating the 
impact of childhood influenza vaccination programmes in England and Wales." 
Vaccine 26(41): 5321-5330.
Walsh, E. E., J. J. Schlesinger and M. W. Brandriss (1984). "Protection from respiratory
syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies." 
Infectlnunun43(2): 756-758.
Wang, E. E., B. J. Law and D. Stephens (1995). "Pediatric Investigators Collaborative 
Network on Infections in Canada (PICNIC) prospective study of risk factors and 
outcomes in patients hospitalized with respiratory syncytial viral lower respiratory 
tract infection." J Pediatr 126(2): 212-219.
Waris, M. (1991). "Pattern of respiratory syncytial virus epidemics in Finland: two-year
cycles with alternating prevalence of groups A and B." J Tnfect Pis 163(3): 464-469.
Waris, M., O. Meurman, M. A. Mufson, O. Ruuskanen and P. Halonen (1992). "Shedding of 
infectious virus and virus antigen during acute infection with respiratory syncytial 
virus." J Med Virol 38(2): 111-116.
Weber, M. W., R. Dackour, S. Usen, G. Schneider, R. A. Adegbola, P. Cane, et al. (1998). 
"The clinical spectrum of respiratory syncytial virus disease in The Gambia."
Pediatric infectious disease journal 17(3): 224-230.
Weber, M. W., P. Milligan, B. Giadom, M. A. Pate, A. Kwara, A. D. Sadiq, et al. (1999). 
"Respiratory illness after severe respiratory syncytial virus disease in infancy in The 
Gambia." J Pediatr 135(6): 683-688.
Weber, M. W., P. Milligan, M. Sanneh, A. Awemoyi, R. Dakour, G. Schneider, et al. (2002). 
"An epidemiological study of RSV infection in the Gambia." Bull World Health 
Organ 80(71: 562-568.
Weber, M. W., E. K. Mulholland and B. M. Greenwood (1998). "Respiratory syncytial virus 
infection in tropical and developing countries." Tropical Medicine and Intemationl 
Health 3(4): 268-280.
West, K., J. Bogdan, A. Hamel, G. Nayar, P. S. Morley, D. M. Haines and J. A. Ellis (1998). 
"A comparison of diagnostic methods for the detection of bovine respiratory syncytial 
virus in experimental clinical specimens." Can J Vet Res 62(4): 245-250.
279
White, L. J., J. N. Mandl, M. G. Gomes, A. T. Bodley-Tickell, P. A. Cane, P. Perez-Brena, et 
al. (2007). "Understanding the transmission dynamics of respiratory syncytial virus 
using multiple time series and nested models." Math Biosci 209(1): 222-239.
White, L. J., M. Waris, P. A. Cane, D. J. Nokes and G. F. Medley (2005). "The transmission 
dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & 
Wales and Finland: seasonality and cross-protection." Epidemiol Infect 133(2): 279- 
289.
WHO (2006) "Collecting, preserving and shipping specimens for the diagnosis of avian
influenza A(H5N1) virus infection: Guide for field operations." Viral transport media 
(VTM). 42 DOI: WHO/CDS/EPR/ARO/2006.1.
Widjojoatmodjo, M. N., J. Boes, M. van Bers, Y. van Remmerden, P. J. Roholl and W.
Luytjes (2010). "A highly attenuated recombinant human respiratory syncytial virus 
lacking the G protein induces long-lasting protection in cotton rats." Virol J 7: 114.
Wilson, J. N., D. J. Nokes, G. F. Medley and D. Shouval (2007). "Mathematical model of the 
antibody response to hepatitis B vaccines: implications for reduced schedules." 
Vaccine 25(18): 3705-3712.
Wright, P. F., R. A. Karron, R. B. Belshe, J. R. Shi, V. B. Randolph, P. L. Collins, et al.
(2007). "The absence of enhanced disease with wild type respiratory syncytial virus 
infection occurring after receipt of live, attenuated, respiratory syncytial virus 
vaccines." Vaccine 25(42): 7372-7378.
Wright, P. F., R. A. Karron, R. B. Belshe, J. Thompson, J. E. Crowe, Jr., T. G. Boyce, et al. 
(2000). "Evaluation of a live, cold-passaged, temperature-sensitive, respiratory 
syncytial virus vaccine candidate in infancy." J Infect Pis 182(5): 1331-1342.
280
Zagheni, E., F. C. Billari, P. Manfredi, A. Melegaro, J. Mossong and W. J. Edmunds (2008). 
"Using time-use data to parameterize models for the spread of close-contact infectious 
diseases." Am J Epidemiol 168(9): 1082-1090.
Zambon, M. C., J. D. Stockton, J. P. Clewley and D. M. Fleming (2001). "Contribution of
influenza and respiratory syncytial virus to community cases of influenza-like illness: 
an observational study." Lancet 358(9291): 1410-1416.
Zlateva, K. T., P. Lemey, E. Moes, A. M. Vandamme and M. Van Ranst (2005). "Genetic
variability and molecular evolution of the human respiratory syncytial virus subgroup 
B attachment G protein." J Virol 79(14): 9157-9167.
Zlateva, K. T., L. Vijgen, N. Dekeersmaeker, C. Naranjo and M. Van Ranst (2007). 
"Subgroup prevalence and genotype circulation patterns of human respiratory 
syncytial virus in Belgium during ten successive epidemic seasons." J Clin Microbiol 
45(9): 3022-3030.
281
10 APPENDICES
A number of appendices are attached. These attachments provide further details on study 
starting with the study proposal, scientific and ethical approval letters, field worker training, 
consent documents, data collection tools, and standard operating procedures on sample 
collection and testing. Additional results are also included in the appendix such as on RSV 
infection patterns within the 47 households, estimates of duration of RSV shedding, recovery 
rates and unadjusted hazard ratios for factors likely to influence cessation of RSV shedding. 
Finally, the R code used in estimation of susceptibility and transmission parameters is also 
attached.
282
Appendix A. The study Protocol
a) Title o f the Project
Household transmission of respiratory syncytial vims (RSV): Who acquires infection from 
whom
b) Investigators and Institutional Affiliations
Name
Principal Investigator 
Patrick Munywoki
Co-Investigators
Dr. James Nokes 
Mwanajuma Ngama 
Charles Nyaigoti 
AnnBett 
Dorothy Koech 
Dr Laura Hammit 
Dr Patricia Cane 
Prof. Graham Medley
Institution
CGMRC
CGMR-C, University of Warwick, UK
CGMR-C
CGMR-C
CGMR-C
CGMR-C
CGMR-C
Health Protection Agency, UK 
University of Warwick, UK
c) Abstract
Respiratory syncytial vims (RSV) is a major cause of childhood acute respiratory infection 
worldwide. Studies from Kilifi District show that around 1 in every 100 infants are admitted 
to hospital with RSV associated severe pneumonia each year. A vaccine is not yet available 
to prevent RSV infection but is under development. The potential usefulness of such a 
vaccine and information on how best it can be implemented requires a better understanding 
of the spread of the vims within the community. The family or household unit is an important 
element in the spread of infections transmitted by close contact in the community and better 
understanding of household transmission may inform on the merits of targeted control 
strategies. Data is scarce on RSV transmission within families, particularly on who acquires 
infection from whom (WAIFW). Mathematical modelling of infection transmission has been 
previously used to evaluate the impact of different population-based vaccination strategies. 
However, for such models to be realistic requires well-determined parameters on WAIFW 
and especially who is infecting the vulnerable infants.
With an aim of elucidating who infects the infant within the household, we intend to recmit 
50 households prior to, and undertake intensive follow-up during a RSV epidemic. 
Households will be eligible if they have a child bom after the previous RSV epidemic and 
with at least one elder sibling to the infant. Nasal samples will be taken every 3-4 days from 
all household members, irrespective of symptoms, for 4-5 months (while the RSV epidemic 
persists). Oral fluid will be collected once a week. Samples will be screened using PCR 
methods for a range of respiratory vimses including RSV and other co-circulating vimses 
with similar transmission routes such as rhinovims, human metapneumovims (hMPV) and
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parainfluenza vims 3 (PIV 3). Saliva samples will be screened using the antibody capture 
ELISA methods and directly for viral antigens by molecular methods. The detailed multiple 
infection data, arising from the study, will be used to define and quantify who infects whom 
within the household, and especially who is the source of the vims that infects the infant. 
Understanding of transmission dynamics of RSV will help elucidate the potential of different 
vaccination strategies and the impact at the population level of such approaches on RSV 
infection especially on the vulnerable infants.
d) Introduction/Background 
RSV disease burden and control
RSV is a major cause of childhood acute respiratory infection (ARI) worldwide. It is 
estimated that about 60% of all children are infected during their first year of life and almost 
all by their third year (Glezen et al. 1986). Our surveillance of paediatric admissions in mral 
coastal Kenya, (Kilifi district), over the period 2002-07 has defined incidence estimates (per 
100,000 per year) of RSV-associated severe or very severe pneumonia admissions of 1107 
(95% Cl, 1012-1211) in infants, and 293 (271-317) in the under 5 year olds, contributing 
some 15% and 12%, by age group, respectively, of all admissions for these conditions (Nokes 
DJ et al 2009). This is comparable with the proportion of clinical severe pneumonia 
prevented by 9-valent conjugate pneumococcal vaccine in The Gambia (12%)(Cutts et al. 
2005). Spatial analysis suggests that the tme incidence of RSV pneumonias is well in excess 
of these estimates (due to distance effects on health service access).
RSV repeatedly reinfects throughout life (Hall et al. 1976; Henderson et al. 1979). 
Undoubtedly this translates to a large pool of infectious individuals likely to be fundamental 
to endemic maintenance of infection and transmission to young children. The contribution of 
re-infections to the spread of RSV within the community is not well elucidated, but will be 
dependent upon the prevalence of individuals with re-infections, and their infectivity and 
patterns of contact with others in the population. These factors combine to define ‘who 
acquires infection from whom’ (WAIFW), which is central to understanding the transmission 
dynamics, and predicting vaccine impact (Anderson and May 1991).
There is a body of evidence which demonstrates that viral infection of respiratory epithelial 
cells promotes bacterial colonization of the nasopharynx. RSV infection is associated with 
secondary bacterial infections caused by Streptococcus pneumonia and Haemophilus 
influenza (Avadhanula et al. 2006; Pettigrew et al. 2008). As such, the burden of RSV-related 
disease may be much higher than is estimated by the number of RSV infections alone. 
Currently there is no licensed RSV vaccine but promising live-attenuated vaccines are under 
development (Karron et al. 2005). With most severe RSV disease occurring in the first year 
of life, and especially in the first 6 months, it is a priority that a vaccine protects this early age 
group. A highly attenuated recombinant vaccine variant for delivery to infants under 3 
months of age, was found to be well tolerated, but was insufficiently immunogenic, although 
in children 6 months of age and older (naive and seropositive) it was well tolerated, and 
immunogenic (Karron et al. 2005; Wright et al. 2007). The potential of such vaccines to 
protect the most vulnerable children depends not only on the direct protection to the
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vaccinated (>3 month old) individuals but also on resultant reduced spread of infection from 
those vaccinated to those too young to receive vaccine (<3 months). This indirect protection 
may be in the form of a reduced risk of transmission between presumed key transmission 
contacts (for example, mother to infant), or more generally due to reduced circulation of the 
infectious agent in the population, the so called herd immunity effect (Anderson and May 
1991). These indirect protective or herd immunity effects are largely unquantified. 
Mathematical modelling of infection transmission has been previously used to evaluate the 
impact of different vaccination strategies (Anderson and Grenfell 1986; Babad et al. 1995; 
Vynnycky et al. 2008). However, for such models to be realistic requires well-determined 
parameters for WAIFW and, in the case of RSV, who is infecting vulnerable infants.
Other respiratory viruses
The advent of molecular diagnostics for a broad range of respiratory viruses has enhanced the 
study of virus epidemiology, due to increased sensitivity and range of pathogens detectable 
over traditional methods. Throughout 2007 we used molecular methods to investigate the 
occurrence of 13 respiratory viruses in 760 severe and very severe pneumonia paediatric 
admissions to Kilifi District Hospital (Dr. Jay Berkley, unpublished data, SSC no. 815). RSV 
was detected in 34% of cases (compared to only 5% of 56 well controls) using molecular 
methods, compared to 21% of cases by immunofluorescence. At least one virus was present 
in 56% of cases, with peak occurrence in the months of November, December and January to 
March, coincident with peak pneumonia admissions. Other respiratory viruses have the same 
mode of transmission as RSV via large droplets and fomites. In the study described above we 
found co-occurrence temporally of hMPV and PIV3 in particular. Furthermore, rhinovirus is 
elsewhere reported to be prevalent throughout much of the year and not uncommonly co- 
circulating with RSV (Phillips et al. 1990; Monto 2002; Souza et al. 2003; Kusel et al. 2006). 
Screening for viruses with similar epidemiology (such as rhinovirus, hMPV and PIV3) to 
RSV would increase the capacity of the present study to identify infection spread in the 
household and hence improve the definition and quantification of WAIFW for a given sample 
size.
Who contacts whom and who infects whom
RSV is transmitted by large nasal droplets and fomites, with short survival time in the 
environment. This suggests that close contact is important for effective transmission. Social 
interaction patterns (contacts and mixing patterns among individuals) have thus a direct 
impact on transmission dynamics of respiratory infections. This underlies the growing 
interest in describing and quantifying contacts that can lead to infection spread (Edmunds et 
al. 1997; Edmunds et al. 2006; Mossong et al. 2008; Read et al. 2008; Vynnycky et al. 2008; 
Zagheni et al. 2008). The use of contact data to define infectious contact rates in transmission 
dynamics modelling requires inference of the transmission probability following contact -  
which is a serious obstacle due to its considerable uncertainty. Longitudinal studies of 
infection and contact can estimate this transmission probability more directly (Melegaro et al. 
2004).
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It is plausible that social contexts with high contact rates such as households and schools 
would provide very favourable environments for infection transmission. Family studies 
indicate the importance of household size and number of school-age siblings as risk factors of 
RSV infection in infants, and partly explain re-infection rates (Hall et al. 1976; Okiro 2007). 
Various studies indicate RSV infection is frequently introduced to the home by siblings, 
resulting in high secondary attack rates within households (Berglund 1967; Hall et al. 1976; 
Okiro 2007). However a recent study has had contrasting findings, reporting little evidence 
for infection from sibling in families (Crowcroft et al. 2008). Direct evidence of mother-to- 
child infection has been reported in one study from Guinea Bissau (Stensballe et al. 2004). It 
remains, however, that patterns of transmission, so important to determine the influence of 
infection (or control) in one age group on other groups, are poorly defined.
Household studies
The family or household unit is an important element in the spread of infectious disease in 
communities, especially where transmission is effected by close contact, and has provided the 
focus of observational studies in the past. Better understanding of household transmission 
may inform on the merits of targeted control strategies. For example, investigation of who 
introduces infection into the household, and who infects the infant, could identify key groups 
for vaccination such as elder and school age siblings. Recent data is scarce on intra-family 
spread of RSV and other viral respiratory infections especially in the developing countries.
Of the few studies undertaken, most were conducted in 1960s - 70s in developed countries 
(Monto et al. 1971; Fox and Hall 1972; Hall et al. 1976), with only a single exception in a 
developing country (Okiro 2007). However the Okiro study had limitations as explained 
later. The classic family study on RSV spread recruited 36 US families for intensive 
surveillance over two months in one RSV season, with repeated nasal sampling every 3-4 
days regardless of illness (Hall et al. 1976). The authors reported an appreciable secondary 
attack rate within the family of 27%, rising to 45% in infants.
The study conducted by Okiro et al in our settings aimed at investigating the risk factors of 
RSV spread and severity and thus its methodology had limitations for the purpose of 
evaluating WAIFW in the household (Okiro 2007; Okiro et al. 2008; Okiro et al. 2008).
Home visits were conducted once-a-week with nasal washings (NW) collected only when 
symptoms of ARI were reported. Acceptance of the NW method in older children and 
especially in adults was poor. Screening was by immunofluorescence antigen test (IFAT), 
which is less sensitive than molecular methods (Casiano-Colon et al. 2003).
We plan to adopt an alternative nasal specimen collection method, the nasopharyngeal 
flocked swab, (Chan et al. 2008)) which our studies (SSC No. 1527) have shown to be more 
acceptable without loss of sensitivity compared to nasal washing (Patrick Munywoki et al, 
unpublished data). Reliance on the occurrence of symptoms to identify infected persons will 
almost certainly result in failure to recognize links in transmission events. Effort is needed to 
detect all RSV infection which may frequently be mild, of short duration or sub-clinical in 
older children and adults (Henderson et al. 1979). Given a mean duration of RSV shedding of 
between 3.5 and 9 days (dependent upon age, severity, mode of collection and method of 
antigen detection)(Hall et al. 1976; von Linstow et al. 2006; Okiro 2007), sampling intervals
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less frequent than 2 times per week will result in a significant loss in cases detectable (see 
protocol methods). Recent studies in Kilifi use intensive nasopharyngeal swabbing, including 
newborns, more than once a week, similar to that proposed in the present study (SSC nos. 
782, 1048 and 1071).
The study of Okiro et al collected oral fluid samples to detect specific anti-RSV antibodies to 
supplement infection data. However, we now know the sampling interval was too infrequent 
(once every 3 months) to be able to identify infections at the required temporal resolution 
based on antibody profiles (Okiro et al. 2008). Our recent work suggests that levels of RSV 
specific IgG (and to a lesser extent IgA) in OF track those of serum, but with very rapid post­
infection antibody dynamics (Okiro et al. 2008), suggesting that weekly sampling could help 
in identifying of infections. Emerging evidence indicates OF samples can be used to detect 
viral infections using PCR methods but with relatively low sensitivity, and this will 
specifically be explored (von Linstow et al. 2006).
With the chief aim of defining “Who Acquires Infection From Whom”, we plan to mitigate 
the above limitations by using the most favourable infection detection methods. This will 
include frequent nasal (twice-a-week) and OF (once-a-week) sampling irrespective of 
symptoms, and use of highly sensitive assays for identification of viruses. Antibody profiling 
of OF will provide additional data on infection status. No previous study has combined all 
these characteristics. Furthermore, the use of PCR based methods to genotype the infecting 
strain will provide an added benefit in offering a degree of finger printing of clusters of 
infection.
e) Justification for the Study
Infants are highly vulnerable to severe RSV pneumonia and/or bronchiolitis, and are of 
crucial importance to control efforts, but no detailed data exists on who infects the infant. 
Such data would be useful in considering targeted vaccination options. More generally, the 
role of the household in maintaining transmission of this important virus in the community is 
not known. Only detailed studies of the intensity proposed will inform our understanding of 
who is infecting whom and the population-level impact of various vaccination strategies. 
Twice-a-week nasopharyngeal sampling and once-a-week oral fluid collection, irrespective 
of symptoms, is critical to ensuring all RSV (and other respiratory viruses) infections 
occurring in household are identified. Frequent nasal swabbing has been successfully used in 
Kilifi for pneumococcal carriage studies (SSC nos. 1071,1048 and 782) and elsewhere (Hall 
et al. 1976). Use of more sensitive viral screening methods (PCR) is expected to significantly 
improve detection of RSV and other respiratory pathogens.
f )  State the Null Hypothesis
The study is descriptive in nature and has no primary hypothesis.
g) Objectives 
General objective
To develop understanding of who acquires infection from whom in the context of 
introduction and spread of RSV within the household in a developing country setting
Primary objectives
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i) To determine the proportion of primary RSV infections in infants that arises from 
infection from elder siblings or from mothers.
ii) To quantify the rate of infection and recovery of RSV in the family, stratified by age 
group.
iii) To estimate the household reproductive potential of RSV and risk of transmission per 
contact.
Secondary objectives
i) To evaluate the use of oral fluids in detecting viral infections using PCR methods.
ii) To estimate the rate of infection and recovery of a range of respiratory viruses for 
various age groups in the family
iii) To evaluate the effect of viral infection on bacterial colonization of the nasopharynx.
h) Design and Methodology 
Study site (geographical')
This study will be conducted within Kilifi District on the Kenyan coast. A suitable location 
will be selected through an ongoing consultative engagement between the Ministry of health 
and KEMRI/Wellcome Trust Research Programme.
Study population
The basic study unit will be households defined as people eating from the same kitchen 
regardless of their relationships.
Criteria for inclusion of households
Households:
i) Within a pre-defined location of Kilifi District
ii) With a child bom after the previous RSV epidemic and with at least one elder sibling 
to the infant (minimum number per household 3 i.e. infant, sibling and parent).
iii) Willingness (including consent) of household to participate in full knowledge of 
sampling regime and method (demonstrated during the early phase of the study).
Criteria for exclusion of households
i) Failure to get individual consent from all the family members
ii) Household planning to move out of the study area in the next 4 months.
Sampling
Sample size determination
The sample size was set at 50 households on the basis of past evidence on household 
infection rates and of practical considerations of workload.
Based on previous studies we expect 60% or over of families to be infected during the 
epidemic. A sample of 50 will give adequate precision in estimates of the prevalence of key 
outcomes: (i) households with one occupant infected with RSV at the end of the study, (ii) 
infants experiencing a primary RSV infection and (iii) infants being infected from within 
(elder siblings or parents) and from outside the immediate household. For the sample size of 
50, a proportion of households having an RSV infection of 60% will have 95% confidence 
limits of 45% and 74% based on binomial exact methods.
Sampling frequency
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The following rationale was used to determine the twice-weekly (every 3.5 days) nasal 
sampling frequency. Assuming individuals shed virus with mean duration of between 3.5 and 
9 days, with a constant rate of recovery from shedding, and an onset on average half way 
between any sampling interval, then the proportion of individuals predicted to remain 
shedding, and thus detectable, will range from 61%-82% (for 3.5-9 days duration) for a 3.5 
day sampling interval (Figure in Appendix B). The comparable range is 37%-68% for a 7- 
day interval. Given the need to detect infection in mild cases and in older children and adults 
with likely lower range of shedding duration, sampling twice weekly is indicated.
Sampling procedures
A quick mapping exercise will be carried out to identify eligible households within the 
selected study location before the start of forthcoming RSV epidemic (in October 2009). 
Specimen collection will be initiated in November 2009. The first 4 weeks will allow time for 
the study team to develop a logistical framework/system synchronised with the community 
activities and culture, and replace non-compliant households, before the epidemic starts. We 
will use the KDH inpatient RSV surveillance (SSC No. 1055) data to determine the 
beginning of the RSV season, defined as two successive weeks with > 2 RSV infections 
(Nokes et al. 2004). Nasopharyngeal flocked swabs (NPS) will be used to collect specimens 
every 3-4 days from all household members, irrespective of symptoms, throughout the RSV 
epidemic. During the twice-a-week home visits data on history of respiratory illness will be 
taken and oral fluid sample collected on one of the visits. Data on a range of household 
characteristics (e.g. income, education level etc) will also be collected after one month of 
surveillance, after a good relationship with the family has been established. Follow-up will be 
terminated for an individual household when its members repeatedly fail to comply with 
sampling. The study will be ended for all households when the RSV epidemic ends (<2 RSV 
infections detected from the KDH inpatient admission samples on two successive weeks).
Procedures
Clinical
Preliminary data from a study evaluating the diagnostic performance of the nasal flocked 
swab as a specimen option for RSV screening in the community (SSC No. 1527) indicate it is 
has similar diagnostic performance and more acceptable than our routine method of nasal 
washing. A brief description of the two specimen collection methods follows.
i) Nasopharyngeal flocked swab (NPS) method 
A modified procedure to that of Chan et al and described in the SSC protocol no. 1527 will 
be adopted (Chan et al. 2008). This is a simple procedure making use of a double-headed 
nasopharyngeal swab whose the tip diameter is less than 3mm. Briefly, the distance between 
the participant’s nares and earlobe is measured to estimate the length of insertion. The swab 
is then gently inserted up the nostril towards the pharynx for the measured distance. The 
swab is rotated 3 times, to obtain epithelial cells and surface colonising bacteria and held in 
place for 5 seconds to ensure maximum absorbency. The swab is then withdrawn gently and 
put in an appropriate transport medium. One tip of the swab will be placed in skim-milk
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tryptone glucose glycerol (STGG) transport media and the other into viral transport media 
and processed with minimal delay (<6 hours) at the KEMRI CGMR-Coast laboratory.
ii) Oral fluid (OF) collection procedure 
Oral fluid will be collected using a sponge swab (Oracol, Malvern Medical Developments, 
Worcester, UK), consisting of a cylinder of expanded polystyrene foam attached to a plastic 
stick and is used like a toothbrush (Nokes et al. 2001; Okiro et al. 2008). The swab is brushed 
along the gums and mouth for 60 seconds and the device is then inserted into a plastic tube, 
stoppered, stored on ice and returned to the laboratory upon return from the field. In the 
laboratory 1ml of preservative buffer (20% foetal calf serum and 0.2% sodium azide in PBS) 
is added to the sample. The oral fluid is then squeezed out of the foam and clarified by 
centrifugation and the supernatant stored in a -70° C freezer for processing at a later stage.
Laboratory
All specimens will be immediately stored in a cool box (with ice packs) before being 
transported to the RSV lab for storage in 4°C fridge. For longer-term storage the samples will 
be kept at -70°C.
i) Molecular methods for respiratory viruses
Nasopharyngeal swabs (in viral transport medium) will be screened for RSV A and B, 
hMPV, PIV3 and rhinovirus and 8 other respiratory viruses using a multiplex (MPX) PCR 
real time assay system (Gunson et al. 2005). Real time RT-PCR will enable quantification of 
viral load in virus positive household members (van Elden et al. 2003). G-gene genotyping, 
selective sequencing, and recombinant expression, will be undertaken for RSV variant 
molecular and immunological characterisation (Scott et al. 2004; Scott et al. 2006; Scott et al. 
2007). Real time PCR methods will also be used for the detection of viral antigens in OF 
samples. All assays are, or will shortly be, established in the Kilifi laboratory.
ii) RSV Antibody assays (OF)
OF will be tested for RSV specific IgG by optimised indirect ELISA (Okiro et a l , 2008). 
Interpretation of changes in specific antibody concentration and the definition of re-infection 
will be made based on the antibody profiles as described elsewhere (Okiro et al. 2008)
iii) Nasopharyngeal bacterial carriage tests
The sample placed in skim-milk tryptone glucose glycerol (STGG) transport media will be 
inoculated onto appropriate culture media, before storing the residual sample in STGG in a 
freezer at -80°C. Bacteria will be identified from culture media using standard 
microbiological/molecular methods. Pneumococci will be identified from gentamicin-blood 
agar by Optochin susceptibility testing and Quellung serotyping. Haemophilus influenzae 
will be identified from bacitracin-chocolate agar by X and V factor dependence and slide 
agglutination serotyping. If necessary, PCR of bacterial isolates will be utilized to confirm 
identity (e.g., to distinguish non-typeable Haemophilus influenzae from Haemophilus 
haemolyticus, or to serotype pneumococci (O'Brien and Nohynek 2003; Antonio et al. 2009).
Quality assurance and control
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Standard procedures for quality control of assays and apparatus are operating the laboratory 
and will be monitored throughout. All laboratory staff are trained in Good Laboratory 
Practice.
Sample storage and exportation
At the end of the study, residues of clinical specimens (nasal samples, oral fluids) and viral 
isolates will be archived indefinitely in KEMRI-Wellcome Trust research laboratories for 
future use in the study of RSV or other respiratory pathogens. In addition to assay quality 
assurance and molecular studies on RSV described above for the present study, it is 
envisaged that future studies may be undertaken involving laboratory techniques not 
supported in Kilifi and requiring export to collaborators at the University of Warwick, and 
Health Protection Agency, UK. A separate proposal will be submitted prior to conducting any 
future studies on the archived samples either in Kilifi or elsewhere (University of Warwick or 
Health Protection agency, UK) with relevant documentations. Where reasonably possible, a 
Kenyan laboratory technician or research scientist will assist or lead in any work being 
undertaken abroad to strengthen capacity in Kilifi and Kenya.
i) Data Management and analysis 
Data Storage
Clinical data will be entered directly onto the Kilifi Integrated Data Management System 
(KIDMS) existing at the Centre for Geographic Medicine Research Coast, Kilifi. All 
databases are backed up to a local alternative hard-drive on a weekly basis and to a remote 
hard-drive at the Wellcome Trust Research Laboratories in Nairobi on a monthly basis. 
Laboratory data will be stored separately on Filemaker and Excel files and will be backed up 
on a separate hard drive and CD. Extraction of data for analysis will be via password- 
protected access to the study investigators under the control of the PI and computer services 
manager. Laboratory and clinical data will be merged and analysed using STATA v9 
(StatCorp, US).
Data analysis
Defining of transmission data and calculation of simple statistics
Using the RSV infection and G-gene sequencing data ‘temporal’ links of RSV transmission 
based on established methods for determining possible successive cases will be defined (Fine 
2003). This will be repeated for the other viruses. For RSV infection the following estimates 
will be calculated; (i) the proportion of households at the end of the study with at least one 
infected occupant, (ii) the proportion of infants, siblings, parents who were infected, (iii) the 
proportion of primary RSV infections in infants that are from within and from without the 
immediate household, (iv) for within household transmissions, the proportion of the infants 
acquiring RSV infection from parents and/or elder siblings. The above estimates will be 
stratified on the various characteristics such as household size and viral load where numbers 
permit. Crude attack rates and secondary attack rates of RSV (also for other viruses) within 
the household stratified by age group and on basis of the initial source of infection (infants,
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siblings and parents (mother)) will also be computed. The above calculations will be repeated 
for the other respiratory viruses.
Estimation of incidence rate of infection and recovery of RSV and other respiratory viruses
Poisson regression methods will be used to estimate the incidence of RSV (and repeated for 
other viruses) infection (using person-days of observation as denominator) estimating relative 
rates in (a) different age groups (b) between households of different size (c) previously 
infected or uninfected groups. The analysis will adjust for age and presumed past history of 
infection. Similar analysis will be utilized to estimate the rate of loss of shedding (or average 
duration of shedding) in relation to age, past exposure and other demographic factors. 
Comparison of our estimates of incidence rates of infection and recovery with those from our 
previous birth cohort (Nokes et al. 2004; Nokes et al. 2008) and household study (Okiro 
2007) will also be made (the original datasets are available for this analysis).
Household reproduction number. Rh and transmission probability
We define a household reproduction number (R h ) as the average number of secondary cases 
arising from one case throughout the infectious period following introduction into a 
household. Stratifying the household into two groups (infant and older (siblings and adults)) a 
reproduction potential matrix will be generated e.g. Rni0 is the number of secondary cases 
among the older (o) ages arising from an introduced infant (i) case. The Rh will inform on the 
household transmission potential, where an average R h < 1  would indicate little potential for 
household spread.
We can estimate the probability of transmission per separate contact between infant and older 
individual, from the household reproductive potential. If c;0 is the number of contacts made 
between the infant and older individuals per day, throughout the infant infectious period, D; 
and pio is the risk of acquiring infection per contact event, then the infant household 
reproduction potential can be defined as
R H i = P i o CioD i (!)}
Hence, with independent knowledge of the average duration of infection, the household 
reproduction potential and contact rates the transmission probability per contact can be 
estimated. This can be modified to identify the transmission probability per contact with a 
different individual (rather than per separate contact). The same can be estimated for the 
introduction of an infected older individual, Rh0 where
R Ho = PooCooD o + P oiCoiD o (2),
bearing in mind that older individuals can infect the infant and other older individuals. We 
intend to estimate the rates of contact (total or new) between individuals through parallel 
contact pattern studies.
Data on other viruses will allow us to determine more generally the importance of certain 
groups in household introduction and transmission, and the relationship between contact 
pattern data and transmission of respiratory viruses.
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Evaluation of the diagnostic performance of OF in detecting viral infections using PCR
methods
Paired OF and NPS samples will be screened using RT-PCR for RSV and other respiratory 
viruses. The diagnostic performance of OF PCR evaluated against NPS PCR (used as the 
gold standard). Sensitivity, specificity, positive predictive value and negative predictive value 
of the OF PCR will be compared using McNemar’s chi-square test. The effect of age and 
disease severity on test performance will also be checked through stratification.
Evaluation of the association between RSV infection and acquisition of pneumococcus or 
haemonhilus influenza
Using Poisson regression methods we will compare the rate of bacterial (pneumoccus or 
Haemophilus influenza) nasopharyngeal colonisation following an RSV infection with those 
who have not had RSV infection. Similar analysis will be repeated for the other viral 
infections where the numbers permit.
j) Time Frame/Duration o f the Project
• Proposal development and Ethical approval: March to July 2009
• Study preparations -  Field worker recruitment and training: August to September 
2009
• Mapping exercise and initial piloting phase: October 2009
• Data collection: November 2009 to April 2010 (depending on the duration of the RSV 
epidemic)
• Laboratory screening of samples: November 2009 to July 2010
• Data analysis and final report writing: August 2010 to December 2011
k) Ethical Consideration 
Risks.
No procedures used in this study represent a significant risk to the participants. The nasal 
sampling may result to mild discomfort which will be explained to each participant prior to 
collection. Suitably trained staff will undertake all procedures, which will be carefully 
explained in advance to the participants and their children (as appropriate). The frequency of 
home visits will be discussed with the household head and all individual members so that a 
convenient schedule is agreed upon. We aim to recruit staff from the study area who would 
understand the local culture.
Benefits
There are no direct benefits accruing from the frequent nasal/oral sampling and testing for 
there is no established treatment for viral respiratory infections. However, participants will 
benefit from close monitoring for any illness by a nurse during the home visits and will be 
referred to the health centre promptly for treatment where necessary. Costs of treatment of 
acute illnesses incurred in the nearby government health facility will be paid for plus costs of 
referral. We will address the issue of how to compensate the participants for their time 
through a process of consultation with local community leaders and representatives, 
facilitated by the centre's Community Liaison Group. We will seek to provide this 
compensation in kind where this is considered appropriate.
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Community benefit
Benefits to the community are general and the effects will not be immediate. We aim to 
generate data that will inform the development of vaccines, and are useful to the public health 
policy makers in optimising the use of a future RSV vaccine.
Consent
Consent will be obtained from the household head and all members of the household only 
after adequate explanation of the study (see Appendix G). The study will be explained to 
those aged less than eighteen years (who are able to understand the study) and their verbal 
assent obtained before a signed informed consent is obtained from their parents or guardians. 
The individual informed consent forms will be translated into Giriama and Kiswahili and 
administered in the appropriate language, to all the study participants by trained field workers 
-  conversant with the local languages. Specific consent will be sought for storage and later 
use of samples, and for exportation of samples. It will be explained that use of archived 
samples and associated data, and exportation, for new studies, will only be possible after 
scrutiny and approval from the independent National Research Ethics Committee.
Confidentiality
Data will be stored on password-protected database, accessible only to study investigators. 
Data will be archived with the database administrator.
Community engagement strategy
A community engagement advisory group (CEAG) spearheaded by the centre’s community 
liaison department will oversee community sensitisation and provide support during the study 
implementation (Marsh et al. 2008). Multiple approaches including holding (i) consultative 
meetings with the community leaders and representatives, (ii) public meetings and (iii) 
meetings with the household heads are some of the suggested community engagement 
strategies. It is essential to establish communication channels and foster a favourable 
environment in the community for this intensive study to be successful.
Training/support for those involved in community engagement
Fieldworkers and clinical team involved in the household recruitment and collection of 
specimens are all familiar with the goals of KEMRI and the consent process. Any additional 
staff will be trained on communication process and consenting procedures. We will work in 
conjunction with the KEMRI community liaison group, and the CEAG will provide support 
to our community activities.
Feedback of information
The individual test results of the nasal and oral samples will not be conveyed to the 
participants for they do not affect their health care. This will be clearly explained during the 
consenting process. A feedback meeting will be organised at the end of the study to share the 
major study experiences and results. The study findings will be published in peer reviewed 
journals.
Animal Subjects
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Not applicable
I) Expected Application o f the Results
The findings will inform mathematical models on RSV transmission dynamics and in 
evaluation of population level impact of various vaccination strategies. This later analyses 
will be useful in informing the public health policy makers in ways to optimise the use of a 
RSV vaccine in future.
m) Budget
Item KSH GBP
1. Personnel -  salaries and other benefits 2,406,162 20,923
2. Patient costs, travel, food and/or supplies 50,000 435
3. Equipment- motorcycles and bicycles 976,772 8,494
4. Supplies and laboratory tests 17,624,040 153,253
5.. Transportation, vehicle repairs, insurance etc 249,716 2,171
6. Operating expenses - postage, printing etc 82,000 713
7. Animals acquisition, food, cages etc N/A N/A
8. Consultancy fees N/A N/A
9. Contingency (15% of above total)
10. Institutional administrative overheads*
3,203,534 27,857
Total 24,560,424 213,846
* The project forms part of the KEMRI/Wellcome Trust Collaborative Programme and will 
attract no overheads.
Justification of the Budget
Personnel Salaries and Benefits - this includes cost of hiring project coordinator and study 
fieldworkers to help in the study implementation for a period of one year.
Patient costs, travel, and food and/supplies -  this includes medical expenses in the 
outpatient clinic, fare refunds and cost of the possible compensation packages for the study 
participants.
Equipments -  This includes the cost of purchasing new motorcycles, bicycles, desktop (for 
data entry) and laptop (for the ARO) personal computers. Mobile phones are also included. 
Clinical supplies and laboratory tests -  this is the estimated cost of study supplies (nasal 
swabs, rubber bulbs, gloves etc plus the cost of the 13+ multiplex virus screen, real time RT- 
PCR, oral fluid ELISA and bacterial work.
Transportation, vehicle/motorcycle repairs, insurance - includes the estimated cost of 
fuel, servicing, insurance and riding gears of the motorcycles, bicycles, and vehicles used in 
the participant follow-up.
Operating costs - these includes all costs of photocopying, stationery, printing and all 
communication costs. Costs incurred during the community engagement and sensitisations 
are also included.
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n) Attachments:
• Role of investigators
• Information and consent form for the Household study (included in this thesis as a 
stand alone appendix
o) Role o f investigators
i) Patrick Munywoki (Assistant research Officer); the principal investigator with the 
overall responsibility for all aspects of the work.
ii) Dr James Nokes (Infectious disease epidemiologist); responsible for the project 
conception and involved in protocol design, data collection and analysis and final 
report writing.
iii) Charles Nyaigoti (Assistant Research officer), Anne Bett (senior Lab. Technician): 
Laboratory staff involved in molecular diagnosis of respiratory viruses. Charles 
Nyaigoti will be particularly involved in establishing of real time RT-PCR methods.
iv) MJ Ngama (Clincial Officer) and Dorothy Koech(Graduate Nurse) are responsible for 
study coordination including field worker training (consenting process and study 
procedures), liaising with community leaders and offer clinical care to the 
participants. Contributors to study implementation and report writing.
v) Dr Laura Hammit (Paediatrician): Contributor to study design, implementation, and 
analysis and report writing. Provide clinical support.
vi) Dr Pat Cane (molecular biologist): will provide molecular biology support in the UK, 
including quality control. Undertake G gene genotyping, sequencing, and GST fusion 
protein expression.
vii) Prof Graham Medley (Infectious disease epidemiologist): Contributor to study design, 
epidemiological analysis and report writing. Based in the University of Warwick, UK.
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Appendix B. Estimated proportion shedding at different sampling intervals
The estimated proportion of individuals who remain shedding virus after t days post onset of 
shedding (St), where the (constant) rate of recovery is r, s(t) is given by:
s(t) = exp(-r/).
Assuming the average rate of recovery (cessation of shedding) is the reciprocal of the mean 
duration of shedding (i.e. between 3.5 and 9 days), and that shedding onset occurs on average 
mid-way between the sampling interval on average, then we generate the following 
relationship in Figure 2 between shedding duration (i.e. r=l/3.5, 1/7 and 1/9 day"1) and 
proportion shedding (S(t)), for intervals of 3.5 days (i.e. t=1.75 days) and 7 days (i.e. t=3.5 
days)
§*
0.8  -
c o   □
jj------0.6  -
0.4  -
co Interval 3.5 days
5
-  -a- -  Interval 7 days
a.
7 93.5
Average duration of shedding (D days)
Figure: Proportion of shedding at the next sampling by average duration of shedding by 
sampling interval
The proportion of individuals predicted to remain shedding, and thus detectable, will range 
from 61%-82% (for 3.5-9 days duration) for a 3.5-day sampling interval (Figure). The 
comparable range is 37%-68% for a 7-day interval. Given the need to detect infection in mild 
cases and in older children and adults with likely lower range of shedding duration, sampling 
twice weekly was indicated.
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Appendix C. Household study flyer:
A KEMRI study on how a germ (RSV) causing pneumonia passes between people in families
a) What is KEMRI?
KEMRI is a Government organization under the Ministry of Health that carries out health 
research to learn more about diseases that affect children and adults in Kenya. Scientists 
working at the programme come from all over Kenya, East Africa, and other countries 
worldwide. Research results are used in Kenya and throughout the world to improve health. 
All studies conducted at KEMRI Kilifi have been approved in advance by expert committees 
in Kilifi and Nairobi who check the research question is important, the study will be 
conducted well and that the safety and rights of participants are protected.
b) What is this study about?
This study is about finding new ways of protecting children from one type of pneumonia. 
Pneumonia is one of the most common serious illnesses in Kenya and other parts of Africa, 
causing cough, fever and difficulty in breathing. It is usually caused by different types of 
germs that enter the body through the nose. Pneumonia germs pass from one person to 
another, particularly when they cough or sneeze. Respiratory syncytial virus (RSV) is one 
type of germ that can cause pneumonia in young children. However, RSV does not always 
cause illness. Commonly people (especially older children and adults) have this germ in their 
noses and throats without any symptoms at all. However, when they pass it on to someone 
else, that person may develop symptoms. This study will also find out more about why it 
sometimes causes illness and sometimes does not. RSV occurs mainly during the season 
between November and May. Every year about 1 in every 100 young children in Kilifi 
District are admitted to the hospital with pneumonia caused by RSV. At the moment, RSV 
pneumonia has no specific treatment so it is very important to find ways of protecting 
children from this infection. A vaccine for RSV is under development at the moment. In 
order to know the best way of using such a vaccine, we need to understand how the virus 
spreads from person to person, particularly in families. This study aims to find out the way 
that RSV spreads between members of 50 families living in this area who volunteer to take 
part.
c) What does the study involve for those who are in it?
This study will be conducted in Matsangoni location. It will start around October 2009 and 
continue for 4 or 5 months. We would like all family members and other permanent residents 
from 50 households to participate. In order to participate, families must have a child under 
one year and at least one older child. It is also important that they will be available to take 
part from the beginning to the end of the study. For families that agree to participate, a field 
worker will visit the home twice a week for 4 to 5 months to collect samples from the noses 
or mouth of all household members. We will make sure that samples are taken at a time that 
causes as little inconvenience to families as possible. Families will also be visited weekly by 
a nurse to advise on health issues. KEMRI will provide some types of treatment for family 
members who become unwell during this study. All details of the study will be explained to
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families before they decide if they would like to participate. By participating in this study, 
families will be helping to find a vaccine for RSV pneumonia that could benefit many 
children in Kenya in the future.
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Appendix D. Frequently asked questions about RSV
This leaflet contains salient information about RSV infection and disease.
a) Introduction
Respiratory syncytial virus, or RSV, is a respiratory virus that infects the lungs and breathing 
passages. Most otherwise healthy people recover from RSV infection in 1 to 2 weeks. 
However, infection can be severe in some people, such as infants, young children, and older 
adults. In Kilifi, we have found that RSV is the most common cause of severe respiratory 
illness in children under one year of age.
b) What is RSV?
RSV causes upper respiratory infections (such as colds) and lower respiratory tract infections 
(such as bronchiolitis and pneumonia). In children under 1 year of age, RSV is the most 
important cause of bronchiolitis, an inflammation of the small airways in the lung.
Almost all children will have had an RSV infection by their second birthday. When infants 
and children are exposed to RSV for the first time, 25% to 40% of them have signs or 
symptoms of bronchiolitis or pneumonia, and 0.5% to 2% will require hospitalization. Most 
children hospitalized for RSV infection are under 6 months of age.
c) Is RSV an important cause o f respiratory illnesses in Kenya?
RSV is a very common cause of respiratory illness in Kenya and in Kilifi in particular. Each 
year, one in every 100 children in their first year of life is hospitalized with severe RSV 
disease in Kilifi District Hospital.
d) How is RSV spread?
RSV can be spread when droplets containing the virus are sneezed or coughed into the air by 
an infected person. Such droplets can linger briefly in the air, and if someone breathe in the 
particles or the particles contact their nose, mouth, or eye, they can become infected.
Infection can also result from direct and indirect contact with nasal or oral secretions from 
infected persons. Direct contact with the virus can occur, for example, by kissing the face of a 
child with RSV. Indirect contact can occur if the virus gets on an environmental surface, such 
as a doorknob, that is then touched by other people. Direct and indirect transmissions of virus 
usually occur when people touch an infectious secretion and then rub their eyes or nose. RSV 
can survive on hard surfaces such as tables and doorknobs for many hours. RSV typically 
lives on soft surfaces such as tissues and hands for shorter amounts of time.
People infected with RSV are usually contagious for 3 to 8 days. However, some infants and 
people with weakened immune systems can be contagious for as long as 4 weeks. Once RSV 
is introduced in the household is it can be rapidly transmitted to other members of the family, 
often infecting about 50% of other household members.
e) What are the symptoms o f disease caused by RSV?
Symptoms of RSV infection are similar to other respiratory infections. A person with an RSV 
infection might cough, sneeze, and have a runny nose, fever, and decrease in appetite. 
Wheezing may also occur. In very young infants, irritability, decreased activity, and 
breathing difficulties may be the only symptoms of infection. Most otherwise healthy infants
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infected with RSV do not need to be hospitalized. In most cases, even among those who need 
to be hospitalized, hospitalization usually last a few days, and recovery from illness usually 
occurs in about 1 to 2 weeks.
j) Who is at riskfor severe illness?
Premature infants, children less than 6months, children less than 2 years of age with 
congenital heart or chronic lung disease, and children with compromised (weakened) immune 
systems due to a medical condition or medical treatment are at highest risk for severe disease. 
Adults with compromised immune systems and those 65 and older are also at increased risk 
of severe disease.
g) When is the risk for infection the greatest?
RSV infections generally occur in Kilifi, Kenya from November to April. However, the 
timing of the season may differ among locations and from year to year.
h) How can I  provide care to someone with RSV?
There is no specific treatment for RSV infection. However, there are simple ways to help 
relieve some of the typical symptoms. Your doctor can give advice on how to make people 
with RSV infection more comfortable and assess whether hospitalization is needed.
i) How is the infection prevented?
Researchers are working to develop RSV vaccines, but none is available yet. However, there 
are steps that can be taken to help prevent the spread of RSV. Specifically, people who have 
cold-like symptoms should:
• Cover their mouth when they cough and sneeze
• Wash their hands frequently and correctly (with soap and water for 15-20 seconds)
• Avoid sharing their cups and eating utensils with others
• Refrain from kissing others
In addition, cleaning contaminated surfaces (such as doorknobs) may help stop the spread of 
RSV.
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Appendix F. The field workers’ manual
Household transmission of respiratory syncytial virus (RSV): Who acquires infection from 
whom
Compiled bv: Patrick Munvwoki. Dorothy Koech. and D James Nokes:
First draft on 20th July 2009; last updated on 10th January 2010
I. Introduction
KEMRI is a Government organization under the Ministry of Public Health and Sanitation that 
carries out health research to learn more about diseases that affect children and adults in 
Kenya. Scientists working at the programme come from all over Kenya, East Africa, and 
other countries worldwide. Research results are used in Kenya and throughout the world to 
improve health. All studies conducted at KEMRI, Kilifi, have been approved in advance by 
expert committees in Kilifi and Nairobi who check the research question is important, the 
study will be conducted well and that the safety and rights of participants are protected.
The current study is organised by KEMRI-Wellcome Trust Research Programme in 
collaboration with University of Warwick, England. We are investigating an infection caused 
by a germ (virus) that is known to be a major cause of chest (respiratory) infections through 
out the world. The virus is called Respiratory Syncytial Virus or RSV.
RSV is considered the major pathogen causing severe lower respiratory infections among 
infants and young children worldwide. It is the single most important cause of pneumonia 
and bronchiolitis in infants and young children less than one year of age. For infants who are 
infected in their first year of life, the symptoms can frequently be severe enough for the 
parent to feel the need to take the child to hospital. The virus is unusual in that it can 
repeatedly re-infect individuals throughout life though subsequent infections are associated 
with decreasing severity. Because of the severity of RSV disease, its treatment and 
prevention are important public health concerns.
Studies from Kilifi District show that around 1 in every 100 infants are admitted to hospital 
with RSV associated severe pneumonia each year and there is a clear seasonal pattern on the 
occurrence of RSV epidemics every year. RSV infections usually start in November and 
peaks in January-to-February lasting about 4 to 5 months.
We have currently an on-going study in children wards in Kilifi District Hospital (KDH). 
Briefly, this is a long-term surveillance of Respiratory Syncytial Virus (RSV) in children 
admitted with lower respiratory tract infections (LRTI) to KDH which aims at:
a) Determining seasonal and longer-term periodicity of RSV infection,
b) Obtaining an accurate estimate of RSV associated mortality in acute respiratory 
infection (ARI) admissions,
c) Monitoring group and genotype prevalence, and relating variant type to severity,
d) Creating a panel of RSV isolates, with associated acute and convalescent sera, and 
stratified by patient HIV status, suitable for functional strain-specific immunity 
assays,
e) Comparing RSV disease in HIV infected and uninfected children,
f) Investigating other viral causes of ARI admissions in children less than 2 months old.
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A vaccine is not yet available to prevent RSV infection but is under development. The 
potential usefulness of such a vaccine and information on how best it can be implemented 
requires a better understanding of the spread of the virus within the community. The family 
or household unit is an important element in the spread of infections, transmitted by close 
contact, in the community. Better understanding of household transmission may inform on 
the merits of targeted control strategies. Data on within-family spread of RSV, particularly on 
who infects the infant, are scarce. Close monitoring of infections within families will provide 
this vital information hence need for household-based studies
II. The household study
There are a number of studies planned to investigate the spread of RSV within the 
community. A brief summary of household study, which has since been approved, is 
presented in this manual. The study seeks to understand the spread of RSV within the 
community particularly in households generating data that can help in assessing who infects 
the young children and particularly the infants. The study will be conducted during the 
forthcoming season of RSV likely to start from November 2009 to May 2010.
III. The Household study: An overview
a) Study Area
The study will be conducted in Matsangoni Location, Kilifi district, mainly within Uyombo 
and Mtasangoni sublocation but may spill over to the neighbouring sublocation near 
Matsangoni dispensary i.e. Mkongani (these may be revised). The community strategy (every 
20 households are under surveillance of a Community Health Worker) spearheaded by the 
Ministry of health has been successfully implemented in making it easier to identify the 
eligible households and carry out community sensitisation.
b) Aims o f Study
The focus of the study will be to monitor RSV infections within a group of households with 
an infant and at least one older child (ren) during a season of high transmission of RSV(4 to 5 
months period starting in November 2009). The study aims to to understand who acquires 
infection from whom (WAIFW) by answering the following questions:
i) Who brings infection into the household?
ii) Who gets initially infected in the household?
iii) Who infects whom?
iv) What proportion of the household members become infected, and, in particular,
v) Who infects the infant?
In particular, we are interested in assessing whether it is school-age children who are source 
of infection for their younger housemates (usually siblings) who are at greater risk of 
subsequent disease. Nasal swabs and oral fluid samples will be collected from each member 
of the household regardless of their symptoms.
c) Study design
This is a household-based cohort study involving about 50 households with an average of 7 
individuals per household. Recruitment procedures will include community sensitization, 
identification of households, consenting of the participants and collection of demographic 
data.
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The participating households will be followed up during the RSV season (the start identified 
by an increase in RSV-associated admissions in KDH, and probably running for about five 
months). We will make twice a week home visits in which each household member will 
have the samples collected (oral and nasal). These specimen will help us determine whether 
RSV is present and will also determine the strain of the virus if they are currently infected. 
The household members will further be asked about their health status and history of any 
respiratory symptoms. Any sick individuals will be referred to the Matsangoni dispensary 
where they will receive treatment free of charge.
Once again, the main aim of this is to identify every RSV infection within the households to 
be able to determine who acquires infection from whom and in particular, who infects the 
infant.
IV. The roles of a field worker
a) General
As a field worker (FW), it is your job to ensure the smooth running and success of the study. 
It is crucial that you fully understand what the study is all about so that you will be able to 
handle any issues that arise during your work. You are a very important person for the 
success of the program and your dedication and commitment will determine the 
outcome of the study. You will therefore be expected to present yourself well to the 
community so as to be respected and accepted within the area. As you visit each home, be 
courteous and make the participants comfortable.
i) Always introduce yourself.
ii) Always wear your KEMRI T-shirt (if you don't have one we will provide).
iii) Always wear your KEMRI ID.
b) Skills you will need for this study
The various specific skills required for this study are listed and details are provided elsewhere 
in the document:
i) Able to deliver accurate information to the participants or parent/caretaker (if child) 
and obtain informed consent.
ii) Conduct simple questionnaires
iii) Taking of vital signs, temperature taking, respiratory rate taking, elicit history of 
respiratory illness, in particular accurately assess breathing rate.
iv) Collect nasal specimen by use of the nasal flocked swab
v) Collect oral-fluid specimen by use of the ORACOL device.
vi) Be able to correctly deal with questions arising from either the study and non-study 
participants in the community (and refer appropriately)
vii) Ability to correctly deal with issues arising that may be associated to the commitment 
of the households.
V. Informed consent
Consent for participation of household members into the study will be obtained at the home. 
The consent form includes considerable detail about the study, the level of involvement of the 
household in the study, including the advantages and disadvantages of participating.
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You may be required to obtain informed consent, and the family/guardian/parent may ask 
you questions about it then or at a later stage, when you make home visits. You therefore 
need to understand the information sheets and consent forms, how they are delivered, and to 
be able to answer questions from the household members on the issues given above. All 
participants receive a copy of the signed consent form and the study information sheet. 
Informed consent can only be taken from persons above 18 years. In the case of children the 
respective parents or guardians will have to provide consent. When providing consent, the 
following points should be emphasized:
i) Participation in the study is voluntary and anyone is free to. It is necessary if the study 
is to be effective that the household remains in the study for the entire study period.
ii) Fieldworkers will visit the homes of the participants twice a week during the RSV 
season (which might be half the year) for the purpose of collection of samples as well 
as identifying illness related symptoms of each of the household members.
iii) The study will run for about 4-5 months and will then stop.
iv) We will need to collect a nasal sample from each member of the household twice a 
week.
v) An oral sample will be collected from each of the household members once a week.
vi) Field workers are not medically trained. You should not be asked for advice on the 
child’s other household members’ medical conditions neither will you carry any drugs 
to the field. If any of the participants is ill during the period of study refer them to the 
Matsangoni dispensary where we will provide definitive treatment free of charge.
VI. Home visits by field worker
This is the main component of the household study. There are certain actions that need to be 
taken during each of the home visits made by the field worker.
a) Before you depart for the households you should ensure the following:
• Obtain list of households to be visited on that including details of how to locate 
them.
• Fill out date of the visit at top of the surveillance form and date of next 
appointment (3 -4 days)
• Confirm whether you will be collecting both oral and nasal samples or only nasal 
samples for that particular visit.
• Check to take adequate materials/supplies for nasal swabs and oral fluid sample 
collection (See Appendix for list of required materials.)
bj At the household
• Remember to introduce yourself to the family/mother/head of household and 
identify yourself as from KEMRI for the household study.
• Remember to always be polite and to respect the wishes of the family.
• Enter participants study ID number and NAMEs/SEX into the illness assessment 
form. Confirm the data to ensure you are accurate.
• Conduct an illness assessment for each of the household members just before you 
collect the samples.
• Inform the participants of what you intend to do and request for their permission 
before proceeding.
• Collect the samples from each participant in a secluded area away from the other 
household members.
308
• Fill in the details of sample collection in the form
• Thank the participant for their cooperation and ask if they have any concerns or 
questions.
• Plan for the date of next visit (including time), which should be within 3-4 days 
and find out whether they will be available. If not you may have to schedule the 
visit at a different time (After discussion with the participant or parent if the 
participant is a child).
c) Sample collection
The sample will be collected following the respective approved standard operating 
procedures (SOP). The SOPs for Nasopharyngeal flocked swab (NPS) and oral fluid (OF) 
collection procedures are attached.
d) Household Illness Assessment form
This is a form that a field worker will be required to fill during each of the visits to the 
households. It serves the purpose of documenting whether specimens have been collected as 
well as an illness assessment of each of the household members. Refer to appended form and 
notes for further details.
The key symptoms you should be able to identify:
• Difficulty in breathing-whose signs are nasal flaring, use of accessory muscles, e.g. 
neck muscles and chest in drawing (sucking in of lower bony chest wall on 
inspiration) and wheezing [This is a high-pitched whistling sound made when air 
flows through narrowed airways in the lungs, usually when people breathing out],
• Cough (less than 30 days);
• Fever (hot body or axillary >37.5C);
• Nasal congestion/ discharge;
• Fast breathing; Breathing rate is > 50 AND age < 12 months OR breathing rate is > 40 
AND age >12 months (WHO guidelines).
If a child appears to have any cough or difficulty in breathing or fast breathing, refer to 
Matsangoni dispensary by completing the RSV referral note in RSV field book. Inform the 
participant he or she will receive fare reimbursement at the dispensary. Emphasize that the 
participant or child should go there the same day.
Remind them to come to the clinic with their study ID cards.
The nasal specimen should be transported back to the lab AS SOON AS POSSIBLE.
VII. Accuracy in data collection and storage of samples
Accuracy in data collection is a top priority. The following are some simple guidelines:
Label all bottles and tubes for saliva and nasal swab collection just before collection of 
sample- it is easy to forget to label materials in the noise and confusion of sample taking. All 
samples should be labelled with the individual’s name, serial number and the date and time of 
collection of the sample. You are discouraged from labelling all the samples tubes 
together before the collection as this may lead to placing the samples in the wrong tubes.
• Make every effort to return collected specimens to the research unit as quickly as 
possible, maintaining cold conditions as required.
309
• Complete forms and questionnaires carefully. Complete all sections required. Do not 
be hurried. Do not make assumptions about answers elicited - if unsure, return to the 
question and ask again.
• Be methodical in your actions. Make sure you are clear about exactly what you intend 
to do before arriving at the household.
On return to the dispensary
• Go through the forms to ensure that there are no blatant mistakes and hand in the 
forms to the field coordinator.
• Relate all the problems encountered in the field to the study coordinator and also note 
them down for discussion.
• Enter study numbers into logbook in the dispensary of individuals from whom nasal 
swabs and oral fluid samples have been collected.
VIII. Procedures
a) Temperature Recording
All temperatures will be taken from the armpit (axillary temperatures). Do not round off the 
figures on the thermometer but record it as it is on the forms.
b) Recording breathing rates
Defined as the number of breaths per minute. Obtained by observing the frequency of 
inspiratory phase over 30 seconds then multiply by 2.
c) Collecting o f specimens
Nasopharyngeal swabs (NPSi (Refer to SOP for detailed explanation of the procedure)
The NPS is a simple procedure making use of a commercially available flocked swabs. 
Briefly, the distance between the participant’s nares and earlobe is measured to estimate the 
length of insertion. The swab is then gently inserted up the nostril towards the pharynx for the 
measured distance. The swab is rotated 3 times, to obtain epithelial cells and surface 
colonising bacteria and held in place for 5 seconds to ensure maximum absorbency. The swab 
is then withdrawn gently and put in an appropriate transport medium.
Oral fluid (OF) samples (Refer to SOP for detailed explanation of the procedure)
The OF will be collected using a sponge swab, consisting of a cylinder of expanded 
polystyrene foam attached to a plastic stick and is used like a toothbrush. The swab is 
brushed along the gums and mouth for 60 seconds and the device is then inserted into a 
plastic tube, stoppered, stored on icebox.
d) Storage o f specimens
Immediately after collection, and securing screw cap lid tightly, put the specimen in the 
icebox. Transport the specimen to the lab together with the filled microbiology request form 
to the lab as soon as possible.
IMPORTANT; Contamination between containers, gloves, and swabs should be avoided. 
Very sensitive techniques will be used to detect the virus and any contamination will be 
detectable. So, DO dispose off gloves, or store separately used ones, after each procedure, 
make sure lids of vials are in firmly, DO NOT reuse storage tubes.
IX. Anticipated challenges
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Fieldwork rarely goes as smoothly as is planned and if we can anticipate some problems and 
know how to go round them earlier in the study, it will make work easy for us. As the study 
continues, more problems are sure to arise. We will discuss these problems as a group once a 
week and decide ways in which to handle them. Do not give random explanations when 
accosted with a question that is difficult to answer. If you do not know the answer to an issue 
that is raised say so, note the comment on a piece of paper and we will discuss it to allow for 
uniformity of our answers. ‘White lies’ may lead to a lot of complications in the future and 
should be avoided since we intend to stay in the study area for a long time. Some of the 
problems anticipated include:
a) Absent participants
If no any of the participants is present in the house on arrival, check at the neighbours if the 
person is in a nearby shop or has gone to fetch water and if all these are close by, wait for the 
person. If the person is still not available, follow up later in the day. Meanwhile collect 
samples from the household members available. If they have gone to the shamba, find out 
how far it is and whether it is possible to go there.
b) Very sick people in need o f urgent treatment
If you come across a very sick person, whether or not they are a study member, the golden 
rule is to seek help from the nearest available source. You are not trained to manage sick 
individuals and should not take responsibility for sick patients. In most instances, the first 
line of help should be the nearest clinic which is staffed with qualified nurses from 8.00 am - 
5.00 pm during the working week. If for any reason the clinic is closed, you should advise the 
patient to seek help at the hospital by the quickest available transport. This will usually be a 
Matatu or private vehicle. If the Unit vehicle is, soon due to return for pick up, it may be 
appropriate to help transport the patient with you to Kilifi District Hospital. However, this 
should only happen under exceptional circumstances, as passengers are not authorized.
c) People asking for drugs
Let everyone know that you will not be carrying any drugs with you as you do your work. 
Those study participants that have any common illnesses will be referred to Matsangoni 
dispensary where they will receive free medical care and their fare to the place will be 
reimbursed. Severe cases may further be referred to Kilifi District Hospital. This will only be 
applicable for acute illnesses.
Participants with other conditions not urgent but needing care and advice seeking on 
management of diseases
If any of the participants may have illnesses (such as scabies, head lice, minor injuries etc) 
you should advise them to seek help preferably from a medical professional. You should 
make it clear that you are not trained to give such advice yourself. You should the 
participants that they have two main choices:
• Matsangoni dispensary: Participants will be encouraged to come for assessment at 
the matsangoni dispensary during normal opening hours whenever they are ill. We 
will pay the bus fare and they will not have to pay the normal user fee and will 
receive routine treatment without charge. If we cannot treat them at the clinic,
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(including that the appropriate drugs are not available), we will refer them to the Kilifi 
District hospital and will also cater for their medical expenses.
• To seek advice through the normal sources (usually a shop, herbalist, the nearest 
private clinic). Some participants may decide to use other preferred sources of health 
care, which may be more convenient for them. In such cases, it is important to remind 
them that we will not reimburse for such costs.
d) Anger from the excluded the households in the homestead.
Such households will be reminded that the study requires households that have an infant and 
an older child. If they are eligible but were not included in the study, inform them that 
research work had funds for only a particular number of people.
X. Attachments (note: Included as stand alone appendices in this thesis)
• Study Information sheet and consent forms-English
• Study Information sheet and consent forms-Swahili (not presented in this thesis)
• Study Information sheet and consent forms-Giriama (not presented in this thesis)
• Initial Home Visit form
• Home Visit form
• Clinic Visit form
• Nasal Flocked Swab Procedure SOP
• Oral Fluid Sampling Procedure SOP
• Household Risk Survey questionnaire
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Appendix G. Household study information sheet and consent forms
I. Household study Information Sheet
a) Study title
Household transmission of respiratory syncytial virus (RSV): Who Acquires Infection From 
Whom
b) Investigators____________ ________________________________________________
Institution Investigators
KEMRI CGMRC, Kilifi Principal investigator: Patrick Munywoki 
Co-investigators: D James Nokes, Laura Hammitt, 
Mwanajuma Ngama, Dorothy Koech. Ann Bett, Charles 
Nyaigoti
University of Warwick D James Nokes, Graham Medley
Health Protection agency, UK Pat A Cane
c) What is KEMRI and why am I  here?
I work for KEMRI. KEMRI is a government organisation that carries out medical research to 
find better ways of preventing and treating illness in the future for everybody’s benefit. One 
illness KEMRI is currently trying to learn more about is pneumonia caused by ‘germs’ called 
respiratory syncytial virus (RSV), which commonly affects children. These germs are spread 
through close contacts via large nasal droplets from infected persons. A vaccine is not yet 
available to prevent RSV infection but is under development. In order to know which group 
to target for vaccination in future when that vaccine becomes available, we need to know 
how the virus is spread within the community. We aim to closely monitor respiratory 
infections within members of the household in order to understand who transmits the RSV 
infection to young children.
To help us learn more we are asking members (about six per household) of 50 households, to 
allow us to take nasal mucus samples two times per week, and saliva samples once a week 
for 4-5 months when RSV infections are common. We have selected to ask you since your 
household has a child aged less than one year and with at least one elder sibling to the child.
d) What will it involve for me/my household i f  we agree?
If you agree, we will take a sample of mucus from the nose twice a week and saliva once a 
week (only two home visits per week) for a period of about 4-5 months from all members of 
the household. The nasal specimen will be collected by inserting a sterile cotton swab in one 
nostril and twisting 3 times before gently removing it (takes about 10 seconds) -  show 
devices and methods. The saliva specimen will be collected by inserting a sterile cotton swab 
in one’s mouth and rubbing against the gums (as in a toothbrush) for a period of one minute. 
[Show the device and the method].
During every home visit, we would also like to ask you some simple questions about 
you/your household related to history of respiratory illness, and take a temperature.
e) Are there any risks or advantages to my household or me if  we participate?
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When we collect a nasal mucus sample you/your child may experience some mild discomfort 
but there are no known risks associated with taking this sample. There are also no known 
risks involved when taking saliva sample from the mouth. Trained and experienced staff will 
undertake all the procedures. Frequent home visits might cause some inconveniences but 
considerate schedules based on agreed times will be set.
You/your child will benefit from close monitoring for any illness by a nurse during the home 
visits and will be referred to the health centre for further consultation and treatment where 
necessary. Medical expenses for outpatient treatment of acute illnesses will be paid for and 
where applicable transport costs to the nearest hospital will be met by KEMRI. These 
benefits will be applicable during the period of participation in this study only.
J) What happens i f  I  refuse to participate?
All participation in research is voluntary. You are free to decide if you /your household can 
take part. If you agree you can change your mind at any time and withdraw (yourself/your 
child/your household) from the research. This will not affect you/your child’s/your 
household’s care now or in the future.
g) What happens to the samples?
Individual names are removed from all samples and replaced by codes, to ensure that samples 
can only be linked to the participants by people closely concerned with the research.
Most of the research tests on the nasal and saliva samples will be done here in Kilifi.
However for some test that cannot be done in Kenya, part of the samples will be sent to 
laboratories overseas.
We would also like to store any nasal mucus or saliva sample that is left over after we have 
done these tests in case they may help us to investigate new research questions. This means 
we are able to learn new things without taking other samples from other individuals in the 
future. Future research on these samples must first be approved by a national independent 
expert committee in Nairobi.
h) Who will have access to information about me/my child in this research?
All our research records are stored securely in locked cabinets and password protected 
computers. Only a few people who are closely concerned with the research will be able to 
view information from participants.
i) Who has allowed this research to take place?
An independent national committee and a committee in Kilifi have looked carefully at this 
work and agreed that the research is important, it will be conducted properly and participant’s 
safety and rights have been respected.
j) What i f  I  have any questions?
You may ask any of our staff questions at any time. You can also contact those who are 
responsible for the care of your child and this research:
P i’s name(s) and contacts
Mr. Patrick Munvwoki and Dr. James Nokes 
KEMRI- Wellcome Trust -Kilifi District Hospital,
P.O.Box. 230, Kenya. Tel: 041 7522 063, Mobile: 0725 242233 or 0733 268290
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If you want to ask someone independent anything about this research please contact
Community Liaison Manager. KEMRI -  Wellcome Trust
P.O.Box 230, Kilifi. Tel: 041 7522 063, Mobile: 0723342780 or 0738472281
Or
The Secretary - KEMRI/National Ethics Review Committee
P. O. BOX 54840-00200, Nairobi, Tel: 020 272 2541 Mobile: 0722205901 or 0733400003
II. Consent form for adults 
Household spread of RSV infections: Who Acquires Infection from Whom
I ,________________________________(name of participant)], have had the research
explained to me. I have understood all that has been read and had my questions answered 
satisfactorily. I understand that I can change my mind at any stage and it will not affect 
me/child in any way.
Please insert the boxes below where relevant:
□ I agree to take part/allow my child to take part in this research
□ I agree to samples being stored
□ I agree to samples being exported
Participant’s signature:___________________________Date_____________
Participant’s name:  Time____________
(Please print name)
I certify that I have followed all the study specific procedures in the SOP for obtaining 
informed consent.
Designee/investigator’s signature:__________________________Date____________
Designee/investigator’s name:________________________ Time____________
(Please print name)
Only necessary if the participant cannot read:
I5 attest that the information concerning this research was accurately explained to and 
apparently understood by the participant and that informed consent was freely given by the 
participant.
Witness’ signature: ________________________________ Date_____________
Witness’ name: ________________________________ Time_____________
(Please print name)
Thumbprint of the participant as named above if they cannot write:___________________
The participant’ should now be given a signed copy to keep.
5 A witness is a person who is independent from the study or a member o f staff who was not 
involved in gaining the consent.
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III. Consent form for infants and under age (<18 years) children
Household spread of RSV infections: Who Acquires Infection from Whom
I, (being a parent/guardian o f________________________________ (name of child), have
had the research explained to me. I have understood all that has been read and had my 
questions answered satisfactorily. I understand that I can change my mind at any stage and it 
will not affect me/my child in any way.
Please insert the boxes below where relevant:
□ I agree to take part/allow my child to take part in this research
□ I agree to samples being stored
□ I agree to samples being exported
Parent/guardian’s signature:___________________________ Date_____________
Parent/guardian’s name:____________________________ Time____________
(Please print name)
I certify that I have followed all the study specific procedures in the SOP for obtaining 
informed consent.
Designee/investigator’s signature:__________________________Date____________
Designee/investigator’s name:______________________________ Time____________
(Please print name)
Only necessary if the parent/guardian cannot read:
I6 attest that the information concerning this research was accurately explained to and 
apparently understood by the parent/guardian and that informed consent was freely given by 
the parent/guardian.
Witness’ signature:______________________________________ Date____________
Witness’ name:________________________________________ Time____________
(Please print name)
Thumbprint of the parent as named above if they cannot write:____________________
The parent/guardian should now be given a signed copy to keep.
6 A witness is a person who is independent from the study or a member ofstaff who was not 
involved in gaining the consent.
316
Appendix H. Initial Home Visit form
I. Study on transmission of respiratory viruses within household: baseline data
Initial home visit questionnaire
Date today (DD/MM/YYYY) /____ 120____ Time:___ :___ (in 24hrs)
Household Head details
HH head names 1_________________ 2 __________________ 3 __________________
Marital status:______________
How many wives/co-wives? (Indicate number)
Residence: Sub-location:_______________
Village:_______________________
How many year have you spent in school?____________ numbers
Household members:
How many families are in this household: (indicate number)
How many adults (18 years and above) are in this household:_____________ (indicate
number)
How many children (under 18 years) are in this household: (indicate number)
How many children in this household are less than five years old:_________ (indicate
number)
How many children are in this household are less than one year old:_______ (indicate
number)
NB: Please enter the details o f all the household members starting with the infant in the 
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II. Notes to the FW for completion of the Initial Home Visit form
The field workers will fill the form. It aims at collecting information about the demographic 
variables related to the household. Only one form is to be filled per household. It will be 
more appropriate if the household head (or their spouse) responds to the questions. The field 
worker SHOULD NOT GIVE THE RESPONDENT to fill it in by themselves.
Below is a step-by-step guide to help you administer the questionnaire effectively:
Date today and time: Note the date and time of collection of the data. The date format will be 
dd/mm/yyyy e.g. 28/04/2009, time, 15:30. Use the 24-hour clock system.
HH head name: Note the household head full names in the order indicated. Note this should 
be the name of the living household head.
Marital status: This relates to the household head and the options include married, divorced, 
separated, single parent and widowed. Indicate number of wives or co-wives to the HH head. 
Sub-location and village: Residence details e.g. Uyombo sub-location. Possible villages 
include Wireless, Uyombo-centre, Uyombo-maweni, Chambuko and Madeteni.
Years spent in spend in school: Count starting from class one and indicate the number of 
complete years spent in school e.g. if parent dropped out of school at class 7 the years spent 
in school are 7 year; dropped in form 2,10 years etc
Household members:
Household: a group people living in the same compound and with similar cooking 
arrangements with or without a common household head.
Family unit: Units consisting of father, mother and/or children (nuclear family unit). Indicate 
the number of family units, adults and children within the household
The participants’ table:
Please enter the details of all the household members starting with the youngest child (herein 
referred as index child) in the table. This will allow easy reference when filling details on 
relationship and sleeping arrangement.
• Indicate the person id (unique study number), participant’s full names (including 
initials of their names in brackets), sex and date of birth. For the under five children 
make effort to get the exact date of birth in this format day/month/ year 
(DD/MM/YYYY) from vaccination or clinic cards while for adults you can refer on 
their national identity card.
• Indicate the occupation of the participant e.g. Farming, fishing, housewife, house- 
help, teacher, casual work, business, carpenter, masonry, tapers, quarry, pupil(in 
primary), students(in secondary and colleges), shopkeepers, retired etc. this should be 
the main occupation/activity that brings income to the participant or the main activity 
the participant is involved in.
• Note the highest level of education attained or current level of education. Indicate the 
highest level attained by the HH head e.g. Class 7, form 3, diploma etc:
• Relation to the study infant: Note the relationship of all the participants in the 
household to the index child e.g. self, Father, Mother, brother, sister, grandfather, 
grandmother, stepmother, step father, uncle, aunt, househelp etc
• In reference to the index child indicate whether the participants live in the same 
house, sleep in the same room and /or sleep in the same bed as the index child.
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II. Notes to the FW for completion of the Home Visit form
a) Before you depart
Obtain list of households to be visited today + details of how to locate the homesteads
Fill out date of the visit at top of the home visit form
Fill in the Lab request forms for both oral and nasal swab collection
Check to take adequate materials/supplies for nasal swabbing and oral fluid collection.
b) At the household
Remember to introduce yourself to the family/mother/head of household and identify 
yourself as from KEMRI for the household study. Remember to always be polite and to 
respect the wishes of the family.
• Take care to be accurate on the Names and studyid for all the study participants 
Illness assessment
• Sick today: Ask if the person has any signs and /or symptoms of respiratory illnesses 
on the day of the visit.
• Duration of illness: Ask when the respiratory illness started i.e. when the first signs or 
symptoms of respiratory illness were identified. Record duration in days e.g. Indicate 
0 if only today, 1 if ill yesterday, 2 if ill day before yesterday etc. The duration should 
not exceed the number of days since the last home visit.
• Cough: Ask the participants (caretakers for the young children) if they have had 
(heard) cough today or note if you have heard the person cough during this visit.
• Runny nose/congestion: Check if the participant has running nose (common cold) or 
blocked nose (nasal congestion)
• DIB (Difficulty in breathing): Check participants for difficulty in breathing.
• Other complaints: especially non-respiratory symptoms: Indicate any other 
complaints at the back of the form indicating the duration of the symptoms.
• Temp: Take axillary temperature and record here.
Respiratory rate: Also referred as breaths per minute. Record the breathing rate as 
accurately as possible. Ensure the participant has settled before recording. Assess if 
the participant has fast breathing (i.e. >50 for all ages, and >40 if 12 months or over). 
This will be collected only for under 5 years old or persons with respiratory illness.
• Any treatment: Did you seek any treatment for this illness? Provide details of the 
treatment sought in the box provided. The details should include the type of drugs 
taken, source of the treatment, when the treatment was sought.
• Refer: Record here if the participant was referred to either Matsangoni dispensary. If 
child has fast breathing for age OR difficulty in breathing AND cough OR nasal 
discharge/congestion), then refer the child to the Matsangoni dispensary for further 
review and treatment (complete referral note in RSV exercise book). Also refer if the 
temperature >=37.5°C to get a malaria blood slide. Emphasise that the mother should 
take the child today.
• Any comments: Any other findings/observations. Indicate more details in the box 
provided
Specimen collection
• NPSwab: Record if nasopharyngeal flocked swab has been collected. If not taken 
indicate the reason.
• Oral fluid: Record if saliva sample was taken. If not taken indicate the reason.
c) Note: Plan for the next appointment (within 3 to 4 days)
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Appendix J. Clinic Visit Form
I. The form
Date today (DD/MM/YYYY) /____ / 20_
a) Person details
Patient Names: 1 2
Time: hrs
Study Person i d : _______________
DSS PID:_________________
Sex:____ (M/F)
Residence (Village):_____________
Brought to clinic by (caretaker names):__________
Relation to the patient: 
Referred by:____________FW/Self/Study clinician
b) Illness assessment 
Anthropometries:
Weight [ ][
MUAC [
Height/Length [ ] [
Oxygen saturation 
Heart rate
Axillary temperature
Respiratory rate
Is the participant sick today?
How long has the patient been sick?
] [  ]•[ ][ ]kg 
] [  ]•[ ]cm
][  ]•[ ]cm 
[ ][ ][ ]%
[ ][
[
[
][
][
][
[
][
]/min
]•[ 
]/min 
] y/n 
] days
]°C
What are the main complaints? (Please indicate Yes or No)
Fever [ ] y/n
Cough [ ] y/n
Nasal discharge/congestion[ ] y/n 
Difficulty in breathing [ ] y/n 
Nasal flaring [ ] y/n
Sore throat [ ] y/n
Chest wall indrawing [ ] y/n
Conscious level (please tick one) 
Alert □  Lethargic
Prostrate |-----1 Unconscious
To be 
filled by 
the FW
Crackles [ j y/u
Wheezes [ ] y/n
Unable to feed [ ] y/n
Head nodding [ ] y/n
Cyanosis [ ] y/n
Unable to talk in complete sentences 
[ ]y/n
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i) Other complaints (specify in the box below)
ii) Laboratory tests:
iii) Malaria test: Indicate results as either positive, negative, equivocal or not done
iv) Rapid diagnostic test: [ ]
v) Peripheral blood slide: [ ]
vi) HIV test done: [ ] y/n
vii)Primary diagnosis (specify): ________________________________________
viii) Other diagnoses (specify in the box below)
ix) Treatment given (List all the drugs prescribed in the box below)
x) Does the child require referral for hospital (KDH) admission [ ] (y/n)
xi) Initials of the clinician reviewing the patient [ ]
c) Specimen Collection
i) Does the patient require a nasal sample? [ ] (y/n)
ii) If yes, has the swab been collected: [ ] (y/n)
iii) If nasal sample is not collected specify reason:_______________________
iv) Nasal specimens collected by (indicate your initials) [ ]
II. Notes for the completion of the Clinic visit Form
a) General instructions
The form will be filled by the clinician but could be assisted by the study field worker.
This clinical assessment form is to be filled for all clinic visits made by the household study 
participants presenting at Matsangoni Dispensary or KDH outpatient with any illness 
Confirm the participant’s particulars from their study cards/book.
b) Patient details
Indicate the patient full names, the person id (unique study number) and the DSS PID as 
indicated in the study card/book.
• Sex: Indicate whether male or female
• Residence: This should be the village of residence
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• Caretaker: Refers to the person who brought or accompanied the patient to the clinic. 
Note the relation of the caretaker with the patient. He/she could be from the same 
household as the patient or not.
• Referral: Establish who referred the patient to the clinic. Whether it’s the study FWs, 
clinician or it’s a self referral
c) Illness assessment
• Weight: measured in Kgs into 2 decimal places. Ensure the weighing scales are 
calibrated every week
• MUAC: mid-upper arm circumference; reported in cm. This will only be collected in 
children who are below 13 years old.
• Height/Length: measure in cms
• Oxygen saturation: Use pulse oximeter to measure oxygen saturation. Recheck if the 
oxygen saturation is below 95% and if it is less than 50% there is likely to be a 
problem with the Oximeter -  repeat measurement. If less than 90% repeat the 
procedure and compare the two readings. Ensure person is at rest and at ease.
• Heart rate: or pulse rate: Use the readings from the pulse oximeter or count peripheral 
pulse rate for one complete minute.
• Axillary temperature: Take axillary temperature using a digital thermometer e.g. 
accuracy 37.3
• Respiratory rate: Also referred to as breaths per minute. Count respirations for one 
complete minute. Ensure person is in calm stated and rested before starting. If a child 
it should not be agitated or crying for example. Record the breathing rate as 
accurately as possible. Ensure the participant has settled before recording. Assess if 
child has fast breathing (i.e. >50 for all ages, and >40 if 12 months or over).
• Sick today: Ask if the participant has any illness today.
• Duration sick: note the duration the patient has been ill in days. Indicate 0 if only 
today, 1 if ill yesterday, 2 if ill day before yesterday etc
• Main complaints: during the clinical assessment of the illness establish whether any
of the listed respiratory-related signs and symptoms are reported.
• Other complaints: Note the presence of any other complaints which might be 
accompany respiratory illness e.g. diarrhoea, vomiting
• Laboratory tests: Please indicate any malaria parasite test results for Rapid diagnosis 
and or blood slide as positive, negative, equivocal or not done. Establish if a HIV test 
has been done.
• Primary diagnosis: Indicate the final/main diagnosis based on patient complains and 
any laboratory tests done
• Other diagnoses: Note any other diagnosis where applicable.
• Referral: Indicate if the child requires further clinical care (hospital admission) in the 
Kilifi District Hospital.
d) Specimen Collection
Assess if the patient requires a nasal specimen. If the last sample was collected more than 2 
days ago please take a nasal swab. If nasal sample is not collected specify reasons. Please 
indicate the initials of the FW/clinician collecting the sample.
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Appendix L. Nasopharyngeal flocked swab procedure
The standard operating procedure
I. Introduction
This SOP describes the nasal flocked swab procedure for collecting nasopharyngeal epithelial 
cells for viral and bacterial analysis. This procedure has previously been considered more 
acceptable than other nasal specimen collection methods.
The Nasal flocked swab is simple procedure, which entails use of commercially available 
flocked swabs in collection of nasal mucous specimen. A flocked swab is a plastic shaft with 
a tip covered with nylon fibres that acts like a soft brush. It is the responsibility of the RSV 
household field workers to do this procedure regularly under training and supportive 
supervision from the project coordinator and the PI.
II. Purpose
This SOP describes the nasal flocked swab procedure for collecting nasopharyngeal 
epithelial cells for viral and bacterial analysis.
This procedure has previously been considered more acceptable than other nasal specimen 
collection methods.
III. Scope
This SOP targets designated RSV household Field Workers.
IV. Responsibility
It is the responsibility of the RSV household field workers to do this procedure regularly 
under training and supportive supervision from the project coordinator and the PI.
V. Definitions
The Nasal flocked swab is simple procedure, which entails use of commercially available 
flocked swabs in collection of nasal mucous specimen. A flocked swab is a plastic shaft with 
a tip covered with nylon fibres that acts like a soft brush.
VI. Abbreviations and Terms:
• RSV -  respiratory syncytial Virus
• NPS- Nasopharyngeal Flocked Swab
• FW-Field Worker
• SOP -  Standing Operating Procedure
• QA -  Quality Assurance
• PI -  Principal Investigator
VII. Specimen
Nasopharyngeal epithelial cells.
VIII. Equipment/ materials/ reagents
• RSV Household study laboratory request form (attached)
• Gloves
• Pliers
• Sterile nasopharyngeal flocked swabs
• Specimen tubes with 1ml of Universal transport medium
• Indelible marker pen
• Cool box with ice packs
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IX. Procedures:
a) Preparation:
• Ensure all materials required are available
• Confirm that the participant (>18 years) and or parent/guardian (if child) has signed 
informed consent form for the RSV household study.
• Explain the procedure to the participant or parent/guardian (if child) demonstrating 
the equipment and the materials to be used.
• Reassure the participant in case they are anxious that the procedure will cause very 
mild discomfort and will be quick (-10 secs)
b) Methodology
1. Wash hands and wear clean gloves
2. Label specimen bottle with study Identification number, name, and date.
3. Hold person’s head firm and steady (if infant or child-immobilize arm)
4. Measure the distance between the patient’s nares and earlobe to estimate the length of 
insertion.
5. Insert the flocked swab into the nostril towards the pharynx until a slight resistance is 
met.
6. Rotate the swab three times to obtain epithelial cells and hold the swab in place for 5 
seconds to ensure maximum absorbency.
7. Withdraw the swab gently and put in 2ml of transport medium and break the shaft at 
the painted breakpoint.
8. Place specimen container in the cool box immediately
9. Dispose off the gloves and wash hands
10. Fill in the sample form -  remember to include time of collection
11. Ensure the sample is transported to the Lab as soon as possible where it will be stored 
at 4°c.
o
NB: Do not delay in getting sample to a 4 C fridge. If cannot get to Fridge immediately, store
in cool box temporarily.
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Appendix M. Oral fluid sample collection procedure
The standard operating procedure
I. Introduction
This SOP describes the oral fluid sampling procedure for collecting gingivo-crevicular fluid 
from between the gums and teeth. This procedure has previously been considered more 
acceptable than other specimen collection methods particularly in non-clinical settings. This 
SOP targets designated field workers for the study on RSV transmission within households. It 
is the responsibility of the field workers to do this procedure regularly under training and 
supportive supervision from the project coordinator and the PI.
Oral fluid sampling is a simple procedure, which entails use of commercially available 
devices to collect gingivo-crevicular fluid from between the gums and teeth.
II. Purpose
This SOP describes the oral fluid sampling procedure for collecting gingivo-crevicular fluid 
from between the gums and teeth
This procedure has previously been considered more acceptable than other specimen 
collection methods.
III. Scope
This SOP targets designated field workers for the study on RSV transmission within 
households.
IV. Responsibility
It is the responsibility of the field workers to do this procedure regularly under training and 
supportive supervision from the project coordinator and the PI.
V. Definitions
Oral fluid sampling is a simple procedure, which entails use of commercially available 
devices to collect gingivo-crevicular fluid from between the gums and teeth.
VI. Abbreviations and terms
• RSV -  respiratory syncytial Virus
• OF -  Oral fluid
• FW- Field Worker
• SOP -  Standing Operating Procedure
• QA -  Quality Assurance
• PI -  Principal Investigator
VII. Specimen 
Gingivo-crevicular fluid
VIII. Equipment/ materials/ reagents
• Lab request form (attached)
• Disposable gloves and Paper towel
• ORACOL collection device (Malvern Medical Developments, Worcester, UK)
• Labels
• Indelible marker pen
• Cool box with ice packs
IX. Procedures:
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a) Preparation:
• Ensure all materials required are available
• Confirm that the participant (>18 yrs) and or parent/guardian (if child) has signed 
informed consent form for the RSV household study.
• Explain the procedure to the participant or parent/guardian (if child) demonstrating 
the equipment and the materials to be used.
• Reassure the participant in case they are anxious that the procedure will not cause any 
discomfort and will last for about a minute.
b) Methodology
1. Wash hands and wear clean gloves
2. Label specimen tube with study Identification number, name, and date.
3. Remove ORACOL device from covering and transport tube
4. Holding by stick rub sponge gently but firmly around gums (front and back, upper 
and lower, including base) for 1 minute.
IMPORTANT: The sponge must be fully saturated with oral fluid and so one minute of use 
is required.
5. Replace device into stoppered tube (sponge at bottom).
6. Dispose of gloves and wash hands.
7. Place specimen container in the cool box immediately
8. Dispose off the gloves and wash hands
9. Fill in the sample form -  remember to include time of collection
10. Ensure that the sample is transported to the Lab as soon as possible, where it will be 
stored at 4°c.
NB: Do not delay in getting sample to a 4 C fridge. If cannot get to Fridge immediately, store 
in cool box temporarily.
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X. Attachment: Household study specimen collection form
Household study: LAB REQUEST FORM
Partcipant's name:_______________  DATE____ /____/.
Study No. T IM E  ___
Other details
Sample details (please tick)
Flocked Swab □  Oral Fluid □
Collected by (initials)
FOR LAB USE ONLY
Results(Please indicate appropriately; Postive, negative or equivocal)
Done By(initials)
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Appendix N. Real time multiplex PCR (M-PCR) detection of respiratory viruses
The Standard Operating Procedure
I. Introduction
Influenza A and B are important viral infections of the respiratory tract of adults and 
children. Most cases occur during the annual winter epidemics. Severe infections can occur in 
the immunocompromised, those with chronic cardiac, pulmonary or metabolic disease and in 
the extremes of age. Most symptoms include fever, myalgia, sore throat and cough. In 
children, gastrointestinal symptoms also are present. Complications of influenza infection 
include primary (viral) or secondary (bacterial) pneumonia, cardiac involvement and 
neurological illness (including encephalopathy, encephalitis, Reyes syndrome and Guillain- 
Barre Syndrome.
Influenza C is a common cause of mild or asymptomatic respiratory infection. However, 
please note that testing has not been common in the past and therefore we may find this 
pathogen in a wide range of previously unrecognised clinical situations.
Parainfluenza viruses are common causes of upper and lower respiratory tract infection. 
Types 1 and 2 tend to occur mostly in the winter months whereas type 3 occurs mainly in the 
spring. It is unclear if parainfluenza 4 has a defined seasonality. Type 1 and 2 are commonly 
associated with croup in young children. Type 3 is second only to RSV as a cause of 
bronchiolotis and pneumonia in infants. Type 4, like influenza C, is thought to be a common 
cause of mild or asymptomatic respiratory infection. Please note that these pathogens can 
also cause severe infection in immunocompromised patients, especially type 3. 
Rhinovirusescause -one third of colds. They are common in all age groups and can cause 
upper and lower respiratory tract infection. Increased testing has implicated these viruses in 
severe infections especially in those with asthma and COPD. Severe infections are also likely 
to occur in the immunocompromised. There are over 100 types of rhino virus known to cause 
respiratory infection in humans.
Coronaviruses 229E, OC43 and NL63 are frequent causes of the common cold (2nd only to 
rhinoviruses). There have also been reports of pneumonia in the elderly, infants and 
immunocompromised. Outbreaks of pneumonia have also been described in healthy adults. 
Increased testing will probably lead to detection of coronaviruses in severe upper and lower 
respiratory tract infection in other patient groups.
Respiratory syncytial virus is a common cause of respiratory illness in all age groups. Most 
infections tend to occur during the winter season (December-March) in temperate areas, and 
with the rainy seasons in the tropics. RSV is of particular importance as a cause of severe 
lower respiratory tract infection in infants (causing bronchiolitis and pneumonia), the 
immunocompromised (especially BMT patients) and the elderly.
Adenovirus is a common cause of respiratory infection (ranging from pharyngitis to severe 
pneumonia).
Mycoplasma is a bacterial pathogen recognised to be a cause of atypical pneumonia in all 
age groups. PCR has shown to be a sensitive alternative to culture and serology.
Five triplex RT-PCR reactions are performed to detect the following pathogens:
• Set 1 - Influenza A, B and C viruses
• Set 2 - Parainfluenza viruses 2, 3 and 4
• Set 3 - Adenovirus, Respiratory syncytial viruses A and B
• Set 4 - Coronaviruses 229E, OC43 and NL63
• Set 5- Parainfluenza virus 1 and human metapneumovirus (hMPV) + Mycoplasma
Pneumonia
• Set 6- Single RT-PCR Reaction to detect Rhino virus
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II. Scope / Responsibility
Viral Epidemiology and Control (VEC) lab personnel
III. Definitions
• PC - Positive control.
• NTC - Non template control.
• NC - Negative control.
• NA - Nucleic acids.
• VEC- Virology epidemiology cluster.
• RNA - Ribonucleic acid.
• DNA- Deoxyribonucleic acid.
• CDNA - Complimentary deoxyribonucleic acid.
• NPA- Nasal pharyngeal aspirate
• GW - Gastric washing.
IV. Safety/ Risk Assessment:
1. Avoid any loose disconnection of electrical wire that can cause shock.
2. All respiratory samples are potentially infectious; ensure all proper protective 
equipment are used.
3. All work should be done in safety cabinets
V. Specimen:
Samples submitted are likely to be RNA/DNA from respiratory samples (throat/nasal swabs, 
NPA, sputum). In some cases other sample types may be tested including post mortem 
material (heart and lung), induced sputum, oral fluid, GW, and CSF.
VI. Materials:
a) Equipment
• ABI Prism 7500
• ABI Prism reaction plates
• ABI Prism reaction plate seals
• Pipettes for l-1000pl
• Tips for 1-lOOOpl
• Multichannel Pipettes
b) Reagents: RT-PCR Reactions
• Quantifast Multiplex RT-PCR kit
• Respiratory pathogen triplex-set mixes oligonucleotides (attached)
• FLU (Influenza A, B and C) primer and probe mix
• PIV (Parainfluenza virus types 2, 3 and 4) primer and probe mix
• RSV (Adenovirus, RSV-A, RSV-B) primer and probe mix
• HCoV (Coronavirus 229E, OC43 and NL63) primer and probe mix
• OTHER (Parainfluenza Type 1, Human Metapneumovirus A + B and Mycoplasma 
Pneumonia) primer and probe mix.
• RHINO (Rhinovirus primer and probe mix)
• Nuclease free or Molecular Biology grade water
• The positive control material can be either pooled cultured virus, extracted RNA or 
PCR product. Working stocks of each control, diluted so they will have a Ct between 
25 and 30 in a standard reaction, are stored in single target aliquots at -20 0 C. One 
control to be included for each viral target.
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VII. METHODOLOGY:
a) Principle
Viral RNA is transcribed into cDNA using a specific primer mediated reverse transcription 
step followed immediately in the same tube by polymerase chain reaction. Detection of 
product is via a dual labeled molecular probe for each virus of the triplex PCR.
b) PCR procedure
1. Prepare the RT-PCR Master Mix and Primer/Probe Mixes correctly (see table below) 
for preparation procedure.
2. For stored NA remove the sample plates from the -80°C freezer and leave to defrost 
on ice in the PCR template addition room. For fresh NA place on ice and proceed to 
the master mix room.
3. Remove all the tubes from a Quantifast Multiplex RT-PCR kit and the aliquots of 
primers and probe needed for the PCR from -20 °C freezer and defrost on ice. Move 
everything to the PCR master mix room.
4. Make up the master mix for the PCR according to table 1. Always make up enough 
master mix to allow for controls and pipetting errors. For example, for a full 96-well 
plate make up enough master mix for 110 reactions.
5. Vortex the master mix and then pipette 8ul of the PCR mix into the 96-well plate.
6. Move to the template addition room and add 2ul of the NA from the Sample Plate to 
the PCR plate. At each stage visually check the volume of liquid in the pipettes before 
adding it to the PCR plate.
Table 1: Mastermix volumes for the triplex reactions. _________ _________ __________
Reaction Reagent lrxn(pl) 12rxn(pl) 50rxn(pl) 110rxn(pl)
RSV
Corona
Flu
PIV
2x Quantifast 5.0 60 250 550
50x ROX 0.2 2.4 10 22
Primer/Probe
Master 1.5 18 75
165
Quantifast RT 0.1 1.2 5.0 11
Water 1.2 14.4 60 132
Other 2x Quantifast 5.0 60 250 550
50x ROX 0.2 2.4 10 22
Primer/Probe
Master 2.0 24 100
220
Quantifast RT 0.1 1.2 5.0 11
Water 0.7 8.4 35 77
Rhino 2x Quantifast 5.0 60 250 550
50x ROX 0.2 2.4 10 22
Primer/Probe
Master 0.5 6.0 25
55
Quantifast RT 0.1 1.2 5.0 11
Water 2.2 26.4 110 242
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7. In the general lab bench add 2ul of PC and NTC in respective wells. For each plate 
there should be an individual control for each target and then a control where all three 
targets are mixed in one well.
8. Seal the PCR plate with an optical sealing sheet, ensuring all the edges are firmly 
sealed to prevent possible evaporation in the thermocycler. Pulse vortex, spin and 
load the plate to the machine.
9. On the ABI 7500, open up the RV_MPX template and either add your sample ID’s 
manually or import from the library save and start run.
10. Once the PCR has finished analyze, record and report the results to the appropriate 
people, (for analysis see attachment 3)
VIII. Attachments:
• List of the primer and probe sequences
• Guide to preparing the RT-PCR Master Mix aliquots and Triplex-mix aliquots
• Results analysis
• Sample Extraction Sheet
• Sample Plate Sheet
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b) Attachment 2: Preparation o f RT-PCR mastermix andprimer-probe mixes 
The primers and probes will arrive from the manufacturers either lyophilised or at a 
concentration of lOOuM. Lyophilised primers or probes will come with details on how to re­
suspend them to a concentration of lOOuM. This should be done with molecular grade PCR 
water or TE buffer. All re-suspended oligos should be stored at -20 until needed. Freeze thaw 
cycles should be kept to an absolute minimum to avoid degradation of the primers and 
probes. A working concentration of 50uM should be created from the lOOuM stock. This can 
achieved by adding 250ul of Master stock (lOOuM) to 250ul of molecular grade PCR water 
or TE buffer. The purpose of the working stock is to avoid repeated freeze-thaws of the 
master stock.
The working concentration of all primers is 5uM and all probes is 2.5uM. The oligos should 
be diluted in molecular grade PCR water or TE buffer from the working stock (20uM) using 
the following protocol:
RSV, PIV, FLU, Corona (final volume of 500ul)
5mM Concentration Volume Final concentration
Water n/a 125ul n/a
RSV A* fwd 50uM 50ul 5mM
RSV A rev 50uM 50ul 5mM
RSVAprb 50uM 25ul 2.5mM
RSVB* fwd 50uM 50ul 5mM
RSV B rev 50uM 50ul 5mM
RSB B prb 50uM 25ul 2.5mM
Adeno* fwd 50uM 50ul 5mM
Adeno rev 50uM 50ul 5mM
Adeno prb 50uM 25ul 2.5mM
Other (final volume of 500ul)
Water n/a Oul (no water needed) n/a
PIV 1 fwd 50uM 50ul 5mM
PIV 1 rev 50uM 50ul 5mM
PIV 1 probe 50uM 25ul 2.5mM
hMPV A fwd 50uM 50ul 5mM
hMPV A rev 50uM 50ul 5mM
hMPV A prb 50uM 25ul 2.5mM
hMPV B fwd 50uM 50ul 5mM
hMPV B rev 50uM 50ul 5mM
hMPV B prb 50uM 25ul 2.5mM
M.p fwd 50uM 50ul 5mM
M.p rev 50uM 50ul 5mM
M.p prb 50uM 25ul 2.5mM
Rhino (final volume of 500ul)
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Water n/a / ;  --c -7 425ul ■ n/a ■ 7- 7  :
Rhino fwd 50uM 50ul :  ^ ^ 5mM .<77 7 7
Rhino rev 50uM . . • .. -y 50ul . • 7 " 5mM • 7  y  • •
Rhino prb 50uM 7  v / • 25ul - 7 - - :i.-":7- 2.5mM ,
*In this set you should replace these listed primers for those relevant to.the triplex reaction : . ? •  ^
involved. ^ :
c) Attachment 3: Results Analysis > . . * ; -’7*; • •:7 7 ,/
As part of quality assurance results should be double-checked. ■ ■ • '7  r' ^
This is done by dragging the “Baseline-End” icon manually to the required position. ' . <• .
You can also adjust the threshold by dragging if you wish to remove some Tate noise’ >: . "
positive that have crept above the threshold: However* if you.are unsure about any possible .. -- 
positive then it is a good idea to view the component graph for that welL This may give you a . v T 
more accurate picture of whether there was amplification in that well.or not. Compare the 
component traces of your unknown samples againsfthe control well or any other positive - y  - 
sample. v. ■ " „-7 v
The graph axis can also be altered to get a more accurate placement of your threshold level.
Some reactions will result in higher fluorescence than other leading to difficultly analysing -
the lower level reactions. Manually ;alter the y-axiS scale in the graph settings tabs to solve. ' . *
thisproblem.
The results should then be saved in-monthly folders. ’ V..’;., -  7. /
Run manual back up. 7 7  - ‘
Export your results to a folder and send by mailing. . *
Upload results to file maker. 7 _ 7 -  “ • .
This sheet should ALWAYS be ddtibrpchecked. ’ , * *7
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Appendix O. Database screen shots
a) The database home page
fit •r-VAT-*-. . I^KV ■ 1 ww;'
Fic EUl V'v* j u u i  Fv-"fcl FL.-i<1, S u h b  " v .b  W'ncv.v H„y
WAIFW STUDY: Home page
Which data do you want to enter?
Household
P a rtic ip a n t
V is its
A  sc r e e n sh o t  o f  th e  d a ta b a se  h o m e p a g e . L a y o u ts  fo r  en te r in g  sa m p le  d e ta ils  ( fr e e z e r  sto r a g e  
p o s it io n s  and  la b o ra to ry  r e su lts )  w e r e  a c c e s s e d  b y  c lic k in g  th e  ‘V is i t s ’ tab in  th e  h o m e p a g e .  
T h ere  w e r e  se v e ra l a lter n a tiv es  to  th is  w h e n  in  o th er  la y o u ts .
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b) Table relationships
WAJFWStutfy
The database has four main tables with one-to-many relationship. The tables contain 
household, participant, visits and samples variables (fields)
345
c) Sample layout fo r data entry
j§£ FileMaker Pro Advanced -
t  File tcfft View Insert Format Records Scnpts Tools Window Help
Y study househoW 5 I participants
Household head names Participant names
nasal swab taken
Reason of not colactng a rasa' specimen
I  Home O  Clink:
#  Yes O rio  0 » 9
Oral Pud collected ♦ Y es  O «0 0 9 9 9
Reason of not cotecting OF
Data entered on:
data entry
346
Appendix P. Scientific and ethical approval letters
I. Approval letter from Biomedical Research Ethics Sub-Committee, Warwick 
Medical School, UK
\ w /
N \ \ ' :
8m September 2009
PO Box 230 
Kilifi 80108 
Kenya 
East Africa
Dear James 
Project Title:
Transmission of RSV within the household
Thank you for submitting your revisions for the above-named project to the University of 
Warwick Biomedical Research Ethics Sub-Committee for Chair's Approval.
I am pleased to confirm that the revised documentation meets the required standard. I am 
also able to confirm that BREC has received confirmation from the University’s insurance 
office that cover is in place under the University's Professional Indemnity insurance and that 
the study will be sponsored by the University of Warwick. This means that the above study 
has been granted full approval by BREC allowing the study to commence as confirmed in 
our 8th September 2009 email to you.
May I remind you any substantial amendments require approval from the Committee and 
that, once your study is completed, the Committee should receive an End of Project Report.
Yours sincerely,
Professor Jane Barlow 
Chair
Biomedical Research 
Ethics Sub-Committee
Copy:
Lynn Green, Research Governance Facilitator, WMS, University of Warwick 
Mrs Carol Howes. Executive Officer, Biological Sciences, University of Warwick 
David Bennett, Senior Research Manager, WMS,, University of Warwick
Dr James Nokes
do  KEMRI/WT Research Programme
centre for primary 
— health care studies
o  M l * v
'M l * *
Warwick Warwick Medical SchoolCoventry CV4 7AL United Kingdom  General Enquiries: +44 (0)24 7 6 5 7  2 9 5 0  
Fax: + 44  (0)24 7 6 5 2  8 3 7 5M edical School
Website: http://www.warwlck.ac.uk/primary_care
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II. KEMRI-SSC approval letter
KENYA MEDICAL RESEARCH INST1TUTB
P . 0 . 6 «  £*549 • 002C0 NAIROBI, Kenya 
Tel: (254) {020} 2722541 , 2713342. C 722.205931. 0733-400003: f a t :  (254) (023) 2T2C030 
E-rrail: kt«*;-»ivigi>airobt,nir»t£!n,n«t: director § lenrl. erg: wetsiie, Kww.Uirn.orj
E S A C I P A C / S S C / 4 7 6 6
P a t r i c k  M  u n y w o k i  
T h r o ’
D ir e c t o r ,  C G M R - C  
P .O . B o s  4 2 8  
KIIJFI
c c n f
1 4 th J u l y ,  2 0 0 9
n ■& r; ~ t c r  |
k e S f y i c C H .  C C .- , .
K E M R I  / W C r .L C O M E  T R l ' S r  
RHSEaRCJI PRuGRam ,..1£
1 n  2 0  JUL 2009
j .  r e v i v e  d
'v 1 I p» o. Bvntw-mm m i n
R E F -’ S S C  N o .  1 6 5 1  ( R e v i s e d )  -  I l o s e h o l d  t e r a n s m is s io n  o f  r e s p i r a t o r y  s y n c y t i a l  v i r u s  
( R V S ) :  w h o  a c q u i r e s  in f e c t i o n  f r o m  w h o m _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
f a m  p le a s e d  to  in fo r m  y o u  th at th e  a b o v e -m e n t io n e d  p r o p o s a l ,  in  w h ic h  y o u  a re  th e  P I .  w a s  
d is c u s s e d  b y  th e  K E M R I  S c ie n t i f i c  S t e e r in g  C o m m it te e  ( S S C ) ,  d u r in g  i t s  1 5 8 th m e e t i n g  h e ld  o n  
3 0 ,!s J u n e ,  2 0 0 9  a n d  h a s  s in c e  b e e n  a p p r o v e d  fo r  im p le m e n ta t io n  b y  th e  S S C .
T h e  S S C  h o w e v e r ,  a d v is e s  th a t w o r k  o n  th is  p r o je c t  c a n  o n ly  s ta r t w h e n  E R C  a p p r o v a l i s  
r e c e iv e d .
j t iu L
< 4 tK  C .  M w a n d a w i r o ,  P h D  
D S S C  S E C R E T A R Y
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III. Ethical review letters
a) First approval letter
KENYA MEDICAL RESEARCH INSTITUTE
Make reference to your letter dated September 1, 2009. This is to inform you that the issues 
raised during 169th meeting of KEMRI/National Ethics Review Committee held on Tuesday 18th 
August 2009, have been adequately addressed.
Due consideration has been given to ethical issues and the study is hereby granted approval 
for implementation effective this 16th day of September 2009, for a period of twelve (12) 
months.
Please note that authorization to conduct this study will automatically expire on 
Wednesday, 15th September 2010. If you plan to continue with data collection or 
analysis beyond this date, please submit an application for continuing approval to the ERC 
Secretariat by Wednesday, 4th August 2010.
You are required to submit any amendments to this protocol and other information pertinent 
to human participation in this study to the ERC prior to initiation. You may embark on the 
study.
Yours sincerely,
R. C. KITHINJI,
FOR: SECRETARY
KEMRI/NATIONALETHICS REVIEW COMMITTEE
P .O .B o x  S 4 8 4 0  - 0 0 2 0 0  NA IROBI. K enya  
Tel: (254 ) (020 ) 2722541  , 2 7 1 3 3 4 9 . 0 7 2 2 -2 0 5 9 0 1 . 0 7 3 3 -4 0 0 0 0 3 : Fax : (254 ) (0 20 ) 2720030  
E -m ail: k e m fi-h q g r .a lro b i.m ir ic o m .n e t:  d ire c to r  @ kerr.ri. o rg ; w e b site : w w w .kem ri.org
KEMRI/RES/7/3/1 September 16,2009
THRO':
SSC No. 1G51{ETHICSREVIEW): HOUSEHOLD!SEHOLDOEANSM^ 
RESPIRATORY SYNCYTIAL VIRUS (RSV): WHO ACQUIRES 
INFECTION FROM WHOM? __________
“1
349
b) ERC annual ethical approval
KENYA MEDICAL RESEARCH INSTITUTEr- -i i  - - -| i r - —- ----- - ■ r—~i i r - -1 —  , »-   —-    ■   ■ »■■   ■ ■ ■   ■ "
RE: SSC PROTOCOL NO. 1651 {REQUEST<
HOUSEHOLD TRANSMISSION OF RESPIRATORY SYNCYTIAL VIRUS 
(RSW. WHO ACQUIRES INFECTION FROM WHOM?_______________
This is to inform you that during the 182^ meeting of the KEMRI/ERC meeting held on 6th 
September 2010, the Committee conducted the annual review and approved the above, 
referenced application for another year.
This approval is valid from today September 10, 2010 through to September 9,2011. 
Piease note that authorization to conduct this study will automatically expire on September 
9,2011. If you plan to continue with data collection or analysis beyond this date please 
submit an application for continuing approval to the ERC Secretariat by August 5, 2011.
Yours sincerely,
TO:
THRO': DR. NORBERT PESHU,
THE DIRECTOR, CGMR-C, 
KILIFI
KEMRI/RES/7/3/1
P.O. Box 54840 • 00200 NAIROBI, Konya 
Tel: (254} (020) 2722541. 2713349, 0722-205901, 0733-4G0003; Fax: (254) (020) 2720030 
E-mail: <&ector@l<«mrf.ofg Wo@J1emrl.or5 Webs»e:wviw.kem»l<#B
DR. PATRICK MUNYWOKI, 
PRINCIPAL INVESTIGATOR
September 10,2010 ^
R. C. KITHIN3I,
FOR: SECRETARY,
KEMRI/NATIONAL ETHICS REVIEW COMMITTEE
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c) Second annual approval letter
KENYA MEDICAL RESEARCH INSTITUTE
Thank you for the Continuing Review Report for the period 10m September 2010 to 9th 
September, 2011.
This is to inform you that at the 193rd meeting of the KEMRI Ethics Review Committee held on 
1301 September 2011, your request for continuing approval was considered.
The Committee noted that:
a. Reid work was completed on 31st June 2010.
b. 60 households were enrolled with a total of 596 participants. 13 household withdrew. 
On average each household had 10 participants with a median (interquartile range, 
IQR) of 8 (6,11).
c. A total of 19,816 home visits resulting in 16,284 (82% nasal swabs and 9,226 (93%) 
oral fluids (OF) from 554 participants collected. In 3,624 (18%) visits the participants 
had symptoms of acute respiratory infection (ARI)
d. The planned activities for the next project year include screening of nasal swabs using 
multiplex PCR for 7 respiratory virus, sequencing of RSV and rhinovirus positive 
samples; finalising of data cleaning and descriptive analysis and preparing the data for 
inferential analysis once the nasal sample screening is completed.
The Committee concluded that the progress made in the reporting period is satisfactory and 
grants approval for continuation with the study effective Septem ber 14, 2011. Please note 
that authorization to conduct this study will automatically expire on Septem ber 12, 2012.
If you plan to continue with data collection or analysis beyond this date, please submit an 
application for continuing approval to the ERC Secretariat by 1st August, 2012.
P.O. Box 54840 - 00200 NAIROBI, Konya 
Tel: (254) (020) 2722541, 2713349,0722-205901,0733-400003; Fax: (254) (020) 2720030 
E-mail: diroctor@kemri.org lnro@kemri.org Websi!o:v,vrw.kemri.org
KEMRI/RES/7/3/1 September 14, 2011
TO:
THROUGH: DIRECTOR, CGMR-C
KIU FI
Dear Sir,
RE: SSC PROTOCOL No. 1651 (REQUE.
HOUSEHOLD TRANSMISSION OF RESPIRATORY SYNCYTIAL VIRUS 
(RSV): WHO ACQUIRES INFECTION FROM WHOM?________________
PATRICK MUNYWOKI (PRINCIPA
R b ,e a r c m _  p r o g r a m ,, .e  
^ § 0  SEP 2011 
- ? ^ E I V E  d  i
U .  l i n r  ) . A  O / i i n u   ...................- ?F- O. Cox z.tn.Rmrw"’u
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d) Third annual approval letter
KENYA MEDICAL RESEARCH INSTITUTE
P.O. Box 54840-00200. NAIROBI. Kenya 
Tel (254} (020} 2722541. 2 7 1 3 3 4 3 ,0 7 2 2 -2 0 5 3 0 1 .0 7 3 3 -4 0 0 3 0 3 ; Fax; (254} (020) 2720030  
E-mail, director@kemri.org W cgk 8m fl.org  W eb5ite.wnv.kem ri.org
KEM RI/RES/7/3/1 Septem ber 26, 2012
PRINCIPAL INVESTIGATOR^-—- ^TO: MR. PATRICK MUNYWOKI (PRINCIPAL INVES }---
THROUGH: DR. SABAH OMAR,
THE DIRECTOR, CGMRC,
Dear Sir, “
RE: SSC PROTOCOL No. 1651 ( RE-SUBMISSION: REQUEST FOR ANNUAL
RENEWAL,h HOUSEHOLD TRANSMISSION OF RESPIRATORY SYNCYTIAL 
VIRUS (RSV): WHO ACQUIRES INFECTION FROM WHOM?_______________
Reference is made to your letter dated September 19,2012. The ERC Secretariat acknowledges 
receipt of the revised Continuing Review Report of September 20, 2012.
This is to inform you that the Committee notes that the reporting period is deHneu as 1*’ August 
2011 to 18th July 2012 and Is of the view that the progress made In the reporting period is 
satisfactory. Consequently, the study is granted approval for continuation effective this 26th day 
of September 2012. Please note that authorization to conduct this study will automatically 
expire on September 25, 2013. If you plan to continue with data collection or analysis beyond 
this date, please submit an application for continuing approval to the ERC Secretariat by August 
14, 2013.
You are required to submit any proposed changes to this study to the SSC and ERC for review 
and the changes should not be Initiated until written approval from the ERC is received.
Please note that any unanticipated problems resulting from the conduct of this study should be 
brought to the attention of the ERC and you should advise the ERC when the study is completed 
or discontinued.
You may continue with the study.
DR. CHRISTINE WASUNNA,
ACTING SECRETARY,
KEMRI ETHICS REVIEW COMMITTEE
k h m p j  /  wnrj.coj.fE trcs 
e e s e a ; g r a m n
28 SEP 2012
P? ~
O  1;
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Appendix Q. Sensitivity of Qiagen and HP extraction methods in detection of RSV 
A, B and adenovirus
Samples used in the experiment reported in chapter3 were used. The 111 nasal samples had 
been screened by the ‘RSV A and B and adenovirus’ triplex assay based on Qiagen extraction 
method. Comparing the Qiagen results with the HP method allowed for assessing the 
differences in the two extraction methods, Table. The HP method had higher sensitivity in 
detection of RSV A and B relative to Qiagen method which was statistically significant for 
RSV A (p=0.0074). On comparison of the Ct values, HP had statistically significant lower 
Cts than Qiagen for all the viruses except for RSV B which was marginal (p=0.062). The 
correlation of the Ct values by the two methods was 83%, 87% and 65% for RSV A, B and 
adenovirus respectively as shown in Figure below.
I. Table: Respiratory pathogens detected and their sensitivity by extraction method
Viruses HP Sensitivity Qiagen Sensitivity
N n % (95% Cl) n % (95% Cl) P value1
Any Virus 99 ~86 86.9 (78.6-92.8) ~81 8 i y ( 7 r 7 9 ^ ^ )  0.3593.......
RSV A 45 41 91.1(78.8-97.5) 30 66.7(51.0-80.0) 0.0074
RSV B 37 35 94.6(81.8-99.3) 30 81.1 (64.8-92.0) 0.1797
Adenovirus 39 22 56.4(39.6-72.2) 28 71.8(55.1-85.0) 0.2632
Key: N, total number of virus detections by PCR using either HP or TNA RNA extraction 
kits which is used as the reference for calculation of sensitivity; n, number of positive 
samples by the respective kit; %, sensitivity; Cl, confidence interval; RSV, respiratory 
syncytial virus; 1, exact McNemar’s significance probability values reported.
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II. Figure showing the correlation of Qiagen with HP triplex Ct Values for RSV A,
RSV B and Adenovirus.
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Appendix R. Distribution of Ct values
a) Approach
For this exploratory analysis, the frequency distributions of the Ct values for the various 
targets in the M-PCR assay were examined. The mean Ct value for the different viruses by 
age was also assessed. The aim was to check for any age-related association of the recorded 
Ct values.
b) Findings
Of the 16924 screened NPS collections, 1226 (7.2%) recorded a Ct value (value of greater 
than zero) for either RSV group A or B. Of the common respiratory pathogens screened for, 
a bimodal distribution was observed in RSV group A and B, NL63 and 2293 Ct values 
(Figure Ax). Adenovirus, OC43 and rhino virus had a unimodal distribution of the recorded 
Ct values. The mean Ct values increased with age of the individual from whom the NPS was 
collected. Individuals aged 5 years or more had higher mean Ct values than the younger 
counterparts. This phenomenon was observed for the other targets (adenovirus and 
coronaviruses) except human rhino virus where older ages (>15years) had similar Ct values as 
the under one year olds.
Table: Mean Ct values stratified by age for the most prevalent viruses as detected by M-PCR
Virus Age, years n Mean Ct 95% Cl P-value
RSV1 <iy 232 30.4 29.6-31.1 ...... Ref.......
l-<5y 253 31.8 30.1 -33.6 0.005
5-<15 413 33.5 31.9-35.2 <0.0001
15- <40y 241 35.0 33.2-36.8 <0.0001
>40 87 35.0 32.8-37.1 <0.0001
Adenovirus <iy 237 31.4 30.9-32.0 Ref
l-<5y 507 31.2 30.0-32.3 0.418
5-<15 678 32.8 31.7-34.0 <0.0001
15- <40y 255 33.7 32.5-35.0 <0.0001
>40 71 33.9 32.3-35.6 <0.0001
Coronavirus2 <iy 249 25.9 24.9-26.8 Ref
l-<5y 369 27.5 25.3-29.7 0.009
5-<15 604 28.7 26.5-30.8 <0.0001
15- <40y 340 30.1 27.9-32.4 <0.0001
>40 90 29.3 26.4-32.1 <0.0001
Rhinovirus <iy 511 30.2 29.8-30.6 Ref
355
l-<5y 521 31.3
5-<15 774 31.3
15- <40y 259 30.5
>40 64 31.0
30.4-32.2
30.4-32.1
29.5-31.6
29.5-32.5
<0.0001
<0.0001
0.322
0.162
Key: 1, comprise of the best (lowest) Ct values for RSV group A or B; 2, comprise of the best 
(lowest) Ct values for OC43, NL63 and 229E strains; RSV, respiratory syncytial virus; Ref, 
reference group
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Figure A1: Frequency distribution of Ct values for RSV (group A or B) detection by age 
groups in years
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Appendix S. Sensitivity of oral fluid in detection of RSV by Fast Track diagnostics
Characteristic Categories n No. of RSV 
Positives
Sensitivity
(%)
95% Cl
Overall ~..All................ 58 16 27.6 16.7-40.9
NPS CTs 31-35 23 4 17.4 5.0-38.8
26 -3 0 25 7 28.0 12.1-49.4
<25 16 6 37.5 15.2-64.6
RSV Group RSV A 36 12 33.3 18.6-51.0
RSV B 28 5 17.4 6.1-36.9
Age (years) <5 y 26 12 46.2 26.7-66.6
>5y 33 4 12.1 3.4-28.2
Age groups <i y 9 4 44.4 13.7-78.8
1 — <5 y 17 8 47.1 23.0-72.2
5 -  <10 y 13 2 15.3 1.9-45.4
>10 y 20 2 10.0 1.2-31.7
Gender Female 29 9 31.0 15.3-50.8
Male 30 7 23.3 9.9-42.3
ARI Yes 23 8 34.8 16.4-57.3
No 36 8 22.2 10.1-39.2
For the Fast Track Diagnostics, the RNA in the samples was extracted using the EasyMAG 
NucliSENS Extractor and tested for RSV by fast-track diagnostics respiratory pathogens 
multiplex real-time RT-PCR assay following manufacturers instructions and as described 
elsewhere (Sakthivel et al. 2012)
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Appendix U. Figure: RSV shedding patterns for the 205 episodes
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Figure: RSV infection episodes by order of occurrence within their respective households.
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Appendix V. Figure: The correlation of sampling intervals before and after RSV 
episodes
Correlations of sampling intervals before and after RSV episodes
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Appendix BB. R code
I. Log likelihood function and fitting
##################### START ############################
# Written by PMunywoki April 2013,
# Modified by GFMedley May 2013 for faster execution
#Function for assigning proportionate contribution to infections by GFMedley May 
2013
# Final code updated by PMunywoki in May 2013 
#Working directory
setwdC’/Users/pmunywoki/My Work/KILIFI/Household study/data/rstudio") 
rm(list=ls())
#GET the data
source('create_data.R') # code shown below
#MANIPULATE the data
#make the contact parameter index array
#This array has values from l..np where np is the number of contact #parameters+l. 
#For example, if there are 3 contact parameters, then the values are 1,2,3,4 #where 2 
indicates the 1st contact parameter. A value 1 indicates no HH #contact. The diagonal 
is set to 1 to avoid self contact
cpa = rlns3gps 
diag(cpa)<-0 
cpa <- cpa+1
#Create the age matrix as an index for the age parameters 
sus.A <- matrix(l,l,n)
sus.A[agegpl_5] <- 2 #the second parameter - the first parameter is a dummy, 
so that the value is always 1 
sus.A[agegp5_15] <- 3 
sus.A[agegpl5_40] <- 4 
sus.A[agegp40] <- 5
#Create the post infection matrix 
sus.B <- matrix(l,d,n) # post infection 
sus.B [postlnf] <- 2 #the second parameter
#Create the contact matrix as an index of the contact parameters 
CPI <- rlns3gps + 1
#MAKE the likelihood functions 
source("funDefs.R") # the script is defined below
#TESTING the function
pars <- cbind (-4.605, -1.050, matrix(-1.5,1,4), matrix(-4,1, 9), -0.916 )
378
11 <- cal.nLL(pars,sus, d,n,atRisk,shedDen,latency,onset.latency,CPI,HH8gps)
#llold <- cal.nLLold(pars,d,n,atRisk,shedDen, latency, onset.latency, postInf,rlns3gps, 
HH8gps)
#OPTIMISE the function to get estimates of pars 
A <- optim(pars,cal.nLL, gr=NULL, sus, d, n, atRisk, shedDen, 
latency,onset.latency,
CPI, HH8gps, method-BFGS',
control = list(maxit = 500, trace = TRUE, REPORT = 5))
#Plot the age effects
agePars <- matrix ( c( 1, exp ( A$par[4:7]) ), 2, 5, byrow="TRUE" ) 
ageLims <- matrix ( c(0,l, 1,5, 5,15,15,40,40,100), 2, 5 ) 
plot(ageLims, agePars, type-'o",main="Age parameters", xlab="Age (yrs)", ylab 
-'Susceptibility1",ylim=c(0,1))
#Get the mixing parameters
conPars <- matrix ( c( 1, exp(A$par[8:15])), 3, 3 )
cat("Contact parameters:")
print(conPars)
#CALCULATE the individual contributions to infections 
#Get the list of days and individuals when onset occurred 
onsets <- which ( onset, arr.ind=TRUE) 
colnames(onsets) <- c("DAY", "INDIV")
#Retums the relative contribution for each onset: 1...7 where 7 is the community 
con <- cal.contrib (A$par, d, n, atRisk, shedDen,latency,onset.latency, postlnf,
CPI, HH8gps,rlnship, onsets )
#Collect together the results for each infected relationship group 
results = matrix (0, 6, 12) 
for ( ir in 1:6) { 
cc <- con[rlnship[onsets[,2]]==ir,]
results[ir,l] <- tabulate ( rlnship )[ir] #the number of individuals with this
relationship status
results [ir,3] <- dim(cc)[l] #the number of onsets with this relationship status 
results[ir,5:11 ] <- colSums(cc)
}
cat("Table of contributions:") 
print(results)
II. Script For Data Input (Create_data.R)
#####create_data.R #############
#Input data and create objects for use in the various models shown in the main text 
#Working directory
setwd("/Users/pmunywoki/My Work/KILIFI/Household study/data/rstudio") 
rm(list=ls())
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#Load data 
library(foreign)
hh.data <- read.csv("hh_all.csv") 
dim(hh.data)
##Create list of hh names
names <-substr(list.files(path="/Users/pmunywoki/My Work/KILIFI/Household 
study/data/rstudio/hhs", pattem="hh_+.*csv"), 1,5)
## RSV infections for all individuals 
rsv <- as.matrix(hh.data) 
rsv <- rsv[,-l]
#Number days of follow up 
d <- as.numeric(nrow(hh.data)) 
days <- matrix(l:d,d,l)
#Number of participants 
n <- as.numeric(ncol(rsv))
#Load age data
age.data <- as.matrix(read.csv('agey.csv')); sid <- as.vector(age.data[,l]);
#agey
agey <- as.numeric(age.data[,2])
#Create age groups
#agegps <- C(,agegp0',,agegpl,,,agegp5,,'agegpl5,,’agegp40')
agegpO_l <- t(as.matrix(agey>=0 & agey<l)); colnames(agegpO_l) <- sid
agegpl_5 <- t(as.matrix(agey>=l & agey<5)) ; colnames(agegpl_5) <- sid
agegp5_15 <- t(as.matrix(agey>=5 & agey<15)) ; colnames(agegp5_15) <- sid
agegpl5_40 <- t(as.matrix(agey>=l 5 & agey<40)); colnames(agegpl5_40) <- sid
agegp40 <- t(as.matrix(agey>=40)); colnames(agegp40) <- sid
agey <- t(as.matrix(as.numeric(agey))) ; colnames(agey) <- sid
#Create relationships 
#rlns / / I  - self; 2 siblings/cousins; others 
rlns <- t(age.data[,3]); colnames(rlns) <- sid 
rlns.t <- t(rlns)
#rlns / / I  - self; 2 siblings; 3 cousins; 4 mother; 5 father; 6 others 
rlnship <- as.numeric(age.data[,4]); rlnship <- t(as.matrix(rlnship)) 
colnames(rlnship) <- sid 
rlnship.t <- t(rlnship)
#Format dates
dates <- as.Date(c('01 dec2009'), "%d%B%Y") 
sampledates <- as.Date(seq(dates, (dates+185),l))
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#HHID list
hh.list <- c(l,3,5,6,10,11,12,14,16,17,IB,19,20,21,22,23,25,26,27,28,29,30,31,
33,34,35,36,38,39,40,41,42,43,44,45,46,47,48,49,51,53,54,55,56,57,58,60)
#hh sizes by order of the hh
hh.sizes <- c(9,16,37,6,8,9,20,6,12,5,8,14,8,8,15,5,4,5,7,7,7,8,11,8,7,8,16,23, 
4,5,8,6,10,28,10,6,5,19,12,15,10,7,11,11,16,4,9)
#HHID matrix // both col and row matrix 
HH.t <- as.matrix(as.mimeric(substr(sid,4,5)))
HH<- t(HH.t)
#Household sizes 
HHsizes <- matrix(0,1 ,n) 
for (i in 1:47) { 
for (c in 1 :n) {
if (HH[c]==hh.list[i]) {HHsizes[c] <- hh.sizes[i]}
}
}
HHsizes <- t(matrix(as.numeric(rep(HHsizes,d),l),n,d)); colnames(HHsizes) <- sid
HH8gps <- HHsizes>=8; colnames(HH8gps) <- sid
#Extract individual ID: sid and serial
SID <- t(as.matrix(as.numeric(substr(sid,4,7))))
Serial <- t(as.matrix(as.numeric(substr(sid,6,7))))
#Susceptibility matrix
sus <- matrix(l, d ,n) #dummy matrix
#Shedding matrix
shedding <-(rsv[,]=l)*l ; colnames(shedding) <- sid
#Infection // a day before the onset
s.diff <- diff(shedding); infection <-rbind(s.diff, 0);
infection <- infection>0 ; colnames(infection) <- sid
#Recovery
onset <-rbind(0,s.diff) ; rm(ls=s.diff) 
recover <- onset<0 ; colnames(recover) <- sid
#Onset... allow multiple infections (reinfections) 
onset <- onset>0; colnames(onset) <- sid
#Latency periods
pdf <- c(0, 0 ,4 ,4 , 3 ,1)/12
latency <- onset* 1
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for (c in 1 :n) { 
fo r(rin l:d ){  
if (onset[r,c]=l) {latency [r,c] <- pdf[l] } 
if (onset[r,c]=l) {latency[r-l,c] <- pdf[2]} 
if (onset[r,c]==l) {latency [r-2,c] <- pdf[3]} 
if (onset[r,c]==l) {latency [r-3,c] <- pdf[4]} 
if (onset[r,c]==l) {latency[r-4,c] <- pdf[5]} 
if (onset[r,c]==l) {latency[r-5,c] <- pdf[6]}
}
}
onset.latency <- latency>0
#Post infection matrix 
postlnf <- matrix(0,d,n)
osre <- onset+recover; osre.t <- t(osre) ; nosre.t <- osre.t 
for(i in 2:ncol(nosre.t)){ 
nosre.t[,i] <- apply(osre.t[,l:i],l,sum)
}
nosre <- t(nosre.t) 
for (c in 1 :n) { 
for (r in 1 :d) { 
if (nosre[r, c]>l) { postInf[r, c] <-1 }
}
}
postlnf <- postInf==l ; colnames(postInf) <- sid 
rm(ls=nosre.t); rm(ls=osre); rm(ls=osre.t); rm(ls=nosre)
# Status denotes when persons were away (0), or within household(l) 
status <- as.matrix(rsv)
status <- status!=-1; status <- status* 1
#At risk when on observation and not infected
atRisk <- status= l & shedding!=l ; colnames(atRisk) <- sid
# Present
present <- onset | atRisk
# Absent 
absent <- Ipresent
#Contact matrix // infants and others 
Infant <- as.matrix(agegpO_l*l)
Infant.t <- t(Infant)
require(Matrix) 
for (i in 1:47) {
assign(names[i], matrix(l ,hh.sizes[i],hh.sizes[i]))
}
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Rlns <-
as.matrix(bdiag(hh_01 ,hh_03 ,hh_05,hh_06,hh_l 0,hh_l 1 ,hh_l 2,hh_l 4,hh_l 6,hh_l 7, 
hh_ 18,hh_ 19,hh_20,hh_21 ,hh_22,hh_23,hh_25,hh_26,hh_27,hh_28, 
hh_29,hh_30,hh_31 ,hh_33,hh_34,hh_35,hh_36,hh_38,hh_39,hh_40, 
hh_41 ,hh_42,hh_43,hh_44,hh_45,hh_46,hh_47,hh_48,hh_49,hh_51, 
hh_5 3 ,hh_54 ,hh_5 5 ,hh_5 6,hh_5 7,hh_5 8 ,hh_60))
Rlnship <- Rlns 
colnames(Rlns) <- sid
for (r in l:n ) { 
for (c in 1 :n) {
if (Rlns[r,c]==l & Infant[c]==l & Infant.t[r]=l) {Rlns[r,c] <-1} 
if (Rlns[r,c]==l & lnfant[c]==0 & Infant.t[r]=l) (Rlns[r,c] <-2} 
if (Rlns[r,c]==l & Infant[c]==l & Infant.t[r]==FALSE) {Rlns[r,c] <-3} 
if (Rlns[r,c]==l & lnfant[c]=0 & Infant.t[r]=FALSE) {Rlns[r,c] <-4} 
if (r==c) {Rlns[r,c] <- 0 }
}
}
#Relations status; [123][456] 
rlnsl23gps <- Rlnship 
for (r in 1 :n ) { 
for (c in 1 :n) {
if (Rlnship[r,c]==l & rlnship[c]>=l & rlnship[c]<=3 & # child -> child 
rlnship.t[r]>=l & rlnship.t[r]<=3) {rlnsl23gps[r,c] <-1} 
if (Rlnship[r,c]=l & rlnship[c]>=4 & rlnship[c]<=6 & # other -> child 
rlnship.t[r]>=l & rlnship.t[r]<=3) {rlnsl23gps[r,c] <- 2} 
if (Rlnship[r,c]==l & rlnship[c]>=l & rlnship[c]<=3 & # child -> other 
rlnship.t[r]>=4 & rlnship.t[r]<=6) {rlnsl23gps[r,c] <-3} 
if (Rlnship[r,c]=l & rlnship[c]>=4 & rlnship[c]<=6 & # other -> other 
rlnship.t[r]>=4 & rlnship.t[r]<=6) {rlnsl23gps[r,c] <- 4} 
if (r==c) {Rlns[r,c] <- 0 }
}
}
colnames(rlnsl23gps) <- sid
#Relations nuclear vs. non-nuclear family ; [1245] [3 6] 
rlnsFam <- Rlnship 
for (r in 1 :n ) { 
for (c in 1 :n) {
if (Rlnship[r,c]==l & rlnship[c]>=l & rlnship[c]<=5 & rlnship[c]!=3 & #
family -> family
rlnship.t[r]>=l & rlnship.t[r]<=5 & rlnship.t[r]!=3) {rlnsFam[r,c] <-1} 
if (Rlnship[r,c]==l & (rlnship[c]==3 | rlnship[c]=6) & # other -> family 
rlnship.t[r]>=l & rlnship.t[r]<=5 & rlnship.t[r]!=3) {rlnsFam[r,c] <- 2} 
if (Rlnship[r,c]==l & rlnship[c]>=l & rlnship[c]<=5 & rlnship[c]!=3 & #
family -> other
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(rlnship.t[r]==3 | rlnship.t[r]==6)) {rlnsFam[r,c] <-3} 
if (Rlnship[r,c]==l & (rlnship[c]==3 | rlnship[c]==6) & # other -> other 
(rlnship.t[r]=3 | rlnship.t[r]==6)) {rlnsFam[r,c] <- 4} 
if (r==c) {Rlns[r,c] <- 0 }
}
}
colnames(rlnsFam) <- sid
#Relations status; infant, children and adults [1][23][456] 
rlns3gps <- Rlnship 
for (r in 1 :n ) { 
for (c in 1 :n) {
if (Rlnship[r,c]==l & (rlnship[c]==l | Infant[c]==l) &
(rlnship.t[r]==l | Infant.t[r]=l)) {rlns3gps[r,c] = 1} 
if (Rlnship[r,c]=l & rlnship[c]>=2 & rlnship[c]<=3 & # child -> infant 
rlnship.t[r]==l) {rlns3gps[r,c] <- 2} 
if (Rlnship[r,c]==l & rlnship[c]>=4 & rlnship[c]<=6 & # other -> infant 
rlnship.t[r]==l) {rlns3gps[r,c] <-3} 
if (Rlnship[r,c]==l & rlnship[c]=l & # infant -> child
rlnship.t[r]>=2 & rlnship.t[r]<=3) |rlns3gps[r,c] <- 4} 
if (Rlnship[r,c]==l & rlnship[c]>=2 & rlnship[c]<=3 & # child -> child 
rlnship.t[r]>=2 & rlnship.t[r]<=3) |rlns3gps[r,c] <-5} 
if (Rlnship[r,c]==l & rlnship[c]>=4 & rlnship[c]<=6 & # other -> child 
rlnship.t[r]>=2 & rlnship.t[r]<=3) |rlns3gps[r,c] <- 6} 
if (Rlnship[r,c]==l & rlnship[c]==l & # infant -> other
rlnship.t[r]>=4 & rlnship.t[r]<=6) {rlns3gps[r,c] <- 7} 
if (Rlnship[r,c]==l & rlnship[c]>=2 & rlnship[c]<=3 & # child -> other 
rlnship.t[r]>=4 & rlnship.t[r]<=6) {rlns3gps[r,c] <-8} 
if (Rlnship[r,c]==l & rlnship[c]>=4 & rlnship[c]<=6 & # other -> other 
rlnship.t[r]>=4 & rlnship.t[r]<=6) {rlns3gps[r,c] <-9} 
if (r==c) {Rlns[r,c] <- 0 }
}
}
colnames(rlns3gps) <- sid
# Exposure to virus in the household 
exposure <- matrix(0,d,n) 
for (c in 1 :n) { 
indl <- Rlns[c,]==l 
ind2 <- Rlns[c,]==2 
ind3 <- Rlns[c,]==3 
ind4 <- Rlns[c,]==4 
for (r in l:d) {
exposure[r,c] <- (sum(shedding[r,ind 1 ]))+(sum(shedding[r,ind2]))-i- 
(sum(shedding[r,ind3]))+sum(shedding[r,ind4])
}
}
colnames(exposure) <- sid
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#Community infection varying; shedding data summed across all individuals 
virus <- matrix(apply(shedding, 1, sum))
quartz() 
plot (l:d,virus, 
type-o', 
xlim=c( 1,200), 
xlab-Days',
ylab=,No. of individuals infected', 
col="blue")
# lines(sampledates, virus,
# col=,blue')
#Function for fitting time-dependent community infection rate 
comlnf <- matrix(0,dim(virus))
#Time dependent exposure from wider community 
#Values for the function from Matlab by GFMedley 
shed.fit <- matrix(0,dim(shedding))
al <- 9.387 ; bl <-141.3 ; cl <-14.77 ; a2 <- 30.5 ; b2 <-108.1; c2 <- 35.78 
for (r in 1 :d) {
shed.fit[r] <-al*exp(-((r-bl)/cl)A2) + a2*exp(-((r-b2)/c2)A2)
}
lines(l:d, shed.fit, 
col='red', 
lwd=4)
#Insert a legend
legend(l50, 35,c('Observed','Fitted'),lty=l,col=c('blueVred')) 
shedDen <- shed.fit/shed.fit[which.max(shed.fit)]
III. Script Defining The Functions (funDefs.R)
ffffffff* ********* *LOGLIKFT JHOOD FUNCTION***************************
^ • } ' h*•i ' * i * • I * ^ Q f j j  | ^ y  y^
#Age, HH, 3 contact groups
#sus - the structures for susceptibility.
#sus.A are the age groups set for indexing into age parameters. sus.B are the post 
infection groups set for indexing
cal.nLL <- function (pars, sus, d, n, atRisk, shedDen, latency, 
onset.latency, conParIndex,HH8gps) { 
logLike <- matrix(0, d, n)
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#Parameters to estimate 
pC <- exp(pars[l]) #comrrmnity 
pHHl <- exp(pars[2]) #beta 
pHH2 <- exp(pars[16]) #HH
# Age effect
agePars <- c (1, exp(pars[4:7]))
susA <- matrix ( agePars [ sus.A ], nrow=d, ncol=n, byrow=TRUE )
# Make the PI matrix and combine the susceptibility effects 
piPars <- c (1, exp(pars[3]))
sus <- matrix ( piPars [ sus.B ]*susA, nrow=d, ncol=n)
# Contact structure
conPars = c (0,1,  exp(pars[8:15])) 
exposure <- matrix(0,d,n) 
for (i in l:n) { #for each individual 
ee <- conPars[ conParIndex[ i, ] ] #exposure to each individual 
exposure[,i] <- shedding %*% ee #matrix multiplication - probably faster if
#shedding was a sparse array
}
# Force of infection
lambdaC <- matrix (pC*shedDen,d,n) # varying community transmission rate over
# time
lambda <- lambdaC + (pHHl*exposure*(l*(!HH8gps))) + (pHH2* 
exposure*(HH8gps* 1)) # community+HH infection rate
# Calculate negative log likelihood 
prlnf <- log(l-exp(-lambda)) + log(sus) 
prNInf<- log( 1 -sus*( 1 -exp(-lambda))) 
logLike[atRisk] <- prNInf[atRisk]
logLike[onset.latency] <- latency [onset.latency] *prInf[onset.latency] 
return (-sum(logLike))
}
********** nT.J-, ENI)***********************************#####:
*********COIltnl) | l** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * jIII
#Function to calculate the contributions to observed infection -
# uses the same logic as the LL calculation 
#Must supply the rlnship vector
#Works for a particular onset - defined as INDIV, DAY 
cal.contrib <- function (pars, d, n, atRisk, shedDen, latency,
onset.latency, postlnf, conParIndex,HH8gps, rlnship, onsets) {
# pars - the model parameters (optimised already)
# conParlndex - the index to the contact parameters+1;
#i.e. "2" means the value is the 1st parameter; diagonals 11
#Parameters
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numOnsets = dim ( onsets )[1] 
pO <- pars[l] 
pi <- pars[2] 
p3 <- pars[3] 
p4 <- pars[4] 
p5 pars[5] 
p6 <- pars [6] 
p7 <- pars [7]
cp = c(0,l,exp(pars[8:15])) #make an array of the contact parameters 
p8 <- pars[16]
nDays = 7 #number of days latency considered over
contrib <- matrix( 0,205, 7 ) #the matrix of contributions, final column is the
# community contribution
# Calculate the force of infection (FOI) from the community 
lambdaC <- matrix(exp(pO)*shedDen,d,l) # varying community transmission rate
# over time
for (ii in l:dim(onsets)[l]) { # for each individual onset 
INDIV = onsets[ii,"INDIV"]
DAY = onsets[ii,"DAY"] 
dayRange <- (DAY-6):DAY
commCon <- sum(lambdaC[dayRange] * latency[dayRange,INDIV])
# Generate the exposure and FOI from the HHs
contacts <- which ( conParIndex[INDIV,]>l) #people who might have infected
# this person
nContacts <- length ( contacts )
RR <- matrix ( conParIndex[INDIV,contacts], nrow=nDays, ncol=nContacts, 
byrow=TRUE) #the section of the contact data 
exposure <- matrix ( cp[RR], nDays, nContacts )
HH <- HH8gps [ DAY, INDIV ] #the HH grouping for the HH of this individual
lambdaH <- (exp(pl)*exposure)*(!HH) + (exp(p8)*exposure)*HH
hhCon <-lambdaH * latency[ dayRange, INDIV ] * shedding [dayRange, contacts]
sumCon <- sum(hhCon)+commCon
hhCon <- colSums ( hhCon ) / sumCon
commCon <- commCon / sumCon
for ( jj in 1 inContacts ) { 
contrib[ ii, rlnship[ contacts[ jj ]]] <- contrib [ ii, rlnship[contacts[ jj ]]] + hhCon[
j j ]}
contrib[ commCon
}
return (contrib)
}
contrib EN
